• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Fight Aging! Newsletter


  • Please log in to reply
62 replies to this topic

#1 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 25 March 2012 - 09:38 PM


FIGHT AGING! NEWSLETTER
March 26th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- SENS5 Video: Correcting Mitochondrial Mutations
- Another of the Cryonics Pioneers is Cryopreserved
- Theorizing on Evolution and Longevity
- Discussion
- Latest Headlines from Fight Aging!

SENS5 VIDEO: CORRECTING MITOCHONDRIAL MUTATIONS

Here is more on the new method for working around mitochondrial DNA damage that has been in the news recently:

http://www.fightaging.org/archives/2012/03/sens5-video-more-on-that-general-method-of-correcting-mitochondrial-mutations.php

"Mitochondria crowd your cells, roving descendants of ancient bacteria that were long ago co-opted to serve as power plants, turning food into adenosine triphosphate (ATP), the energy store chemical used to power cellular machinery. As a legacy of their bacterial origins, mitochondria carry their own DNA, separate from that in the cell nucleus. Making ATP is a messy business, creating all sorts of reactive molecules as byproducts, and that mitochondrial DNA is more vulnerable than the safely enclosed nuclear DNA. The balance of evidence strongly implicates mitochondrial DNA damage as one of the contributing causes of aging. A damaged gene can no longer be used as a blueprint for the process of gene expression that produces the protein machinery that is vital to the operation of a mitochondrion, and from there matters only go downhill - it's a long road that ends up at atherosclerosis, neurodegeneration, and many other forms of advanced age-related degeneration.

"Thus finding ways to repair mitochondrial DNA (mtDNA) is of great importance - but this is still a minority field of science in comparison to stem cell medicine or cancer research. Nonetheless, mitochondrial repair has been attracting some attention in the past week, as an important new line of research made it to the press release and publicity stage. The technique demonstrated is not really repair, per se, more a method of working around damage to mitochondrial genes - but it looks to be a great improvement over existing methodologies in terms of cost, time, and difficulty. This may enable broader and faster progress towards therapies that can remove the harm caused by damaged mitochondria.

"The new method is a way to deliver more or less arbitrary RNA to mitochondria, which should allow for continued function even after mutational damage to important genes. Production of RNA is a first step in the convoluted process of gene expression - by which genes are used as a blueprint for proteins - so it's quite possible to skip the gene and start with the RNA. This shortcut is the basis for a range of modern life science research, and one obvious use is to correct for a missing or damaged gene: find a way to provide the patient with an ongoing supply of suitably crafted RNA molecules targeted to the right places in his or her cells and it won't matter that the gene is broken.

"I should note that there are only thirteen genes in the mitochondria that are important for the purposes of this discussion, but the process of producing repairs or workarounds for each one has been hard, very different for each of them, slow, and difficult up until this point. A method that works in a very similar way for all of them is a big deal."

ANOTHER OF THE CRYONICS PIONEERS IS CRYOPRESERVED

The people who founded the cryonics movement in the late 60s and early 70s are being cryopreserved, one by one. The latest was Fred Chamberlain, co-founder of cryoncis provider Alcor:

http://www.fightaging.org/archives/2012/03/another-of-the-early-cryonics-pioneers-cryopreserved.php

"The first generation of the modern cryonics community, people who were middle-aged in the 1970s, is benefiting from the technologies and visions that they built. They founded a movement that has sustained itself for four decades in providing steadily improved cryopreservation services through organizations such as Alcor and the Cryonics Institute. The growth that would remake cryonics as from a non-profit community into a for-profit business with a healthy research and development arm has yet to happen, unfortunately, despite the clear need for the ability to preserve the brains and minds of those who will age to death before the advent of working rejuvenation biotechnology. But the present level of success is enough to provide a shot at renewed life in the future for the few who are determined enough and organized enough to take it.

"Fred Chamberlain III who, with his wife Linda, incorporated Alcor in 1972, was cryopreserved by Alcor on March 22, 2012. One week earlier, Fred relocated from Florida to a Scottsdale hospice. This allowed us to watch over him and respond immediately when needed. We believe that Fred received an excellent cryopreservation. More details will be released later.

"Fred Chamberlain was a NASA-JPL electrical engineer working on the Mariner-Jupiter-Saturn mission in 1973 [and] was and is of absolutely critical importance to cryonics. While most people with more than a passing acquaintance with cryonics will associate his importance with the founding of Alcor, that is in reality only a surrogate marker for his deeper importance. Fred came on the scene in cryonics in what was unarguably its darkest hour. It had degenerated into little more than a fraudulent cult in California and, everywhere in the US, it had lost all vestiges of technical and scientific rigor. When Fred discovered this in his role as Vice President of the Cryonics Society of California (CSC) he not only left CSC and founded Alcor, he and Linda Chamberlain established, for the first time anywhere, the practice of scientific, evidence based cryonics; cryonics based on the scientific method, on documentation of procedures, policies, cryopreservation protocols and rigorous patient case reports. He and Linda mandated not only scientific and technical accountability, but administrative, financial and legal accountability as well."

THEORIZING ON EVOLUTION AND LONGEVITY

Some thoughts on the bigger picture of evolution and longevity:

http://www.fightaging.org/archives/2012/03/theorizing-more-broadly-on-the-topic-of-the-evolution-of-longevity.php

"The evolution of aging and longevity is a field in which it's still comparatively easy to make a mark and carve out an area of new theory. For most species it is still the case that ideas on their longevity are comparative unsettled: why they live as long as they do, what mechanisms may have determined their life span, and how it all fits in to the bigger picture of metabolism and the evolution of specific biological processes. There is far more data than any one group of researchers could hope to organize in a lifetime, and new information continues to flood in ever faster as the biotechnology revolution unfolds.

"At some point this rich wealth of data starts to give rise to hypotheses that are more holistic: evolution as a system of systems linked by feedback loops, thousands of species interacting with one another in any given biome, and the evolution of each species highly connected to that of its peers. Embarking upon this level of modeling and understanding, all the way down to biomolecular processes, will keep evolutionary biologists busy for the next century or so, I'd imagine - and give them something to do with the staggering levels of computing power that will be available by that time.

"Here is an interesting open access paper that gives a hint of the shape of this sort of future research, whilst considering the evolution of longevity amongst interacting species ... the researchers propose that such things as the ability of rapamycin (produced by soil bacteria) to extend life in mice or the beneficial effects of mammalian bile acid on yeast life span are late manifestations of cross-species evolutionary processes that have been going on since the very earliest epoch of multicellular life. The suggestion is that we should expect there to be a wide range of compounds produced by varied species that will have some beneficial effect on the life span of another species (such as by improving cellular housekeeping processes), because the existence of such relationships between species is a fundamental characteristic of diverse ecosystems produced by evolution."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

AN INTERVIEW WITH DMITRY ITSKOV OF RUSSIA 2045
Friday, March 23, 2012
http://www.fightaging.org/archives/2012/03/an-interview-with-dmitry-itskov-of-russia-2045.php
The founder of the Russia 2045 initiative is interviewed here: "Dmitry Itskov is the founder of Global Future 2045, which recently held its first conference. The Russian entrepreneur gathered scientists from around the world to discuss many topics that will help achieve one goal: life extension. ... The main idea of the project and my mission is to help people, to eliminate disease and death probably in the future, to overcome the limitations of our body, and to help humanity grow out of the crisis. As for my personal background, I have always been in the IT business, internet technologies. I published a few internet newspapers in Russia, I produce internet TV channel, a kind of blog service, email service, so being in this business I have always been interested in science and technologies that can extend life. Of course, like anybody, I have seen death and diseases in my family, my grandparents have gone, I've always been thinking how can I personally help. I've also been interested in science and I've seen an example of scientists who haven't gone, who are with us, like Stephan Hawking. He can't even move, he can't even normally talk to people, so this experience inspired me, this made me think how can I participate and help people. I decided to launch such an initiative with the help of Russian scientists who I knew like me. What helped me was that talking to them I was pretty sure that if we launched a kind of a big technical project, a big social initiative, if we work together, if we make our thinking global, and if we are able to launch a global network, then there is a very big chance we make our dreams come true. ... [The Avatar initiative] is the main technological project of the initiative which consists of four steps. One is human-like robot controlled by brain-computer interface. ... the second part is about producing life support system for the human brain. ... The third part is reverse engineering for the brain." The fourth step is to replace the biological brain with an artificial system that is more durable and extendable - which is a long way out, but something that has to be accomplished carefully and thoughtfully to be anything other than an expensive form of suicide that happens to leave behind a copy of the original you. Acceptable means include slowly replacing neurons one by one with nanomachinery that replicates their function and data storage whilst interfacing with the remaining brain tissue - but again, this sort of technology is a long way out from where we stand now, and there are many other challenges to be overcome along the way.

TRANSDIFFERENTIATION TO SIMPLIFY GENERATION OF CELLS TO ORDER
Friday, March 23, 2012
http://www.fightaging.org/archives/2012/03/transdifferentiation-to-simplify-generation-of-cells-to-order.php
Researchers are slimming down the process of generating specific types of cell to order, turning the multi-step induced pluripotency processes of the last couple of years into a single step: researchers "have succeeded in obtaining somatic stem cells from fully differentiated somatic cells. [Scientists] took skin cells from mice and, using a unique combination of growth factors while ensuring appropriate culturing conditions, have managed to induce the cells' differentiation into neuronal somatic stem cells. ... Our research shows that reprogramming somatic cells does not require passing through a pluripotent stage. Thanks to this new approach, tissue regeneration is becoming a more streamlined - and safer - process. ... One factor in particular, called Brn4, which had never been used before in this type of research, turned out to be a genuine 'captain' who very quickly and efficiently took command of his ship - the skin cell - guiding it in the right direction so that it could be converted into a neuronal somatic stem cell. ... This interconversion turns out to be even more effective if the cells, stimulated by growth factors and exposed to just the right environmental conditions, divide more frequently. ... Gradually, the cells lose their molecular memory that they were once skin cells. ... It seems that even after only a few cycles of cell division the newly produced neuronal somatic stem cells are practically indistinguishable from stem cells normally found in the tissue. ... So far, insights are based on experiments using murine skin cells; the next steps now are to perform the same experiments using actual human cells. In addition, it is imperative that the stem cells' long-term behaviour is thoroughly characterized to determine whether they retain their stability over long periods of time."

AN UPDATE ON BACTERIAL AGING
Thursday, March 22, 2012
http://www.fightaging.org/archives/2012/03/an-update-on-bacterial-aging.php
The aging of bacteria has been a topic of interest in the years since its discovery; firstly, it overturns the long-held assumption that bacteria are essentially immortal, and secondly it provides insight into the very early evolutionary origins of aging. Here is a recent update: "Evidence for aging in symmetrically dividing bacteria such as Escherichia coli has historically been conflicting. Early work found weak or no evidence. More recent studies found convincing evidence, but negative results are still encountered. Because bacterial aging is believed to result from non-genetic (e.g. oxidative) damage, we tested the possibility that the negative outcomes resulted from the lack of an extrinsic damage agent. We found that streptomycin, which produces mistranslated proteins that are more vulnerable to oxidation, was able to induce both damage and aging in bacterial populations. A dosage effect relating the level of damage to the concentration of streptomycin was observed. Our results explain the previous inconsistencies because all studies that failed to find evidence for bacterial aging did not use a damage agent. However, all studies that succeeded in finding evidence utilized fluorescent proteins as a visual marker. We suggest that aging in those studies was induced by the harmful effects of an extrinsic factor, such as of the proteins themselves or the excitation light. Thus, all of the previous studies can be reconciled and bacterial aging is a real phenomenon. However, the study and observation of bacterial aging requires the addition of an extrinsic damage agent."

POPULAR PRESS ON ORGAN REGROWTH
Thursday, March 22, 2012
http://www.fightaging.org/archives/2012/03/popular-press-on-organ-regrowth.php
A BBC News article: "It might seem unbelievable, but researchers can grow organs in the laboratory. There are patients walking around with body parts which have been designed and built by doctors out of a patient's own cells. ... There is a pressing need. A shortage of available organs means many die on waiting lists and those that get an organ must spend a lifetime on immunosuppressant drugs to avoid rejection. The idea is that using a patient's own stem cells to grow new body parts avoids the whole issue of rejection as well as waiting for a donor. ... Dr Anthony Atala [has] made breakthroughs in building bladders and urethras. He breaks tissue-building into four levels of complexity. 1) Flat structures, such as the skin, are the simplest to engineer as they are generally made up of just the one type of cell. 2) Tubes, such as blood vessels and urethras, which have two types of cells and act as a conduit. 3) Hollow non-tubular organs like the bladder and the stomach, which have more complex structures and functions. 4) Solid organs, such as the kidney, heart and liver, are the most complex to engineer. They are exponentially more complex, have many different cell types, and more challenges in the blood supply. ... We've been able to implant the first three in humans. We don't have any examples yet of solid organs in humans because its much more complex. ... One of the problems when you move to larger organs is the getting the blood supply to work, connecting arteries, capillaries and veins to keep the organ alive. It is why some researchers are investigating 'decellularisation' - taking an existing donated organ, stripping out the original cells and replacing them with new cells from the patient who will receive the organ."

AN OUTSIDER'S OVERVIEW OF CRYONICS, PART II
Wednesday, March 21, 2012
http://www.fightaging.org/archives/2012/03/an-outsiders-overview-of-cryonics-part-ii.php
The second part of an article in CMAJ that shows off some of the subtle prejudices against cryonics that exist in the medical scientific community (such as in the choice of title) while attempting objectivity: "Although death and taxes are said to be the only two certainties in life, a small but vocal community takes issue with the inclusion of the former. There is, they say, the alternative of cryonics, in which a legally dead person is preserved at -196C in hopes that he will ultimately be revived and rejuvenated, once a cure for his ailment is found. And it's entirely consistent with the basic tenets of medicine, providers argue. ... Although it seems like an unusual and radical idea to many people, I think in the very truest sense of the term, this is conservative medicine. This is literally conserving a patient rather than giving up on them by today's standards of medicine. It's true a doctor can't do anything more for these people, but that doesn't mean the future cannot. ... Those interested in cryonics tend be optimistic, hopeful about technological developments and dissatisfied with an ordinary life span, says Ben Best, president of the Cryonics Institute. ... a miniscule chance is better than none, enthusiasts say. ... Nobody has come up with a better idea yet, so therefore myself, as well as some others, believe that cryonics is simply the second worst thing that can happen. You're going to die. You're going to stop breathing. Whether you be buried or cremated or cryopreserved, it's going to happen. There's nothing we can do about this now, but I know that if I'm cremated or buried, even if technology vastly increased, I'm never coming back. ... Enthusiasts are mystified that only a small segment of the general population has investigated the cryonic option. ... I don't know why there are far more people who don't sign up for cryonics arrangements. It's true that what we do is unorthodox and different, at least in 2012. But there are so many bizarre ideas out there which have no evidence to support them and get many, many people fascinated ... Yet we only have less than 1000 members after 40 years. ... People tend in my experience to kind of rely on this naturalistic [fallacy] that because people have always gotten older and died, therefore they should get older and die as a result of simply living longer."

VERNOR VINGE ON RADICAL LIFE EXTENSION
Wednesday, March 21, 2012
http://www.fightaging.org/archives/2012/03/vernor-vinge-on-radical-life-extension.php
From an interview with Vernor Vinge at Wired: "First of all, I'm all for human life extension. In The Singularity is Near, I think, [Ray Kurzweil] has a nice discussion of the situation that a lot of essayists have where they say, 'Oh, we really don't want that. A wise and philosophical person realizes that life needs be limited, and that's a good thing,' these essayists say. He does a good job of criticizing that point of view, and I certainly agree with that. Furthermore, I think that a human lifespan of a thousand years with post-Singularity technology is easily doable. I think a lifespan of a thousand years would actually - Singularity aside - would do human society and human nature a great deal of good, and don't think it is that difficult, it probably can even be achieved without having a Technological Singularity. Life spans of 10,000 to 100,000 years, then you begin to look at what's involved, the humans that are involved, and how capable a human mind is of absorbing variety. ... The complaint or the criticism here is that the human mind has a certain level of ability to handle different sorts of complexity, and if you believe that you could go 100,000 years and not be turned into a repeating tape loop, well, then let's talk about longer period of time. How about a billion years, or a hundred billion years? At a hundred billion years, you're out there re-engineering the universe. The age of the universe becomes your chief longevity problem. But there's still the issue of, what would it be like to be you after that? This raises the point, which actually I'm sure is also on Ray's mind, that if you're going to last that long you have to become something greater, and the Singularity is ideally set up to supply that. So the people who are into the intelligence amplification mode of looking at these things, this all fits. And I'm not saying that in a critical and negative way, it does all fit, and it puts you in a situation where you are talking realistically about living very long periods of time, perhaps so long that you have to re-engineer the universe because the universe is not long-lived enough. At the same time, you have to be growing and growing and growing. I mean, intellectually growing. Now, if you look at that situation, it ultimately gets you, I think, to a very interesting philosophical point, which really I don't think was within the horizon of what people normally thought about two or three or four hundred years ago."

ROUTINE PERIODIC FASTING LOWERS DISEASE RISK
Tuesday, March 20, 2012
http://www.fightaging.org/archives/2012/03/routine-periodic-fasting-lowers-disease-risk.php
Here is more evidence for modest benefits derived from common forms of minimal intermittent fasting, though as is often the case one may suspect that other associations with lifestyle choices cloud the picture: "Previously we discovered that routine periodic fasting was associated with a lower prevalence of coronary artery disease (CAD). Other studies have shown that fasting increases longevity in animals. A hypothesis-generating analysis suggested that fasting may also associate with diabetes. This study prospectively tested whether routine periodic fasting is associated with diabetes mellitus (DM). Patients (n = 200) undergoing coronary angiography were surveyed for routine fasting behavior before their procedure. ... Meta-analyses were performed by evaluation of these patients and 448 patients from a previous study. DM was present in 10.3% of patients who fasted routinely and 22.0% of those who do not fast. CAD was found in 63.2% of fasting and 75.0% of nonfasting patients, and in nondiabetics this CAD association was similar. Meta-analysis showed modest differences for fasters versus nonfasters in glucose concentrations (108 ± 36 vs 115 ± 46 mg/dl) and BMI (27.9 ± 5.3 vs 29.0 ± 5.8 kg/m(2)). In conclusion, prospective hypothesis testing showed that routine periodic fasting was associated with a lower prevalence of DM in patients undergoing coronary angiography. A reported fasting association with a lower CAD risk was also validated and fasting associations with lower glucose and BMI were found."

AN EXAMPLE OF CANCER IMMUNOTHERAPY DEVELOPMENT
Tuesday, March 20, 2012
http://www.fightaging.org/archives/2012/03/an-example-of-cancer-immunotherapy-development.php
Another promising form of immunotherapy in mice: "researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors. In early studies, 60 percent of tumor-burdened mice were cured in fewer than three months and with minimal side effects. ... We believe that this new technique will help us to identify a whole new set of genes that encode antigens that are important in stimulating the immune system to reject cancer. In particular, we have seen that several proteins need to be expressed together to generate the most effective rejection of the tumors in mice. ... The immune system functions on a seek-and-destroy platform and has fine-tuned its capacity to identify viral invaders such as vesicular stomatitis virus. Part of the appeal of building cancer vaccines from the whole spectrum of tumor DNA is that tumors can adapt to the repeated attacks of a healthy immune system and display fewer antigens (or signposts) that the immune system can identify. Cancers can learn to hide from a normal immune system, but appear unable to escape an immune system trained by the vesicular stomatitis virus with the wide range of DNA used in the library approach. ... Nobody knows how many antigens the immune system can really see on tumor cells. By expressing all of these proteins in highly immunogenic viruses, we increased their visibility to the immune system. The immune system now thinks it is being invaded by the viruses, which are expressing cancer-related antigens that should be eliminated."

AN OUTSIDER'S OVERVIEW OF CRYONICS
Monday, March 19, 2012
http://www.fightaging.org/archives/2012/03/an-outsiders-overview-of-cryonics.php
If you read the whole thing, this outsider's view of cryonics at CMAJ illustrates a few of the subtle prejudices held in the medical and scientific community in the course of trying to be objective: "cryonics - the practice of preserving a legally dead person at a temperature far below freezing in hopes of someday being revived and rejuvenated after advances in science have provided a cure for their ailment. The appeal is self-evident, enthusiasts say. 'It certainly offers an opportunity, although remote and probably speculative, as an ambulance to the future so to speak. If I die from something that is not preventable today, maybe future technology will offer the means of reviving me, figuring out the condition I have and fixing it.' Yet, however appealing the notion of a second life may be, the number of people who've actually been frozen is miniscule: about 250, according to the Cryonics Institute, a cryonics services provider located in a regional township of the state of Michigan. ... But far more people appear interested in being frozen. Membership in the two biggest cryonics providers in the United States - the Cryonics Institute and the Alcor Life Extension Foundation in Scottsdale, Arizona - is close to 2000. ... The cryonics process involves draining a patient's fluids and replacing them with a vitrification solution, essentially a preservative cocktail of cryoprotectant chemicals such as dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol that are believed to prevent ice crystal formation and reduce the extent of tissue damage that occurs after flesh is frozen. The corpse is allowed to cool and then dropped into liquid nitrogen for indefinite preservation at a brisk -196°C. Or as Ben Best, president of the Cryonics Institute, writes in an email 'the perfusion process involves replacing body water in cells, not just blood in the blood stream. By perfusing vitrification solution into the blood stream, there is an exchange of vitrification solution for water. Water is removed from the body (and tissues) as vitrification solution replaces it by the diffusion process. With vitrification solution in brain tissue (especially) there should be no ice formation whatsoever. The flesh is therefore vitrified, not frozen (freezing means ice). The patient is cooled under a computer controlled cooling box to liquid nitrogen temperature, not simply 'dropped' in liquid nitrogen.'"

SENS FOUNDATION ON RECENT MITOCHONDRIAL RESEARCH
Monday, March 19, 2012
http://www.fightaging.org/archives/2012/03/sens-foundation-on-recent-mitochondrial-research.php
The SENS Foundation here comments on recent research that may make it easier to build therapies to treat mitochondrial DNA damage in order to remove its contribution to aging: "The UCLA group's approach is highly promising. Their work builds upon and may potentially supersede several previous approaches to the problem of mitochondrial mutations that occur as a result of the degenerative aging process, including allotopic protein expression, its optimization using [a mitochondrial targeting sequence], and the exploitation of the multiprotein RNA import complex (RIC) of the protozoal parasite Leishmania tropica (which the investigators characterize as 'requir[ing] the introduction of nonnative tRNAs with foreign protein factors or the transfer of a large multisubunit aggregate into cells, which is of low efficiency and difficult to reproduce in desirable disease-relevant settings' ... As compared to allotopic protein expression, an RNA-based approach has the theoretical advantage of abrogating the difficulties encountered thus far with the mitochondrial import of large and hydrophobic proteins. But as we suggested in discussion of their earlier, more discovery-phase research, allotopic protein and RNA approaches are not mutually exclusive: different mitochondrially-encoded proteins could be either allotopically expressed, or their mRNAs generated allopically and imported for in situ translation, depending on the ease or efficiency of each approach for the protein in question. ... For their part, Dr. Teitell's group is evidently optimistic, and have clearly moved beyond the basic science focus of their earlier report. ... In response to this report, SENS Foundation CSO Dr. Aubrey de Grey has said that 'If this is as good as it looks, I think it could be a real game-changer', and Dr. O'Connor and his team at the SENS Foundation RC are considering testing a construct based on Teitell's methods in a system that the RC has already generated and used for testing of allotopic expression of cytochrome B. The race is on -- as it should be, for the stakes are large. Large, age-related deletions in mtDNA are likely responsible for the systemic rise in oxidative stress with aging, and for localized but terrible pathologies of skeletal muscle and substantia nigra dopaminergic neurons in aging bodies. The obviation of these mutations is a desperate medical need, and biomedicine is shamed for every day that a solution is delayed. This new method must be tested and exploited to its limits, and all approaches must be trialed, until the fires of life are once again burning in rejuvenated cells, in bodies restored to their youthful prime."

______________________________


View the full article

#2 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 April 2012 - 05:03 PM

FIGHT AGING! NEWSLETTER
April 2nd 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- SENS Foundation Annual Report for 2011 Released
- SENS5 Video: AGES and Aging
- More Commentary on Russia 2045
- On Indifference to the Future
- Discussion
- Latest Headlines from Fight Aging!

SENS FOUNDATION ANNUAL REPORT FOR 2011 RELEASED

The SENS Foundation budget is growing, and projects are being initiated in all of the areas of rejuvenation biotechnology described by the Strategies for Engineered Negligible Senescence proposals:

http://www.fightaging.org/archives/2012/03/sens-foundation-annual-report-for-2011-released.php

"You might say that the past three years have been SENS Foundation's 'Mercury project' - our proof-of-concept phase - during which we've worked to establish the feasibility of our line of inquiry through our research, education, and outreach programs. And in this we have been successful. The Thiel Foundation's substantial and continued funding has been met both with broader-based support and more key individual backers. Edward James Olmos has volunteered to lend his voice to our message. Jason Hope's philanthropic gift has launched our glucosepane research program at Cambridge and Yale Universities. We've worked hard to build new collaborations and outreach opportunities, and 2012 will show a significant research project in every major category of damage in the SENS technological proposal.

"What has changed [in the SENS Foundation messaging] is the fact that we now have specific research, details, and ongoing proof-of-concept work to discuss. SENS Foundation has matured as an organization. We have moved well beyond the point of needing to defend the SENS platform as worth testing out in the laboratory; we have won that battle. Instead, we are discussing how SENS Foundation can best go about its work of building an industry and creating a comprehensive, practical suite of rejuvenation biotechnologies. And so, I no longer discuss and emphasize what the future might hold. Rather, I discuss and emphasize what is going on right now at the SENS Foundation Research Center in Mountain View, California, and in Foundation-funded laboratories across the world.

"We are delighted that SENS Foundation was able to make expenditures of $1,518,000 in 2011. This was an increase of over $400,000 from 2010, overwhelmingly in support of direct research and conference projects. ... We greatly appreciate the support of the many individuals who contributed to our mission. We would like to thank Peter Thiel, Jason Hope, the Methuselah Foundation, and all of our contributors and volunteers for their on-going generosity. We expect a significant increase in both revenues and expenses for 2012, as we begin to see distributions from a de Grey family trust, under a grant from SENSF-UK. This support will be in addition to the contributions we receive from other sources."

By way of comparison with the 2010 report showed a $1 million budget or so for that year, about a third of which went to LysoSENS research - working on the foundation of a biomedical remediation strategy that could use bacterial enzymes to safely break down the age-related build up of harmful aggregates in the body. That build up is one of the fundamental causes of aging, but suitable biotechnologies such as biomedical remedication can and should be developed to address it. A successful technology platform for therapies will allow for both extension of healthy life span and restoration of health to those who are already damaged and suffering.

It has to be said, I'm pleased to see work on finding a safe agent to break down glucosepane moving forward. The lack of significant progress anywhere in the world on AGE breakers targeting the most common AGE - glucosepane - over the past decade has been enormously frustrating. It is one of the few areas of SENS in which the traditional and massive drug development industry is perfectly suited to the task. It may as well have had a big red target painted on it given the size of the market for a working drug that actually, legitimately, literally reversed skin aging - amongst other important body parts such as blood vessels - and yet nothing much has happened.

SENS5 VIDEO: AGES AND AGING

Since we are on the topic of AGEs and what to do about them, here is a counterpoint to the usefulness of the existing drug development industry - made by the UK researchers working in collaboration with the SENS Fundation to break down glucosepane:

http://www.fightaging.org/archives/2012/03/sens5-video-talking-about-ages-and-aging.php

"Advanced glycation end-products (AGEs) such as glucosepane are what you might think of as a sort of biological rust. They build up as an undesirable side-product of the chemistry of life and damage important molecular machinery in and around cells by sticking to molecules or sticking molecules together, making it impossible for them to do their jobs. The increase in AGE levels in the body with advancing age isn't a matter of straight accumulation over time - it's more dynamic than that, and the level of AGEs in the diet may play some role - but eventually it becomes enough to cause serious harm. Aging is little more than damage, and AGEs are one form of that damage.

"There are two difficulties with creating AGE-breaker drugs. Firstly, AGEs are chemical targets, not genes or proteins. Almost all of pharmaceutical research over the last 40 years has been orientated to finding drugs that interact with proteins, and with the genes that make those proteins. So we cannot call on the trillions of dollars of research and technology development that have created the modern drug industry to help us (very much - we can use some of it). Secondly, AGEs are pretty stable and tough. That is inevitable - they are in essence the physiological equivalent of the black stuff on the bottom of your baking tin - what is left after years of use and the dishwasher. (In the case of humans, 'the dishwasher' is an array of mechanisms that take care of nearly all the waste products of metabolism.) We know how to break them quite easily, but only using a process that would also dissolve every protein in your body. The trick is finding a way to cleave them and leave all the rest of you intact."

MORE COMMENTARY ON RUSSIA 2045

The Russia 2045 initiative is attracting attention from the English-language community, and here is more on that topic:

http://www.fightaging.org/archives/2012/03/more-commentary-on-russia-2045.php

"For 3 days in late February, Russian businessman Dmitry Itskov gathered 500+ futurists in Moscow for a 'Global Future 2045 Congress' - the latest manifestation of his "Russia 2045" movement. ... The occurrence of a conference like this in Russia is no big shock, of course. Russia has a huge contingent of great scientists in multiple directly Singularity-relevant areas; and it also has an impressively long history of advanced technological thinking . My dear departed friend Valentin Turchin wrote a book with Singularitarian themes in the late 1960s, and the Russian Cosmists of the early 1900s discussed technological immortality, space colonization and other futurist themes long before they became popular in the West.

"It's unclear from the online conference abstracts and other Russia 2045 materials just how much actual work is going in Russia on right now, explicitly oriented toward realizing the exciting visions Itskov describes; and it's also unclear to what extent Itskov's 'Russia 2045' movement serves an active R&D role, versus a visionary and publicity role. It appears that most of the concrete science and engineering work at the conference was presented by scientists who had made their breakthroughs outside the context of the 'Russia 2045' project; whereas Itskov and the other Russia 2045 staff were largely oriented toward high-level visioning. But of course, Russia 2045 is a new initiative, and may potentially draw more researchers into its fold as time progresses.

"Ray Kurzweil gave a fairly glowing report, noting 'It was a well funded conference, funded by a number of major corporations in Russia..... There was significant representation from the mainstream press. The ideas were taken seriously. There were people from companies, from academe, from government.... The comparison to Humanity+ or the Singularity Summit is reasonable.... The people at the conference (about 500-600) were pretty sophisticated about all the issues you and I talk and write about.'

"Clearly there are many smart scientists and engineers in Russia doing directly Singularity-relevant things; and Itskov's Russia 2045 organization seems to be doing a good job of attracting public and political attention to this work. What amount of concrete work is actually going on toward Itskov's list of grand goals is unclear to me at present, but certainly seems something to keep an eye on."

ON INDIFFERENCE TO THE FUTURE

If we judge by actions and not words, we might conclude that most people don't really care one or another when it comes to influencing the future:

http://www.fightaging.org/archives/2012/03/greeting-your-personal-future-with-indifference.php

"Someone who didn't take note of the eagerness with which people throw money at the shams, fakes, and security blankets of the 'anti-aging' marketplace might be forced to conclude that the world's inhabitants are on balance indifferent as to whether they live long or die young, whether they suffer for decades or live healthily some years down the line. There are many common sense health practices that people can undertake to maximize their remaining life expectancy and reduce the risk of age-related disease - and that's even before we start in on supporting research and development of rejuvenation biotechnology - but the majority don't do anywhere near as much as they might, and in consequence they come to suffer for it. Are we a species whose dominant trait is actually nihilism? One wonders at times.

"But the personal future of aging isn't the only thing that most people, judging by their actions, are indifferent to. We might also consider the preventable nature of well known conditions like cancer, to pick one example. Most people know that they should be exercising, they should not let themselves get fat, and they also know how to halve the risk of suffering cancer - but do they adopt the necessary changes in lifestyle? Largely no:

"More than half of all cancer is preventable, and society has the knowledge to act on this information today ... What we know [is] that lifestyle choices people make and that society can influence in a number of ways - from tobacco use to diet and exercise - play a significant role in causing cancer. Specifically, the researchers cite data demonstrating that smoking alone is responsible for a third of all cancer cases in the United States. Excess body weight and obesity account for another 20 percent."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

A TRANSCRIPT OF "ELIXIR OF LIFE"
Friday, March 30, 2012
http://www.fightaging.org/archives/2012/03/a-transcript-of-elixir-of-life.php
An Australian program featuring researchers Aubrey de Grey and David Sinclair: "It feels like science fiction, but it's actually true. And we're really at the cutting edge, it's a really exciting time in the field right now. ... There's no such thing as ageing gracefully. I don't meet people who want to get Alzheimer's disease, or who want to get cancer or arthritis or any of the other things that afflict the elderly. Ageing is bad for you, and we better just actually accept that. As far as I'm concerned, ageing is humanity's worst problem, by some serious distance. ... Now if you think that's an overstatement, consider this: world-wide, a hundred and fifty thousand people die each day, two-thirds of them from ageing. That means potentially one hundred thousand people could be saved every day with therapies that combat ageing. ... Ageing is simply and clearly, the accumulation of damage in the body. That's all that ageing is. What it's going to take is development of thoroughly comprehensive regenerative medicine for ageing. That means medicine which can repair the molecular and cellular damage that accumulates in our bodies throughout life, as side effects of our normal metabolic processes. ... We do not know what humanity of the future is going to want to do. If thirty or fifty years from now people don't have the problems that we thought they might have, but we didn't develop those therapies, so those people have to die anyway, after a long period of decrepitude and disease, then they're not going to be terribly happy are they? That's why we have a moral obligation to develop these technologies as soon as possible."

SEPARATING OUT THE EFFECTS OF RAPAMYCIN
Friday, March 30, 2012
http://www.fightaging.org/archives/2012/03/separating-out-the-effects-of-rapamycin.php
Via EurekAlert!: researchers have "explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively. The study suggests that molecules that specifically inhibit mTORC1 may combat age-related diseases without the insulin-resistance side effect. ... The mTOR complexes, for mammalian (or mechanistic) target of rapamycin, are proteins that regulate cell growth, movement, and survival, as well as protein synthesis and transcription. Specifically, there are two mTOR complexes and one mTOR protein. The mTOR protein is the core of both complexes (mTORC1 and mTORC2), which behave differently based on their associated proteins. One or both of the mTOR complexes can be inappropriately activated in certain cancers, and dual-specific inhibitors are being developed as chemotherapeutic agents. Several theories have been put forward by researchers to explain the observations that patients receiving rapamycin are more prone to developing glucose intolerance, which can lead to diabetes. Chronic treatment with rapamycin impairs glucose metabolism and the correct functioning of insulin in mice, despite extending lifespan. The research team demonstrated that rapamycin disrupts mTORC2 in the mice, and that mTORC2 is required for the insulin-mediated suppression of glucose metabolism in the liver. On the other hand, they also demonstrated that decreasing mTORC1 signaling was sufficient to extend lifespan independently from changes in glucose metabolism. They used a mouse strain in which mTORC1 activity was decreased and saw that lifespan was extended by 14 percent, yet the animals had normal glucose metabolism and insulin sensitivity."

INVESTIGATING INTESTINAL BACTERIA AND AGING IN NEMATODES
Thursday, March 29, 2012
http://www.fightaging.org/archives/2012/03/investigating-intestinal-bacteria-and-aging-in-nematodes.php
There's a range of research to indicate that gut bacteria are important in the relationship between metabolism and aging, though the situation in higher animals is probably far more complex than in nematode worms: "A powerful approach to understanding complex processes such as aging is to use model organisms amenable to genetic manipulation, and to seek relevant phenotypes to measure. Caenorhabditis elegans is particularly suited to studies of aging, since numerous single-gene mutations have been identified that affect its lifespan; it possesses an innate immune system employing evolutionarily conserved signaling pathways affecting longevity. As worms age, bacteria accumulate in the intestinal tract. However, quantitative relationships between worm genotype, lifespan, and intestinal lumen bacterial load have not been examined. We hypothesized that gut immunity is less efficient in older animals, leading to enhanced bacterial accumulation, reducing longevity. To address this question, we evaluated the ability of worms to control bacterial accumulation as a functional marker of intestinal immunity. ... We show that as adult worms age, several C. elegans genotypes show diminished capacity to control intestinal bacterial accumulation. We provide evidence that intestinal bacterial load, regulated by gut immunity, is an important causative factor of lifespan determination; the effects are specified by bacterial strain, worm genotype, and biologic age, all acting in concert. ... In total, these studies focus attention on the worm intestine as a locus that influences longevity in the presence of an accumulating bacterial population. Further studies defining the interplay between bacterial species and host immunity in C. elegans may provide insights into the general mechanisms of aging and age-related diseases."

MORE VISCERAL FAT MEANS MORE INFLAMMATION
Thursday, March 29, 2012
http://www.fightaging.org/archives/2012/03/more-visceral-fat-means-more-inflammation.php
Yet another study showing a correlation between chronic inflammation and abdominal fat: "Obesity-related increases in multiple inflammatory markers may contribute to the persistent subclinical inflammation common with advancing age. ... We used factor analysis to identify inflammatory factor(s) and examine their associations with adiposity in older adults at risk for disability. ... [Inflammatory markers] were measured in 179 participants from the Lifestyle Interventions and Independence for Elders Pilot (Mean ± SD age 77 ± 4 years, 76% white, 70% women). Body mass index, waist circumference, and total fat mass were assessed by anthropometry and dual-energy x-ray absorptiometry. ... Greater total and abdominal adiposity are associated with higher levels of an inflammatory factor related to CRP, IL-1ra, and IL-6 in older adults, which may provide a clinically useful measure of inflammation in this population. ... [The associations were determined] after adjusting for age, gender, race/ethnicity, site, smoking, anti-inflammatory medications, comorbidity index, health-related quality of life, and physical function. These associations remained significant after further adjustment for grip strength, but only waist circumference remained associated with inflammation after adjusting for total lean mass." Waist circumference is a better correlation with the amount of visceral fat packed around the organs in comparison to body mass index.

EXCESS BODY FAT DAMAGES THE MIND
Wednesday, March 28, 2012
http://www.fightaging.org/archives/2012/03/excess-body-fat-damages-the-mind.php
There is plenty of evidence to show that being overweight for any great length of time in life causes harm, either fairly directly by boosting levels of chronic inflammation, or because that fat tissue is associated with a lack of exercise and consequent development of vascular dementia, or for a range of other possible reasons. Here is another study on this topic: "High midlife body mass index (BMI) has been linked to a greater risk of dementia in late life, but few have studied the effect of BMI across midlife on cognitive abilities and cognitive change in a dementia-free sample. ... We investigated the association between BMI, measured twice across midlife (mean age 40 and 61 years, respectively), and cognitive change in four domains across two decades in the Swedish Adoption/Twin Study of Aging. ... Latent growth curve models fitted to data from 657 non-demented participants showed that persons who were overweight/obese in early midlife had significantly lower cognitive performance across domains in late life and significantly steeper decline in perceptual speed, adjusting for cardio-metabolic factors. Both underweight and overweight/obesity in late midlife were associated with lower cognitive abilities in late life. However, the association between underweight and low cognitive abilities did not remain significant when weight decline between early and late midlife was controlled for. ... There is a negative effect on cognitive abilities later in life related to being overweight/obese across midlife. Moreover, weight decline across midlife rather than low weight in late midlife per se was associated with low cognitive abilities." The weight decline association shows up in a range of studies on weight and health; one common conclusion is that it reflects the impact that more serious medical conditions - related to weight or otherwise - can have on people.

ANALYZING THE METABOLISMS OF LONG-LIVED MICE
Wednesday, March 28, 2012
http://www.fightaging.org/archives/2012/03/analyzing-the-metabolisms-of-long-lived-mice.php
Advances in biotechnology are greatly reducing the cost of performing broad analyses of metabolism - and so researchers are gathering ever more data on the various breeds of long-lived mice that have been created in recent years: "Significant advances in understanding aging have been achieved through studying model organisms with extended healthy lifespans. Employing (1)H NMR spectroscopy, we characterized the plasma metabolic phenotype (metabotype) of three long-lived murine models: 30% dietary restricted (DR), insulin receptor substrate 1 null (Irs1(-/-)), and Ames dwarf (Prop1(df/df)). A panel of metabolic differences were generated for each model relative to their controls, and subsequently, the three long-lived models were compared to one another. Concentrations of mobile very low density lipoproteins, trimethylamine, and choline were significantly decreased in the plasma of all three models. Metabolites including glucose, choline, glycerophosphocholine, and various lipids were significantly reduced, while acetoacetate, d-3-hydroxybutyrate and trimethylamine-N-oxide levels were increased in DR compared to ad libitum fed controls. Plasma lipids and glycerophosphocholine were also decreased in Irs1(-/-) mice compared to controls, as were methionine and citrate. In contrast, high density lipoproteins and glycerophosphocholine were increased in Ames dwarf mice, as were methionine and citrate. Pairwise comparisons indicated that differences existed between the metabotypes of the different long-lived mice models. Irs1(-/-) mice, for example, had elevated glucose, acetate, acetone, and creatine but lower methionine relative to DR mice and Ames dwarfs. Our study identified several potential candidate biomarkers directionally altered across all three models that may be predictive of longevity but also identified differences in the metabolic signatures. This comparative approach suggests that the metabolic networks underlying lifespan extension may not be exactly the same for each model of longevity and is consistent with multifactorial control of the aging process."

LOWER LDL FROM AN EARLY AGE IS BETTER FOR LONG TERM HEALTH
Tuesday, March 27, 2012
http://www.fightaging.org/archives/2012/03/lower-ldl-from-an-early-age-is-better-for-long-term-health.php
Some people have an objectively better metabolism than others when it comes to longevity - perhaps better mitochondrial DNA, perhaps less LDL cholesterol, for example: "Coronary atherosclerosis - a hardening of the arteries due to a build-up of fat and cholesterol - can lead to heart attacks and other forms of coronary heart disease (CHD). Lowering low-density lipoprotein (LDL), or 'bad' cholesterol, reduces the risk of CHD ... By the time most people begin treatment to lower LDL, CHD has often been quietly developing for decades. Because coronary atherosclerosis begins early in life, lowering LDL at a younger age may produce even greater reductions in the risk of CHD. Researchers sought to test this hypothesis by using genetic data to conduct a series of 'natural' randomized controlled trials involving over one million study participants. ... researchers used a novel study design called a Mendelian randomized controlled trial (mRCT) to study the effect of nine single-nucleotide polymorphisms (SNPs), or single-letter changes in DNA sequence, each of which is associated with lower levels of LDL cholesterol. Because each of these SNPs is allocated randomly at the time of conception, inheriting one of these SNPs is like being randomly allocated to a treatment that lowers LDL cholesterol beginning at birth. The researchers found that all nine SNPs were associated with a consistent 50-60 percent reduction in the risk of CHD for each 1 mmol/L (38.67 mg/dl) lower lifetime exposure to LDL cholesterol. "

CD47 AS A POTENTIAL TARGET FOR MANY CANCERS
Tuesday, March 27, 2012
http://www.fightaging.org/archives/2012/03/cd47-as-a-potential-target-for-many-cancers.php
Commonalities between many different forms of cancers will become increasingly important as biotechnology offers the ability to target them. They offer the prospect of a simplifying of cancer research and development, and far more cost-effective therapies - the big question is to what degree they exist at all: "A decade ago, biologist Irving Weissman [discovered] that leukemia cells produce higher levels of a protein called CD47 than do healthy cells. CD47, he and other scientists found, is also displayed on healthy blood cells; it's a marker that blocks the immune system from destroying them as they circulate. Cancers take advantage of this flag to trick the immune system into ignoring them. In the past few years, Weissman's lab showed that blocking CD47 with an antibody cured some cases of lymphomas and leukemias in mice by stimulating the immune system to recognize the cancer cells as invaders. Now, he and colleagues have shown that the CD47-blocking antibody may have a far wider impact than just blood cancers. ... What we've shown is that CD47 isn't just important on leukemias and lymphomas. It's on every single human primary tumor that we tested. ... Moreover, Weissman's lab found that cancer cells always had higher levels of CD47 than did healthy cells. How much CD47 a tumor made could predict the survival odds of a patient. ... To determine whether blocking CD47 was beneficial, the scientists exposed tumor cells to macrophages, a type of immune cell, and anti-CD47 molecules in petri dishes. Without the drug, the macrophages ignored the cancerous cells. But when the CD47 was present, the macrophages engulfed and destroyed cancer cells from all tumor types. Next, the team transplanted human tumors into the feet of mice, where tumors can be easily monitored. When they treated the rodents with anti-CD47, the tumors shrank and did not spread to the rest of the body. In mice given human bladder cancer tumors, for example, 10 of 10 untreated mice had cancer that spread to their lymph nodes. Only one of 10 mice treated with anti-CD47 had a lymph node with signs of cancer. Moreover, the implanted tumor often got smaller after treatment."

A REPORT ON HAIR REPIGMENTATION
Monday, March 26, 2012
http://www.fightaging.org/archives/2012/03/a-report-on-hair-repigmentation.php
Hair color - and loss - is one of the aspects of aging that people care about too much in comparison to its effects on health. There are far more important degenerations to consider. Nonetheless, here is a report suggesting that better control over the cell signaling could restore lost hair color by directing pigment cells to get back to work: "We report the first case of progressive hair repigmentation associated with the use of lenalidomide in an elderly patient with multiple myeloma. The influence of lenalidomide on follicular melanogenesis may involve removing the inhibitory influences of some cytokines such as IL-1, IL-6 and TNF-α. In addition, certain endocrine effects of lenalidomide on the hypophyseal-adrenal axis could explain its action on hair pigmentation. We further hypothesize that lenalidomide may be capable of stimulating migration and/or differentiation of melanocytes to promote repigmentation of gray hair follicles. Pending the clarification of how hair repigmentation occurs with lenalidomide, our observation materializes the concept that hair graying may not be an irreversible process." This sort of brute force approach is, however, far less desirable than working to fix the underlying levels of cellular damage that lead to changed signaling and the decline of melanocyte activity in the first place.

AGE HAS LITTLE IMPACT ON THE VIABILITY OF A DONOR KIDNEY
Monday, March 26, 2012
http://www.fightaging.org/archives/2012/03/age-has-little-impact-on-the-viability-of-a-donor-kidney.php
This research should be added to that showing that failure of systems in the body, such as stem cells, is as much a consequence of the overall bodily environment and the biochemical signals it generates as it is damage to the systems specifically: "People with kidney failure may think that they're better off getting a new kidney from a young and spry donor, but a recent study indicates that for those over 39 years old, the age of a live donor - ranging from 18 to 64 years - has an insignificant effect on the long-term health of a transplanted kidney. ... [Researchers] analyzed the survival of kidneys from donors of different age groups that were transplanted into recipients of different age groups. Their study included data from all adult kidney transplants from living donors that were performed in the United States from January 1988 to December 2003, with follow-up through September 2007. With the exception of recipients aged 18 to 39 years, who benefited the most when they received kidneys from donors aged 18 to 39 years, donor age between 18 and 64 years had minimal effect on the survival of transplanted kidneys. ... many patients will likely find that participating in living donor paired exchanges - and possibly receiving a kidney from an older-aged donor - is a better option than continuing to wait for a deceased donor transplant."

______________________________


View the full article

Click HERE to rent this BIOSCIENCE adspot to support LongeCity (this will replace the google ad above).

#3 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 08 April 2012 - 04:43 PM

FIGHT AGING! NEWSLETTER
April 9th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- SENS Foundation 2011 Research Report Released
- Volunteers Wanted for the SENS Foundation Academic Initiative
- A Histogram of Results from Life Span Studies
- Spurring Stem Cells to Rebuild Cartilage
- Discussion
- Latest Headlines from Fight Aging!

SENS FOUNDATION 2011 RESEARCH REPORT RELEASED

As a companion to the 2011 annual report, the SENS Foundation released their 2011 research report this past week. It goes into much more depth on the laboratory work and results: the foundations for future rejuvenation biotechnology capable of repairing the damage of aging.

http://www.fightaging.org/archives/2012/04/sens-foundation-2011-research-report.php

"The subtitle on our logo banner reads 'advancing rejuvenation biotechnologies', and in keeping with the dynamic connotations of that statement, we've spent 2011 engaged in focused, concrete actions toward embodying it. ... We're excited to be a part of this revolution in scientific innovation, grateful to everyone who has supported us through their generous gifts of time and funding, and delighted to have multiple exciting developments to report on the research front. ... There is a lot of material in the report, and I encourage you to read the whole thing - it's very approachable for the layperson, and a good way to obtain a top to bottom view of the Foundation's research strategy at present. That more or less encompasses these questions: what exactly causes aging, and what can be done here and now to make progress towards preventing it and reversing it? For example, here's an excerpt from the GlycoSENS category, research with the potential to reverse the cause of much of the chemical and structural aging of skin, blood vessel walls, and many forms of connective tissue:

"The elasticity of the artery wall, the flexibility of the lens of the eye, and the high tensile strength of the ligaments are examples of tissues that rely on maintaining their proper structure. But chemical reactions with other molecules in the extracellular space occasionally result in a chemical bond (a so-called crosslink) between two nearby proteins that were previously free-moving, impairing their ability to slide across or along each other and thereby impairing function. It is the goal of this project to identify chemicals that can react with these crosslinks and break them without reacting with anything that we don't want to break. ... In 2011, we established a Center of Excellence for GlycoSENS and other rejuvenation research at Cambridge University and hired postdoctoral student Rhian Grainger to design and perform experiments to develop reagents that can detect proteins bearing glucosepane crosslinks, facilitating further studies on its structure, abundance, and cleavage by small molecules. We also established a collaboration with researchers at Yale University, who will lend their expertise in generating advanced glycation end-products and lead efforts in developing agents which may be able to cleave glucosepane."

VOLUNTEERS WANTED FOR THE SENS FOUNDATION ACADEMIC INITIATIVE

A portion of the work of the SENS Foundation is directed towards ensuring that the life science community of tomorrow is more focused on longevity science than the community of today. The project of building the SENS vision of rejuvenation biotechnology will stretch over decades, and life science students presently earning their degrees will be the ones to perform the bulk of the work, with careers focused on the defeat of aging:

http://www.fightaging.org/archives/2012/04/volunteers-wanted-for-the-sens-foundation-academic-initiative.php

"Are you studying for a life science or biotechnology degree, teaching students, or otherwise a part of the academic life science community? Do you have an interest in helping to advance longevity science and the development of cures for the diseases of aging? The SENS Foundation Academic Initiative is looking for volunteers to help with their growth in funding and interest: Over the last few months, the SENS Foundation Academic Initiative has witnessed a rapid increase in its membership numbers, and in the interest it receives from students across the United States and the world. In order to properly utilize and expand upon this interest, the Initiative will need new volunteers, new ideas, and new projects. For this reason, the Academic Initiative is seeking additional volunteers to help it fulfill its purpose: specifically, to help the Initiative craft itself into an organization capable of launching a legitimate grassroots youth movement in support of SENS Foundation. To join us in this mission, you can either fill out our brief online volunteer application or email Daniel Kimbel, the Academic Coordinator, at daniel dot kimbel at sens dot org. If you are interested in being involved, please don't hesitate to contact us. We can use volunteers from nearly any background.

"The Initiative is focused on the groundwork necessary to build tomorrow's rejuvenation biotechnology research community: people who will enter the workforce to repair mitochondria, build the ultimate cure for cancer, find ways to safely break down the aggregated proteins and crosslinks that cause age-related degeneration - and more. The defeat of aging through biotechnology is a program that will last for decades and radically transform the medical and life science communities along the way. Working with the SENS Foundation and the Academic Initiative is a way to get in on the ground floor of this grand venture, and build connections that will serve you well in future years. The Foundation stands at the center of a web of medical and biotechnology research, with labs and projects around the world, involving many of the most noteworthy researchers in their fields - this is what the beginning of a great revolution looks like, and the years ahead will see great change and great excitement."

A HISTOGRAM OF RESULTS FROM LIFE SPAN STUDIES

You may find this to be of interest - a graphical illustration of decades of work by scientists noting how to move the needle when it comes to altering life span in diverse species:

http://www.fightaging.org/archives/2012/04/a-histogram-of-results-from-life-span-studies.php

"Kingsley G. Morse Jr. is one of the regulars at the Gerontology Research Group mailing list. He maintains a spreadsheet of all the life span studies in various organisms that he has been able to find, and is generally willing to sell that data at white paper rates, should you happen to be interested. He recently posted a histogram assembled from the study results, which I'm sure you'll agree is interesting.

"The history of working to extend life in laboratory animals - and of studying effects on longevity and mortality in humans - is largely a big null result. Other than calorie restriction, the effects of which were first formally cataloged by scientists in the 1930s, all of the excitement shows up in the past twenty years or so. The successes are a tiny fraction of the studies that showed nothing, or showed a result well within the margin of error, or produced results that could not be replicated. In mammals, mostly mice, the bulk of studies that do extend life significantly fall in to the 15% to 30% life extension bracket - on a par with moderate to severe calorie restriction. Only a few methods have been demonstrated to reach beyond that point.

"To a large degree this is because near everything tried to date has been a form of metabolic manipulation - change the operation of metabolism to slow the effective rate at which damage accrues to the organism. I would be surprised to see any great improvement in the length of life lived by laboratory animals until the research community changes strategy to focus on actually repairing and reversing the cellular and molecular damage that causes aging. The difference between slowing aging and repairing aging will be as night and day when it comes to the practical results that can be achieved."

SPURRING STEM CELLS TO REBUILD CARTILAGE

Signs of progress in cartilage engineering achieved by directing existing cells in the body to undertake the work of repair that normally doesn't occur:

http://www.fightaging.org/archives/2012/04/spurring-stem-cells-to-rebuild-cartilage.php

"A small molecule dubbed kartogenin encourages stem cells to take on the characteristics of cells that make cartilage, a new study shows. And treatment with kartogenin allowed many mice with arthritis-like cartilage damage in a knee to regain the ability to use the joint without pain. ... The new approach taps into mesenchymal stem cells, which naturally reside in cartilage and give rise to cells that make connective tissue. These include chondrocytes, the only cells in the body that manufacture cartilage. 'In the blue-sky scenario, this would be a locally delivered therapy that would target stem cells already there,' says study coauthor Kristen Johnson, a molecular biologist at the Genomics Institute of the Novartis Research Foundation in San Diego. Johnson and her colleagues screened 22,000 compounds in cartilage and found that one, kartogenin, induced stem cells to take on the characteristics of chondrocytes. The molecule turned on genes that make cartilage components called aggrecan and collagen II. Tests of mice with cartilage damage similar to osteoarthritis showed that kartogenin injections lowered levels of a protein called cartilage oligomeric matrix protein. People with osteoarthritis have an excess of the protein, which is considered a marker of disease severity. Kartogenin also enabled mice with knee injuries to regain weight-bearing capacity on the joint within 42 days."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

RESTORING SOME YOUTHFUL GENE EXPRESSION LEVELS IN AN AGED LIVER
Friday, April 6, 2012
http://www.fightaging.org/archives/2012/04/restoring-some-youthful-gene-expression-levels-in-an-aged-liver.php
An interesting experiment, especially when compared with work on brain aging that focuses on levels of cell proliferation: "During the past decade, it has become increasingly clear that consistent changes in the levels of expression of a small cohort of genes accompany the aging of mammalian tissues. In many cases, these changes have been shown to generate features that are characteristic of the senescent phenotype. Previously, a small pilot study indicated that some of these changes might be reversed in rat liver, if the liver cells became malignant and were proliferating. The present study has tested the hypothesis that inducing proliferation in old rat liver can reset the levels of expression of these age-related genes to that observed in young tissue. A microarray approach was used to identify genes that exhibited the greatest changes in their expression during aging. The levels of expression of these markers were then examined in transcriptomes of both proliferating hepatomas from old animals and old rat liver lobes that had regenerated after partial hepatectomy but were again quiescent. We have found evidence that over 20% of the aging-related genes had their levels of expression reset to young levels by stimulating proliferation, even in cells that had undergone a limited number of cell cycles and then become quiescent again. Moreover, our network analysis [may] provide insights into mechanisms involved in longevity and regeneration that are distinct from cancer."

GROWING STEM CELLS INTO LUNG TISSUE
Friday, April 6, 2012
http://www.fightaging.org/archives/2012/04/growing-stem-cells-into-lung-tissue.php
An example of work that lays the foundations for lung tissue engineering, which has been lagging behind advances for other organs: "How do you grow stem cells into lungs? The question has puzzled scientists for years. First you need the right recipe, and it took [researchers] seven years of trial and error and painstaking science to come up with it. ... Some tissues, like muscle and nerves, are relatively easy to grow, but others, including liver, lung, thyroid, and pancreas, have been much more difficult. These troublesome tissues all spring from the endoderm, the innermost layer of an early embryo. The endoderm forms when an embryo is about three weeks old and differentiates into organs as early as five weeks. Somehow, in these two weeks the endoderm transforms into differentiated organs as diverse as the lungs and the stomach. ... [Researchers] decided to create a knock-in reporter gene that would glow green during the 'fate decision' - the moment when the stem cells expressed a gene called Nkx2-1 and thereby took a step toward becoming lungs. This allowed the team to track the cells as they developed, mapping each of the six critical decisions on the path to lung tissue. ... Once [the] team had grown what appeared to be lung cells, they had to make sure they had the recipe right. They took samples of mouse lungs and rinsed them with detergent until they became cell-free lung-shaped scaffolds. They seeded one lung with 15-day-old homegrown lung cells that they had purified from stem cells. As a control, they seeded another lung with undifferentiated embryonic stem cells. Within 10 days after seeding, the lung cells organized themselves and populated the lung, creating a pattern recognizable [as] lung tissue. ... A happy side effect of the discovery was that the scientists also mapped out the road from stem cell to thyroid. [The] thyroid, it turns out, also comes from the endoderm layer, deriving from a progenitor that expresses the same key gene as lung progenitors. [The] work will likely have a huge impact on lung stem cell researchers, who have been waiting for a discovery like this to propel their research on inherited lung disease."

BUILDING INSULIN-PRODUCING PANCREATIC CELL CLUSTERS
Thursday, April 5, 2012
http://www.fightaging.org/archives/2012/04/building-insulin-producing-pancreatic-cell-clusters.php
Progress in the tissue engineering of cell structures for use as research tools, and later as the basis for therapies: "Three-dimensional clusters of pancreatic beta-cells that live much longer and secrete more insulin than single cells grown in the laboratory are valuable new tools for studying pancreatic diseases such as diabetes and for testing novel therapies. This cutting-edge advance is described in [an open access paper] ... Finding a solution for the culturing and final transplantation of pancreatic cells will be an enormous breakthrough for the treatment of diabetes ... Growing pancreatic cells in the laboratory is challenging, in part because to survive and function normally they require cell-cell contact. [Researchers] developed an innovative method that uses photolithography to create microwell cell culture environments that support the formation of 3-D pancreatic beta-cell clusters and control the size of the cell aggregates. They describe the ability to remove these cell clusters from the microwells and encapsulate them in hydrogels for subsequent testing or implantation."

LINKING AUTOIMMUNITY AND ATHEROSCLEROSIS VIA INFLAMMATORY PROCESSES
Thursday, April 5, 2012
http://www.fightaging.org/archives/2012/04/linking-autoimmunity-and-atherosclerosis-via-inflammatory-processes.php
Via ScienceDaily: "Individuals who suffer from autoimmune diseases also display a tendency to develop atherosclerosis - the condition popularly known as hardening of the arteries. Clinical researchers [have] now discovered a mechanism which helps to explain the connection between the two types of disorder. The link is provided by a specific class of immune cells called plasmacytoid dendritic cells (pDCs). ... Using laboratory mice as an experimental model, the researchers were able to show that pDCs contribute to early steps in the formation of athersclerotic lesions in the blood vessels. Stimulation of pDCs causes them to secrete large amounts of interferons, proteins that strongly stimulate inflammatory processes. The protein that induces the release of interferons is produced by immune cells that accumulate specifically at sites of inflammation, and mice that are unable to produce this protein also have fewer plaques. Stimulation of pDCs in turn leads to an increase in the numbers of macrophages present in plaques. Macrophages normally act as a clean-up crew, removing cell debris and fatty deposits by ingesting and degrading them. However, they can also 'overindulge,' taking up more fat than they can digest. When this happens, they turn into so-called foam cells that promote rather than combat atherosclerosis. In addition, activated, mature pDCs can initiate an immune response against certain molecules found in atherosclerotic lesions, which further exacerbates the whole process. ... The newly discovered involvement of pDCs in the development of atherosclerosis [reveals] why the stimulation of pDC that is characteristic of autoimmune diseases contributes to the progression of atherosclerosis. The findings also suggest new approaches to the treatment of chronic inflammation that could be useful for a whole range of diseases."

CALORIE RESTRICTION AND LONGEVITY
Wednesday, April 4, 2012
http://www.fightaging.org/archives/2012/04/calorie-restriction-and-longevity.php
An introduction to calorie restriction at h+ Magazine: "In the early twentieth century nutrition researchers found that rats maintained on reduced caloric intake showed lower spontaneous tumors compared to rats fed ad libitum (allowed to eat as much as they chose). Although this work did not address caloric restriction (CR) and aging, it suggested that CR might slow the onset of age-associated disease in rodents. ... Numerous follow-up studies demonstrated that a micronutrient adequate CR diet significantly increased the lifespan of many species, largely crossing species boundaries. ... While CR increases the lifespans of most species examined, it also suppresses many of the diseases associated with human aging, thus increasing the 'health-span.' Over short periods, CR lowers blood pressure, heart rate, and glucose levels, and improves memory in older individuals and measures of cognitive performance in animals. Over longer periods CR significantly reduces the risk for many different types of cancer, age-related brain atrophy, heart disease (and atherosclerosis related diseases), autoimmune disease, and adult onset diabetes. CR appears to lessen the risk for, and attenuates or even reverses the symptoms of Alzheimer's and possibly Parkinson's diseases; two major age-related neurodegenerative diseases that cause enormous human suffering. ... Interestingly, CR appears to promote the progression of Amyotrophic Lateral Sclerosis (Lou Gehrig's disease), indicating it does not protect from all human diseases. Aging causes extensive, often organ-specific changes in gene expression patterns. Analysis [has] shown that aging, calorically restricted mice show gene expression patterns resembling those of young animals, compared to ad libitum-fed mice of the same age. CR also lowers cellular oxidative damage by reducing mitochondrial oxygen free radical production, lessens age-related telomere shortening, lowers inflammation, increases DNA damage repair efficiency and lowers damage to DNA and RNA (thus promoting genomic stability), lowers insulin levels while promoting insulin sensitivity, reduces the number of senescent (non-dividing) cells that accumulate with aging, attenuates age-related cellular protein cross-linking, and increases the removal of damaged cellular proteins - a process called 'autophagy' which declines with age and plays a role in resistance to infection, cancer, heart disease, and neurodegeneration. "

CAN NEURAL STEM CELLS ADDRESS COGNITIVE DECLINE?
Wednesday, April 4, 2012
http://www.fightaging.org/archives/2012/04/can-neural-stem-cells-address-cognitive-decline.php
An open access review paper: "Several studies suggest that an increase in adult neurogenesis has beneficial effects on emotional behavior and cognitive performance including learning and memory. The observation that aging has a negative effect on the proliferation of neural stem cells has prompted several laboratories to investigate new systems to artificially increase neurogenesis in senescent animals as a means to compensate for age-related cognitive decline. ... recent evidences indicate that the relative abundance of stem cells in certain organs does not necessarily correlate with their impact on organ function. Specifically, the mammalian brain is perhaps the organ with the lowest regenerative potential but the one in which the signs of aging are more manifested. Using the words of the renaissance writer Michel de Montaigne, 'age imprints more wrinkles on the mind than it does on the face' indicating that age-related cognitive decline has the highest impact on the quality of life. To which extent this decline is dependent on neural stem and progenitor cells (together referred to as NSCs) is hard to tell but growing evidences indicate that, despite their negligible numbers, the few resident NSCs that are located in specific brain regions, most notably the subgranular zone of the hippocampus, seem to play a major role in cognitive functions such as learning, memory, and emotional behavior by generating, through intermediate progenitors, neurons that are constantly added to the brain circuitry throughout life. ... the available data strongly suggests that aging almost exclusively acts at the level of NSC proliferation. Yet, the many contradicting results and uncertainties on identifying the exact causes of this 'decreased proliferation' [need] to be fully acknowledged in order to give a rigorous and meaningful direction to this relatively new field. ... The fact that NSCs can efficiently respond to physiological and pathological stimuli to increase neurogenesis indicates that stimulation of endogenous NSCs offers a promising alternative to transplantation approaches that until now were intensely investigated."

WORK ON REVERSING SCAR TISSUE IN THE HEART
Tuesday, April 3, 2012
http://www.fightaging.org/archives/2012/04/work-on-reversing-scar-tissue-in-the-heart.php
A look at some of the research aimed at reversing the damage caused by heart attacks: "Our ultimate hope is that, during the acute period following myocardial infarction (MI), patients will be able to receive direct injections of factors that transform the existing fibroblast cells in the 'scar' into new myocytes. The resulting increase in muscle mass should help MI survivors to live more normal lives. ... When heart muscle cells become injured and die following an MI, patients have the major problem that these cells have little or no capacity for regeneration. ... Part of the process of remodelling that occurs following the injury is that fibroblast cells migrate to the site and create the scar. ... The process at first can be considered beneficial since without fibroblasts adding structural support damaged hearts would rupture. But later difficulties arise when the fibrotic scar doesn't contract like the muscle it has replaced. Reduced global contractility means the heart has to work much harder, and the extra stress can ultimately lead to heart failure and even death. ... One of the Holy Grails of cardiovascular research has been to replace these lost myocytes and return functionality to the heart. Some of the first approaches to be investigated were the introduction of stem or progenitor cells to the sites of injury. ... But many hurdles have been encountered including getting cells to integrate with neighbouring cells in the heart, and there have been concerns that residual 'rogue' cells could persist with the potential to keep dividing and give rise to tumours. Harnessing the vast reservoir of fibroblasts already present in the heart, we felt, could overcome many of these issues. They've the big advantage they're already present in the organ and closely integrated with neighbouring cells. ... the team were able to identify three [genes] Gata4, Mef2c, and Tbx5 that could convert fibroblasts taken from the hearts of adult mice into new myocytes. ... In the second part of the study, the team injected fibroblasts that already had the three genes inserted directly into the scar tissue of mice. They were able to show the fibroblasts differentiated into cardiomyocyte-like cells. ... The fibroblasts converted into cells with nice patterns of striations, typical of myocytes, and developed units that could generate force. ... In the latest study [they] have been able to take the process one step further by injecting a viral vector encoding the genes for Gata4, Mef2c, and Tbx5 directly into the scar tissue of mice who had just experienced an MI. ... With these studies we've obtained even better results showing that the fibroblasts become more like cardiomyocytes and functionally couple with their neighbours. They could beat in synchrony and improve the function of the heart."

INTERVENING IN THE MECHANISMS OF MEMORY LOST TO AGING
Tuesday, April 3, 2012
http://www.fightaging.org/archives/2012/04/intervening-in-the-mechanisms-of-memory-lost-to-aging.php
Via ScienceDaily: scientists "have shown in animal models that the loss of memory that comes with aging is not necessarily a permanent thing. ... [Researchers] took a close look at memory and memory traces in the brains of both young and old fruit flies. What they found is that like other organisms - from mice to humans - there is a defect that occurs in memory with aging. In the case of the fruit fly, the ability to form memories lasting a few hours (intermediate-term memory) is lost due to age-related impairment of the function of certain neurons. Intriguingly, the scientists found that stimulating those same neurons can reverse these age-related memory defects. ... This study shows that once the appropriate neurons are identified in people, in principle at least, one could potentially develop drugs to hit those neurons and rescue those memories affected by the aging process. In addition, the biochemistry underlying memory formation in fruit flies is remarkably conserved with that in humans so that everything we learn about memory formation in flies is likely applicable to human memory and the disorders of human memory. ... Olfactory memory, which was used by the scientists, is the most widely studied form of memory in fruit flies - basically pairing an odor with a mild electric shock. These tactics produce short-term memories that persist for around a half-hour, intermediate-term memory that lasts a few hours, and long-term memory that persists for days. The team found that in aged animals, the signs of encoded memory were absent after a few hours. In that way, the scientists also learned exactly which neurons in the fly are altered by aging to produce intermediate-term memory impairment. ... the scientists took the work a step further and stimulated these neurons to see if the memory could be rescued. To do this, the scientists placed either cold-activated or heat-activated ion channels in the neurons known to become defective with aging and then used cold or heat to stimulate them. In both cases, the intermediate-term memory was successfully rescued."

IMMUNE THERAPIES TO REDUCE ATHEROSCLEROSIS
Monday, April 2, 2012
http://www.fightaging.org/archives/2012/04/immune-therapies-to-reduce-atherosclerosis.php
Via EurekAlert!: "injecting cardiovascular disease (CVD) patients with vaccines and monoclonal antibodies to combat atherosclerosis could soon change the treatment landscape of heart disease. Both approaches [can] be considered truly ground breaking since for the first time they target the underlying cause of CVD. ... with phase 2a trials on recombinant antibodies currently ongoing, [such] treatments could soon become a clinical reality. ... If all goes well, the first in class of these treatments could be licensed within four to five years ... Established therapies against atherosclerosis almost exclusively focus on risk factor modification - that is reduction of dyslipidaemia, hypertension and hyperglycaemia. ... It was in the early 1990s that identification of antibodies against oxidised low density lipoproteins (LDL) in artery plaques, first gave rise to the concept that CVD might be an autoimmune disease where the immune system attacks oxidised LDL. ... Since it is impractical to develop vaccines based on oxidised LDL (due to difficulty of standardising the particle) [researchers] looked to identify structures within the oxidised LDL that triggered the desired protective response. ... The team were able to identify three [peptides], which when formulated with a carrier and adjuvant, reduced development of atherosclerosis in mice by 60 to 70%. ... Further along the development pathway, and already in clinical trials, is an altogether different immune approach involving injection of antibodies directly targeting oxidised LDL. ... The rationale is that since oxidised LDL plays a major role in the development of atherosclerotic plaques and harmful inflammatory processes, directly targeting oxidised LDL should prevent plaque formation and reduce inflammation ... Preclinical studies show that administration of the BI-204 monoclonal antibody [reduced] the formation of atherosclerotic plaques and plaques already present by 50%. In the phase I study, which took place in 80 healthy volunteers with elevated levels of LDL, BI-204 was found to be safe and well tolerated. Now for the current phase 2a double blind [study], BI-204 is being delivered intravenously to 144 patients with stable coronary artery disease in addition to standard care."

THE EARLY DEVELOPMENT OF SYNTHETIC CELLS
Monday, April 2, 2012
http://www.fightaging.org/archives/2012/04/the-early-development-of-synthetic-cells.php
Artificial cells will be useful tools in the medicine of tomorrow: "Daniel Hammer, professor of chemical engineering and biological engineering at the University of Pennsylvania, is building white blood cells in the lab from plastics that can act as artificial cell walls. Think of a gel capsule of your preferred headache medicine but on a much smaller scale and with a programmable molecular brain. These synthetic cells, known as leuko-polymersomes, could one day deliver the latest cancer-killing drugs directly to a tumor or send out a chemical beacon that signals natural white blood cells to come and join the fight against a disease. ... Ultimately I think that we could program these cells to do things that we never thought white blood cells could do ... Instead of boosting immune response, for example, Hammer envisions synthetic cells that could act as inhibitors to the body's defenses, providing relief for people suffering from autoimmune disorders. Hammer has been studying how to turn plastics into cellular structures for more than a decade, but it's just in the past few years that the field has kicked into high gear. His team is learning to mimic the targeting capabilities that let natural white blood cells take the fight to viruses and bacteria - what Hammer describes as a kind of 'molecular zip coding' - and the adhesive properties that let them stand their ground when they arrive. In 2010, Hammer and colleagues from Duke University designed synthetic molecules shaped like the receptors white blood cells use to find and adhere to inflamed tissue. In-vitro tests showed that synthetic cells could seek out inflamed tissue and stick to it once they arrived."

______________________________


View the full article

#4 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 15 April 2012 - 05:33 PM

FIGHT AGING! NEWSLETTER
April 16th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- SENS5 Video: Increased Damage to Proteins in Aging
- Revisiting Resveratrol and the Big Red Lever
- From the Mainstream: Old Age is not for Sissies
- No Genetic Longevity-Cancer Balance for Humans?
- Discussion
- Latest Headlines from Fight Aging!

SENS5 VIDEO: INCREASED DAMAGE TO PROTEINS IN AGING

Another video from the SENS5 conference is posted online:

http://www.fightaging.org/archives/2012/04/sens5-video-increased-damage-to-proteins-in-aging.php

"At its simplest, aging is nothing more than damage and the flailing of adaptive systems that try and fail to cope with operating while damaged. The damage of aging comes in a variety of forms, but much of it involves broken proteins. Proteins are the cogs and wheels of cellular machinery, intricate assemblies of atoms encoded in your DNA and tailored by evolution to specific roles. The inside of any cell is a madhouse of flowing material and chemical reactions, however, not all of them benign. There is constant turnover as proteins are damaged, recycled, and replaced, some more often than others. In this dynamic environment of wear and repair, it takes decades for forms of damage to begin to overwhelm the recycling machinery, but the downward slide only gets faster with time."

REVISITING RESVERATROL AND THE BIG RED LEVER

The hype machines that accompany research that produces something the supplement industry can latch onto and sell are predictable. Don't fall for it next time:

http://www.fightaging.org/archives/2012/04/resveratrol-and-the-big-red-lever-revisited.php

"Our metabolic biochemistry looks like a big wall full of levers. Some of them are painted red, and we think we understand what the instructions beneath these red levers say. Maybe. How much information do you feel you would like before you pull the big red levers in your own personal metabolism? What level of risk due to disease would you presently need to be suffering in order to take the risk represented by a new compound? How do you evaluate these levels of risk?

"Resveratrol has turned out, almost predictably, to be another heaped mound of hype that buries a modest kernel of interesting-but-not-terribly-applicable metabolic research. At this stage it seems fairly certain that resveratrol does not extend life in mammals to any great degree - when you find compounds that can do that, there is little uncertainty once the life span studies are in and replicated. See the past couple of years of work on rapamycin in mice as a contrasting example to the uncertainty and lack of verifiable effects for resveratrol and its derived compounds.

"The sensible thing to do whenever another of these oral-fixation ingested substance hype machines emerges from the juncture of the scientific and business worlds is to balance the purported results against the clear, proven, and solid benefits of exercise and calorie restriction. The risks in moderate exercise and calorie restriction are minimal, while the evidence for great benefit to long-term health is gold-plated and voluminous. When someone is trying to convince you to spend money on something that seems unlikely to produce even a pale shadow of the health benefits of either exercise or calorie restriction, and has largely unknown long term risks - then why even try? It just doesn't make sense.

"The research community, and just as importantly the public at large, needs to move beyond their enthusiasm for metabolic manipulation through ingested substances as a path to extending healthy life. It's a grand example of looking for the lost keys under the lamp post - doing something just because it's easier and the path of least resistance, regardless of the likelihood of significant results at the end of the day. Real progress towards longer lives is only going to come through building medical technology capable of repair and rejuvenation at the level cells, organs, and systems within the body: very specific biotechnologies engineered to perform very specific jobs within and around cell structures, and aim to exactly reverse aging by doing so. That couldn't possibly be further removed from the present dominant strategy of mining the natural world for compounds that might or might not cause more minor benefits than minor disadvantages."

FROM THE MAINSTREAM: OLD AGE IS NOT FOR SISSIES

A piece from the heads of the Alliance for Aging Research and the Buck Institute for Research on Aging:

http://www.fightaging.org/archives/2012/04/a-view-from-the-mainstream-old-age-is-not-for-sissies.php

"Bette Davis was right - old age is not for sissies. One hundred years ago most of us didn't have the luxury of old age. Today, life expectancy is almost 80 years. But while we've gotten very good at adding life-years, we've yet to master how to keep those years healthy and vigorous. Eighty percent of seniors have at least one major chronic condition and half have two or more. Chronic diseases of later life are costing the nation more than $1 trillion per year - a figure expected to increase to $6 trillion by the middle of this century.

"Scientists who study aging are in general agreement that the process isn't set in stone - the aging process can be sped up by genetics or poor lifestyle choices, but it can also be slowed down. With sufficient funding and focus, research that slows aging has the potential to do what no drug, surgical procedure, or behavior modification can do - add healthy years of life, and simultaneously postpone the costly and harmful conditions of old age.

"Age is the common denominator and number one risk factor to virtually every chronic disease we face. Scientists know that alterations in cell replacement and repair, stress response, and inflammation are the key influencers to the development of cancer, heart disease, diabetes, and other debilitating (and costly) conditions later in life. These are also the essential changes taking place in our aging bodies."

NO GENETIC LONGEVITY-CANCER BALANCE FOR HUMANS?

Work in laboratory animals has strongly suggested that cancer risk and longevity trade off against one another. A simplistic way of looking at it is this: if your stem cells are active enough to keep your tissues running well for longer, then they are also active enough to be at greater risk of producing a cancerous mutation. A recent twin study suggests that the genetics of the situation might not work that way for we humans:

http://www.fightaging.org/archives/2012/04/no-longevity-cancer-balance-for-natural-variations-in-human-lifespan.php

"Animal models and a few human studies have suggested a complex interaction between cancer risk and longevity indicating a trade-off where low cancer risk is associated with accelerating aging phenotypes and, vice versa, that longevity potential comes with the cost of increased cancer risk. This hypothesis predicts that longevity in one twin is associated with increased cancer risk in the cotwin. ... A total of 4,354 twin pairs born 1900-1918 in Denmark were followed for mortality in the Danish Civil Registration System through 2008 and for cancer incidence in the period 1943-2008 through the Danish Cancer Registry. ... The 8,139 twins who provided risk time for cancer occurrence entered the study between ages 24 and 43 (mean 33 years), and each participant was followed up to death, emigration, or at least 90 years of age. The total follow-up time was 353,410 person-years and 2,524 cancers were diagnosed. ... This study did not find evidence of a cancer-longevity trade-off in humans. On the contrary, it suggested that longevity in one twin is associated with lower cancer incidence in the cotwin, indicating familial factors associated with both low cancer occurrence and longevity."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

EFFICIENT TRANSDIFFERENTIATION OF SKIN CELLS TO NERVE CELLS
Friday, April 13, 2012
http://www.fightaging.org/archives/2012/04/efficient-transdifferentiation-of-skin-cells-to-nerve-cells.php
Transdifferentiation is showing up more often of late - the ability to switch somatic cells directly between types without having to go through an intermediate stage of reprogramming into stem cells. It should in theory make obtaining specific cells for research and therapy a cheaper and more reliable process in the future: "it has become possible to directly convert cells of the body into one another - without the time-consuming detour via a pluripotent intermediate stage. However, this method has so far been rather inefficient. [Scientists] have now developed the method to the point that it can be used for biomedical applications. ... [Researchers] are interested in the biomedical utilization of artificially produced human nerve cells for disease research, cell replacement, and the development of active substances. ... By blocking the so-called SMAD signaling pathway and inhibiting glycogen synthase kinase 3 beta (GSK3ß), they increased the transformational efficiency [of skin cells to neurons] by several times - and were thus able to even simplify the means of extraction. Using only two instead of previously three transcription factors and three active substances, [the] researchers were able to convert a majority [of] skin cells into neurons. In the end, their cell cultures contained up to more than 80% human neurons. ... We were able to demonstrate how the genes typical for skin fibroblast were gradually down-regulated and nerve-cell-specific genes were activated during the cell transformation. In addition, the nerve cells thus obtained were functionally active, which also makes them interesting as a source for cell replacement."

WHITE MATTER PATHWAYS AND COPING WITH THE UNFAMILIAR
Friday, April 13, 2012
http://www.fightaging.org/archives/2012/04/white-matter-pathways-and-coping-with-the-unfamiliar.php
As time progresses, researchers are increasingly able to correlate changing mental characteristics in aging with changing structure in the brain. Here is one example: "A brain-mapping study [has] found that people's ability to make decisions in novel situations decreases with age and is associated with a reduction in the integrity of two specific white-matter pathways that connect an area in the cerebral cortex called the medial prefrontal cortex with two other areas deeper in the brain. Grey matter is the part of the brain that contains the bodies of the neurons while white matter contains the cable-like axons that carry signals from one part of the brain to another. In the past, most brain-imaging research has concentrated on the grey matter. Recently, however, neuroscientists have begun looking more closely at white matter. It has been linked to the brain's processing speed and attention span, among other things, but this is the first study to link white matter to learning and decision making. ... The evidence that this decline in decision-making is associated with white-matter integrity suggests that there may be effective ways to intervene. Several studies have shown that white-matter connections can be strengthened by specific forms of cognitive training. ... The critical white-matter connections that the experiment identified run from the thalamus, a highly connected relay center in the brain, to the medial prefrontal cortex, an area of the brain involved with decision making, and from the medial prefrontal cortex to the ventral striatum, which is associated with the emotional and motivational aspects of behavior." You might also look at past research on age-related damage to white matter and its consequences on metal capacity.

ON THE STATE OF CANCER STEM CELL RESEARCH
Thursday, April 12, 2012
http://www.fightaging.org/archives/2012/04/on-the-state-of-cancer-stem-cell-research.php
An article from the Scientist: "Based on new intelligence, oncologists are making informed battle plans to attack a particularly pernicious enemy - the cancer stem cell (CSC). Controversial though they are, cancer stem cells are an incredibly promising target. If treatment-resistant cancer, and the metastases that transplant the cancer throughout the body, could be attributed to the actions of a single cell type, it could explain many of the treatment failures and provide a novel way to attack the disease. The idea that cancers are driven by cells with 'embryonic features' is an old one. Many cancers regress to a less differentiated state, expressing proteins that are usually expressed only in the embryo or during early development. It is only in the past 20 years or so, however, that additional observations led to the hypothesis that these embryonic-like cells were a separate subpopulation that fueled tumor expansion, much the same way that stem cells churn out the cells that make up a particular organ. ... In the past 5 years there has been an exponential increase in CSC research. This research has helped to resolve a number of controversies regarding identification of these cells and their role in driving tumor growth and mediating treatment resistance. Despite these advances, the CSC field is still in its relative infancy, and many questions and challenges remain. More than a dozen biotechnology and pharmaceutical companies are now vigorously pursuing CSC research. As a result, a number of early-phase clinical trials targeting CSCs are in progress. These studies and the later-stage efficacy trials that follow them should indicate whether successful targeting of CSCs significantly improves outcomes in cancer patients. If this is found to be the case, it may usher in the beginning of a new era of cancer therapy."

LONGEVITY RISK
Thursday, April 12, 2012
http://www.fightaging.org/archives/2012/04/longevity-risk.php
A look at why, in this age of biotechnology and great uncertainty over the degree to which life spans will be extended in the next few decades, it is unwise to trust your financial future to large pension and welfare institutions. Any significant progress over the present very modest baseline of incidental life extension through general advances in medicine will likely bring down much of the existing system in the years ahead - which of course suggests that big centralized pension systems should be avoided like the plague, but that won't happen. If today's politics are any guide, politicians will continue to aggressively devalue their national currencies, taking wealth from their broader population to pay for what cannot be afforded until such time as the house of cards cannot be propped up any longer. The lesson to be taken away here: expect to provide for your own financial security in later life, and act accordingly now: "Here's the issue: governments have done their analysis of the aging issue largely based on best guesses of population developments in the future. These developments include further drops in fertility and some further increase in longevity. The trouble is that in the past, longevity has been consistently and substantially underestimated. We all live much longer now than had been expected 30, 20, and even just 10 years ago. So there is a good chance in the future people will live longer than we expect now. We call this longevity risk - the risk we all live longer than anticipated. ... Why is that a risk, you may ask. We all like to live longer, healthy lives. Sure, but let's now return to those pension worries. If you retire at 65 and plan your retirement finances expecting to live another 20 years (assuming you have enough savings for at least that period), you would face a serious personal financial crisis if you actually live to 95, or - well in your 100s. You could rely on your social security system at that point, but the program is also counting on people not living much beyond their mid-80s in most countries. Your personal financial problem multiplies by the size of the population, and, for society as a whole, becomes a very large problem." An example of how the present politics and systems of wealth transfer reward irresponsibility at all levels until such time as growth in collective irresponsibility sinks the whole venture.

EXPLAINING HOW ALTERED IGF-1 SIGNALING EXTENDS LIFE
Wednesday, April 11, 2012
http://www.fightaging.org/archives/2012/04/explaining-how-altered-igf-1-signaling-extends-life.php
Signs of progress in understanding the mechanisms of induced longevity through altered insulin/IGF-1 signaling are shown in this paper. This is one of the most-studied class of longevity mutations in lower animals, despite there being some debate over whether it is relevant to mammal biochemistry. Here, the basic mechanism is explained as being hormetic, centering on the mitochondria: researchers "elucidate a conserved mechanism through which reduced insulin-IGF1 signaling activates an AMP-kinase-driven metabolic shift toward oxidative proline metabolism. This, in turn, produces an adaptive mitochondrial [reactive oxygen species (ROS)] signal that extends worm life span. These findings further bolster the concept of mitohormesis as a critical component of conserved aging and longevity pathways. ... Impaired insulin and IGF-1 signaling (iIIS) in C. elegans daf-2 mutants extends life span more than 2-fold. Constitutively, iIIS increases mitochondrial activity and reduces reactive oxygen species (ROS) levels. By contrast, acute impairment of daf-2 in adult C. elegans reduces glucose uptake and transiently increases ROS. Consistent with the concept of mitohormesis, this ROS signal causes an adaptive response by inducing ROS defense enzymes, culminating in ultimately reduced ROS levels despite increased mitochondrial activity. Inhibition of this ROS signal by antioxidants reduces iIIS-mediated longevity by up to 60%. ... IIIS upregulates mitochondrial L-proline catabolism, and impairment of the latter impairs the life span-extending capacity of iIIS while L-proline supplementation extends C. elegans life span. Taken together, iIIS promotes L-proline metabolism to generate a ROS signal for the adaptive induction of endogenous stress defense to extend life span."

AN UPDATE ON COMPARATIVE STUDIES OF LONGEVITY
Wednesday, April 11, 2012
http://www.fightaging.org/archives/2012/04/an-update-on-comparative-studies-of-longevity.php
Researchers are comparing the biochemistry of long-lived species to better understand the roots of large differences in life span: "The team looked at the genome of more than 30 mammalian species to identify proteins that evolve in connection with the longevity of a species. They found that a protein, important in responding to DNA damage, evolves and mutates in a non-random way in species that are longer-lived, suggesting that it is changing for a specific purpose. They found a similar pattern in proteins associated with metabolism, cholesterol and pathways involved in the recycling of proteins. Findings show that if certain proteins are being selected by evolution to change in long-lived mammals like humans and elephants, then it is possible that these species have optimized pathways that repair molecular damage, compared to shorter-lived animals, such as mice. ... The genetic basis for longevity differences between species remains a major puzzle of biology. A mouse lives less than five years and yet humans can live to over 100 for example. If we can identify the proteins that allow some species to live longer than others we could use this knowledge to improve human health and slow the aging process."

EVIDENCE FOR CALORIE RESTRICTION TO IMPROVE HEART CELL BEHAVIOR
Tuesday, April 10, 2012
http://www.fightaging.org/archives/2012/04/evidence-for-calorie-restriction-to-improve-heart-cell-behavior.php
This is work performed on cells rather than organisms, but it still might be added to the great weight of existing evidence to suggest that calorie restriction improves most aspects of health: "Heart cells starved of nutrients are less likely to be damaged during periods of decreased blood flow and sudden influxes of blood, known as ischemia and reperfusion, and are also less likely to get out of synch with their cellular neighbors, the damaging phenomenon called arrhythmia. ... scientists learned that starved heart cells maintain normal calcium cycling and basic mitochondrial function far longer than non-starved cells during periods of extreme stress. The findings [add] to a growing body of scientific evidence that suggests the consumption of less energy - while maintaining balanced nutrition - can benefit tissues by enhancing cell performance and reducing DNA damage associated with the aging process. ... We are connecting several loose facts about calorie restriction and heart function, in particular, arrhythmias. We have shown why nutrient restriction protects the cells from ischemia and reperfusion. Normal function means less risk of arrhythmias, during which heart cells stop communicating properly with each other, and which can cause further damage, even sudden cardiac death. ... The scientists studied cultured heart cells originally derived from young rats. The cells were grown in a 2 cm-by-2 cm monolayer, to allow ease of study. The researchers mapped intracellular calcium ions and mitochondrial membrane potential with the help of fluorescent tags. Ischemia was simulated by placing a 1.8 cm-by-1.8 cm cover slip over the center of the cell culture, which limited oxygen and nutrient flow to that portion of the culture. Reperfusion was simulated by the removal of the cover slip. ... These experiments are not yet telling us whether we can emulate the effects of nutrient restriction in humans to lessen the damage of ischemia-reperfusion. But we have shown one way nutrient restriction may be acting to reduce heart tissue damage, a subject of interest to many laboratories."

IMMUNE SYSTEM AGING IN A NUTSHELL
Tuesday, April 10, 2012
http://www.fightaging.org/archives/2012/04/immune-system-aging-in-a-nutshell.php
A review paper: "With the improvement of medical care and hygienic conditions, there has been a tremendous increment in human lifespan. However, many of the elderly (older than 65 years) display chronic illnesses, and a majority requires frequent and longer hospitalization. The robustness of the immune system to eliminate or control infections is often eroded with advancing age. Nevertheless, some elderly individuals do cope better than others. The origin of these inter-individual differences may come from genetic, lifestyle conditions (nutrition, socio-economic parameters), as well as the type, number and recurrence of pathogens encountered during life. The theory we are supporting is that chronic infections, through life, will induce profound changes in the immune system probably due to unbalanced inflammatory profiles. Persistent viruses such as cytomegalovirus are not eliminated and are a driven force to immune exhaustion. Because of their age, elderly individuals may have seen more of these chronic stimulators and have experienced more reactivation episodes ultimately leading to shrinkage of their repertoire and overall immune robustness." Evidence in recent years suggests that this issue can be addressed by selectively destroying immune cells devoted to largely useless causes such cytomegalovirus - a goal that becomes ever more practical as targeted cell-killing therapies move closer to the clinic.

INVESTIGATING AGELESSNESS IN SEA URCHINS
Monday, April 9, 2012
http://www.fightaging.org/archives/2012/04/investigating-agelessness-in-sea-urchins.php
Some species of sea urchin, you may recall, age so slowly that it is hard to talk about life expectancy or pin down the likely age of a particular specimen with any ease. As for lobsters, another near-ageless collection of species, there isn't actually all that much research taking place into the biology of aging and longevity in these animals. Here is an example, however: "The life history of sea urchins is fundamentally different from that of traditional models of aging and therefore they provide the opportunity to gain new insight into this complex process. Sea urchins grow indeterminately, reproduce throughout their life span and some species exhibit negligible senescence. Using a microarray and qRT-PCR, age-related changes in gene expression were examined in three tissues (muscle, esophagus and nerve) of the sea urchin species Strongylocentrotus purpuratus. The results indicate age-related changes in gene expression involving many key cellular functions such as the ubiquitin-proteasome pathway, DNA metabolism, signaling pathways and apoptosis. Although there are tissue-specific differences in the gene expression profiles, there are some characteristics that are shared between tissues providing insight into potential mechanisms that promote lack of senescence in these animals. As an example, there is an increase in expression of genes encoding components of the Notch signaling pathway with age in all three tissues and a decrease in expression of the Wnt1 gene in both muscle and nerve. The interplay between the Notch and Wnt pathways may be one mechanism that ensures continued regeneration of tissues with advancing age contributing to the general lack of age-related decline in these animals."

______________________________


View the full article

#5 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 April 2012 - 03:58 PM

FIGHT AGING! NEWSLETTER
April 23rd 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Managing Expectations
- Fully Functional Hair Regeneration Demonstrated
- Sitting Time and Mortality
- Discussion
- Latest Headlines from Fight Aging!

MANAGING EXPECTATIONS

There is work ahead of us, and foundations behind us - benefits to longevity have not yet been realized:

http://www.fightaging.org/archives/2012/04/managing-expectations.php

"If you are around 40 years of age and basically average in terms of genes and health, the odds are good that in your first few decades you gained little in the way of longevity advantages over someone 20 years your senior, living in the same location. Medical science is progressing, but the young in wealthier regions of the world don't really use or need all that much medical technology once past the point of vaccinations and the standard - and diminishing - brace of infectious childhood diseases. The point here is that the bulk of any technology-dependent difference in your life span has yet to be engineered: it depends on how well you take care of the health basics from here on out, and far more on how rapidly medical technology progresses towards working rejuvenation biotechnology. If that medical technology isn't researched, isn't developed, isn't made available in a competitive marketplace, then the life trajectory of your parents is not an unreasonable model for your life.

"If medical technology stopped moving forward now, then, sad to say, most people would not live a great deal longer than their parents. Gains due to medical technology are all in the future - they can be seen, discussed, and worked on in detail, but they are not here yet. What does that mean? It means that if you are 40, you're half-way done. You have half of the hour-glass left in which to make a difference - to help build the technologies that will smash this limitation of the human condition.

"Life expectancy at birth is an artificial construct - it is a measure of quality of health and medical technology, useful for comparisons, not a number that corresponds to what will happen to people born now or who are alive now. It reflects the life expectancy of a person born now if every statistical measure of health and mortality derived from the present population remained the same into the future. So in an age of advancing technology you would expect life expectancy figures to be lower than what will turn out to be the average age attained by your peers.

"But still, it should be clear that unless progress in extending healthy life becomes more radical and less incremental, there are fair odds of 40-year-old you not living to see 80. This is not what anyone wants to hear, but it is what it is - the only way to make this different is to work to make it different. Support the work of the SENS Foundation, for example, or other causes that are involved in the science of extended human longevity and repair of aging."

http://www.fightaging.org/take-action/

On a related note, you might look at a recently posted SENS5 video in which Caleb Finch presents his view of the future of human longevity:

http://www.fightaging.org/archives/2012/04/sens5-video-caleb-finch-on-the-future-of-human-life-spans.php

"The historical improvements in life expectancy that accompany lower levels of chronic disease are an excellent illustration of aging as an accumulation of damage - that data fits well with the application of reliability theory to aging, for example. Find a way to reduce exposure to damage at the level of cells and molecular machinery and life will lengthen. Researchers like Finch - epidemiologist S. Jay Olshansky being another with similar views - see the most plausible future as an extension of this gradual improvement from the past. It won't be the same processes at work, because the easy gains accruing from control over infectious disease have been achieved, but it will be another gradual shifting of the chart of life expectancy, just a little progress achieved with each passing year of modestly longer lives. In this view of the world, growing levels of obesity form a very serious threat that may reduce life expectancy by causing more harm than incremental medical progress will prevent.

"This sort of viewpoint is, I think, harmful to the prospects for significant advances to arise from initiatives like the Strategies for Engineered Negligible Senescence. When gradualism is institutionally entrenched, radical investigations with radical goals are discouraged at every level, from student education through to the funding rat race, and cautious predictions in public do not attract the sort of supporters and researchers who can make bold strides. This is why we need philanthropists willing to back those who can credibly think outside the box and shoot for the moon. Big risks and potentially very large payoffs. In this time of revolution and progress in biotechnology, when better to break out of the straightjacket vision of incremental progress and tinkering with metabolism?"

FULLY FUNCTIONAL HAIR REGENERATION DEMONSTRATED

Structure turns out to be very important in tissue engineering, and here researchers seem to have found a solution to guiding structure in hair follicles:

http://www.fightaging.org/archives/2012/04/fully-functional-hair-regeneration-demonstrated.php

"Researchers have been manipulating stem cells to cause hair follicles to form and hair to grow for a few years now. ... Bald skin and haired skin have the same cell populations needed to grow hair, as it turns out, so this sort of cell-based approach has merit. The end of the story will likely be some form of cell signalling treatment to instruct cells already present in the body to form hairs in an area of skin rather than cell transplants - but transplants are first in line for development. The process is not exactly straightforward, unfortunately. Much like the tissue engineering of teeth, some form of guiding technology must be established to ensure that the cells grow as they should - without it, you end up with misshapen or broken structures.

"On this subject, the work of a Japanese group on hair regeneration has been in the news of late, and they seem to have established a proof of principle for guiding correct hair growth. ... In the new work, the team transplanted a group of the engineered follicles into the skin on the backs of hairless mice. After about two weeks, hairs began to sprout. Under the microscope, the hair grown from the bioengineered mouse follicles resembled normal hair, scientists found. And the mouse follicles went through the normal cycle of growing hair, shedding and making new hair.

"When researchers injected the region around the bioengineered follicle with acetylcholine, a drug that causes muscles to contract, the hairs perked up. This suggests that the transplanted follicles had integrated with surrounding muscle and nerves like normal hair follicles do. Importantly, the researchers were able to ensure hair didn't become ingrown or point in the wrong direction by attaching a nylon thread to the engineered follicles and guiding the hair to grow outward."

SITTING TIME AND MORTALITY

A recent analysis of study data concludes that sitting correlates with increased mortality, but separately and independently from levels of physical activity - and on that point I am dubious:

http://www.fightaging.org/archives/2012/04/sitting-time-correlating-with-mortality-independently-of-exercise.php

"One has to wonder what the mechanism is here - my suspicion is that it actually does all come back down to the level of physical activity in the end. In these massive studies the level of exercise and activity is reported by the participants. A person who stands and works is going to be somewhat more active than a person who sits and works, even though that time may not be categorized as physical activity, or reported differently. Exercise is much like calorie restriction - the effects are so large in comparison to other factors we have easy access to that they are likely to creep into any study.

"You might look at a recent study on activity and Alzheimer's disease that was one of the few to use measuring devices rather than reports of activity. One point that emerges is that a fair degree of ongoing low level activity and exercise won't be classified as such by the participants of study without machine measurement. Housework, taking out the trash, the small increase in energy expenditure from standing while waiting versus sitting while waiting, that sort of thing repeated day in and day out. How much you are sitting really does sound a lot like a proxy for how much activity you are undertaking when you are doing things that most people don't really count as activity."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

PEROXISOMAL AND MITOCHONDRIAL GENES IMPORTANT IN DETERMINING LONGEVITY
Friday, April 20, 2012
http://www.fightaging.org/archives/2012/04/peroxisomal-and-mitochondrial-genes-important-in-determining-longevity.php
Researchers continue to investigate the genetics of natural variations in aging, such as those that can be generated through diet (e.g. calorie restriction) in mice: "Dietary interventions are effective ways to extend or shorten lifespan. By examining midlife hepatic gene expressions in mice under different dietary conditions, which resulted in different lifespans and aging-related phenotypes, we were able to identify genes and pathways that modulate the aging process. We found that pathways transcriptionally correlated with diet-modulated lifespan and physiological changes were enriched for lifespan-modifying genes. Intriguingly, mitochondrial gene expression correlated with lifespan and anticorrelated with aging-related pathological changes, whereas peroxisomal gene expression showed an opposite trend. Both organelles produce reactive oxygen species, a proposed causative factor of aging. This finding implicates a contribution of peroxisome to aging. Consistent with this hypothesis, lowering the expression levels of peroxisome proliferation genes decreased the cellular peroxide levels and extended the lifespan of Drosophila melanogaster and Caenorhabditis elegans. These findings show that transcriptional changes resulting from dietary interventions can effectively reflect causal factors in aging and identify previously unknown or under-appreciated longevity pathways, such as the peroxisome pathway."

CALORIE RESTRICTION SLOWS AGE-RELATED AUTONOMIC DECLINE
Friday, April 20, 2012
http://www.fightaging.org/archives/2012/04/calorie-restriction-slows-age-related-autonomic-decline.php
Another aspect of aging slowed by calorie restriction: "Caloric restriction (CR) retards aging in laboratory rodents. [Little] information is available on the effects of long-term CR on physiologic markers of aging and longevity in humans. Heart rate variability (HRV) is a marker for cardiac autonomic functioning. The progressive decline in HRV with aging and the association of higher HRV with better health outcomes are well established. HRV assessment is a reliable tool by which the effects of CR on autonomic function can be assessed. Time and frequency domain analyses compared 24-hr HRV in 22 CR individuals aged 35-82 yrs and 20 age-matched controls eating Western diets (WD). The CR group was significantly leaner than the WD group. Heart rate was significantly lower, and virtually all HRV significantly higher in the CR than in the WD group. HRV in the CR individuals was comparable to published norms for healthy individuals 20 years younger. In addition, when differences in HR and HRV between CR and WD were compared with previously-published changes in HRV induced in healthy adults given atenolol, percent differences in each measure were generally similar in direction and magnitude and suggested declines in sympathetic and increases in parasympathetic modulation of HR and increased circadian variability associated with CR. These findings provide evidence that CR has direct systemic effects that counter the expected age-associated changes in autonomic function so that HRV indexes in CR individuals are similar to those of individuals 20 years younger eating WDs,"

CELEBRATING PROGRESS IN REGENERATIVE MEDICINE
Thursday, April 19, 2012
http://www.fightaging.org/archives/2012/04/celebrating-progress-in-regenerative-medicine.php
Nature comments on recent advances: "At the turn of the twentieth century, the promise of regenerating damaged tissue was so far-fetched that Thomas Hunt Morgan, despairing that his work on earthworms could ever be applied to humans, abandoned the field to study heredity instead. Though he won the Nobel Prize in 1933 for his work on the role of chromosomes in inheritance, if he lived today, the advances in regenerative medicine may have tempted him to reconsider. Three studies published this week show that introducing new cells into mice can replace diseased cells - whether hair, eye or heart - and help to restore the normal function of those cells. These proof-of-principle studies now have researchers setting their sights on clinical trials to see if the procedures could work in humans. ... You can grow cells in a Petri dish, but that's not regenerative medicine. You have to think about the biology of repair in a living system. ... Japanese researchers grew different types of hair on nude mice, using stem cells from normal mice and balding humans to recreate the follicles from which hair normally emerges. ... A second study using regenerative techniques helped to restore some vision to mice with congenital stationary night blindness, an inherited disease of the retina. ... [Researchers reprogrammed] cardiac fibroblasts into cardiomyocytes - the muscle cells of the heart that are permanently lost after a heart attack. The team used a retrovirus to deliver three transcription factors that induced the reprogramming in adult mice, and improved their cardiac function. ... These three papers are just the tip of the iceberg. By the time we grow old, doctors are going to look back and say, 'Can you believe people used to go bald, go blind or even have their leg cut off from vascular disease?' - and then the doctor will treat the problem with an injection of cells."

EXERCISE REDUCES RISK OF ALZHEIMER'S DISEASE
Thursday, April 19, 2012
http://www.fightaging.org/archives/2012/04/exercise-reduces-risk-of-alzheimers-disease.php
Via EurekAlert!: "Daily physical exercise may reduce the risk of Alzheimer's disease, even in people over the age of 80 ... The study showed that not only exercise but also activities such as cooking, washing the dishes and cleaning are associated with a reduced risk of Alzheimer's disease. These results provide support for efforts to encourage physical activity in even very old people who might not be able to participate in formal exercise but can still benefit from a more active lifestyle. ... For the study, a group of 716 people with an average age of 82 wore an actigraph, a device that monitors activity, on their non-dominant wrist continuously for 10 days. All exercise and non-exercise was recorded. They also were given annual tests during the four-year study that measured memory and thinking abilities. During the study, 71 people developed Alzheimer's disease. ... The research found that people in the bottom 10 percent of daily physical activity were more than twice as likely to develop Alzheimer's disease as people in the top 10 percent of daily activity. The study also showed that those people in the bottom 10 percent of intensity of physical activity were almost three times as likely to develop Alzheimer's disease as people in the top 10 percent of intensity of physical activity."

DEL-1 AND INFLAMMATORY GUM DISEASE
Wednesday, April 18, 2012
http://www.fightaging.org/archives/2012/04/del-1-and-inflammatory-gum-disease.php
From Queen Mary, University of London, investigation of the mechanisms of periodontitis in aging: "New research [sheds] light on why gum disease can become more common with old age. The study, published in Nature Immunology, reveals that the deterioration in gum health which often occurs with increasing age is associated with a drop in the level of a chemical called Del-1. The researchers say that understanding more about Del-1 and its effects on the body's immune system could help in the treatment or prevention of serious gum disease. ... As people age they are more likely to suffer from inflammatory diseases, including gum disease. The new research investigated gum disease in young and old mice and found that an increase in gum disease in the older animals was accompanied by a drop in the level of Del-1. This protein is known to restrain the immune system by stopping white blood cells from sticking to and attacking mouth tissue. Mice that had no Del-1 developed severe gum disease and elevated bone loss and researchers found unusually high levels of white blood cells in the gum tissue. When they treated the gums of the mice with Del-1, the number of white blood cells dropped, and gum disease and bone loss were reduced. The researchers say their findings could be the basis for a new treatment or prevention of gum disease."

ANOTHER GENOME-WIDE SEARCH FOR LONGEVITY GENES
Wednesday, April 18, 2012
http://www.fightaging.org/archives/2012/04/another-genome-wide-search-for-longevity-genes.php
Researchers are not having as much success as they'd like in finding unambiguous associations between specific genes and human longevity - studies are turning up results, but few are similar between populations, indicating that the genetics of natural variations in longevity are probably very complex: "It has long been thought that related individuals share a familial predisposition to longevity, and for more than a century numerous studies have investigated the degree to which human longevity might be an inherited characteristic. Most studies of this type have reported small (∼10%) to moderate (∼30%) heritability of human longevity, amid differences in definitions of longevity, methods of measuring it, ascertaining individuals who demonstrate it, and in various behavioral and environmental settings. These methodological differences likely account for much of the variation in the resulting estimates of the heritability of longevity. ... We identified individuals from a large multigenerational population database (the Utah Population Database) who exhibited high levels of both familial longevity and individual longevity. This selection identified 325 related 'affected individuals', defined as those in the top quartile for both excess longevity (EL=observed lifespan - expected lifespan) and familial excess longevity (FEL=weighted average EL across all relatives). A whole-genome scan for genetic linkage was performed on this sample using a panel of 1100 microsatellite markers. A strongly suggestive peak was observed in the vicinity of D3S3547 on chromosome 3p24.1, at a point nearly identical to that reported recently by an independent team of researchers from Harvard Medical School (HMS). ... Corroboration of the linkage of exceptional longevity to 3p22-24 greatly strengthens the case that genes in this region affect variation in longevity and suggest, therefore, an important role in the regulation of human lifespan. Future efforts should include intensive study of the 3p22-24 region."

BREAKOUT LABS ANNOUNCES FIRST GRANTEES
Tuesday, April 17, 2012
http://www.fightaging.org/archives/2012/04/breakout-labs-announces-first-grantees.php
Breakout Labs is a part of Peter Thiel's vision of radical philanthropy in science and technology funding, modeled on the venture capital industry and aiming to invest in high risk, high reward programs: "The Thiel Foundation announced today the first grants awarded through Breakout Labs, its revolutionary revolving fund to promote innovation in science and technology. ... it provides teams of researchers in very early-stage companies with the means to pursue their most radical goals in science and technology. Breakout Labs has awarded six grants, of up to $350,000 each, to the following recipients: ... 3Scan, to develop 3-D digital reconstruction of brain tissue, using a novel, faster, less expensive microscope technology. Building a map of connections in the brain-the connectome-is a critical step to understanding what makes the human brain unique. ... Arigos Biomedical, to develop methods of cooling organs for long-term storage. When combined with emerging advances in cryopreservation, tissue engineering, and stem cell therapies to eliminate graft rejection, this technology would make banked organs immediately available to anyone needing a transplant. ... Immusoft, to re-program human immune cells to produce therapeutics in the body. This technology could dramatically improve the ability to treat a range of diseases, as well as enhance human health and longevity. ... Longevity Biotech, to develop an entirely new class of therapeutics via artificial protein technology ("Hybridtides"). Hybridtides are targeted biologic-like molecules which are highly-resistant to breakdown by natural digestive enzymes and tunable to very stable molecular structures. These features have demonstrated potent therapeutic activity with the possibility of oral biologic delivery. ... In the past, people dreamed of the future as a radically better, more technologically advanced place: you might live for centuries, delegate work to your robots, and take your vacations on the moon. Now, many people expect their children to inherit a world worse than today's. With Breakout Labs, we want to rekindle dreams of an amazing future. That's why we're supporting researchers who dream big and want to build a tomorrow in which we all want to live."

A PUZZLING FULLERENE STUDY
Tuesday, April 17, 2012
http://www.fightaging.org/archives/2012/04/a-puzzling-fullerene-study.php
A research group is claiming that fullerenes (C60, ingested and injected) greatly extend life span in rats; this is meeting with some considerable skepticism, given the degree of life extension and the lack of a plausible mechanism. "In the current study researchers fed the molecule dissolved in olive oil to rats and compared outcomes to a control group of rats who got plain olive oil. The main question they wanted to answer was whether chronic C60 administration had any toxicity, what they discovered actually surprised them. ... Here we show that oral administration of C60 dissolved in olive oil (0.8 mg/ml) at reiterated doses (1.7 mg/kg of body weight) to rats not only does not entail chronic toxicity, but it almost doubles their lifespan. ... The estimated median lifespan (EML) for the C60-treated rats was 42 months while the EMLs for control rats and olive oil-treated rats were 22 and 26 months, respectively. Using a toxicity model the researchers demonstrated that the effect on lifespan seems to be mediated by 'attenuation of age-associated increases in oxidative stress'." So what might be going on here? The average life span of the Wistar rats used is 2-3 years (24 - 36 months). This was a small study size, but that's not so important in determining whether you have an actual means of life extension if you can show that any of your study group lived much longer than usual - but it is important when it comes to the degree of life extension. If the study group is small, as it is here, using only a handful of rats, then the size of the effect can be much more readily distorted by chance. This line in the paper jumped out at me: "Before C60 administration, the rats were fasted overnight but with access to water." If they failed to fast the control group, then we're looking at yet another study that failed to control for calorie restriction, and this is actually largely an intermittent fasting study - which has certainly been shown to extend life in rats.

AUBREY DE GREY ON THE COSTS AND COST-EFFECTIVENESS OF SENS
Monday, April 16, 2012
http://www.fightaging.org/archives/2012/04/aubrey-de-grey-on-the-costs-and-cost-effectiveness-of-sens.php
Following on from a recent presentation on cost-effectiveness in longevity research, here's an interview with Aubrey de Grey of the SENS Foundation at 80,000 hours: "ZR: Back to matters financial... How much funding would your programme actually need to complete its goals? Paraphrasing your talk again, you guesstimated '$50,000,000 allocated appropriately would be 'enough for the next while''. Can you be a bit specific about what 'the next while' means? ... AdG: I think I said $50M per year. 20M/year would be a good start, and I think above $100M/year we'd be reaching diminishing returns. This is tiny compared to (for instance) the NIH budget, but that's because it's only the budget for the next several years, when the key work will be on mice rather than humans. ... It's pretty clear that a dollar makes more difference when spent on early-stage biomedical research (which is what we'd spend it on) than on the delivery of existing therapies. ... ZR: How confident are you about the success of your program? I'll paraphrase a couple of off-the-cuff remarks on the subject you made in your 80K talk: 'We'll get to robust human rejuvenation - within the next 25 years with 50% probability.' 'I'd give a 10% chance we won't get there for 100 years.' Would you modify these now you're not on the spot? What exactly do you mean by robust human rejuvenation? Is that the same thing as reaching what you call the ageing escape velocity? (for the benefit of readers: the point at which progress in our ability to extend our lifespans surpasses the rate at which we age, effectively making us immune to age-related death) ... AdG: I still stand by both those statements, but please note that I always add the caveat that the former depends on adequate funding, especially in the coming decade. I define 'robust human rejuvenation' (RHR) as the addition of 30 years of extra healthy life to those who are already 60 when the therapies are first given. Longevity escape velocity is different - it's the postponement of aging faster than time is passing, which results from continued progress in improving the comprehensiveness of the therapies. The moment at which we reach LEV, which we call the Methuselarity (and we're pretty sure there will be inly one such moment, i.e. that once we exceed LEV we will never fall below it again), will probably occur at around the same time when we achieve RHR - maybe a little sooner, maybe a little later."

ADAPTING IMMUNOTHERAPIES TO PERFORM WELL IN THE AGED IMMUNE SYSTEM
Monday, April 16, 2012
http://www.fightaging.org/archives/2012/04/adapting-immunotherapies-to-perform-well-in-the-aged-immune-system.php
Researchers manage to make an immunotherapy work well in aged immune systems - which is important, as most of the potential uses for immune therapies will target older people: "a new study [shows] that some types of immunotherapy previously thought to work only in younger patients can be used to help the elderly, with less toxic effects than many common therapies, if combined in ways that account for age-related changes in the immune system. ... We've shown that immunotherapy for cancer not only works in aged mice, but actually can work better in aged hosts than in young counterparts by capitalizing on the immune changes that happen with age ... As you age, most parts of your body begin to wear out. They keep doing what they're made to do [but] over time, they don't do it as well. The general perception is that the immune system also simply declines with age. ... That's really too simplistic. That's really not the full picture of what's happening. ... The body's immune system does weaken with age, but it also changes, and that changes the rules for fighting disease within the body. [The researchers] started by examining an immune therapy that they previously had shown to work in younger hosts, including cancer patients. It's designed to eliminate regulatory T cells (called Tregs), which are cells that turn off immune responses, allowing cancer to progress. Tregs increase in cancer. In young hosts, the drug turns off Treg activity, allowing the immune system to function better. In older hosts, even though the drug turns off the Tregs, it has no clinical benefit. ... In older mice, when the drug turned off the Tregs, the researchers found that another type of immune suppressor cell (a myeloid-derived suppressor cell or MDSC) exploded in number to take the Tregs' place, hampering clinical efficacy. That did not happen in young mice. The team added a second drug that targets the MDSC, and found that with those tools to help immunity, the older hosts can combat cancer just as well as the younger hosts."

______________________________


View the full article

#6 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 29 April 2012 - 03:52 PM

FIGHT AGING! NEWSLETTER
April 30th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- An Interview with Michael Batin
- Conflating Aging and Degeneration
- The FDA is a Destructive Force
- Discussion
- Latest Headlines from Fight Aging!

AN INTERVIEW WITH MICHAEL BATIN

The 2nd International Conference on the Genetics of Aging and Longevity was held this past week in Moscow, well-attended by the aging research community. Here is an interview, machine translated from Russian:

http://www.fightaging.org/archives/2012/04/an-interview-with-michael-batin.php

"Earlier this month, the Moscow News ran an interview with Michael Batin, one of the [conference] organizers. His views are representative of the Russian community, whose members tend to be forthright and direct when it comes to the end goals of longevity science: to defeat aging entirely, banish the suffering it causes, and usher in an era of ageless humans. More power to them - we could do with a lot more of that sort of outspoken advocacy here in the Anglosphere.

"Q: What is the real goal that we set ourselves right now? Can you say, talk about extending the life of ten years from now?

MB: In ten years? It is not even present, and yesterday. It has long been proven that reducing caloric intake [and even] just a healthy lifestyle [lead to a longer life]. Our goal is different - a victory over an aging, it is by and large the whole purpose of medical science. After all, if you think about all of the doctors [dedicated to the] prolongation of life, the estrangement of death. A person does not want to die right now, well, anti-aging does not differ fundamentally, it is also the struggle with death.

Q: So you're talking about immortality?

MB: Yes. This is the ultimate goal. In the coming ten years, you can raise the life expectancy [to] 150 years, with adequate [resources and large enough research community]. If, for example, to do research megaproject like the American lunar program. And if we know in ten years that will live more than a hundred years, this will give us more time to find a way to further extend [life].

Q: But how? Are there any pills?

MB: If you're talking about a miracle pill, then, of course not. Aging depends on many factors, and is now the main problem is just that we do not know them all. And the proposed mega-project just involves a systematic search for the causes of aging.

Q: And it's all in the mega-project? [It's] going to cost [a] quite impossibly high sum.

MB: But now we are spending huge amounts of money on arms - you've seen defense spending in Russia? - And do not invest in [biogerontology], fundamental research on the causes of aging. Even in the U.S., [where] gerontology takes a billion dollars, [that is] their total spending, of that billion is spent on Alzheimer's disease, [on] geriatrics, and [only a small fraction of it on] the fundamental work on finding the root causes of aging."

CONFLATING AGING AND DEGENERATION

Aging absent degeneration would be a wonderful thing:

http://www.fightaging.org/archives/2012/04/conflating-aging-and-degeneration.php

"There's a lot to be said for aging. The passage of years offers many opportunities to master favored skills, figure out solutions to the issues and upsets of youth, earn the resources and connections needed for true self-sufficiency and confidence, and much more. You can build a great life, given just the time to work on it and a modicum of common sense - and then keep on building atop the foundation of that great life. Humans age like distillates: it can just keep getting better. But of course there is the matter of degeneration and death, of disease and decrepitude. The fact that older people are generally happier, more secure, and more confident despite what happens to the body with age is a testament to just how good being aged is. That the majority evaluate their position as far superior to that of earlier years despite the increasing corrosion of the body and the ticking away of time remaining is a powerful statement.

"On this topic, I should note that over the years an unfortunately large number of apologists for aging have become somewhat dazzled by the good parts of the package, to the point at which they are unwilling to talk about picking apart aging and degeneration, or trying to radically change aging through medical technology. To their view, the world is what it is, and we should just focus on the positives and suffer the negatives with dignity. Not that that last point is easy at all - there is no dignity in the failing of the body and mind, only horrors that the dominant voices of this society seem to have chosen to try to close away behind the curtains.

"It is both somewhat strange and somewhat understandable to find so many conservatives - in the dictionary definition of the word, not the political definition - in an age of rampant, ongoing, omnipresent change. Those who benefit the most from technological progress, and consequent decade by decade shifts in the minutiae of the human condition, nonetheless adopt positions based on the idea that what presently exists will continue to exist as-is into the future. It's denial, it's letting the ape inside drive - the ape who really, really, doesn't like change or upsets to the present carefully constructed social hierarchy, no matter how beneficial it might be.

"Being aged is great, but it's just plain dumb to try to turn that into an argument that being sick, lessened, in agony, and driven mad is also great. Medicine will be able to remove all of these ugly aspects of old age, provided that we work hard enough and fund the right sort of research and development to a sufficient degree. The people who paint on sunny smiles and say that nothing will ever change are only helping to hold back that future."

THE FDA IS A DESTRUCTIVE FORCE

We would be so much further along in applied biotechnology if not for the perverse engines of regulation that hold back progress in much of the world:

http://www.fightaging.org/archives/2012/04/the-fda-is-a-destructive-force.php

"The employees and appointees of the US Food and Drug Administration have caused an incredible destruction of value and progress over the time that the agency has existed. Their regulatory policies become ever more onerous with each passing year, as unaccountable bureaucrats follow their incentives: nothing good can happen to their careers as a result of approving new technologies, and nothing bad tends to happen to their careers as a result of making it really, really hard to bring new medicine to the clinic. So of course you wind up with an organization whose members collectively pay nothing more than lip service to their declared mission, while working to make sure that medicine stays moribund in a slow-motion stasis. This is most evident in the cancer research community, largely because of its size, but it applies just as evenly across all forms of medicine:

"A 2010 study in the Journal of Clinical Oncology by researchers from the M.D. Anderson Cancer Center in Houston, Texas found that the time from drug discovery to marketing increased from eight years in 1960 to 12 to 15 years in 2010. Five years of this increase results from new regulations boosting the lengths and costs of clinical trials. The regulators aim to prevent cancer patients from dying from toxic new drugs. However, the cancer researchers calculate that the delays caused by requirements for lengthier trials have instead resulted in the loss of 300,000 patient life-years while saving only 16 life-years.

"To add to this picture, you must also see incumbent Big Pharma entities and their executives and lobbyists - a deeply enmeshed network of regulatory capture. They are far more willing to use the current system as a weapon to suppress disruptive innovation in their industry than to be a source of innovation themselves. So it goes, just as in any other heavily regulated market. The strategic goals of the major players wind up having very little to do with creating beneficial change, and everything to do with keeping things the same as they are now.

"Though the United States urgently needs new treatments for common illnesses such as heart disease, stroke, and diabetes, the nation's system for drug approval discourages innovation and investment, especially for our most pressing public health challenges. In this paper, we find that the main culprit is the high cost of Phase III clinical trials, which are required for FDA approval of most drugs. We examined drug development in four major public health areas and discovered that for any given drug on the market, typically 90 percent or more of that drug's development costs are incurred in Phase III trials. These costs have skyrocketed in recent years, exacerbating an already serious problem."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

RESEARCHER STEVEN AUSTAD WRITES A BIWEEKLY COLUMN ON AGING SCIENCE
Friday, April 27, 2012
http://www.fightaging.org/archives/2012/04/researcher-steven-austad-writes-a-biweekly-column-on-aging-science.php
This seems like an interesting marker of public awareness of aging science; one of the noted researchers in the field recently started on a biweekly column for a local paper. Links to the columns published to date can be found on this page: "In my last column I discussed something we all know intuitively: Generally speaking, larger species of animals live longer than smaller species and this pattern extends even to whales that live more than 200 years. Are there dramatic exceptions to this rule - like people, for instance? Think of other mammals about our size, such as deer or mountain lions or seals. Don't we live longer than they do? The answer is, 'Yes, we do.' Humans live about five times as long as the average mammal of the same size, which makes us pretty special - but not as special as bats. Texas is bat country, as anyone who has watched millions of bats boil out of Bracken Cave or from under Austin's Congress Avenue Bridge can verify. What many people don't realize is how long bats live. For their size, bats are the longest-lived mammals by far, living up to 10 times as long as an average mammal of similar size. ... Think about this for a second. Your dog or cat, eating the best food science can provide, protected from predators and the elements and vaccinated against all sorts of diseases, is doing well to reach 15 to 20 years of age. By comparison, in order for a bat in the wild to survive it must catch its own prey, elude predators, resist climatic extremes, and avoid a wide range of infectious diseases. Yet despite these challenges, bats can live twice as long as your pampered pet." Current thinking on bat longevity looks to be similar to theories on naked mole rat longevity - it has to do with resistance of cell membranes (and especially mitochondria) to oxidative damage, otherwise known as the membrane pacemaker hypothesis of aging. This is thought to have developed in bats, and in birds, in respond to the metabolic demands of flight.

EXAMINING MITOCHONDRIAL DNA DAMAGE IN DETAIL
Friday, April 27, 2012
http://www.fightaging.org/archives/2012/04/examining-mitochondrial-dna-damage-in-detail.php
Damage to mitochondrial DNA contributes to aging, and mitochondrial function is in general influential upon aging - damage causes harm by preventing the production of protein machinery vital to mitochondrial activity, which is the start of a long process that sees cells overtaken by dysfunctional mitochondria, and exporting their dysfunction to surrounding tissue by emitting harmful reactive molecules. There are numerous different sorts of DNA damage, however. Point mutations, for example, have been shown to do little to aging. Deletions, where whole reaches of DNA are knocked out, are a different story, and here researchers are investigating how this form of DNA damage varies between species: "Deletion mutations within mitochondrial DNA (mtDNA) have been implicated in degenerative and aging related conditions, such as sarcopenia and neuro-degeneration. While the precise molecular mechanism of deletion formation in mtDNA is still not completely understood, genome motifs such as direct repeat (DR) and stem-loop (SL) have been observed in the neighborhood of deletion breakpoints and thus have been postulated to take part in mutagenesis. In this study, we have analyzed the mitochondrial genomes from four different mammals: human, rhesus monkey, mouse and rat ... Our analysis revealed that in the four species, DR and SL structures are abundant and that their distributions in mtDNA are not statistically different from randomized sequences. However, the average distance between the reported age associated mtDNA breakpoints and their respective nearest DR motifs is significantly shorter than what is expected of random chance in human and rhesus monkey, but not in mouse and rat, indicating the existence of species specific difference in the relationship between DR motifs and deletion breakpoints. In addition, the frequencies of large DRs tend to decrease with increasing lifespan among the four mammals studied here, further suggesting an evolutionary selection against stable mtDNA misalignments associated with long DRs in long-living animals."

FURTHER WORK ON EPIGENETIC CHANGES THAT OCCUR WITH AGING
Thursday, April 26, 2012
http://www.fightaging.org/archives/2012/04/further-work-on-epigenetic-changes-that-occur-with-aging.php
Via ScienceDaily: researchers "have identified a group of 'aging' genes that are switched on and off by natural mechanisms called epigenetic factors, influencing the rate of healthy aging and potential longevity. The study also suggests these epigenetic processes - that can be caused by external factors such as diet, lifestyle and environment - are likely to be initiated from an early age and continue through a person's life. The researchers say that the epigenetic changes they have identified could be used as potential 'markers' of biological aging and in the future could be possible targets for anti-aging therapies. ... the study looked at 172 twins aged 32 to 80 from the TwinsUK cohort. The researchers looked for epigenetic changes in the twins' DNA, and performed epigenome-wide association scans to analyze these changes in relation to chronological age. They identified 490 age related epigenetic changes. They also analysed DNA modifications in age related traits and found that epigenetic changes in four genes relate to cholesterol, lung function and maternal longevity. To try to identify when these epigenetic changes may be triggered, the researchers replicated the study in 44 younger twins, aged 22 to 61, and found that many of the 490 age related epigenetic changes were also present in this younger group. The researchers say these results suggest that while many age related epigenetic changes happen naturally with age throughout a person's life, a proportion of these changes may be initiated early in life."

INSIGHTS INTO AGING FROM THE STUDY OF FLIES
Thursday, April 26, 2012
http://www.fightaging.org/archives/2012/04/insights-into-aging-from-the-study-of-flies.php
An open access review paper looks at how the study of fly aging has informed the life sciences: "it is likely that not all senescent physiological changes revealed in flies can be simply translated to humans. However, flies and humans often show very similar age-related physiological phenotypes suggesting that at least some of the basic biological properties and mechanisms that regulate longevity are conserved amongst species. ... It is well-known that advances in medicine and health care have significantly contributed to increased longevity in humans over the last 100 years. There is also a clear trend toward increased life expectancy including an increase in the numbers of people living to an advanced age and the number of people with chronic age-related diseases. These trends emphasize the need to understand the genetic and physiological factors underlying biological aging and particularly, those that promote healthy aging. ... there are three ways to extend lifespan: increasing early survival rate, increasing late survival rate, or delaying senescence. Remarkably, the first two do not affect basic aging processes. For example, the first one leads to a significant increase in mean but not maximum lifespan, while the second one leads to change in a maximum but not mean lifespan. Delayed senescence, in turn, leads to a significant increase in both the mean and maximum lifespan. ... This raises the question as to whether healthspan and delayed senescence are inter related. As stated above, while many genes have been shown to extend lifespan, these may have little or no ability to delay physiological senescence. In other words, the period of functional disability before death may increase despite the fact that the total duration of life is increased. Thus, the search for appropriate biomarkers applicable to monitor functional senescence is highly important with regards to healthy aging and age-related diseases." These cautions are very much focused on the mainstream research goals of slowing the rate of aging through genetic and metabolic alterations; they have little relevance to efforts aimed at producing continuous repair of aging.

RAPAMYCIN AND OXIDATIVE STRESS IN ADULT STEM CELLS
Wednesday, April 25, 2012
http://www.fightaging.org/archives/2012/04/rapamycin-and-oxidative-stress-in-adult-stem-cells.php
Following on from research into the mechanisms of rapamycin released earlier this month, here is more on the way it might generate its benefits to longevity in laboratory mammals: "Balancing quiescence with proliferation is of paramount importance for adult stem cells in order to avoid hyperproliferation and cell depletion. In some models, stem cell exhaustion may be reversed with the drug rapamycin, which was shown can suppress cellular senescence in vitro and extend lifespan in animals. We hypothesized that rapamycin increases the expression of oxidative stress response genes in adult stem cells, and that these gene activities diminish with age. To test our hypothesis, we exposed mice to rapamycin and then examined the transcriptome of their spermatogonial stem cells (SSCs). Gene expression microarray analysis revealed that numerous oxidative stress response genes were upregulated upon rapamycin treatment ... When we examined the expression of these genes in 55-week-old wild type SSCs, their levels were significantly reduced compared to 3-week-old SSCs, suggesting that their downregulation is coincident with the aging process in adult stem cells. We conclude that rapamycin-induced stimulation of oxidative stress response genes may promote cellular longevity in SSCs, while a decline in gene expression in aged stem cells could reflect the SSCs' diminished potential to alleviate oxidative stress, a hallmark of aging."

LESS HAND OSTEOARTHRITIS IN LONGER-LIVED POPULATIONS
Wednesday, April 25, 2012
http://www.fightaging.org/archives/2012/04/less-hand-osteoarthritis-in-longer-lived-populations.php
Age-related diseases are among the more visible signs of accumulated biological damage that occurs over time - aging is damage. So we should expect to see less of all such conditions in longer lived populations, and here researchers demonstrate that point for osteoarthritis: "Previous studies have reported that centenarians escape the major age-related diseases. No studies on prevalence and severity of osteoarthritis (OA) in longevity population have previously been reported. Because OA is associated with morbidity and mortality, we hypothesized that radiographic hand OA would generally be less prevalent and would develop at a later age in longevity populations vs non-longevity populations. ... Longevity index was calculated as a ratio of the number of individuals aged [greater than] 90 years vs the number of people aged [greater than] 60, expressed per mil. A population with longevity index [greater than] 40 was considered as a longevity population. ... A significant difference in age standardized prevalence of hand OA was found between each pair of studied samples ... We observed that the pattern of radiographic hand OA in longevity populations differs from the pattern in non-longevity populations. On average, first joints with OA appear at an older age, and progression of hand OA [is] slower."

AN UPDATE ON CYTOGRAFT'S ENGINEERED BLOOD VESSELS
Tuesday, April 24, 2012
http://www.fightaging.org/archives/2012/04/an-update-on-cytografts-engineered-blood-vessels.php
Cytograft is one of many regenerative science ventures established in the past fifteen years, and a competitor in the space of growing blood vessels: "A lot of people were skeptical when two young California-based researchers set out more than a decade ago to create a completely human-derived alternative to the synthetic blood vessels commonly used in dialysis patients. Since then, they've done that and more. ... First the team created blood vessels from patients' own skin cells. Then, in June, the company announced that three dialysis patients had received the world's first lab-grown blood vessels made from skin cells from donors, which eliminates the long lead time needed for making vessels from a patient's own cells. And now Cytograft has developed a new technique for making human textiles that promises to reduce the production cost of these vessels by half. ... Cytograft's new approach builds on what already has been proved successful. In 2005, the team began extracting fibroblasts from patients' own skin, cultured those cells into thin sheets, rolled up those sheets, cultured them some more so that they would fuse together, and implanted the lab-grown cylindrical vessels. The vessel-growing process was lengthy, at about seven months, but, because the vessels were derived from the patients' own cells, the implants were easily accepted by the patients' bodies, and they held up to the rigors of dialysis, which requires repeated punctures with large-gauge needles. Then the researchers created allogeneic vessels - ones grown from donor cells - with the hope that they were laying the foundation for an off-the-shelf stockpile of 100 percent human replacement parts. ... By combining these two methods we could make something that is allogeneic, cheaper to produce, and that you could store forever, meaning that the clinician can pull it off the shelves whenever they want. If it is frozen and allogeneic, that is kind of the homerun."

STRUCTURES TO GUIDE NERVE REGROWTH
Tuesday, April 24, 2012
http://www.fightaging.org/archives/2012/04/structures-to-guide-nerve-regrowth.php
Via ScienceDaily: researchers "have developed a method of assisting nerves damaged by traumatic accidents to repair naturally, which could improve the chances of restoring sensation and movement in injured limbs. ... the team describes a new method for making medical devices called nerve guidance conduits or NGCs. The method is based on laser direct writing, which enables the fabrication of complex structures from computer files via the use of CAD/CAM (computer aided design/manufacturing), and has allowed the research team to manufacture NGCs with designs that are far more advanced than previously possible. Currently patients with severe traumatic nerve damage suffer a devastating loss of sensation and/or movement in the affected limb. The traditional course of action, where possible, is to surgically suture or graft the nerve endings together. However, reconstructive surgery often does not result in complete recovery. ... When nerves in the arms or legs are injured they have the ability to re-grow, unlike in the spinal cord; however, they need assistance to do this. We are designing scaffold implants that can bridge an injury site and provide a range of physical and chemical cues for stimulating this regrowth. ... Nerves aren't just like one long cable, they're made up of lots of small cables, similar to how an electrical wire is constructed. Using our new technique we can make a conduit with individual strands so the nerve fibres can form a similar structure to an undamaged nerve. ... Once the nerve is fully regrown, the conduit biodegrades naturally. The team hopes that this approach will significantly increase recovery for a wide range of peripheral nerve injuries."

AUBREY DE GREY TO DEBATE PROFESSOR COLIN BLAKEMORE
Monday, April 23, 2012
http://www.fightaging.org/archives/2012/04/aubrey-de-grey-to-debate-professor-colin-blakemore.php
Oxford University in the UK has a long tradition of formal public debating, and this week the Oxford University Scientific Society will be hosting a debate on longevity science between Aubrey de Grey of the SENS Foundation and Colin Blakemore former head of the Medical Research Council. This will be the first time that a fellow of the British biomedical establishment has risen to the challenge of describing publicly, in a forum where he can be challenged, why intervention against aging is not in fact medicine's most pressing priority - an area of debate in which the UK lags behind the US: "Oxford University Scientific Society is hosting a debate on Wednesday, 25th April, 2012. The debate will begin at 7pm local time (11am Pacific, 2pm Eastern) in the University of Oxford's Sheldonian Theatre; doors open 45 minutes earlier. Dr. Aubrey de Grey will propose the motion 'This house wants to defeat ageing entirely' and Professor Colin Blakemore will be opposing. The debate will be chaired and moderated by Professor Sir Richard Peto. This debate will address whether it is feasible and appropriate to consider ageing as a target of decisive medical intervention, raising the possibility of substantial extension of human lifespan. Aubrey de Grey is currently Chief Science Officer of SENS Foundation, a biomedical research charity that aims to develop, promote, and ensure widespread access to rejuvenation biotechnologies that address the diseases and disabilities of ageing. SENS Foundation aims to bring ageing under comprehensive medical control. Its research agenda consists of the application of regenerative medicine to ageing - not merely slowing the ageing clock, but resetting it to early adulthood. Colin Blakemore is Professor of Neuroscience at the University of Oxford Nuffield Department of Clinical Neurosciences. He is an expert in vision, development of the brain and neurodegenerative disease. He is active in communication of science and is president and adviser to several charities concerned with brain disorders. Prof. Blakemore was formerly Chief Executive of the Medical Research Council, the UK's largest public funder of biomedical research."

COMMENTARY ON THE NAYSAYERS
Monday, April 23, 2012
http://www.fightaging.org/archives/2012/04/commentary-on-the-naysayers.php
From the Daily Mail: "The Elixir of Youth has a terribly bad press. As soon as any scientist mentions that they have discovered a way of making fruit flies or worms or even mice live a bit longer and furthermore states that this might, just might, work in humans (after lots of tests, refinements, clinical trials and so on and anyway it is decades away at best, the caveats will be longer than the original research paper), you can bet a small vat of snake oil that the naysayers will soon weigh in. 'Who wants to live forever? Not me!' one curmudgeonly columnist will opine. 'What would a world be like with all those ancient people walking around, ugh!' will say another writer who, like the first, will have been commissioned mainly on the basis of their own rather advanced years. Because although the bizarre prejudice against anti-ageing research runs deep and wide, it doesn't quite run deep and wide enough for it to be all right for someone the right side of forty, say, to opine that the old really should shuffle off and leave the field clear. Up to now this has been pretty academic as anti-ageing potions have been little more than science fiction but, as an interesting feature in Nature magazine points out, it is beginning to look like a perfect storm of recent serendipitous discoveries and hard-won genetic advanced might - just might - put the holy grail of increasing human lifespan (as opposed to life expectancy, a very different thing) within reach."

______________________________


View the full article

Click HERE to rent this BIOSCIENCE adspot to support LongeCity (this will replace the google ad above).

#7 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 06 May 2012 - 03:55 PM

FIGHT AGING! NEWSLETTER
May 7th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Video: "this house wants to defeat aging entirely"
- Radical Life Extension at the Melbourne Humanity+ Conference
- Plausible, Possible, Expensive, Prohibited
- Cryonics Magazine, March-April 2012
- Discussion
- Latest Headlines from Fight Aging!

VIDEO: "THIS HOUSE WANTS TO DEFEAT AGING ENTIRELY"

Video has been posted of the recent Oxford University Science Society public debate between Aubrey de Grey of the SENS Foundation and Colin Blakemore, former head of the Medical Research Council.

http://www.fightaging.org/archives/2012/04/video-this-house-wants-to-defeat-ageing-entirely.php

"Formal debates in science and medicine, sponsored by academic societies, are a long-standing tradition in England: in the history of the sciences many of the important inflection points and transitions between eras of knowledge were marked by public debates held between the worthies of the time. The debates do not in and of themselves determine anything: they are a reflection of ongoing matters of interest and the clash of strategies or theories that currently engage the scientific community. Thus it should be taken as a promising sign that awareness of SENS-style rejuvenation biotechnology is at a level at which such debates are held and well-attended.

"Rejuvenation through medical technology is in our future, and factions within the scientific and medical development communities are forming and polarizing around opinions on plausibility, how to construct therapies for aging, and just how urgent it is to take action on this issue. Much of the ongoing debate within the scientific community is invisible to the world at large - but make no mistake, it is taking place, and has been for the better part of a decade. When it comes to aging and what to do about it, the research community of today is a radically different place from the research community of the first years of this century."

RADICAL LIFE EXTENSION AT THE HUMANITY+ MELBOURNE CONFERENCE

And here is Aubrey de Grey in the news again, getting good press in Australia on the occasion of the 2012 Humanity+ conference in Melbourne held this past weekend:

http://www.fightaging.org/archives/2012/05/radical-life-extension-at-the-melbourne-humanity-conference.php

"When British gerontologist Aubrey de Grey talks about radical life extension for humans - decades, even centuries more of existence - he is not imagining us slogging by with brain plaque, loose dentures and walking frames. Rather, we would be in rude health, with all the hallmarks of age in abeyance, even retreat. No wrinkles, fraying organs, leaky bladders or aching joints. And not much need for aged care or pensions. ... In a world where life expectancy has already dramatically increased over the past century or two, we now face the likelihood of being able to custom-order fresh organs and body parts on 3D-printers, and to treating the basic causes of ageing with the likes of stem-cell therapy and nanotechnology.

"De Grey and [Natasha] Vita-More, in Melbourne for this weekend's Humanity+ conference, are in the vanguard of futurists who believe that looking great or designing our bodies to suit (blue skin and magenta eyes anyone?) will be fringe benefits. That is because, in a fast-approaching era of living longer, healthier lives, it is expected we will have time to enjoy the wisdom and opportunities of getting older - we won't be so focused on all the medical appointments, decrepitude and fragility associated with old age. ... de Grey, who once said some of today's infants might live to 1000 years old, and who not so long ago was viewed sceptically by other scientists for his insistence that ageing is a preventable, treatable medical condition, now sees much broader acceptance of his ideas among scientists.

'"'Attitudes have changed enormously,' he says. 'The feasibility of what I have been proposing is now generally accepted. It took a long time, because essentially ... people who were expert in regenerative medicine didn't know about ageing; and people expert in ageing didn't know about regenerative medicine.'

"A bigger battle has been with the attitudes of the general population, who view ageing as natural and inevitable and who, asked if they would like to have much longer lifespans, deliver predictable objections, often saying they would get bored (so much for the human imagination). De Grey says these responses are because people don't think of ageing in the same category as other diseases: if they understood they could live much longer without medical problems or signs of ageing, they would be enthusiastic. 'They just don't think of [ageing] as a plausible target for medicine.'"

PLAUSIBLE, POSSIBLE, EXPENSIVE, PROHIBITED

What could you choose to do today, if you had enough money for a major medical procedure, and the legion of medical regulators didn't exist? If you were free to choose your own risks in medicine, and doctors and researchers were free to be paid to help you? Here are a few examples, with varying degrees of risk, reward, and unknown factors:

http://www.fightaging.org/archives/2012/05/plausible-possible-expensive-prohibited.php

"Have your aging immune system wiped out with chemotherapy and replaced from your stem cells. Your wager here would be that undergoing chemotherapy (not a wonderful experience under the best of circumstances) will cause you less harm in the long term than keeping your original, increasingly misconfigured immune system. Alternately, you could wait a decade for targeted cell-killer therapies demonstrated in mice to become a practical concern in humans.

"Undergo any one of a number of potential enhancing gene therapies. For example, why not pay your way into possessing a myostatin mutation? That boosts muscle mass, increases resistance to a range of age-related conditions, and otherwise seems to be beneficial all-round in mammals.

"Purchase stem cell infusions of the sort that seem to be at least modestly helpful for any number of degenerative conditions - a better option than traditional pharmaceutical medicines. But of course you can't do that in the US, just like you can't benefit from near all of the most recent advances, locked away in trials for years yet. You'd have to head overseas as a medical tourist to become a customer of the more reliable clinics in Asia or the Middle East.

"Decide in your healthy old age that the possible benefits outweigh the risks for infusion-based biphosphonate therapy [which was unexpectedly shown to extend life expectancy by years in the elderly]. Of course you can't obtain that legally as a healthy person - those regulators again, deciding that they know better and anyone who disagrees with them will ultimately wind up in jail.

"Choose to end your own long-lived life in a safe and painless way at the time of your choosing, while attended by cryonics professionals who can provide an immediate and expert preservation - offering absolutely the best chance of later restoration with minimal damage, while keeping the cost to a sensible minimum thanks to scheduling.

"I could go on - that just scratches the surface. But of course any group that gathered in the US to try these things, or offer services, or make the process as safe and transparent as possible would quickly find themselves prosecuted and jailed. The land of the free long ago ceased to have much to do with liberty or personal freedom. Freedom is the freedom to take your own risks and pay the costs if you pull a bad card from the deck - and that freedom is exactly what drives progress. Take it away and what results is the regulatory stagnation you see in medicine today."

CRYONICS MAGAZINE, MARCH-APRIL 2012

The March-April issue of Cryonics is available online:

http://www.fightaging.org/archives/2012/05/cryonics-magazine-march-april-2012.php

"The main topic of the issue ties into the ongoing discussion on maintaining Alcor's reserve of funds at a sufficient level for the long term - which is essentially a battle against the predatory inflation produced by the self-serving actions of politicians and political appointees. The political class can be expected to create ever more money from nothing, continually reducing the value of money in circulation and savings accounts, because it is the most effective way to tax the masses - all other forms of taxation generate far more unrest, resistance, and non-compliance, and are thus much more self-limiting in the revenue they can generate.The battle against the inflation resulting from depreciation of the currency is fought by all entities that must tie contracts inked today to outlays required years from now:

"As evidenced by recent exchanges on the Alcor Member Forums, our members have a wide variety of suggestions for how to close the substantial funding gap that has been produced by Alcor's practice to date of not raising cryopreservation minimums for existing members. If there is one area of strong agreement, however, it is that all members who are underfunded for today's cryopreservation minimums and who can afford to change or upgrade their life insurance, should do so. This will not just reduce Alcor's funding shortfall but it will also allow the member to secure new cryopreservation and storage technologies that cannot be offered without charging an additional amount. Surplus funding can also be allocated to a personal revival trust or to Alcor's hardship fund to help members with poor funding and/or challenges to pay annual dues.

"The March-April issue of Cryonics magazine features an extensive review of life insurance options by Alcor member and life insurance agent Rudi Hoffman. Rudi introduces the topic by presenting the disturbing long-term effects of (medical) inflation. Not all of Alcor's services may be subject to the kind of cost increases we see in medicine but it is prudent to plan using conservative assumptions. After this sobering introduction, Rudi runs us through the various forms of life insurance, their pros and cons, and how to read those long, intimidating policy illustrations. We at Alcor hope that many of you will make efforts to update your cryonics funding to make it easier to solve the underfunding problem and to assist with the really hard cases."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

MAKING OLD STEM CELLS FUNCTIONALLY YOUNG
Friday, May 4, 2012
http://www.fightaging.org/archives/2012/05/making-old-stem-cells-functionally-young.php
More rejuvenation of stem cell function demonstrated in mice: "Researchers have rejuvenated aged hematopoietic stem cells to be functionally younger, offering intriguing clues into how medicine might one day fend off some ailments of old age. ... The paper brings new perspective to what has been a life science controversy - countering what used to be broad consensus that the aging of hematopoietic stem cells (HSCs) was locked in by nature and not reversible by therapeutic intervention. HSCs are stem cells that originate in the bone marrow and generate all of the body's red and white blood cells and platelets. They are an essential support mechanism of blood cells and the immune system. As humans and other species age, HSCs become more numerous but less effective at regenerating blood cells and immune cells. ... Researchers in the current study determined a protein that regulates cell signaling - Cdc42 - also controls a molecular process that causes HSCs from mice to age. Pharmacologic inhibition of Cdc42 reversed HSC aging and restored function similar to that of younger stem cells. ... We know the aging of HSCs reduces in part the response of the immune system response in older people, which contributes to diseases such as anemia, and may be the cause of tissue attrition in certain systems of the body. ... One reason the research team focused on Cdc42 is that previous studies have reported elevated activity of the protein in various tissue types of older mice - which have a natural life span of around two years. Also, elevated expression of Cdc42 has been found in immune system white blood cells in older humans. In the current study, researchers found elevated activity of Cdc42 in the HSCs of older mice. They also were able to induce premature aging of HSCs in mice by genetically increasing Cdc42 activity in the cells. ... To test the rejuvenated cells, the researchers used a process known as serial competitive transplantation. This included extracting HSCs from young (2-4 months) and aged (20-26 months) mice and processing them in laboratory cultures. Young and rejuvenated cells were then engrafted into recipient mice. This allowed scientists to compare how well young and rejuvenated aged HSCs started to repopulate and transform into different types of blood cells. It also confirmed that HSCs rejuvenated by targeting Cdc42 do function similarly to young stem cells."

SELF-ASSEMBLING NANOPARTICLES TO TARGET UNWANTED CELLS
Friday, May 4, 2012
http://www.fightaging.org/archives/2012/05/self-assembling-nanoparticles-to-target-unwanted-cells.php
An example of ongoing work to make targeted cell-killing technologies economically practical: "For more than a decade, researchers have been trying to develop nanoparticles that would deliver drugs more effectively and safely. The idea is that a nanoparticle containing a drug compound could selectively target tumor cells or otherwise diseased cells, and avoid healthy ones. Antibodies or other molecules can be attached to the nanoparticle and used to precisely identify target cells. ... [Researchers] devised a method by which the building blocks of the nanoparticle and the drug self-assemble into a final product. Two types of polymer combine to form the tangled mesh of [a] drug-laden spherical nanoparticle. One of these polymers has two chemically and structurally distinct regions, or 'blocks': a water-insoluble block that forms part of the mesh that encapsulates the drug, and a water-soluble block that gives the final product a stealthy corona to evade the immune system. The other type of polymer has three blocks: the same two as the first, as well as a third region that contains a targeting molecule - the signal that will ensure the final particles attach to the desired cell types. The drug-carrying nanoparticles are formed by simply mixing these polymers together with the drug in the appropriate conditions. The self-assembling polymers can be produced in a repeatable and scalable fashion. But the method has an additional benefit ... The method by which the nanoparticles are built - from individual preparations of the two-block and three-block polymers - would also let researchers use high-throughput screening approaches, akin to how medicinal chemists design and test new drug compounds. Each block could be tweaked - extend one block, change the charge on another - and the relative amounts of each polymer could be varied. With so many parameters for tinkering, [scientists] can screen many combinations."

REPLACING DAMAGED DJ-1 IN PARKINSON'S DISEASE
Thursday, May 3, 2012
http://www.fightaging.org/archives/2012/05/replacing-damaged-dj-1-in-parkinsons-disease.php
It has been a number of years since researchers started to investigate the role of DJ-1 in Parkinson's disease. Here, the work has made it to the stage of a possible therapy: "As we age, we naturally lose dopamine-producing neurons. Parkinson's patients experience a rapid loss of these neurons from the onset of the disease, leading to much more drastic deficiencies in dopamine than the average person. ... Mutations in the gene known as DJ-1 lead to accelerated loss of dopaminergic neurons and result in the onset of Parkinson's symptoms at a young age. The ability to modify the activity of DJ-1 could change the progress of the disease. [Researchers have] now developed a peptide which mimics DJ-1's normal function, thereby protecting dopamine- producing neurons. What's more, the peptide can be easily delivered by daily injections or absorbed into the skin through an adhesive patch. Based on a short protein derived from DJ-1 itself, the peptide has been shown to freeze neurodegeneration in its tracks, reducing problems with mobility and leading to greater protection of neurons and higher dopamine levels in the brain. ... We attached the DJ-1-related peptide to another peptide that would allow it to enter the cells, and be carried to the brain. ... In pre-clinical trials, the treatment was tested on mice ... From both a behavioral and biochemical standpoint, the mice that received the peptide treatment showed remarkable improvement. Symptoms such as mobility dysfunctions were reduced significantly, and researchers noted the preservation of dopamine-producing neurons and higher dopamine levels in the brain. Preliminary tests indicate that the peptide is a viable treatment option. Though many peptides have a short life span and degrade quickly, this peptide does not."

THE POWER OF MODERATE EXERCISE
Thursday, May 3, 2012
http://www.fightaging.org/archives/2012/05/the-power-of-moderate-exercise.php
Moderate exercise improves life expectancy: "Undertaking regular jogging increases the life expectancy of men by 6.2 years and women by 5.6 years, reveals the latest data from the Copenhagen City Heart study ... the study's most recent analysis (unpublished) shows that between one and two-and-a-half hours of jogging per week at a 'slow or average' pace delivers optimum benefits for longevity. ... SThe study, which started 1976, is a prospective cardiovascular population study of around 20,000 men and women aged between 20 to 93 years. The study, which made use of the Copenhagen Population Register, set out to increase knowledge about prevention of cardiovascular disease and stroke. Since then the study, which has resulted in publication of over 750 papers, has expanded to include other diseases ... The investigators have explored the associations for longevity with different forms of exercise and other factors. For the jogging sub study, the mortality of 1,116 male joggers and 762 female joggers was compared to the non joggers in the main study population. All participants were asked to answer questions about the amount of time they spent jogging each week, and to rate their own perceptions of pace (defined as slow, average, and fast). ... The first data was collected between 1976 to 1978, the second from 1981 to 1983, the third from 1991 to 1994, and the fourth from 2001 to 2003. For the analysis participants from all the different data collections were followed using a unique personal identification number in the Danish Central Person Register. ... These numbers have been key to the success of the study since they've allowed us to trace participants wherever they go. ... Results show that in the follow-up period involving a maximum of 35 years, [risk] of death was reduced by 44%."

MORE EVIDENCE TO SHOW THAT EXCESS FAT CAUSES CHRONIC INFLAMMATION
Wednesday, May 2, 2012
http://www.fightaging.org/archives/2012/05/more-evidence-to-show-that-excess-fat-causes-chronic-inflammation.php
Chronic inflammation is a bad thing - it greatly increases your risk of suffering age-related disease, and may be one of the more important mechanisms linking excess fat tissue to risk of disease and lowered life expectancy. Here is more evidence to show that being overweight exposes a person to greater inflammation: "Postmenopausal women who were overweight or obese and lost at least 5 percent of their body weight had a measurable reduction in markers of inflammation. ... Both obesity and inflammation have been shown to be related to several types of cancer, and this study shows that if you reduce weight, you can reduce inflammation as well. ... Women in the trial who were assigned to a weight loss intervention had a goal of 10 percent weight reduction during the course of one year achieved through a diet intervention with or without aerobic exercise. ... The researchers measured levels of C-reactive protein, serum amyloid A, interleukin-6, leukocyte and neutrophil in 439 women. At the end of one year, C-reactive protein reduced by 36.1 percent in the diet-alone group and by 41.7 percent in the diet and exercise group. Interleukin-6 decreased by 23.1 percent in the diet group and 24.3 percent in the diet and exercise group. ... there were greater reductions in these measures among women who lost at least 5 percent of their body weight. They also found that exercise alone, without a dietary weight loss component, had little effect on inflammation markers."

TELOMERES IN DISEASE AND AGING
Wednesday, May 2, 2012
http://www.fightaging.org/archives/2012/05/telomeres-in-disease-and-aging.php
An introduction to what is known of telomeres can be found at the Scientist: "The ends of linear chromosomes have attracted serious scientific study - and Nobel Prizes - since the early 20th century. Called telomeres, these ends serve to protect the coding DNA of the genome. When a cell's telomeres shorten to critical lengths, the cell senesces. Thus, telomeres dictate a cell's life span - unless something goes wrong. Work over the past several decades has revealed an active, though limited, mechanism for the normal enzymatic repair of telomere loss in certain proliferative cells. ... Telomeres shorten as we age. By analogy to the cellular mitotic clock, telomeres have been postulated as a marker of 'genetic age,' and telomere length has been marketed as a simple predictor of longevity. Assays of telomere length have been bundled with recommendations for lifestyle modification and for drug therapy, neither based on appropriate clinical studies. Simple but appealing arguments relating telomeres and aging are currently controversial, likely simplistic, and potentially harmful. Telomere length does indeed reflect a cell's past proliferative history and future propensity for apoptosis, senescence, and transformation. Cellular aging, however, is not equivalent to organ or organismal aging. ... Studies in humans have attempted to relate telomere length to life span. In the provocative initial publication from the University of Utah in 2003, individuals around 60 years of age who had the longest telomeres lived longer than did subjects with the shortest telomeres, but the main cause of death in the latter group was, inexplicably, infectious disease; the persons with shorter telomeres did not have a higher rate of cancer deaths. Moreover, these findings have not been confirmed in other studies of older subjects. In another study evaluating a different population, telomere length failed to predict survival, but interestingly it correlated with years of healthy life. In a Danish study of people aged 73 to 101 years, telomeres correlated with life expectancy in a simple univariate analysis, but only before the researchers corrected for age, suggesting that the correlation was driven simply by the fact that younger subjects had longer telomeres. And a Dutch study of 78-year-old men found that while telomere lengths eroded with age, they failed to correlate with mortality."

MICHAEL BATIN'S SPEECH AT THE 2ND INTERNATIONAL CONFERENCE ON THE GENETICS OF AGING AND LONGEVITY
Tuesday, May 1, 2012
http://www.fightaging.org/archives/2012/05/michael-batins-speech-at-the-2nd-international-conference-on-the-genetics-of-aging-and-longevity.php
Following on from a recent interview with Michael Batin, one of the organizers of the 2nd International Conference on the Genetics of Aging and Longevity, here is a machine translation of his speech to the attendees: "We hope that the conference will identify the most promising points of growth, will contribute to international scientific and research funding [from] international and national foundations, private investors. Let me ask the main question [in biogerontology]. Why [is] aging research funded by the minimum amount? How to change the situation? How to change the attitudes of society and government to seek scientific methods of prolonging life? The first thing that prevents us [is that] aging itself is not considered a disease. Although the aging process fully complies with all common signs of the disease. Aging - a cause of illness and disease. Failure to understand this - [a] deadly mistake. The price of this confusion is very real - [100,000] people die every day from diseases related to aging. Another misconception - aging can be successful and healthy. No, [it] can not! Aging can flow more smoothly. Aging can be slowed down. But you can not make a destructive process or healthy, or successful. As it is impossible to make a decent poverty [or toothache enjoyable]. [This is] the amazing paradox. Nobody disputes the fact that there is nothing more important than human life. All agree that there is nothing more terrible than death. Many suspect that the main cause of death in people [is] aging. But few people make this a logical conclusion. What is the most useful and meaningful activity that has ever engaged [mankind? It is the] struggle with aging. And in particular [the study of] fundamental mechanisms of aging and genetics of longevity. That's what [the scientists in this room do].. And I believe [that they are the] most helpful people on the planet."

MAINTENANCE OR RESERVE IN THE AGING BRAIN?
Tuesday, May 1, 2012
http://www.fightaging.org/archives/2012/05/maintenance-or-reserve-in-the-aging-brain.php
There are numerous high-level hypotheses that seek to explain why different people suffer neurodegeneration to different levels. Some people remain sharp in old age, whilst others descend into dementia. At the fine-grained level of measuring different types of mental capacity, there are also large variations across an aging population: "Episodic memory and working memory decline with advancing age. Nevertheless, large-scale population-based studies document well-preserved memory functioning in some older individuals. The influential 'reserve' notion holds that individual differences in brain characteristics or in the manner people process tasks allow some individuals to cope better than others with brain pathology and hence show preserved memory performance. Here, we discuss a complementary concept, that of brain maintenance (or relative lack of brain pathology), and argue that it constitutes the primary determinant of successful memory aging. We discuss evidence for brain maintenance at different levels: cellular, neurochemical, gray- and white-matter integrity, and systems-level activation patterns. Various genetic and lifestyle factors support brain maintenance in aging and interventions may be designed to promote maintenance of brain structure and function in late life." It makes more sense for neurodegeneration to be more greatly affected by the impact of regular exercise on long-term tissue health than by the genetics of having a cognitive research.

AN INTERVIEW ON AGING AND DEMENTIA
Monday, April 30, 2012
http://www.fightaging.org/archives/2012/04/an-interview-on-aging-and-dementia.php
An interview with a researcher in the field: "the reality is that our brains age throughout life and, in fact, the science tells us that at age 45 we can measure cognitive and memory decline in the average person. There's a steady gradual decline that continues. ... Age is the greatest risk factor. By age 65 or older, your risk is about 10 per cent for Alzheimer's dementia. By 85, it's 40 per cent or more. The implications are that we have a lot more people who have dementia and a lot more people concerned about developing it. ... The studies of successful aging tell us that, when it comes to cognitive success or avoiding dementia or developing it, for the average person only a third of what determines that cognitive outcome results from genetics, from what we inherit. Rarely there are families, less than 2 per cent of cases, with very strong genetic components; they have mutations that cause the disease very early in life. For the vast majority, the genetics are not as strong. They are a factor. About 20 per cent of the population has this risk. It increases the likelihood of getting the disease and the likelihood of getting it at an earlier age but it's not 100 per cent. That means that two-thirds of the formula comes from non-genetic factors: the lifestyle choices we make every day have a major impact on how well our brains age. ... Physical exercise, mental exercise, nutrition, stress management and other behaviours, like avoiding head trauma, not smoking and so forth. ... Exercise seems obvious [but] it may not be completely obvious for people. They know there is a connection between exercise and physical health, exercise and avoiding heart disease. But not everybody is aware of the strong connection between physical exercise and brain health."

SPAWNING DESIGNER LYMPH NODES
Monday, April 30, 2012
http://www.fightaging.org/archives/2012/04/spawning-designer-lymph-nodes.php
Researchers are trying to create new lymph nodes in the body, but tailored to specific needs: "Designer lymph nodes are built with specialized gene-modified cells that are injected into patients and produce a pre-planned immunologic response for cancer patients locally and then throughout their bodies. The researchers are examining a cancer vaccine 'boosting' effect of the manufactured lymph nodes in patients with advanced melanoma. ... Patients with cancer have a dysfunctional immune system either because of the tumor's presence in the body or as a side effect of drugs or radiation used to treat the tumor. The designer lymph nodes, aimed at rebuilding their immune systems, may overcome this dysfunction. ... the researchers are using antigen-presenting cells made from the patient's blood, which are then genetically manipulated to express certain genes before injection into patients. They can inject gene-modified cells at multiple, independent sites throughout the body to create independent lymph nodes that work together. In the trial, the researchers have found early formation of lymph nodes at the vaccine injection sites and are subsequently testing the nature and anti-tumor function of them. [The team] anticipate partnering with [other institutions] to create designer lymph nodes for diseases other than cancer and expand their designer gene immunity boosting research into fighting infectious diseases and even improving the function of immune systems in the elderly."

______________________________


View the full article

#8 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 13 May 2012 - 06:45 PM

FIGHT AGING! NEWSLETTER
May 14th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Maintain Yourself
- A Report from the Genetics of Aging and Longevity Conference
- Metformin, a Review
- Learning from the Regrowth of Feathers and Hair?
- Discussion
- Latest Headlines from Fight Aging!

MAINTAIN YOURSELF

A reminder that it is a good plan to put in the effort on basic health maintenance:

http://www.fightaging.org/archives/2012/05/maintain-yourself.php

"The human body needs to be taken care of in a variety of ways for best performance over the long term. Exercise, keep the weight off, try to avoid stabbing yourself. It's a considerable disadvantage that in our formative years that sort of maintenance just happens as a natural consequence of being a child - so the additional work that has to go into maintaining health as an adult comes as an unexpected chore.

"So: many of us get successful, then get fat, and then suffer age-related conditions more frequently and sooner, and then on average die younger. This isn't rocket science - most people know what they are doing to themselves, even if they aren't up to speed on the details of the biochemistry involved. But the siren song of life in a time of wealth and plenty lures you in. Maybe medical science will save you from yourself ... but I wouldn't count on it.

"So maintain yourself. You stand on the verge of a golden age in biotechnology, one that will offer unlimited healthy, youthful lifespans to those who claw their way over the threshold. Slacking on your health is turning your back on that future, it is making it harder for you to live long enough to benefit from rejuvenation biotechnologies that can be clearly envisaged today."

A REPORT FROM THE GENETICS OF AGING AND LONGEVITY CONFERENCE

Maria Konovalenko recently reported on her attendance at the Moscow conference on the genetics of aging and longevity, held last month. The post includes a great many photographs of folk from the aging research community; browse through if you are interested in putting faces to the names you read about in the science press:

http://www.fightaging.org/archives/2012/05/a-report-from-the-moscow-genetics-of-aging-and-longevity-conference.php

"It has been a while since I've posted my blog updates. The reason was the Genetics of Aging and Longevity conference. I have been involved in preparations of this meeting since December and the last month before the event was especially tough. Anyway, the conference turned out to be pretty good. I was surprised to hear so many good responses and impressions from the attendees and the speakers, so I am proud to say that the meeting was a success. The talks were superb, a lot of new and even unpublished data, a lot of discussions during the breaks and meals. I saw quite many people walking around with burning eyes - from excitement of science, of course) Some of those eyes are in the photos below. I believe this was a ground braking event on life extension topic in Russia, a truly unique gathering of minds. The more meetings like this we have, the more attention they get in the media, the better chances we have to live longer."

METFORMIN, A REVIEW

There are a few established drugs shown to modestly extend life in laboratory animals, with varying degrees of certainty. Rapamycin is probably the most concrete of those drugs at this time. Metformin is another, but the results there are far more ambiguous:

http://www.fightaging.org/archives/2012/05/metformin-a-review.php

"Metformin is a drug that shows up in discussion here every so often. It is thought to be a calorie restriction mimetic, recapitulating some of the metabolic changes caused by the practice of calorie restriction. Its effects on life span in laboratory animals are up for debate and further accumulation of evidence - the results are on balance more promising than the generally dismal situation for resveratrol, but far less evidently beneficial than rapamycin. Like rapamycin, metformin isn't something you'd want to take as though it were candy, even if the regulators stood back to make that possible, as the side effects are not pleasant and potentially serious.

"I should note as an aside that while ongoing research into the effects of old-school drugs of this nature is certainly interesting, it doesn't really present a path to significantly enhanced health and longevity. It is a pity that such research continues to receive the lion's share of funding, given that the best case outcome is an increase in our knowledge of human metabolism, not meaningful longevity therapies. Even if the completely beneficial mechanism of action is split out from the drug's actions - as seems to be underway for rapamycin - the end results will still only be a very modest slowing of aging. You could do better by exercising, or practicing calorie restriction.

"For the billions in funding poured into these drug investigation programs, there should be a better grail at the end of the road - such as that offered by the SENS vision of rejuvenation biotechnology. Targeted repair of the biological damage of aging is a far, far better strategy than gently slowing the pace of damage accumulation through old-style drug discovery programs. This is a biotechnology revolution: time to start acting like it.

Anyway, aside done, let me point you to a recent open access review on metformin: the interesting work that won't really be in any way relevant to the future of your longevity, but which I'll wager has raised more funding as an object of study than the entire present extant SENS program and directly related scientific studies. ... See what you think; it makes for an interesting read - and includes a table of results from a number of life span studies that are, indeed, all over the map. It somewhat reinforces the point that unambiguous success in extending healthy life is not going to arrive from this quarter. Think SENS, not drug discovery - what will come from the drug discovery clade is a slow, grinding, and expensive cataloging of the fine details of genetics, metabolism, and aging in mammals."

LEARNING FROM THE REGROWTH OF FEATHERS AND HAIR?

The animal kingdom is rife with species that do a far better job of regeneration than we humans. What can be learned from the details of their biochemistry?

http://www.fightaging.org/archives/2012/05/learning-from-the-regrowth-of-feathers-and-hair.php

"For some years researchers have been investigating the mechanisms of limb and organ regrowth in lower animals like salamanders, with an eye to finding out how easy or hard it would be to recreate those same capabilities in mammals - such as we humans. Do we retain the core mechanisms, lying dormant in our biochemistry, or have they been completely lost? Time and ongoing research will tell.

"But these are not the only areas of regrowth wherein researchers might learn something of interest to regenerative medicine. Consider that elk regularly regrow their antlers, for example - not a simple organ by any means. Further down the scale of impressiveness, we might consider the many higher animals that regularly regrow feathers or coats of hair. Is there anything in their biochemistry that might be discovered and adapted to cause humans to regenerate in situations where they normally do not? If you buy into the argument that salamander biochemistry is worth investigation, then it's hard to reject similar investigations in other species capable of the lesser forms of regrowth mentioned above."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

STILL WORKING ON AND DEBATING RESVERATROL AND SIRT1
Friday, May 11, 2012
http://www.fightaging.org/archives/2012/05/still-working-on-and-debating-resveratrol-and-sirt1.php
In recent years resveratrol has clearly fallen below the dividing line for work that is useful from a longevity perspective - if it could extend life significantly in mice, that would have been demonstrated by now. You might compare with the size of the effects on mouse lifespan for rapamycin to provide an example of a compound that is worth investigating. There is, however, a lot of money sunk into work on resveratrol and the underlying mechanisms of sirtuins, so don't expect that to halt any time soon. Research and developer institutions are prone to inertia, just like all other fields of human endeavor. In any case, here is some of the latest work on SIRT1: "If resveratrol needs SIRT1 to improve health, then animals lacking the gene should not get any benefits from the chemical. His lab published that experiment in yeast in 2003. But mice lacking SIRT1 die in the womb, or they are born with developmental defects such as blindness. To get around that problem, [researchers] engineered 'conditional knockout' mice whereby SIRT1 can be inactivated in adulthood. ... It took us two weeks to do the experiment in yeast, and five years in mouse, but finally we're there ... In normal mice, resveratrol combated the effects of a high-fat diet by boosting the efficiency of energy-generating organelles called mitochondria in skeletal muscle tissue. This effect vanished in adult mice without a working version of SIRT1. Yet SIRT1 wasn't responsible for all the beneficial effects of resveratrol ... Resveratrol stabilized the blood glucose levels of both normal and SIRT1-lacking mice on fatty diets. The chemical also improved liver health in mice without SIRT1. [The researchers also contend] that a lot the confusion over how resveratrol works comes down to dosage. At very high doses it binds other proteins besides SIRT1 ... For instance, a signalling protein called AMPK is also important to resveratrol's beneficial effects on metabolism. ... low doses of resveratrol boosted AMPK levels in various cells that expressed SIRT1, but not cells without the sirtuin. Much higher doses of resveratrol, however, activated AMPK irrespective of whether the cells expressed SIRT1."

ON THE TISSUE ENGINEERING OF TEETH
Friday, May 11, 2012
http://www.fightaging.org/archives/2012/05/on-the-tissue-engineering-of-teeth.php
Singularity Hub looks at the tissue engineering of teeth: "For years, researchers have investigated stem cells in an effort to grow teeth made for a person's own cells. Toward this end, [scientists] have developed methods to control adult stem cell growth toward generating dental tissue and 'real' replacement teeth. [The] researchers' approach is to extract stem cells from oral tissue, such as inside a tooth itself, or from bone marrow. After being harvested, the cells are mounted to a polymer scaffold in the shape of the desired tooth. The polymer is the same material used in bioreabsorable sutures, so the scaffold eventually dissolves away. Teeth can be grown separately then inserted into a patient's mouth or the stem cells can be grown within the mouth reaching a full-sized tooth within a few months. So far, teeth have been regenerated in mice and monkeys, and clinical trials with humans are underway, but whether the technology can generate teeth that are nourished by the blood and have full sensations remains to be seen. Teeth present a unique challenge for researchers because the stem cells must be stimulated to grow the right balance of hard tissue, dentin and enamel, while producing the correct size and shape."

ON ENGINEERING FUNCTIONAL CARTILAGE
Thursday, May 10, 2012
http://www.fightaging.org/archives/2012/05/on-engineering-functional-cartilage.php
An article from the Wellcome Trust: "Researchers have been engineering cartilage in the laboratory for 15 years or more, but as yet the tissues they have created don't function properly in human joints. [Researchers] are taking a new approach to try to bridge the gap between laboratory-created cartilage and the tissue our bodies make. ... Biological texts show that these lab-grown tissues have the appearance, texture, and protein and mineral components of bone and cartilage. But once they are tested in an animal, these tissues simply don't behave quite like the natural tissues they are supposed to replicate. ... Joints are remarkable feats of engineering, but efforts to grow them in the lab have focused mostly on their biology. ... Biologists attempting to create cartilage and bone over the past 15 years have typically tested the mechanical properties of their laboratory-grown tissue - for example, whether it is rubbery and resilient enough when pressure is applied. ... Just because biological tests indicate a tissue looks like bone and feels like bone, doesn't actually mean it is bone ... This is where an engineering perspective becomes important. To look at how close a match these laboratory-generated tissues really are to native bone and cartilage, [researchers] supplemented the biological analyses with engineering tests, such as bio-Raman microspectroscopy. ... You shine a laser on the material, and the way the light scatters gives you an idea of the bonds between its components. Different mineral types form different bonds, so you get a much more precise picture of what is actually present. ... If a lab-grown tissue seems from some tests to be the real thing but isn't really, then it won't behave like it once it has been implanted in a human body. ... [The researchers aim] to use an engineering approach to create a whole osteochondral interface in which bone and cartilage transition seamlessly into each other like they do in the body. ... That's the only way it will effectively transmit loads to the underlying bone. And because bone will heal, it will heal the construct into the joint."

SEEKING CONTROL OVER THYMIC INVOLUTION
Thursday, May 10, 2012
http://www.fightaging.org/archives/2012/05/seeking-control-over-thymic-involution.php
Following on from a recent post on the involution of the thymus in adults, the process by which it ceases to generate immune cells and atrophies, here is a another paper that considers some of the possible paths to interventions that maintain the thymus into old age. Given experiments in mice showing that transplant of a young thymus extends life, this seems worthy of further investigation: "The thymus is the primary organ for T-cell differentiation and maturation. Unlike other major organs, the thymus is highly dynamic, capable of undergoing multiple rounds of almost complete atrophy followed by rapid restoration. The process of thymic atrophy, or involution, results in decreased thymopoiesis and emigration of naïve T cells to the periphery. Multiple processes can trigger transient thymic involution, including bacterial and viral infection(s), aging, pregnancy and stress. Intense investigations into the mechanisms that underlie thymic involution have revealed diverse cellular and molecular mediators, with elaborate control mechanisms. This review outlines the disparate pathways through which involution can be mediated, from the transient infection-mediated pathway, tightly controlled by microRNA, to the chronic changes that occur through aging."

TOWARDS REGENERATIVE MEDICINE FOR ATHEROSCLEROSIS
Wednesday, May 9, 2012
http://www.fightaging.org/archives/2012/05/towards-regenerative-medicine-for-atherosclerosis.php
An update on the LysoSENS research project from the SENS Foundation, which aims to discover and adapt bacterial enzymes to break down the damaging buildup of unwanted metabolic byproducts in the aging body: "SENS Foundation-funded research shows that expression of a modified microbial enzyme protects human cells against 7-ketocholesterol toxicity, advancing research toward remediation of the foam cell and rejuvenation of the atherosclerotic artery. ... Atherosclerotic cardiovascular disease is the principal cause of ischaemic heart disease, cerebrovascular disease, and peripheral vascular disease, making it the root of the leading cause of morbidity and mortality worldwide. Atherosclerosis begins with the entrapment and oxidation of low-density lipoprotein (LDL) cholesterol in the arterial endothelium. As a protective response, the endothelium recruits blood monocytes into the arterial wall, which differentiate and mature into active macrophages and engulf toxic oxidized cholesterol products (oxysterols) such as 7-ketocholesterol (7-KC). Although initially protective, this response ultimately leads to atherosclerotic plaque: oxidized cholesterol products accumulate in the macrophage lysosome, and impair the processing and trafficking of native cholesterol and other materials, leading macrophages to become dysfunctional and immobilized ... more and more of these disabled "foam cells" progressively accumulate in the arterial wall, generating the fatty streaks that form the basis of the atherosclerotic lesion. Rejuvenation biotechnology can be brought to bear against this disease of aging through the identification, modification, and therapeutic delivery of novel lysosomal enzymes derived from microbes to the arterial macrophage - enzymes which are capable of degrading oxidized cholesterol products. SENS Foundation-funded researchers have been making steady progress in the identification and characterization of candidate enzymes for several years now, and a new report represents a substantial advance in the research: the rescue of cellular oxysterol toxicity by an introduced microbial lysosomal enzyme."

MORE ON NRG-1 IN NAKED MOLE-RATS
Wednesday, May 9, 2012
http://www.fightaging.org/archives/2012/05/more-on-nrg-1-in-naked-mole-rats.php
You might recall research published last near on NRG-1 levels in naked mole-rats. Here is an update: "The typical naked mole rat lives 25 to 30 years, during which it shows little decline in activity, bone health, reproductive capacity and cognitive ability. ... Naked mole rats have the highest level of a growth factor called NRG-1 in the cerebellum. Its levels are sustained throughout their life, from development through adulthood. ... NRG-1 levels were monitored in naked mole rats at different ages ranging from a day to 26 years. The other six rodent species have maximum life spans of three to 19 years. The cerebellum coordinates movements and maintains bodily equilibrium. The research team hypothesized that long-lived species would maintain higher levels of NRG-1 in this region of the brain, with simultaneous healthy activity levels. Among each of the species, the longest-lived members exhibited the highest lifelong levels of NRG-1. The naked mole rat had the most robust and enduring supply. ... In both mice and in humans, NRG-1 levels go down with age ... The strong correlation between this protective brain factor and maximum life span highlights a new focus for aging research, further supporting earlier findings that it is not the amount of oxidative damage an organism encounters that determines species life span but rather that the protective mechanisms may be more important."

CONSIDERING THE THYMUS
Tuesday, May 8, 2012
http://www.fightaging.org/archives/2012/05/considering-the-thymus.php
The thymus is the source of immune cells, but involutes in adults - it shrinks and loses its functionality. Restoring the thymus is one possible way around some of the built-in limitations of the immune system that contribute to age-related immune failure and a shorter life: "Emerging evidence indicates that the immune and metabolic interactions control several aspects of the aging process and associated chronic diseases. Among several sites of immune-metabolic interactions, thymic demise represents a particularly puzzling phenomenon because even in metabolically healthy middle-aged individuals the majority of thymic space is replaced with ectopic lipids. The new T cell specificities can only be generated in a functional thymus and, peripheral proliferation of pre-existing T cell clones provides limited immune-vigilance in the elderly. Therefore, it is hypothesized that the strategies that enhance thymic-lymphopoiesis may extend healthspan. Recent data suggest that byproducts of thymic fatty acids and lipids result in accumulation of 'lipotoxic DAMPs' (damage associated molecular patterns), which triggers the innate immune-sensing mechanism like inflammasome activation which links aging to thymic demise. The immune-metabolic interaction within the aging thymus produces a local pro-inflammatory state that directly compromises the thymic stromal microenvironment, thymic-lymphopoiesis and serves a precursor of systemic immune-dysregulation in the elderly. [This has] implications for developing future therapeutic strategies for living well beyond the expected."

ENHANCED PROTEASOME ACTIVITY IN NAKED MOLE RATS
Tuesday, May 8, 2012
http://www.fightaging.org/archives/2012/05/enhanced-proteasome-activity-in-naked-mole-rats.php
Long-lived naked mole-rats appear to have more effective housekeeping and maintenance activity in their cells: the naked mole-rat "maintains robust health for at least 75% of its 32 year lifespan, suggesting that the decline in genomic integrity or protein homeostasis routinely observed during aging, is either attenuated or delayed in this extraordinarily long-lived species. The ubiquitin proteasome system (UPS) plays an integral role in protein homeostasis by degrading oxidatively-damaged and misfolded proteins. In this study, we examined proteasome activity in naked mole-rats and mice in whole liver lysates as well as three subcellular fractions to probe the mechanisms behind the apparently enhanced effectiveness of UPS. ... We found that when compared with mouse samples, naked mole-rats had significantly higher [activity]. ... the 20S proteasome was more active in the longer-lived species and that 26S proteasome was both more active and more populous. Western blot analyses revealed that both 19S subunits and immunoproteasome catalytic subunits are present in greater amounts in the naked mole-rat suggesting that the observed higher specific activity may be due to the greater proportion of immunoproteasomes in livers of healthy young adults. It thus appears that proteasomes in this species are primed for the efficient removal of stress-damaged proteins. Further characterization of the naked mole-rat proteasome and its regulation could lead to important insights on how the cells in these animals handle increased stress and protein damage to maintain a longer health in their tissues and ultimately a longer life."

AN EXAMPLE OF THE PROLIFERATION OF STUDIES OF HUMAN LONGEVITY
Monday, May 7, 2012
http://www.fightaging.org/archives/2012/05/an-example-of-the-proliferation-of-studies-of-human-longevity.php
Extensive studies of the genetics of human longevity are growing more common - the flow of data is becoming a flood. Here is an example: "we chose to investigate 1,200 individuals of the Danish 1905 birth cohort, which have been followed since 1998 when the members were 92-93 years old. The genetic contribution to human longevity has been estimated to be most profound during the late part of life, thus these oldest-old individuals are excellent for investigating such effect. The follow-up survival data enabled performance of longitudinal analysis, which is quite unique in the field of genetic epidemiology of human longevity. ... However, this study explores the genetic contribution to survival during the ninth decade of life, hence, in order to investigate the genetic contribution to survival in younger elderly we also included 800 individuals of the Study of Middle-aged Danish twins (MADT). ... The analyses of the data set verified the association [with longevity of] SNPs in the APOE, CETP and IL6 genes, [and] pointed to new candidate genes of human longevity: especially SNPs in the INS, RAD52 and NTHL1 genes appeared promising. As part of these investigations, replication studies of the single-SNP level findings were conducted in German case-control samples of 1,613 oldest-old (ages 95-110) and 1,104 middle-aged individuals and in a Dutch prospective cohort of 563 oldest-old (age 85+). ... Interesting aspects of the study were that the majority of the rare alleles of the identified SNPs were longevity variants, not mortality variants, indicating that at least in our study population, longevity is primarily affected by positively acting minor alleles. ... Furthermore, the genotype data generated were used for a number of replication studies on variation in the FOXO3A, TERT and TERC genes. These studies were performed in response to new data being published on the association of genetic variation in the genes with longevity (FOXO3A and TERT) and with telomere length (TERT and TERC). Our studies verified a role of TERC in human telomere length and of FOXO3A in human longevity (survival from middle age to old age), while a novel role of TERC in human longevity was found."

A LOOK AT TISSUE ENGINEERING OF NOSES AND EARS
Monday, May 7, 2012
http://www.fightaging.org/archives/2012/05/a-look-at-tissue-engineering-of-noses-and-ears.php
Tissue engineering is steadily advancing into the easier areas of growing replacement parts: "Other groups have tried to tackle nose replacement with implants but we've found they don't last. They migrate, the shape of the nose changes. But our one will hold itself completely, as it's an entire nose shape made out of polymer. ... Inside this nanomaterial are thousands of small holes. Tissue grows into these and becomes part of it. It becomes the same as a nose and will even feel like one. ... When the nose is transferred to the patient, it doesn't go directly onto the face but will be placed inside a balloon inserted beneath the skin on their arm. After four weeks, during which time skin and blood vessels can grow, the nose can be monitored, then it can be transplanted to the face. At the cutting edge of modern medicine, [researchers] are focusing on growing replacement organs and body parts to order using a patient's own cells. There would be no more waiting for donors or complex reconstruction - just a quick swap. And because the organ is made from the patient's own cells, the risk of rejection should, in theory, be eliminated. ... We seed the patient's own cells on to the polymer inside a bioreactor. ... This is a sterile environment mirroring the human body's temperature, blood and oxygen supply. ... As the cells take hold and multiply, so the polymer becomes coated. The same methods could be applied to all parts of the face to reconstruct those of people who have had severe facial traumas."

______________________________


View the full article

#9 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 20 May 2012 - 09:34 PM

FIGHT AGING! NEWSLETTER
May 21st 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Telomerase Gene Therapy Extends Mouse Lifespan
- The Maintenance Gap
- Resilient Biochemistry in Naked Mole-Rats
- Discussion
- Latest Headlines from Fight Aging!

TELOMERASE GENE THERAPY EXTENDS MOUSE LIFESPAN

Researchers have demonstrated that a genetic alteration previously shown to extend life in mice can be packaged into a gene therapy and used to extend life - though to a lesser degree - in ordinary adult laboratory mice:

http://www.fightaging.org/archives/2012/05/telomerase-gene-therapy-extends-life-eliminates-cancer-in-adult-mice.php

"A few years ago, a Spanish research team created transgenic mice that lived significantly longer than normal by combining increased p53 with increased telomerase. p53 is a cancer suppressor that under usual circumstances reduces the ability of stem cells to replace worn cells in aging tissue - less cell proliferation means a lower chance of cancer over time, but also faster aging as the tissues of the body wear and fail more readily. More telomerase, on the other hand, achieves the opposite end: dynamic, longer lasting cells that also produce way more cancers in the course of their more energetic operations. This, in any case, is the consensus view of how these elements work in the biochemistry of mammals.

"The researchers recently published results for the next stage of their research program: taking the modifications that had been transgenic to date and instead applying them as gene therapies to adult mice. This is a step on the road to building some form of beneficial medical technology for humans ... Mice treated at the age of one lived longer by 24% on average, and those treated at the age of two, by 13%. The therapy, furthermore, produced an appreciable improvement in the animals' health, delaying the onset of age-related diseases - like osteoporosis and insulin resistance - and achieving improved readings on ageing indicators like neuromuscular coordination. The gene therapy utilised consisted of treating the animals with a DNA-modified virus, the viral genes having been replaced by those of the telomerase enzyme, with a key role in ageing. Telomerase repairs the extremes of chromosomes, known as telomeres, and in doing so slows the cell's and therefore the body's biological clock. When the animal is infected, the virus acts as a vehicle depositing the telomerase gene in the cells.

"In 2007, [the researchers] proved that it was feasible to prolong the lives of transgenic mice, whose genome had been permanently altered at the embryonic stage, by causing their cells to express telomerase and, also, extra copies of cancer-resistant genes. These animals live 40% longer than is normal and do not develop cancer. The mice subjected to the gene therapy now under test are likewise free of cancer. Researchers believe this is because the therapy begins when the animals are adult so do not have time to accumulate sufficient number of aberrant divisions for tumours to appear."

THE MAINTENANCE GAP

Here is an addition to one of the traditional views of the evolution of aging, considered in the broader context of current strategic directions in the aging research community:

http://www.fightaging.org/archives/2012/05/the-maintenance-gap.php

"Much of the mainstream aging research community has little interest in building therapies for aging, being focused on investigation only - though, fortunately, this situation is changing rapidly these days. The past stigma associated with public discussion of treating and ultimately preventing aging has largely evaporated within the scientific world. Among those researchers who are interested in therapies for aging, most are focused on the slow boat of metabolic alteration: work that will have comparatively little pay-off even if successful, but which fits more readily into established research programs and the prejudices of research funding institutions.

"The principal downside of metabolic alteration strategies, from my point of view, is that even if successful they cannot produce any significant longevity benefit in a person already old. ... There is another disadvantage, which is illustrated by the different degrees to which life span is enhanced by similar strategies applied in mice versus humans. It is taken for granted in the literature, and thus probably not emphasized to the degree it should be, that an extension of life by 50% in mice based on some genetic or metabolic alteration - such as calorie restriction or growth hormone knockout - is probably not going to map to a similar extension of life in humans. If humans could achieve that sort of life extension through simply eating well and eating less or being growth hormone mutants, we'd have known about it by now. Consider Laron dwarfism, for example, or the generation after generation of practitioners of various degrees of calorie restriction that exist in many cultures.

"With an eye to this second disadvantage, I'll point out an open access paper that considers the evolution of aging from the point of view of the maintenance gap. This is the gap between the cost of maintenance required to keep an organism from aging and the resources actually devoted to maintenance - both of which are subject to evolutionary selection pressures, which operate to maximize success in genetic propagation rather than the comfort or longevity of individual members of a species.

"One of the prevailing theories of aging, the disposable soma theory, views aging as the result of the accumulation of damage through imperfect maintenance. Aging, then, is explained from an evolutionary perspective by asserting that this lack of maintenance exists because the required resources are better invested in reproduction. However, the amount of maintenance necessary to prevent aging, 'maintenance requirement' has so far been largely neglected and has certainly not been considered from an evolutionary perspective. ... This has major implications for our understanding of the aging process on both the evolutionary and the mechanistic level. It means that the expected effect of measures to reallocate resources to maintenance from reproduction may be small in some species.

"The point to take away from this argument is that we should expect to find a broad variation between species in their response to similar forms of metabolic and genetic alteration aimed at extending life span. So far that is what is seen, with we humans having the short end of the stick - though obviously there is an ocean of data yet to be obtained on this topic. On the whole, though, it seems like one more slowly building argument for the research community to focus on repair-based strategies for treating aging: build biotechnologies that are explicitly designed to repair forms of biological damage that existing repair systems either cannot handle or handle too slowly. SENS is the most obvious example, though I expect other, competing repair-focused visions to emerge in the years ahead as the SENS Foundation obtains further scientific support and promising research results."

RESILIENT BIOCHEMISTRY IN NAKED MOLE-RATS

The naked mole-rat is becoming a well-studied species:

http://www.fightaging.org/archives/2012/05/resilient-biochemistry-in-naked-mole-rats.php

"Researchers are attempting to find the root causes of cancer immunity and exceptional longevity in this species, with an eye to creating beneficial medical biotechnologies for humans. .. Present theories are varied, but on the longevity side of the house the consensus appears to lean towards an increased resistance to forms of cellular membrane damage - naked mole rat membranes are built of a more resilient mix of proteins than those of comparable species. This is known as the membrane pacemaker hypothesis of aging.

"This mouse-sized mammal lives ∼8 times longer than do mice and, despite high levels of oxidative damage evident at a young age, it is not only very resistant to [cancer] but also shows minimal decline in age-associated physiological traits. ... naked mole-rat fibroblasts are extremely tolerant of a broad spectrum of cytotoxins including heat, heavy metals, DNA-damaging agents and xenobiotics, showing [median lethal dose] values between 2- and 20-fold greater than those of fibroblasts of shorter-lived mice. Our new data reveal that naked mole-rat fibroblasts stop proliferating even at low doses of toxin whereas those mouse fibroblasts that survive treatment rapidly re-enter the cell cycle and may proliferate with DNA damage. Naked mole-rat fibroblasts also show significantly higher constitutive levels of both p53 and Nrf2 protein levels and activity, and this increases even further in response to toxins.

"Enhanced cell signaling via p53 and Nrf2 protects cells against proliferating with damage, augments clearance of damaged proteins and organelles and facilitates the maintenance of both genomic and protein integrity. These pathways collectively regulate a myriad of mechanisms which may contribute to the attenuated aging profile and sustained healthspan of the naked mole-rat. Understanding how these are regulated may be also integral to sustaining positive human healthspan well into old age and may elucidate novel therapeutics for delaying the onset and progression of physiological declines that characterize the aging process."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

OLD CALORIE RESTRICTED RATS ACT YOUNGER THAN THEIR PEERS
Friday, May 18, 2012
http://www.fightaging.org/archives/2012/05/old-calorie-restricted-rats-act-younger-than-their-peers.php
No great surprise here, given that calorie restriction in mammals slows almost all measures of aging investigated to date: "Long-term caloric restriction (CR) has been reported to extend the life spans, delay the onset and decrease the incidence of a broad spectrum of age-associated diseases. However, its effect on rat explorative behaviour is still unclear. In the present study, a number of behavioural measures were continuously monitored in 3-, 12-, 24-25-, 28-29- and 35-44-month-old male Wistar rats that were fed either ad libitum or placed on a caloric restricted diet. A gradual decline in locomotor activity of the ad libitum fed rats has been determined during aging in the open field test. In the CR groups, 3-month-old rats exhibited lower levels of exploratory behavior, compared to rats on the control diet. 24-25-month-old CR rats exhibited higher levels of exploratory behaviour, compared to ad libitum fed animals of the same age. Chronic dietary restriction nullified the age-dependent decline in locomotor activity and explorative behaviour of rats."

A BRIEF LAYPERSON'S TOUR OF THE PHILOSOPHY OF NONEXISTENCE
Friday, May 18, 2012
http://www.fightaging.org/archives/2012/05/a-brief-laypersons-tour-of-the-philosophy-of-nonexistence.php
It is taken as a tenet around here that involuntary death is a bad thing, and the process of getting to be dead despite your own wishes on the matter is arguably worse - it involves a great deal of ongoing suffering and pain as the body progressively fails. Greatly diminishing the incidence of death is one aim of the longevity science movement, achieved through the elimination of degenerative aging, the greatest cause of death. Can we say why being dead is bad, however? That is supposedly a harder job than declaring suffering to be bad and worthy of amelioration - though most philosophers fail to consider the economic costs of destruction, and in the end it should all come down to "I've decided I don't like it, and so I'll work towards doing something about it through progress in medical science." Reasons beyond personal choice are unnecessary, but here is a brief tour of some of the philosophy of death and nonexistence: "We all believe that death is bad. But why is death bad? In thinking about this question, I am simply going to assume that the death of my body is the end of my existence as a person. But if death is my end, how can it be bad for me to die? After all, once I'm dead, I don't exist. If I don't exist, how can being dead be bad for me? ... there's a puzzle raised by the Roman philosopher Lucretius, who thought it a mistake to find the prospect of my death upsetting. Yes, as the deprivation account points out, after death we can't enjoy life's pleasures. But wait a minute, says Lucretius. The time after I die isn't the only period during which I won't exist. What about the period before my birth? If nonexistence is so bad, shouldn't I be upset by the eternity of nonexistence before I was born? But that's silly, right? Nobody is upset about that. So, he concludes, it doesn't make any sense to be upset about the eternity of nonexistence after you die, either. It isn't clear how best to reply to Lucretius. One option, presumably, is to agree that we really do need to treat those two eternities of nonexistence on a par, but to insist that our prebirth nonexistence was worse than we thought. Alternatively, we might insist that there's an asymmetry that explains why we should care about the one period but not the other. But what is that difference? Perhaps this: When I die, I have lost my life. In contrast, during the eternity before my birth, although I'm not alive, I have not lost anything. You can't lose what you never had. So what's worse about death is the loss."

IGF-1 RECEPTOR VARIATIONS AND SHEEP LONGEVITY
Thursday, May 17, 2012
http://www.fightaging.org/archives/2012/05/igf-1-receptor-variations-and-sheep-longevity.php
Insulin-like growth factor 1 (IGF-1) is one of the more studied areas of known overlap between metabolism and longevity, but given the innate complexity of biology in mammals there is always some debate over the degree to which IGF-1-related mechanisms are actually determinants of life span, or even correlated with life span. Here is a study in sheep, not the usual species in investigations of the biochemistry of aging: "Longevity in livestock is a valuable trait. When productive animals live longer fewer replacement animals need to be raised. However, selection for longevity is not commonly the focus of breeding programs as direct selection for long-lived breeding stock is virtually impossible until late in the animal's reproductive life. Additionally the underlying genetic factors or genes associated with longevity are either not known, or not well understood. In humans, there is evidence that insulin-like growth factor 1 receptor (IGF1R) is involved in longevity. Polymorphism in the IGF1R gene (IGF1R) has been associated with longevity in a number of species. Recently, 3 alleles of ovine IGF1R were identified, but no analysis of the effect of IGF1R variation on sheep longevity has been reported. In this study, associations between ovine IGF1R variation, longevity and fertility were investigated [in] 1716 New Zealand sheep belonging to 6 breeds and 36 flocks. ... Ovine IGF1R C was associated with age when adjusting for flock [and] a weak negative [correlation] between fertility and longevity traits was observed."

INVESTIGATING THE ASSOCIATION OF APOE4 WITH ALZHEIMER'S
Thursday, May 17, 2012
http://www.fightaging.org/archives/2012/05/investigating-the-association-of-apoe4-with-alzheimers.php
Researchers continue to investigate why the ApoE4 gene variant is associated with Alzheimer's disease: "A well-known genetic risk factor for Alzheimer's disease triggers a cascade of signaling that ultimately results in leaky blood vessels in the brain, allowing toxic substances to pour into brain tissue in large amounts, scientists report ... a gene called ApoE4 makes people more prone to developing Alzheimer's. People who carry two copies of the gene have roughly eight to 10 times the risk of getting Alzheimer's disease than people who do not. [Scientists] found that ApoE4 works through cyclophilin A, a well-known bad actor in the cardiovascular system, causing inflammation in atherosclerosis and other conditions. The team found that cyclophilin A opens the gates to the brain assault seen in Alzheimer's. ... In the presence of ApoE4, increased cyclophilin A causes a breakdown of the cells lining the blood vessels in Alzheimer's disease in the same way it does in cardiovascular disease or abdominal aneurysm ... In studies of mice, the team found that mice carrying the ApoE4 gene had five times as much cyclophilin A compared to other mice in cells known as pericytes, which are crucial to maintaining the integrity of the blood-brain barrier. Blood vessels died, blood did not flow as completely through the brain as it did in other mice, and harmful substances like thrombin, fibrin, and hemosiderin, entered the brain tissue. When the team blocked the action of cyclophilin A, either by knocking out its gene or by using the drug cyclosporine A to inhibit it, the damage in the mice was reversed. Blood flow resumed to normal, and unhealthy leakage of toxic substances from the blood vessels into the brain was slashed by 80 percent."

ARGUING A ROLE FOR THE HYPOTHALAMUS IN AGING
Wednesday, May 16, 2012
http://www.fightaging.org/archives/2012/05/arguing-a-role-for-the-hypothalamus-in-aging.php
Researchers here analyze the proteome of the hypothalamus and argue for an important role in coordinating bodily responses to ongoing changes caused by aging: "The aging process affects every tissue in the body and represents one of the most complicated and highly integrated inevitable physiological entities. The maintenance of good health during the aging process likely relies upon the coherent regulation of hormonal and neuronal communication between the central nervous system and the periphery. Evidence has demonstrated that the optimal regulation of energy usage in both these systems facilitates healthy aging. However, the proteomic effects of aging in regions of the brain vital for integrating energy balance and neuronal activity are not well understood. The hypothalamus is one of the main structures in the body responsible for sustaining an efficient interaction between energy balance and neurological activity. Therefore, a greater understanding of the effects of aging in the hypothalamus may reveal important aspects of overall organismal aging and may potentially reveal the most crucial protein factors supporting this vital signaling integration. In this study, we examined alterations in protein expression in the hypothalami of young, middle-aged, and old rats. ... Based upon our rigorous analyses, we show that endogenous physiological responses to aging may be strongly orchestrated by the expression level of the GIT2 protein. The relevance of the hypothalamic expression level of this protein to the aging process in both neuronal and energy-controlling tissues reinforces the importance of this organ in the potential future development of targeted pharmacotherapeutics designed to interdict a multitude of age-related disorders."

S1P AND STIMULATION OF MUSCLE SATELLITE CELLS
Wednesday, May 16, 2012
http://www.fightaging.org/archives/2012/05/s1p-and-stimulation-of-muscle-satellite-cells.php
A possible method of boosting muscle repair, and thus treating muscle wasting conditions - such as the sarcopenia that attends aging: "a lipid signaling molecule called sphingosine-1-phosphate or 'S1P' can trigger an inflammatory response that stimulates the muscle stem cells to proliferate and assist in muscle repair. ... mdx mice, which have a disease similar to Duchenne Muscular Dystrophy, exhibit a deficiency of S1P, [and] boosting their S1P levels improves muscle regeneration ... The ability of muscles to regenerate themselves is attributed to the presence of a form of adult stem cells called 'satellite cells' that are essential for muscle repair. Normally, satellite cells lie quietly at the periphery of the muscle fiber and do not grow, move or become activated. However, after muscle injury, these stem cells 'wake up' through unclear mechanisms and fuse with the injured muscle, stimulating a complicated process that results in the rebuilding of a healthy muscle fiber. S1P is a lipid signaling molecule that controls the movement and proliferation of many human cell types. ... S1P is able to 'wake up' the stem cells at the time of injury. It involves the ability of S1P to activate S1P receptor 2, one of its five cell surface receptors, leading to downstream activation of an inflammatory pathway controlled by a transcription factor called STAT3. [This results] in changes in gene expression that cause the satellite cell to leave its 'sleeping' state and start to proliferate and assist in muscle repair. ... If these findings are also found to be true in humans with Duchenne Muscular Dystrophy, it may be possible to use similar approaches to boost S1P levels in order to improve satellite cell function and muscle regeneration in patients with the disease. Drugs that block S1P metabolism and boost S1P levels are now being tested for the treatment of other human diseases including rheumatoid arthritis. If these studies prove to be relevant in Duchenne patients, it may be possible to use the same drugs to improve muscle regeneration in these patients. Alternatively, new agents that can specifically activate S1P receptor 2 could also be beneficial in recruiting satellite cells and improving muscle regeneration in muscular dystrophy and potentially other diseases of muscle."

A POPULAR PRESS ARTICLE ON LONGEVITY SCIENCE
Tuesday, May 15, 2012
http://www.fightaging.org/archives/2012/05/a-popular-press-article-on-longevity-science.php
The media and public at large have been trained to think of medicine, and especially longevity-related medicine, in terms of pills - things you can consume, colorful drug capsules produced in the old-style fashion by Big Pharma. This is somewhat ridiculous, and leads to a focus on the entirely the wrong branches of research, those unlikely to deliver meaningful healthy life extension. The future of rejuvenation biotechnology involves gene therapies, infusions of bacterial enzymes, and so forth; for the foreseeable future little of that will be stuff that you stick into your mouth. Calling these medicines drugs rather than procedures cheapens the complexity of what is being designed and developed. Nonetheless, the oral fixation in regard to public perceptions of medicine continues, fed by the lazy press and the self-interested supplement industry. Here is an example of that sort of headlining: "But imagine if there were a drug that would slow down the aging process itself, a drug that didn't just treat a single disease but instead targeted multiple diseases of old age at once? It may sound far-fetched, but that's precisely what longevity scientists are working hard to produce. ... It's not just that we're trying to make people live longer; we're trying to make people live healthier. This is an exciting time for research. ... Indeed, top-notch research labs are rolling out studies at a rapid rate, and a growing chorus of experts believe the advances being made will ultimately lead to a crop of drugs capable of extending healthy lifespans. Signs of progress are abundant in medical journals. ... [researchers] published results showing they could markedly delay the onset of age-related diseases in mice by killing off the rodents' senescent cells. Senescent cells have stopped dividing and accumulate as organisms age. Though seemingly dormant, they're not: Just as old cars in junkyards can leak oil for years, they emit harmful substances that appear to fuel many of the diseases that strike older people. ... And it's not just senescence research that is stoking excitement. Another team of scientists [has] managed to control the aging process by targeting specialized structures at the tips of chromosomes called telomeres. ... Other scientists have found that feeding aging mice rapamycin - an immunosuppressant that's used to prevent organ rejection after transplants - can extend the lifespan of mice significantly."

METHIONINE RESTRICTION BENEFICIAL IN OLD RATS
Tuesday, May 15, 2012
http://www.fightaging.org/archives/2012/05/methionine-restriction-beneficial-in-old-rats.php
Calorie restriction extends healthy life span, and that seems to largely work through the level of methionine in the diet, though minimizing visceral fat tissue looks to be an important effect as well: "It is known that a global decrease in food ingestion (dietary restriction, DR) lowers mitochondrial ROS generation (mitROS) and oxidative stress in young immature rats. This seems to be caused by the decreased methionine ingestion of DR animals. This is interesting since isocaloric methionine restriction in the diet (MetR) also increases, like DR, rodent maximum longevity. However, it is not known if old rats maintain the capacity to lower mitROS generation and oxidative stress in response to MetR similarly to young immature animals, and whether MetR implemented at old age can reverse aging-related variations in oxidative stress. In this investigation the effects of aging and 7 weeks of MetR were investigated in liver mitochondria of Wistar rats. MetR implemented at old age decreased mitROS generation, percent free radical leak at the respiratory chain and mtDNA oxidative damage without changing oxygen consumption. Protein oxidation, lipoxidation and glycoxidation increased with age, and MetR in old rats partially or totally reversed these age-related increases. ... In conclusion, treating old rats with isocaloric short-term MetR lowers mitROS production and free radical leak and oxidative damage to mtDNA, and reverses aging-related increases in protein modification. Aged rats maintain the capacity to lower mitochondrial ROS generation and oxidative stress in response to a short-term exposure to restriction of a single dietary substance: methionine."

BMP-2 DELIVERED IN HYDROGEL TO GUIDE BONE REGROWTH
Monday, May 14, 2012
http://www.fightaging.org/archives/2012/05/bmp-2-delivered-in-hydrogel-to-guide-bone-regrowth.php
Bone morphogenetic protein 2 (BMP-2) has been used to spur healing in regenerative medicine research in past years. Here researchers are investigating its use in bone regrowth: scientists are "concentrating on the creation of new bone tissue with the aid of a biomolecule called BMP-2, which is a protein that makes bones grow. The problem with BMP-2 is that it breaks down in the body in just a few minutes. ... What's new, and what I show in my dissertation, is that by having a gel-like substance carry the protein, a so-called hydrogel, you can control both how and where the new bone is to grow ... This hydrogel can be injected and is moreover made from a type of sugar (hyaluronic acid). It occurs naturally in the body in humans and animals and is otherwise used in cosmetic products for treating wrinkles. This offers major advantages. ... On the one hand, you avoid open surgery and the risk of complications and infections that entails, and, on the other hand, there is no risk that the body will reject it. ... Applications in healthcare include both healing complicated bone fractures and growing bone tissue where there is too little or none at all. This involves defects following bone fractures and cancer or when the jawbone is too weak to support a tooth implant. Clinical testing is already underway. ... The tests show that it's working well, but the problem we need to solve is how to determine the optimal dosage of the protein. Otherwise inflammations can occur in surrounding tissue."

DIVERSITY OF REGULATORY T CELLS IN RHEUMATOID ARTHRITIS
Monday, May 14, 2012
http://www.fightaging.org/archives/2012/05/diversity-of-regulatory-t-cells-in-rheumatoid-arthritis.php
Researches make an incremental step forward in understanding the root causes of rheumatoid arthritis: "Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, [researchers] announce that it takes a diverse array of regulatory T cells (a specialized subset of white blood cells) to prevent the immune system from generating the tissue-specific inflammation that is a hallmark of the disease. Regulatory T cell diversity, the researchers say, provides a cumulative protective effect against rheumatoid arthritis. ... regulatory T cells (or Tregs) are a necessary component to either restrain (or encourage) the immune system's inflammatory response. Tregs are activated as molecules on their surface membranes called T cell receptors interact with 'friendly' or 'self' molecules - a way for the immune system to recognize friend from foe. Mismanagement of these Tregs, which normally serve to restrain the immune system from over-reacting to healthy tissue, could then lead to runaway inflammation. In this study, the researchers sought to examine how T cell receptors affect the ability of Tregs to suppress arthritis in a mouse that had been bred to express a 'self' molecule that drives arthritis. They showed that an array of Tregs given to the mice effectively stops arthritis. Unexpectedly, however, Tregs that are specific for the surrogate 'self' molecule do not prevent arthritis. ... We find that [a] diverse repertoire of Tregs are very effective. All of these Tregs, together, influence other components of the immune system which serves to slow down the inflammatory process that causes RA."

____________________


View the full article

#10 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 27 May 2012 - 02:55 PM

FIGHT AGING! NEWSLETTER
May 28th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- The Three Types of Aging Research
- An Interview on Radical Life Extension
- A Tale of Telomerase
- p16INK4A and Biological Age
- Discussion
- Latest Headlines from Fight Aging!

THE THREE TYPES OF AGING RESEARCH

Here is an outline of the way in which I divide the aging research community:

http://www.fightaging.org/archives/2012/05/the-three-types-of-research-into-aging-and-longevity.php

"Class 1: Investigating Aging: By far the largest component of the aging science community is made up of researchers who are not working on ways to alter or repair the aging process. They investigate only, and thus the majority of funds devoted to the science of aging still go towards studies that aim to make no difference to the world beyond gathering data. This group include most of those who run demographic studies of human longevity, for example.

"Class 2: Working to Slow Aging: The larger minority class in aging research is made up of researchers and funding institutions who are working towards ways to slow aging, or working on related areas that will be used in constructing therapies to slow aging. The typical approach here is to reverse engineering the genetic and other low-level biochemical roots of known differences in longevity (such as the effects of calorie restriction, or the differences in life span between similar species), and then try to reproduce some of those differences using drugs, gene therapies, and other similar means. The view of these researchers is largely that we are a long way from any practical results, and those results will only offer incremental gains - a viewpoint I agree with.

"Class 3: Working to Reverse Aging: The smallest and most important cohort of researchers are those who are working on ways to repair, reverse, or work around the root causes of aging - the SENS Foundation research network being the archetype, though not the only set of researchers and laboratories involved in this work. This class are the most important because their approach is the only viable path we can see that has a good chance of producing rejuvenation biotechnology capable of greatly extending healthy life in the elderly - through restoring youthful function and vigor. This is the smallest cohort because we do not live in a particularly rational world.

"The sea change in the aging research community over the past decade or so has largely manifested as a transformation of researchers from the bulk of class 1 into up and coming enthusiasts of class 2. As it became respectable to talk about doing something about aging - thanks to the hard work of a comparatively small number of advocates and visionary scientists - there has been a steady shifting of research priorities. The investigators still outnumber research groups working on ways to alter the course of aging, but the trend is clearly towards a field that develops clinical applications in medicine rather than only informing the medical profession of what to expect in their patients.

"Now that the research community is essentially persuaded to the view that work on aging is good, interesting, and plausible, the next - and equally important - goal of advocacy is to persuade a great many more researchers to work on the SENS vision for rejuvenation biotechnology or equivalent scientific programs: to move in to class 3."

AN INTERVIEW ON RADICAL LIFE EXTENSION

An interview with a philosopher on the topic of radical life extension was published recently at the Atlantic:

http://www.fightaging.org/archives/2012/05/an-interview-on-radical-life-extension.php

"Today I'll point out an interview with Bennett Foddy, the author of The Right and Wrong of Growing Old: Assessing the Argument from Evolution, who fits into the interesting - and possibly small - category of people who both (a) see the only viable way forward in longevity science as being the same old slow boat of small, expensive gains achieved by slowing aging through metabolic manipulation, and (b) think that we'll make good progress that way. ... From the blurb to his book: One argument which is frequently levelled against the enhancement of human biology is that we do not understand the evolved function of our bodies well enough to meddle in our biology without producing unintended and potentially catastrophic effects. In particular, this argument is levelled against attempts to slow or eliminate the processes of human ageing, or 'senescence', which cause us to grow decrepit before we die. In this article, I claim that even if this argument could usefully be applied against attempts to enhance other human traits, it cannot be valid in the case of attempts to enhance the various processes that constitute senescence.

"Now I completely agree with the argument noted in the first sentence above, if not the rest of it - that we don't understand enough about metabolism to make good progress in manipulating it to slow aging to a great enough degree to matter. By which I mean we'll be old and dying by the time that useful results are produced, at staggering cost - and those results won't do much at all for people who are already old and dying, because all they will do is slow down aging. It is far better to focus on the SENS vision of repairing damage rather than just slowing down the pace at which it occurs. For one, repair should be easier as it isn't anywhere near as large a swamp of unknowns: the list of biochemical damage that we need to repair is known, means of repair have been planned in some detail, and effective repair biotechnologies for these known forms of age-related damage will actually produce rejuvenation in the old.

"But on to the interview at the Atlantic, which makes for interesting reading. It would be pleasant to live in a world in which all we argued over was how exactly we should work to extend the healthy human life span and rescue the old from their degenerations. I should note that Foddy is a philosopher rather than a life scientist, so he's not quite as careful with his language as he should be - using 'life span' in place of 'life expectancy at birth', for example. But the general points he makes stand, and it is always good to see another member of the philosophy-slash-bioethics class explicitly place himself in opposition to the deathism of Fukuyama and Kass."

A TALE OF TELOMERASE

From the SENS Foundation, some more background and caveats on the recent study demonstrating an extension of life span in mice using telomerase gene therapy:

http://www.fightaging.org/archives/2012/05/a-tale-of-telomerase.php

"The connection between telomeres, telomerase, and cellular and organismal 'aging' was a matter of significant scientific interest but little public awareness until the early 1990s, when Dr. Michael West founded Geron Corporation. In the process of launching that venture, and in the following years, West succeeded in embedding a controversial thesis deeply into the public imagination: that the (re)activation of telomerase in somatic cells could retard or even reverse the degenerative aging process. There were always problems with this thesis, and with public (mis)understandings of it, but its sheer simplicity and public prominence has in direct and indirect ways advanced scientific research that has answered many of the questions that thesis forced upon the scientific community, and opened up important new avenues for research in telomre biology and in biomedical gerontology.

"The most direct and important fruits of that expansion of research into telomerase have been studies on the pharmacological and transgenic activation of telomerase in the tissues of aging mice. Several such reports have appeared over the years, each hailed prematurely as evidence of the life- and health-extending power of the enzyme. The most important of these studies have been a series of experiments by María Blasco, PhD, SENS Foundation Research Advisory Board member and Director of the Molecular Oncology Programme at Spain's National Cancer Research Centre (CNIO). A tantalizing new report in this series has just appeared - but to understand it in context, we will first review those that led up to it.

"You should read the whole thing; it is very educational, and a good illustration of the way in which there are no sudden breakthroughs in science - just sudden attention paid to steadily ongoing progress. Each new advance rests upon decades of past work and the efforts of a range of other research groups. It also illustrates the need to look past the headlines to pick at the details of heralded research."

P16INK4A AND BIOLOGICAL AGE

p16INK4A is a gene with many aliases, such as p16, CDKN2A, or cyclin-dependent kinase inhibitor 2A. This tends to happen for genes and the resulting protein products that are involved in numerous important mechanisms in the cell and were cataloged comparatively early on. Many different research groups will be working on the gene in isolation, and this results in a range of different names for the same thing. Levels of the protein produced by p16INK4A are associated with cellular senescence and the pace of aging:

http://www.fightaging.org/archives/2012/05/p16ink4a-and-biological-age-at-extreme-longevity.php

"The link between levels of the protein p16INK4A and aging has been known for some years. In particular, it shows up in the senescent cells that accumulate with age, something that researchers have managed to make use of: you might recall last year's study that showed beneficial effects from destroying senescent cells in rats. That research group used p16INK4A as a basis for their method of selective destruction, targeting only those cells that had become senescent and thus removing their contribution to the aging process.

"In this study the researchers examined skin cells from middle aged people aged 43 to 63. They compared a group who had a strongly family history of extreme longevity to age-matched controls. They found that p16 expression in skin cells was significantly lower in the group that had the strong family history of longevity. They conclude 'a younger biological age associates with lower levels of p16INK4a positive cells in human skin.' This study supports the idea that p16 expressing cells are linked to age both from a chronological as well as biological perspective. Work needs to be done to find a way to remove p16 positive cells from all tissues of the body on a regular basis. Such a therapy, if it existed, may act to reduce aging.

"This all ties back in to cancer suppression versus tissue proliferation. Increased senescence in cells is one way of biasing the average over time to a lower rate of cancer - because the cells most likely to cause issues have been taken out of circulation and are no longer replicating. They should be destroyed by the immune system, but the immune system has its own age-related issues and falls down on that job, leaving the senescent cells to lurk and emit harmful signaling chemicals that damage surrounding tissue.

"The flip side of the coin is that less replication among cells translates to less resilient tissues and organs, and thus faster aging. As mammalian biochemistry is set up by default, you can either be generating lots of fresh cells with a higher cancer risk, or aging faster due to poor tissue maintenance, but with a lower cancer risk. Biotechnology will let us escape from this Hobson's choice in due course - a method for tweaking the system associated with another cancer suppression gene to generate both less cancer and slower aging has been demonstrated in mice, for example. More and better technologies will emerge in human medicine in the fullness of time.

"In particular, rather than focusing on metabolic tinkering to incrementally improve matters, the better approaches would be to (a) repair the ability of the immune system to eliminate senescent cells at a youthful level, and (b) develop therapies to regularly completely sweep senescent cells from the body. The effects of reducing senescent cell numbers in rats were sufficiently good that more work will be devoted to that sort of strategy in the future - and a good thing too."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

AMYLOIDOSIS AS THE PRESENT LIMITED FACTOR ON HUMAN LIFESPAN
Friday, May 25, 2012
http://www.fightaging.org/archives/2012/05/amyloidosis-as-the-present-limited-factor-on-human-lifespan.php
A theory that has emerged in recent years points to forms of amyloidosis as the final limiting process for human life span. Extremely long-lived people, who have survived or evaded all the common fatal age-related conditions, appear to die because of amyloid buildup. The evidence is good enough for the SENS Foundation to start funding work on a therapy - like all the mechanisms of aging, this is something that can be fixed through appropriate use of biotechnology. Here's a little more on the topic (and a link to a PDF format research paper): "Supercentenarians are persons who have lived beyond the age of 110. Currently there are only about 80 such known individuals in the world whose age is verified. These people represent the limit of human lifespan. For a variety of reasons not fully understood but including lifestyle choices, genetic variants, and chance, these individuals have escaped the usual causes of death including cancer, heart disease and stroke. However, eventually they too die, with the world record holder being Jeanne Calment who survived until age 122. In a newly published review Drs. Stephen Coles and Thomas Young of the UCLA Gerontology Research Group point out what it may be that is killing supercentenarians: amyloidosis. Amyloidosis is a disease state hallmarked by the deposition of fibers of abnormally clumped masses of transthyretin. The protein transthyretin normally acts to carry thyroid and other hormones. Mutations in the gene make the fibers abnormally sticky and they tend to clump into long fibers which are deposited in multiple organs. Through early onset amyloidosis leads to disease, it is of interests that supercentanarians all seem to have significant amounts of it. Though not proven it is possible the amyloid is killing them. These persons have already escaped the typical causes of death however they have lived for so long, the normally innocuous amounts of amyloid that increase with age may actually become toxic to them because they have lived so many years. Where this line of reasoning gets exciting is that experimental drugs exist which may eliminate amyloid."

A GENE THAT INFLUENCES AGING, CANCER, AND INFLAMMATION
Friday, May 25, 2012
http://www.fightaging.org/archives/2012/05/a-gene-that-influences-aging-cancer-and-inflammation.php
An example of the way in which the machinery of cells is very intertwined, components reused by evolution in many different mechanisms: "This was certainly an unexpected finding. It is rather uncommon for one gene to have two very different and very significant functions that tie together control of aging and inflammation. The two, if not regulated properly, can eventually lead to cancer development. It's an exciting scientific find. ... For decades, the scientific community has known that inflammation, accelerated aging and cancer are somehow intertwined, but the connection between them has remained largely a mystery ... What was known [was] that a gene called AUF1 controls inflammation by turning off the inflammatory response to stop the onset of septic shock. But this finding, while significant, did not explain a connection to accelerated aging and cancer. When the researchers deleted the AUF1 gene, accelerated aging occurred, so they continued to focus their research efforts on the gene. ... The current study reveals that AUF1, a family of four related genes, not only controls the inflammatory response, but also maintains the integrity of chromosomes by activating the enzyme telomerase to repair the ends of chromosomes, thereby simultaneously reducing inflammation, preventing rapid aging and the development of cancer. ... [Researchers are now] examining human populations for specific types of genetic alterations in the AUF1 gene that are associated with the co-development of certain immune diseases, increased rates of aging and higher cancer incidence in individuals to determine exactly how the alterations manifest and present themselves clinically."

METHODS OF WORKING WITH STEM CELLS ARE IMPROVING
Thursday, May 24, 2012
http://www.fightaging.org/archives/2012/05/methods-of-working-with-stem-cells-are-improving.php
The underlying infrastructural methods and technologies for working with stem cells are consistently improving - which lowers cost, thus allowing more research and development to take place. Here is an example: "researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer. An embryo's cells really can be anything they want to be when they grow up: organs, nerves, skin, bone, any type of human cell. Adult-derived 'induced' stem cells can do this and better. Because the source cells can come from the patient, they are perfectly compatible for medical treatments. ... We turn back the clock, in a way. We're taking a specialized adult cell and genetically reprogramming it, so it behaves like a more primitive cell. ... Before stem cells can be used to make repairs in the body, they must be grown and directed into becoming the desired cell type. Researchers typically use surfaces of animal cells and proteins for stem cell habitats, but these gels are expensive to make, and batches vary depending on the individual animal. ... human cells are often grown over mouse cells, but they can go a little native, beginning to produce some mouse proteins that may invite an attack by a patient's immune system. ... [A] polymer gel created by [researchers] in 2010 avoids these problems because researchers are able to control all of the gel's ingredients and how they combine. ... [Researchers] had shown that these surfaces could grow embryonic stem cells, [but] the polymer surface can also support the growth of the more medically promising induced stem cells, keeping them in their high-potential state. To prove that the cells could transform into different types, the team turned them into fat, cartilage and bone cells. They then tested whether these cells could help the body to make repairs. Specifically, they attempted to repair five-millimeter holes in the skulls of mice. The weak immune systems of the mice didn't attack the human bone cells, allowing the cells to help fill in the hole. After eight weeks, the mice that had received the bone cells had 4.2 times as much new bone, as well as the beginnings of marrow cavities. The team could prove that the extra bone growth came from the added cells because it was human bone."

DELAYING THE AGING OF STEM CELLS IN FLIES
Thursday, May 24, 2012
http://www.fightaging.org/archives/2012/05/delaying-the-aging-of-stem-cells-in-flies.php
Changes in the stem cell niche are a good part of the age-related decline in stem cell activity, which explains why old stem cells can perform like young stem cells if put into a young environment, and vice versa. Here researchers compensate for one of those niche changes: "Stem cells reside within a microenvironment of other cells - the niche - that is known to play a role in stem cell function. For example, after a tissue is injured, the niche signals to stem cells to form new tissue. It is believed that stem cells and their niche send signals to each other to help maintain their potency over a lifetime. But while the loss of tissue and organ function during aging has been attributed to decreases in stem cell function, it has been unclear how this decline occurs. [There are] a number of possible scenarios, such as whether the loss of tissue function is due to a decrease in the number of stem cells, to the inability of stem cells to respond to signals from their niche, or to reduced signaling from the niche. ... researchers discovered that as the stem cell niche [in flies] ages, the cells produce a microRNA (a molecule that plays a negative role in the production of proteins from RNA) known as let-7. This microRNA is known to exist in a number of species, including humans, and helps time events that occur during development. This increase in let-7 leads to a domino effect that flips a switch on aging by influencing a protein known as Imp, whose function is to protect another molecule, Upd, which is secreted from a key area of the niche. In short, Upd promotes the signaling that keeps stem cells active and in contact with the niche so that they can self-renew. And as aging advances, increasing expression of let-7 ultimately leads to lower Upd levels, decreasing the number of active stem cells in the niche. What leads to accumulation of let-7 in the niche of aged flies still remains an open question. The researchers also demonstrated they could reverse this age-related loss of stem cells by increasing expression of Imp."

WORKING ON OPTIC NERVE REGENERATION
Wednesday, May 23, 2012
http://www.fightaging.org/archives/2012/05/working-on-optic-nerve-regeneration.php
Researchers are working on creating regeneration in mammals where it does not normally happen: "Researchers have long tried to get the optic nerve to regenerate when injured, with some success, but no one has been able to demonstrate recovery of vision. A team [now] reports a three-pronged intervention that not only got optic nerve fibers to grow the full length of the visual pathway (from retina to the visual areas of the brain), but also restored some basic elements of vision in live mice. ... [the mice were able to] regain some depth perception, the ability to detect overall movement of the visual field, and perceive light. ... Previous studies [have] demonstrated that optic nerve fibers can regenerate some distance through the optic nerve, but this is the first study to show that these fibers can be made to grow long enough to go from eye to brain, that they are wrapped in the conducting 'insulation' known as myelin, that they can navigate to the proper visual centers in the brain, and that they make connections (synapses) with other neurons, allowing visual circuits to re-form. ... [Researchers] combined three methods of activating the growth state of neurons in the retina, known as retinal ganglion cells: stimulating a growth-promoting compound called oncomodulin, [elevating] levels of cyclic adenosine monophosphate (cAMP) and deleting the gene that encodes the enzyme PTEN. ... these interventions have a synergistic effect on growth of optic nerve fibers. ... The eye turns out to be a feasible place to do gene therapy. The viruses used to introduce various genes into nerve cells mostly remain in the eye. Retinal ganglion cells are easily targetable."

SKIN CELLS FROM THE OLD MADE INTO BEATING HEART MUSCLE CELLS
Wednesday, May 23, 2012
http://www.fightaging.org/archives/2012/05/skin-cells-from-the-old-made-into-beating-heart-muscle-cells.php
Ongoing work in regenerative medicine: "scientists have succeeded in taking skin cells from heart failure patients and reprogramming them to transform into healthy, new heart muscle cells that are capable of integrating with existing heart tissue. The research [opens] up the prospect of treating heart failure patients with their own, human-induced pluripotent stem cells (hiPSCs) to repair their damaged hearts. As the reprogrammed cells would be derived from the patients themselves, this could avoid the problem of the patients' immune systems rejecting the cells as 'foreign'. ... Recent advances in stem cell biology and tissue engineering have enabled researchers to consider ways of restoring and repairing damaged heart muscle with new cells, but a major problem has been the lack of good sources of human heart muscle cells and the problem of rejection by the immune system. Recent studies have shown that it is possible to derive hiPSCs from young and healthy people and that these are capable of transforming into heart cells. However, it has not been shown that hiPSCs could be obtained from elderly and diseased patients. In addition, until now researchers have not been able to show that heart cells created from hiPSCs could integrate with existing heart tissue. [Researchers] took skin cells from two male heart failure patients (aged 51 and 61) and reprogrammed them by delivering three genes or 'transcription factors' ... Crucially, this reprogramming cocktail did not include a transcription factor called c-Myc, which has been used for creating stem cells but which is a known cancer-causing gene. ... The resulting hiPSCs were able to differentiate to become heart muscle cells (cardiomyocytes) just as effectively as hiPSCs that had been developed from healthy, young volunteers who acted as controls for this study. Then the researchers were able to make the cardiomyocytes develop into heart muscle tissue, which they cultured together with pre-existing cardiac tissue. Within 24-48 hours the tissues were beating together. ... The tissue was behaving like a tiny microscopic cardiac tissue comprised of approximately 1000 cells in each beating area. ... Finally, the new tissue was transplanted into healthy rat hearts and the researchers found that the grafted tissue started to establish connections with the cells in the host tissue."

RAPAMYCIN SLOWS AGING IN MICE
Tuesday, May 22, 2012
http://www.fightaging.org/archives/2012/05/rapamycin-slows-aging-in-mice.php
Researchers conclude that the extension of life in mice due to rapamycin is in fact a slowing of aging due to the breadth of its effects: "Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action." You might also look at recent research focused on separating the beneficial effects of rapamycin from the undesirable side-effects.

REMOVAL OF ABDOMINAL FAT REDUCES CANCER RISK
Tuesday, May 22, 2012
http://www.fightaging.org/archives/2012/05/removal-of-abdominal-fat-reduces-cancer-risk.php
As an addendum to research showing that removal of visceral fat in mice extends life, here is work showing that it reduces risk of some cancers as well: "obesity increases the risk of heart disease, diabetes and cancer. But there have not been clinical studies to determine if the surgical removal of fat tissue would decrease cancer risk in humans. ... researchers found that surgical removal of abdominal fat from obese mice fed a high-fat diet had between 75-80 percent fewer UV-induced skin cancers than mice that did not undergo fat-removal surgery. Although scientists understand that tissue fat may play a role in tumor formation, there has been little research on the molecular mechanisms of how a high-fat diet increases the formation of skin cancer. This new study suggests that abdominal fat in mice secretes proteins that enhance the risk of cancer. Once the original fat tissue is removed, the biochemical properties of new fat tissue that appear after surgery are less harmful. ... It would be interesting to see if surgical removal of fat tissue in animals would prevent obesity-associated lethal cancers like those of the pancreas, colon and prostate. Whether removal of tissue fat in humans which has certain risks would decrease the risk of life-threatening cancers in humans is not known." A better approach is not to gain the fat tissue, and thus its unfortunate metabolic effects, in the first place - or work to lose it the traditional way, through improved diet and exercise, both of which have broad health benefits.

ALCOR FEATURED IN PHOENIX MAGAZINE
Monday, May 21, 2012
http://www.fightaging.org/archives/2012/05/alcor-featured-in-phoenix-magazine.php
Cryonics provider Alcor gets a section in this Phoenix Magazine article on the industries associated with end of life management. It starts half way down the third page of the piece: "Max More, [the] CEO of the Alcor Life Extension Foundation is discussing the existential benefits of cryonics - i.e. the preservation of clinically-dead human beings at super-cold temperatures for the purpose of resuscitating them, presumably far in the future. Founded in 1972 by California couple Fred and Linda Chamberlain, Alcor relocated to Arizona in 1994 and currently hosts 110 cryopreserved patients in its hangar-like headquarters near the Scottsdale Airport. ... More isn't just the CEO of Alcor - he's also a longtime member. Known and respected as an advocate of transhumanist principles - a movement that proposes to eliminate aging and elevate the human condition to near godly heights - More first became hooked on cryonics as a 22-year-old undergraduate at the University of Oxford. At the time, Alcor was enjoying a surge in membership and positive international publicity. More, a young deep-thinker steeped in the science fiction classics of Philip K. Dick and Robert Heinlein, was intrigued. So he took out a life-insurance policy on himself ('At that age, it cost nothing...') to pay for his eventual one-time Alcor cryopreservation fee, which runs $200,000 for full-body patients and $80,000 for neuropatients. More chose the neuropatient option. 'To revive a cryopreserved patient, science and technology would have to advance to the point where minute repairs could be made to a hundred billion neurons. It seems to me that regenerating or cloning a new body would be relatively easy by comparison,' he says reasonably. 'No reason to preserve my broken down old body.' ... More's main focus is to bolster Alcor's membership rolls, which he concedes have stagnated in recent years, due both to the flagging economy and lax public-outreach efforts by previous CEOs. As of February 2012, Alcor had 957 members - still-living future 'patients' who had paid the one-time cryonics fee or taken out life insurance and made Alcor the beneficiary. The members sustain the nonprofit's day-to-day operations by paying $800 yearly dues until their legal deaths. (More is careful not to use the word 'death' without a qualifier; the foundation's entire doctrine is predicated on the idea that its patients aren't dead in the absolute sense.)"

AUTOPHAGY AND RAPAMYCIN
Monday, May 21, 2012
http://www.fightaging.org/archives/2012/05/autophagy-and-rapamycin.php
A recent paper: "The biological aging process is commonly associated with increased risk of cardiovascular diseases. Several theories have been put forward for aging-associated deterioration in ventricular function, including attenuation of growth hormone (insulin-like growth factors and insulin) signaling, loss of DNA replication and repair, histone acetylation and accumulation of reactive oxygen species. Recent evidence has depicted a rather unique role of autophagy as another important pathway in the regulation of longevity and senescence. Autophagy is a predominant cytoprotective (rather than self-destructive) process. It carries a prominent role in determination of lifespan. Reduced autophagy has been associated with aging, leading to accumulation of dysfunctional or damaged proteins and organelles. To the contrary, measures such as caloric restriction and exercise may promote autophagy to delay aging and associated comorbidities. Stimulation of autophagy using rapamycin may represent a novel strategy to prolong lifespan and combat aging-associated diseases. Rapamycin regulates autophagy through inhibition of the nutrient-sensing molecule mammalian target of rapamycin (mTOR). Inhibition of mTOR through rapamycin and caloric restriction promotes longevity."

______________________________


View the full article

#11 ImmInst

  • Topic Starter
  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 03 June 2012 - 04:44 PM

FIGHT AGING! NEWSLETTER
June 4th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- An Update on the Longecity Crowdfunded Microglia Study
- Video of Aubrey de Grey at TEDxUChicago
- Civilization as a Side-Effect of the Urge to Immortality
- Does Medicine For Aging Exist?
- Discussion
- Latest Headlines from Fight Aging!

AN UPDATE ON THE LONGECITY CROWDFUNDED MICROGLIA STUDY

Last year the Longecity community completed fundraising for a study of microglia transplants as a means to reverse some aspects of neurodegeneration. Here is an update on how that is going:

http://www.fightaging.org/archives/2012/05/updates-on-the-longecity-crowdfunded-microglia-study.php

"Cognitive functions of the brain decline with age. One of the protective cell types in the brain are called microglia cells. However, these microglia cells also loose function with age. Our aim is to replace non-functional microglia with new and young microglia cells derived from adult stem cells. We will inject these young microglia cells into 'Alzheimer mice' - a model for Alzheimers disease. After giving the cells some time to work, we will sacrifice the mice and measure microglia activity, neurogenesis, proliferation of neuroprogenitors and plaque density in the brain. A reduction in plaque density of Alzheimer mice would be a first proof that the transplanted microglia are performing their expected function.

"To visualize microglia and amyloid plaques in vivo, we established different staining protocols (including histology and immunohistology) to later evaluate microglia number after transplantation and also amyloid load. ... Most of our measurements will take place in the hippocampus, one of the brain regions where many of the degenerative changes happen in Alzheimer's disease. ... In summary we have established all necessary methods for brain staining, tested the sterology method using non-transplanted mice and are now ready to transplant. We finally got the approval from our animal guys after waiting for 10 month (they are a bit over-correct here in Germany).

"One thing to note about animal studies, and medical research in general, is the exceedingly heavy layer of regulation that exists in much of the world. There are boards and reviews and an endless procession of paperwork, all apparently devoted to slowing things down. It really can take the better part of a year to obtain institutional approval to perform a comparatively simple study - and it is usually impossible to have that approval timed to allow research to proceed without delay. Another thing to note is that even the comparatively simple work in the life sciences involves many, many details of measurement, cell cultures, and other line items. Much of that is largely hidden from the outside world and glossed over in the popular science press, which prefers to focus on the end results or new achievements rather than all of the well known but time-consuming foundation work that goes into any study."

VIDEO OF AUBREY DE GREY AT TEDXUCHICAGO

TEDxUChicago 2012 was held a little while back, and here is video of SENS Foundation cofounder Aubrey de Grey presenting at the event:

http://www.fightaging.org/archives/2012/05/aubrey-de-grey-at-tedxuchicago-2012.php

CIVILIZATION AS A SIDE-EFFECT OF THE URGE TO IMMORTALITY

Here is an interesting view of the deep cultural roots of the urge to live longer:

http://www.fightaging.org/archives/2012/05/civilization-as-a-side-effect-of-the-urge-to-immortality.php

"Cave's fascinating new book, Immortality, posits that civilization is a major side effect of humanity's attempts to live forever. He argues that our sophisticated minds inexorably recognize that, like all other living things, we will one day die. Simultaneously, Cave asserts, 'The one thing that these minds cannot imagine is that very state of nonexistence; it is literally inconceivable. Death therefore presents itself as both inevitable and impossible. This is what I will call the Mortality Paradox, and its resolution is what gives shape to the immortality narratives, and therefore to civilization.' ... Cave identifies four immortality narratives that drive civilizations over time which he calls; (1) Staying Alive, (2) Resurrection, (3) Soul, and (4) Legacy. Cave gracefully marches through his four immortality narratives citing examples from history, psychology, and religion up to the modern day. 'At its core, a civilization is a collection of life extension technologies: agriculture to ensure food in steady supply, clothing to stave off cold, architecture to provide shelter and safety, better weapons for hunting and defense, and medicine to combat injury and disease,' he writes."

"I think that it is useful to realize that much of our present culture - and that includes the culture of longevity science and its supporters - has very ancient roots indeed. Unbroken lines can be traced from the incentives and psychology of stone age shamans through to the magical thinking and oral fixations of today. Little but technology separates us from our ancestors of five or ten thousand years past, and what to what use do we put that technology? We use it to make our greatest myths real: we are building the world that our ancestors chose to imagine, and which we too imagine, driven by our shared human condition and neural physiology.

"Spend a little time with ancient myth, and you'll soon see there is little fundamental difference between the tales of thousands of years past and the folktales of a few hundred years ago. Our present popular entertainments merely continue the theme, a thousand more frills but the same underlying psychology at work. We humans identify with a certain set of stories, and those stories are found repeated throughout our mythologies. In turn, mythology drives technology, as technology is, at heart, a way to satisfy human desires.

"As to those parts of mythology that we haven't got to yet - such as unbounded longevity, enabled through biotechnology - well, give it time. We have managed flight, standing atop mountains, journeying to the moon, transmuting the elements, growing food in abundance beyond the wildest dreams of past centuries, changing the course of floods and rivers, and far more. Even the oldest myths will in due course be reconstructed in the real world, even if that means we will build cities in the clouds, cats that can talk, and spirits for companionship. Given sufficiently advanced biotechnology and an understanding of the fundaments of intelligence, the world of a century from now will be populated by people who do not age and disembodied machine intelligences - easily enough matched to the roles of hidden peoples and household spirits in legend."

DOES MEDICINE FOR AGING EXIST?

The short answer: arguably yes, but it's generally awful and ineffective in the grand scheme of things. We should look to the future of biotechnologies that can repair cellular damage rather than chase our tails in excitement over present drugs that might incrementally slow aging:

http://www.fightaging.org/archives/2012/05/does-medicine-for-aging-exist.php

"Asking and attempting to answer questions like 'does medicine for aging exist' is going to make you unpopular in some quarters no matter how you answer. The large and energetic 'anti-aging' marketplace, eternally plagued by the dishonesty of its bad apples, has been crying 'yes, yes, get your treatments for aging here' for about as long as mankind has existed. The invention of fraud no doubt followed the discovery of the concepts of value and trade by only a few heartbeats. When no-one could in fact do much of anything about aging, one might say 'so what?' Fraud and lies about extending life were no different then than fraud and lies about anything else that didn't exist and couldn't be made to exist - such as the ownership rights to certain bridges, for example.

"In these later days of science and reason, however, in which we stand upon the verge of building real and meaningful ways to treat aging, that commercial 'anti-aging' market is a millstone around the necks of the scientific community. It is in fact a large part of the reason why up until very recently the aging research field was extremely hostile towards anyone talking seriously about treating aging. So you are going to see care taken when people in the scientific community speak on such topics. For my part, I think it's completely fair to put forward that, by modern standards of drug development, you could point to rapamycin and metformin and say 'these are candidate treatments for aging.' By this I mean that they are likely to produce minimal benefits, have potentially ugly side-effects, and are not yet really tested for that specific usage in humans - which describes both a fair chunk of the drug discovery pipeline and many drugs out there in widespread use. We are willing to call those therapies for the conditions they are used to treat.

"But let's be clear: as prospective therapies for aging, these drugs are terrible. Truly bad. They are far worse than exercise or calorie restriction - they produce lesser benefits and you get unpleasant side-effects into the bargain. So given all of that I don't think it is unreasonable to say that yes, treatments for aging exist at the present time, and they are awful.

"(It is worth pointing out that a gain in life span of 20% in mice is not all that in the grand scheme of things. Exercise can do better, and calorie restriction does twice as well. Further, it is not seriously expected that any gain of 20% in life span in mice through metabolic alteration will translate to a similarly meaningful gain in human life span - which has to do with many of the differences that cause us to be long-lived already for our size. For example, calorie restriction is not thought to be capable of producing more than a few years of gain in maximal human life span, even while it produces large gains in health and resistance to age-related disease).

"The real path to the future, to my eyes, is to skip over all of this longevity-enhancing drug discovery nonsense, interesting though it may be, and focus on repair of specific forms of cellular and molecular damage - such as the detailed methodologies proposed in the SENS vision. If SENS or similar programs for research and development fail to become a dominant approach to longevity science, and the foreseeable future thus remains a heaping helping of more longevity-enhancing drug discovery nonsense, then therapies for aging will continue to be generally awful."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

CREATING PARTIAL REGENERATION IN THE SPINE
Friday, June 1, 2012
http://www.fightaging.org/archives/2012/06/creating-partial-regeneration-in-the-spine.php
Researchers make paralyzed rats walk through a mix of chemical stimulation and structured physical therapy; only a little regrowth in the spine occurs, but the lower spinal column can take over some of the lost functionality under the right circumstances: "a severed section of the spinal cord can make a comeback when its own innate intelligence and regenerative capacity is awakened. ... After a couple of weeks of neurorehabilitation with a combination of a robotic harness and electrical-chemical stimulation, our rats are not only voluntarily initiating a walking gait, but they are soon sprinting, climbing up stairs and avoiding obstacles when stimulated. ... until now the spinal cord expressed so little plasticity after severe injury that recovery was impossible. ... under certain conditions, plasticity and recovery can take place in these severe cases - but only if the dormant spinal column is first woken up. To do this, [researchers] injected a chemical solution of monoamine agonists into the rats. These chemicals trigger cell responses by binding to specific dopamine, adrenaline, and serotonin receptors located on the spinal neurons. This cocktail replaces neurotransmitters released by brainstem pathways in healthy subjects and acts to excite neurons and ready them to coordinate lower body movement when the time is right. ... Five to 10 minutes after the injection, the scientists electrically stimulated the spinal cord with electrodes implanted in the outermost layer of the spinal canal, called the epidural space. ... a stimulated rat spinal column - physically isolated from the brain from the lesion down - developed in a surprising way: It started taking over the task of modulating leg movement, allowing previously paralyzed animals to walk over treadmills. These experiments revealed that the movement of the treadmill created sensory feedback that initiated walking - the innate intelligence of the spinal column took over, and walking essentially occurred without any input from the rat's actual brain. This surprised the researchers and led them to believe that only a very weak signal from the brain was needed for the animals to initiate movement of their own volition. ... newly formed fibers bypassed the original spinal lesion and allowed signals from the brain to reach the electrochemically-awakened spine. And the signal was sufficiently strong to initiate movement over ground."

ON THE LEGAL STATUS OF CRYOPRESERVED PEOPLE
Friday, June 1, 2012
http://www.fightaging.org/archives/2012/06/on-the-legal-status-of-cryopreserved-people.php
There is death and then there is information theoretic death - a person who is cryopreserved is a good deal less dead than someone who went to the grave. The fine structure and data of the mind still exist, in a cold-stored stasis, and thus might be restored through foreseeable future technology. Here are some notes on the legal situation with respect to cryopreserved people: "This article series seeks to compare the legal protection of cryonics patients under their present legal status to the legal protection which would be afforded them if they were recognized as persons under the law, thinking ahead to such future time as it becomes reasonably possible to put legal and political pressure towards enhanced legal recognition of cryonics patients. The previous article examined laws that directly affect what happens to a person's body after legal death, both in the period immediately after declaration of legal death, and indefinitely thereafter. We saw that the amount of prospective autonomy a person is permitted in this regard can vary significantly from jurisdiction to jurisdiction, with more or less consideration afforded to the wishes of the person's next of kin, religious beliefs, societal norms and other public interests. Two other legal structures which can and are used by cryonicists to promote the success and timeliness of cryopreservation, maintenance, and resuscitation are wills and trusts."

WORK ON RESTORING FUNCTION IN HUNTINGTON'S DISEASE
Thursday, May 31, 2012
http://www.fightaging.org/archives/2012/05/restoring-function-in-huntingtons-disease.php
Researchers "have collaborated on a project to restore neuron function to parts of the brain damaged by Huntington's disease (HD) by successfully transplanting HD-induced pluripotent stem cells into animal models. ... Induced pluripotent stem cells (iPSCs) can be genetically engineered from human somatic cells such as skin, and can be used to model numerous human diseases. They may also serve as sources of transplantable cells that can be used in novel cell therapies. In the latter case, the patient provides a sample of his or her own skin to the laboratory. In the current study, experimental animals with damage to a deep brain structure called the striatum (an experimental model of HD) exhibited significant behavioral recovery after receiving transplanted iPS cells. The researchers hope that this approach eventually could be tested in patients for the treatment of HD. ... the transplanted cells will be genetically identical to the patient and therefore no medications that dampen the immune system to prevent graft rejection will be needed. ... transplanted iPSCs initially formed neurons producing GABA, the chief inhibitory neurotransmitter in the mammalian central nervous system, which plays a critical role in regulating neuronal excitability and acts at inhibitory synapses in the brain. GABAergic neurons, located in the striatum, are the cell type most susceptible to degeneration in HD."

EFFECTS OF EXERCISE AND DIET ON MORTALITY IN THE OLD
Thursday, May 31, 2012
http://www.fightaging.org/archives/2012/05/effects-of-exercise-and-diet-on-mortality-in-the-old.php
Via EurekAlert!: researchers "studied 713 women aged 70 to 79 years who took part in the Women's Health and Aging Studies. This study was designed to evaluate the causes and course of physical disability in older women living in the community. ... A number of studies have measured the positive impact of exercise and healthy eating on life expectancy, but what makes this study unique is that we looked at these two factors together. ... Researchers found that the women who were most physically active and had the highest fruit and vegetable consumption were eight times more likely to survive the five-year follow-up period than the women with the lowest rates. ... Study participants' physical activity was measured through a questionnaire that asked the amount of time the spent doing various levels of physical activity, which was then converted to the number of calories expended. The women were then followed up to establish the links between healthy eating, exercise and survival rates. Key research findings included: More than half of the 713 participants (53%) didn't do any exercise, 21% were moderately active, and the remaining 26% were in the most active group at the study's outset. During the five-year follow up, 11.5% of the participants died. Serum carotenoid levels were 12% higher in the women who survived and total physical activity was more than twice as high. Women in the most active group at baseline had a 71% lower five-year death rate than the women in the least active group. Women in the highest carotenoid group at baseline had a 46% lower five-year death rate than the women in the lowest carotenoid group. When taken together, physical activity levels and total serum carotenoids predicted better survival."

A HIGH LEVEL VIEW OF WHAT IS KNOWN OF AGING
Wednesday, May 30, 2012
http://www.fightaging.org/archives/2012/05/a-high-level-view-of-what-is-known-of-aging.php
The Guardian talks to researcher Tom Kirkwood: "We've known for some time that ageing is extremely variable; that everybody is different and that the differences of individuals' experience of ageing are greater than differences in earlier stages of life ... And why so variable? ... Because of the nature of the ageing process. I've been involved in this field for more than 35 years and when I entered it people fondly believed that ageing was programmed; that there was a mechanism inside our bodies that determined how long we would live. It was kind of written into our genes that we would die at a certain age. What we've been able to show is that the idea of this genetically programmed ageing makes no sense at all. There is no evidence. ... But, surely, genetic influences - a family susceptibility to cardiovascular problems, for instance - play a part in determining longevity? Only to a degree. [For example] a Danish study shows that such influences only explain about a quarter of the factors determining a lifespan. ... What we now know is that the genetic factors that influence your longevity are not genes that measure out the passage of time; the reason we age and die is because, as we live our lives, our bodies accumululate a great variety of small faults in the cells, and the molecules that make up the cells in our body - so ageing is driven by this accumulation of faults. The genes that influence longevity are those that influence how well the body copes with damage, how aggressive our repair mechanisms are; they're genes that regulate the house-keeping and maintenance and repair." All the more reason to focus research on the development of biotechnologies that can do a far better job of repair.

FIBROBLAST GROWTH FACTOR AND ZEBRAFISH REGENERATION
Wednesday, May 30, 2012
http://www.fightaging.org/archives/2012/05/fibroblast-growth-factor-and-zebrafish-regeneration.php
Small steps towards understanding the greater regenerative capacity of one species: "When the spinal cord is severed in humans and other mammals, the immune system kicks in, activating specialised cells called glia to prevent bleeding into it. ... Glia are the workmen of the nervous system. The glia proliferate, forming bigger cells that span the wound site in order to prevent bleeding into it. They come in and try to sort out problems. A glial scar forms. ... However, the scar prevents axons, threadlike structures of nerve cells that carry impulses to the brain, of neighbouring nerve cells from penetrating the wound. The result is paralysis. ... The axons upstream and downstream of the lesion sites are never able to penetrate the glial scar to reform. This is a major barrier in mammalian spinal cord regeneration. In contrast, the zebra fish glia form a bridge that spans the injury site but allow the penetration of axons into it. The fish can fully regenerate its spinal cord within two months of injury. ... Scientists discovered the protein, called fibroblast growth factor (fgf), controlled the shape of the glia, and accounted for the difference in the response to spinal cord injury between humans and zebra fish. The scientists showed the protein could be manipulated in the zebra fish to speed up tissue repair even more. ... The hope is that fgf could eventually be used to promote better results in spinal cord repair in people."

TISSUE ENGINEERING OF SMALL BLOOD VESSELS
Tuesday, May 29, 2012
http://www.fightaging.org/archives/2012/05/tissue-engineering-of-small-blood-vessels.php
Researchers are increasingly able to produce networks of small blood vessels - here in a way that is only immediately applicable to testing, but which will no doubt lead to further progress: "bioengineers have developed the first structure to grow small human blood vessels, creating a 3-D test bed that offers a better way to study disease, test drugs and perhaps someday grow human tissues for transplant. ... with this, we can really dissect what happens at the interface between the blood and the tissue. We can start to look at how these diseases start to progress and develop efficient therapies. ... [Researchers] first built the structure out of the body's most abundant protein, collagen, [created] tiny channels and injected this honeycomb with human endothelial cells, which line human blood vessels. During a period of two weeks, the endothelial cells grew throughout the structure and formed tubes through the mold's rectangular channels, just as they do in the human body. When brain cells were injected into the surrounding gel, the cells released chemicals that prompted the engineered vessels to sprout new branches, extending the network. A similar system could supply blood to engineered tissue before transplant into the body. ... The engineered vessels could transport human blood smoothly, even around corners. And when treated with an inflammatory compound the vessels developed clots, similar to what real vessels do when they become inflamed. The system also shows promise as a model for tumor progression. Cancer begins as a hard tumor but secretes chemicals that cause nearby vessels to bulge and then sprout. Eventually tumor cells use these blood vessels to penetrate the bloodstream and colonize new parts of the body. When the researchers added to their system a signaling protein for vessel growth that's overabundant in cancer and other diseases, new blood vessels sprouted from the originals. These new vessels were leaky, just as they are in human cancers. ... With this system we can dissect out each component or we can put them together to look at a complex problem. That's a nice thing - we can isolate the biophysical, biochemical or cellular components. How do endothelial cells respond to blood flow or to different chemicals, how do the endothelial cells interact with their surroundings, and how do these interactions affect the vessels' barrier function?"

A CHEAP AND ABUNDANT SOURCE OF HEART MUSCLE CELLS
Tuesday, May 29, 2012
http://www.fightaging.org/archives/2012/05/a-cheap-and-abundant-source-of-heart-muscle-cells.php
Researchers find a low-cost way of creating cardiomyocytes on demand: they can "transform human stem cells - both embryonic and induced pluripotent stem cells - into the critical heart muscle cells by simple manipulation of one key developmental pathway. ... manipulating a major signaling pathway known as Wnt - turning it on and off at prescribed points in time using just two off-the-shelf small molecule chemicals - is enough to efficiently direct stem cell differentiation to cardiomyocytes. ... The technique promises a uniform, inexpensive and far more efficient alternative to the complex bath of serum or growth factors now used to nudge blank slate stem cells to become specialized heart cells. ... Our protocol is more efficient and robust. We have been able to reliably generate greater than 80 percent cardiomyocytes in the final population while other methods produce about 30 percent cardiomyocytes with high batch-to-batch variability. ... The ability to make the key heart cells in abundance and in a precisely defined way is important because it shows the potential to make the production of large, uniform batches of cardiomyocytes routine. [The] cells are in great demand for research, and increasingly for the high throughput screens used by the pharmaceutical industry to test drugs and potential drugs for toxic effects. ... Scientists also have high hopes that one day healthy lab-grown heart cells can be used to replace the cardiomyocytes that die as a result of heart disease. ... Many forms of heart disease are due to the loss or death of functioning cardiomyocytes, so strategies to replace heart cells in the diseased heart continue to be of interest. For example, in a large heart attack up to 1 billion cardiomyocytes die. The heart has a limited ability to repair itself, so being able to supply large numbers of potentially patient-matched cardiomyocytes could help."

AUTOANTIBODIES IN ALZHEIMER'S DISEASE
Monday, May 28, 2012
http://www.fightaging.org/archives/2012/05/autoantibodies-in-alzheimers-disease.php
Via ScienceDaily, an example of a more recent form of theory to explain the development of Alzheimer's disease: "dying or damaged brain cells release debris into the bloodstream and give rise to specific autoantibodies that appear to be reliable biomarkers for early diagnosis of Alzheimer's and other neurodegenerative diseases. The researchers also identify a key mechanism in the development of Alzheimer's that mirrors a process that is common in such autoimmune disorders as rheumatoid arthritis. ... human blood contains perhaps thousands of autoantibodies for clearing cellular debris, and that some of these autoantibodies can potentially be used to accurately diagnose neurodegenerative diseases ... The researchers focused on the role of enzymes, called PADs, in citrullination, a process that converts one type of amino acid into another (amino acids are the building blocks of proteins). After examining postmortem human brain tissue from individuals with Alzheimer's disease and healthy controls, the researchers found that neurons located in the area of the brain first affected by Alzheimer's disease accumulate both citrullinated proteins and a PAD enzyme. ... Their results suggest that when neuron cells die, they release their contents into the fluid that surrounds the brain. The cellular remains then enter the bloodstream and their presence generates the production of specific autoantibodies that target this neuronal debris. ... Our previous studies provided evidence that some of these autoantibodies may be able to return to the brain through breaches in the blood-brain barrier. Once there, they selectively bind to the surfaces of neurons, disrupting the function of the brain cells and accelerating the accumulation of beta amyloid deposits. This chronic cycle of protein-debris-generating autoantibodies that can then seep through the blood-brain barrier helps explain the long-term, progressive degeneration that results from Alzheimer's disease."

THOUGHTS ON THE DE GREY/BLAKEMORE DEBATE ON LONGEVITY SCIENCE
Monday, May 28, 2012
http://www.fightaging.org/archives/2012/05/thoughts-on-the-de-greyblakemore-debate-on-longevity-science.php
Filmmaker Robert Pappas, who produced To Age or Not to Age, here offers some thoughts on the recent academic debate between Aubrey de Grey and Colin Blakemore: "The debate's title was: 'Resolved this house wants to defeat aging entirely' and was to cover the feasibility and desirability of bringing aging under medical control. After watching the video of the debate; among other things, it strikes me that the title itself helps obscure the nature and process of the scientific research currently underway to extend healthspan, and by implication, lifespan. The problem waxes ironic. To a large degree, Aubrey became 'famous' by uttering the following on camera: 'I'm claiming that the first person to live to a 1,000, subject of course to global catastrophes, is actually, probably only about 10 years younger than the 1st 150 year old, and that's quite a thought.' On the one hand, Aubrey's thesis is provocative and possibly true - but there is a downside to such a framing of the discussion. The viewer or reader reacts - 'What, 10 years after 150, what? A 1,000 years, people from the middle ages would be alive, what? Population, resources? Bombs? - Who wants to live that long, the world sucks now, ahhhhhhh....!' I personally observed similar reactions in a portion of the audience who watched my film." This is a framing of the standard debate in advocacy for any bold new step forward in science: do you plant a flag right out there to set the bounds of the debate, or do you take the softly-softly incremental approach? In this age of pervasive death cult environmentalism, to the point at which the average man in the street thinks - falsely - that living longer will in some way cause catastrophe, I'm in favor of the former approach lest the middle position in the debate become suppression of research and development in medicine.

______________________________


View the full article

#12 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 10 June 2012 - 03:18 PM

FIGHT AGING! NEWSLETTER
June 11th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Growing a Small Mass of Liver Tissue From Stem Cells
- Heart Rate Variability in Calorie Restriction Practitioners
- An Introduction to Microglia in the Aging Brain
- Discussion
- Latest Headlines from Fight Aging!

GROWING A SMALL MASS OF LIVER TISSUE FROM STEM CELLS

The press are noting that a Japanese group has managed to grow a small mass of functional liver tissue from stem cells:

http://www.fightaging.org/archives/2012/06/growing-a-small-mass-of-liver-tissue-from-stem-cells.php

"The liver is likely to be one of the earliest human organs grown to order from a patient's stem cells: liver tissue is already far more capable of regeneration than the tissues of other organs, and researchers have been making good progress in recent years in coaxing stem cells to form live tissue. As of today, a press report is doing the rounds to claim that a Japanese group have managed to grow a small functional mass of liver tissue - calling it a liver is no doubt considerably overstating the case, given the small size. Details are somewhat light on the ground, but we'll no doubt hear more soon.

"Japanese researchers have created a functioning human liver from stem cells, a report says. ... A team of scientists transplanted induced pluripotent stem (iPS) cells into the body of a mouse, where it grew into a small, but working, human liver, the Yomiuri Shimbun said. A team led by professor Hideki Taniguchi at Yokohama City University developed human iPS cells into 'precursor cells', which they then transplanted into a mouse's head to take advantage of increased blood flow. The cells grew into a human liver 5 millimetres (0.2 inches) in size that was capable of generating human proteins and breaking down drugs, the Yomiuri reported. An abstract of Taniguchi's research was delivered to regenerative medicine researchers ahead of an academic conference next week, but Taniguchi declined to comment to AFP before the meeting."

HEART RATE VARIABILITY IN CALORIE RESTRICTION PRACTITIONERS

I recently pointed out research on the younger hearts possessed by long-term practitioners of calorie restriction, and here is more on that topic:

http://www.fightaging.org/archives/2012/06/more-on-heart-rate-variability-in-calorie-restriction-practitioners.php

"People who practice calorie restriction over the long term have physiologically younger cardiovascular systems - meaning notably less low-level cellular damage and better function than their peers of a similar chronological age. ... If there was a drug that did that, its financials would be staggering - and you'd never hear the end of it. It would be publicized and popularized in every corner of the world. But just ask someone to exercise a little willpower and planning in their diet to gain the same results ... and therein lies a lesson with regard to human nature.

"The idea was to learn, first of all, whether humans on CR, like the calorie-restricted animals that have been studied, have a similar adaptation in heart rate variability. The answer is yes. We also looked at normal levels of heart rate variability among people at different ages, and we found that those who practice CR have hearts that look and function like they are years younger ... This is really striking because in studying changes in heart rate variability, we are looking at a measurement that tells us a lot about the way the autonomic nervous system affects the heart. And that system is involved not only in heart function, but in digestion, breathing rate and many other involuntary actions. We would hypothesize that better heart rate variability may be a sign that all these other functions are working better, too. ... Higher heart rate variability means the heart can adjust to changing needs more readily. Heart rate variability declines with age as our cardiovascular systems become less flexible, and poor heart rate variability is associated with a higher risk of cardiovascular death."

AN INTRODUCTION TO MICROGLIA IN THE AGING BRAIN

The immune system is important in aging, and arguably more so in the brain than elsewhere - since we can't just write off and replace the brain wholesale using the regenerative medicine of tomorrow, as we can for other organs.

http://www.fightaging.org/archives/2012/06/an-introduction-to-microglia-in-the-aging-brain.php

"Microglia are immune cells that defend and clean up the brain and spinal cord. Like the rest of the immune system, they progressively fail in their work with age. Worse, like other immune system components, they begin to become actively harmful by causing chronic inflammation and other forms of damage instead of helping. Reversing that trend is one important line of research among many that, as they produce working medical technologies, will extend our healthy life spans. ... So microglia, as an important part of the existing maintenance systems in the brain, are of considerable interest. Can early successes be obtained by boosting their activity, or slowing or reversing their decline with age?"

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

POPULAR PRESS ON INTERMITTENT FASTING
Friday, June 8, 2012
http://www.fightaging.org/archives/2012/06/popular-press-on-intermittent-fasting.php
Andrew Weil, who is something of an apologist for aging, here holds forth on the merits of intermittent fasting (IF) - shown to improve health and extend life in laboratory animals through mechanisms that largely, but not entirely, overlap with those of calorie restriction: "An IF regime works, proponents say, because it aligns with our evolutionary history. Over the 250,000 years that Homo sapiens have been around, food supply has waxed and waned. We evolved to take advantage of this fact, building muscle and fatty tissue during times of abundance, then paring it back during lean ones. Fasting periods accelerate the clearing-out of waste left by dead and damaged cells, a process known as autophagy. A failure of autophagy to keep up with accumulated cellular debris is believed by many scientists to be one of the major causes of the chronic diseases associated with aging. Occasional fasting also seems to boost activity and growth of certain types of cells, especially neurons. This may seem odd, but consider it from an evolutionary perspective - when food is scarce, natural selection would favor those whose memories ("Where have we found food before?") and cognition ("How can we get it again?") became sharper. Research indicates that the benefits of IF may be similar to those of caloric restriction (CR) in which there are regular meals, but portions are smaller than normal. ... The positive effects of IF have been chronicled in a variety of animal and human studies, starting with a seminal experiment in 1946, when University of Chicago researchers discovered that denying food every third day boosted rats' lifespans by 20 percent in males, 15 percent in females. A 2007 review by University of California, Berkeley, researchers concluded that alternate-day fasting may: 1) Decrease cardiovascular disease risk. 2) Decrease cancer risk. 3) Lower diabetes risk (at least in animals, data on humans were less clear, possibly because the trial periods in the studies were not long enough to show an effect). 4) Improve cognitive function. 5) Protect against some effects of Alzheimer's and Parkinson's diseases."

LINKING RUSSIAN COSMISM TO MODERN THOUGHT ON ENGINEERED LONGEVITY
Friday, June 8, 2012
http://www.fightaging.org/archives/2012/06/linking-russian-cosmism-to-modern-thought-on-engineered-longevity.php
This interview, machine-translated from the Russian, will be of interest to those who look into the history of transhumanist thought on the defeat of aging and radical life extension. It has deep roots back into the early 20th century, and one thread of these ideas was evolving through the ongoing disaster that was Russia of that century - the Russian cosmists are thought of as important predecessors to modern transhumanism, for example. These are some thoughts and recollections of someone who was publishing and thinking on the topic in the 1960s and later; note that the Russian end of the longevity science community are far from shy when it comes to talking about physical immortality as the end goal of medicine: "Meanwhile, today, in the [21st] century, when we talk about the necessity of victory over death, of making real the possibility of personal immortality and resurrection [of cryopreserved] people - people often do not even bother to think about it, but with some, or even masochistic pleasure begin to look for rebuttal. One would think, what to look for them? Why create additional obstacles? Chance of dying there at all. So there is nothing to lose. Is not it better to try to work together and find ways to avoid it? ... But, oddly enough, and sadly, no modern humanity, nor any single country (maybe with the exception of Japan, as far as I know), even such a purpose not intended. It's still pretty amazing! After all, people continue to die today, but no action is [taken]. How so? ... And yet ... There is no doubt the science over the past half century has leaped forward. Scientific and technological progress has radically changed many things in our lives. And the inspirational process is irreversible. You ask ... where the source of my optimism. He is in me and outside me. This is my inner conviction, supported by all the progressive tradition of Russian philosophical thought and [unstoppable] scientific thought."

IMPLICATING STEM CELLS IN HARDENED ARTERIES
Thursday, June 7, 2012
http://www.fightaging.org/archives/2012/06/implicating-stem-cells-in-hardened-arteries.php
Via EurekAlert!: "For the first time, we are showing evidence that vascular diseases are actually a kind of stem cell disease. ... It is generally accepted that the buildup of artery-blocking plaque stems from the body's immune response to vessel damage caused by low-density lipoproteins ... Such damage attracts legions of white blood cells and can spur the formation of fibrous scar tissue ... The scar tissue, known as neointima, has certain characteristics of smooth muscle, the dominant type of tissue in the blood vessel wall. Because mature smooth muscle cells no longer multiply and grow, it was theorized that in the course of the inflammatory response, they revert, or de-differentiate, into an earlier state where they can proliferate ... However, no experiments published have directly demonstrated this de-differentiation process ... researchers turned to transgenic mice with a gene that caused their mature smooth muscle cells to glow green under a microscope. In analyzing the cells from cross sections of the blood vessels, they found that more than 90 percent of the cells in the blood vessels were mature smooth muscle cells. They then isolated and cultured the cells taken from the middle layer of the mouse blood vessels. ... Notably, none of the new, proliferating cells glowed green, which meant that their lineage could not be traced back to the mature smooth muscle cells originally isolated from the blood vessels. ... We did further tests and detected proteins and transcriptional factors that are only found in stem cells. No one knew that these cells existed in the blood vessel walls because no one looked for them before. ... In the later stages of vascular disease, the soft vessels become hardened and more brittle. Previously, there was controversy about how soft tissue would become hard. The ability of stem cells to form bone or cartilage could explain this calcification of the blood vessels. ... Other tests in the study showed that the multipotent stem cells were dormant under normal physiological conditions. When the blood vessel walls were damaged, the stem cells rather than the mature smooth muscle cells became activated and started to multiply." Though if you want to consider root causes, look at mechanisms like accumulated damage to mitochondria that leads to a greater level of oxidized low-density lipoproteins in the blood.

ANOTHER LOOK AT THE ECONOMICS OF INACTIVITY
Thursday, June 7, 2012
http://www.fightaging.org/archives/2012/06/another-look-at-the-economics-of-inactivity.php
One of the costs of being sedentary is fiscal: the cost of medical services you would otherwise not have needed due to your increased risk of age-related disease. Here is another researcher running the numbers: "Physical inactivity is a recognized public health issue in Canada and globally ... A common approach for assessing the public health impact of physical inactivity is to measure the prevalence of the population not meeting physical activity guidelines. Recent surveillance data based on objective measures indicate that 85% of Canadian adults do not meet Canada's physical activity guidelines of 150 min/week of moderate-to-vigorous physical activity ... A second approach for assessing the public health impact of physical inactivity is to estimate the proportion of a disease within the population that is directly attributable to physical inactivity. For instance, 19% of the coronary artery disease cases in Canadian men are due to physical inactivity ... A third approach for assessing the public health impact of physical inactivity is to estimate the financial burden it places on the health care system and economy. The most recent Canadian estimates, based on 2001 data, suggest that the annual economic burden of physical inactivity is $5.3 billion. ... Similar to the 2001 estimates, the health care cost of physical inactivity in this report was estimated using a prevalence-based approach, which required 3 pieces of information: (1) the risks of chronic conditions in physically inactive individuals, (2) the direct and indirect costs of these chronic diseases, and (3) the prevalence of physical inactivity in the population. ... The estimated direct, indirect, and total health care costs of physical inactivity in Canada in 2009 were $2.4 billion, $4.3 billion, and $6.8 billion, respectively. These values represented 3.8%, 3.6%, and 3.7% of the overall health care costs." It is interesting to compare these numbers with research on individual lifetime medical cost differences that stem from being out of shape, and with some other number crunching on the economics of health and longevity.

WAIST CIRCUMFERENCE ASSOCIATED WITH TYPE 2 DIABETES
Wednesday, June 6, 2012
http://www.fightaging.org/archives/2012/06/waist-circumference-associated-with-type-2-diabetes.php
Here is a study that points to amount of visceral fat as a dominant contribution to the risk of age-related type-2 diabetes - a condition rarely suffered by people who successfully avoid putting on weight over the years - something that doesn't just happen, but requires exercise and a sensible approach to diet and lifestyle. "A collaborative re-analysis of data from the InterAct case-control study [has] established that waist circumference is associated with risk of type 2 diabetes, independently of body mass index (BMI). Reporting in this week's PLoS Medicine, the researchers estimated the association of BMI and waist circumference with type 2 diabetes from measurements of weight, height and waist circumference, finding that both BMI and waist circumference were independently associated with type 2 diabetes risk but waist circumference was a stronger risk factor in women than in men. ... The prospective InterAct case-cohort study was conducted in 26 centres in eight European countries and consists of 12,403 incident [type 2 diabetes] cases and a stratified subcohort of 16,154 individuals from a total cohort of 340,234 participants with 3.99 million person-years of follow-up. ... These findings indicate that targeted measurement of waist circumference in overweight individuals (who now account for a third of the US and UK adult population) could be an effective strategy for the prevention of diabetes because it would allow the identification of a high-risk subgroup of people who might benefit from individualised lifestyle advice. ... Our results clearly show the value that measurement of [waist circumference] may have in identifying which people among the large population of overweight individuals are at highest risk of diabetes." A risk that is essentially yours to create, remove, or manage through the choices you make.

SENS FOUNDATION ACADEMIC INITIATIVE PLANS FURTHER EXPANSION IN 2013
Wednesday, June 6, 2012
http://www.fightaging.org/archives/2012/06/sens-foundation-academic-initiative-plans-further-expansion-in-2013.php
The SENS Foundation Academic Initiative continues to grow, laying the foundation for the next generation of researchers working on rejuvenation biotechnology: "The Academic Initiative is likely to see another increased budget in 2013. We plan to offer at least as many scholarships and grants as we're offering this year, while we are nearly certain to expand our summer internship program, bringing in more interns overall and sending them to a greater number of labs. This year, some interns have been placed at the SENS Foundation Research Center, while others have gone to the Buck Institute for Research on Aging. We hope to place more interns at each location next year, and to add new locations. The Initiative's budget may not be the only thing that changes with the coming of the new year. SENS Foundation itself is still planning a revamp of its website, and the Academic Initiative won't miss that chance to have its own website enhanced further. Planning for our own next website has begun: long story short, it'll be simpler with less text and will offer very clear and immediate ways for students to get started. Some graphic design work that will go online with that new site is also underway. We'd like to finish by pointing out that we still have enough funding to continue to award materials grants throughout the summer and into the Fall 2012 semester. Since many students have extra time to put a proposal together over the summer, and since we're currently seeing a (likely summer-related) increase in interest in our grants, this is a particularly good time to apply."

SHIFTS IN CELL LINEAGE PROPORTIONS WITH AGING RAISE CANCER RISK
Tuesday, June 5, 2012
http://www.fightaging.org/archives/2012/06/shifts-in-cell-lineage-proportions-with-aging-raise-cancer-risk.php
Researchers dig deeper into the mechanisms of breast cancer risk: "Age-related physiological changes, including endocrine profiles and alterations of the microenvironments surrounding breast cells, have been associated with increased cancer risks, but the underlying cellular mechanisms behind these changes and their links to cancer have not been explained. ... Studying the aging process in any human tissue is a challenge primarily because of limited access to samples ... Human mammary epithelial cells (HMECs) are one of the few examples of an epithelial tissue that affords relatively good access because of mastectomies and cosmetic reduction surgeries. In both cases, surgical discards provide sample tissue for research [and researchers] were able to generate a large collection of normal HMEC strains derived from primary tissue in women aged 16 to 91 years. ... [The result was] a study in which it was determined that aging causes an increase in multipotent progenitors - a type of adult stem cell believed to be at the root of many breast cancers - and a decrease in the myoepithelial cells that line the breast's milk-producing luminal cells and are believed to serve as tumor suppressors. ... [Researchers] discovered that in finite-lifespan cultured and uncultured epithelial cells, the advancing years usher in a reduction of myoepithelial cells and an increase in luminal cells that express the proteins keratin 14 and integrin α6. In women under 30, these proteins are expressed almost exclusively in myoepithelial cells. ... The aging process therefore results in both a shift in the balance of luminal/myoepithelial lineages and to changes in the functional spectrum of multipotent progenitors that together appear to increase the potential for malignant transformation. We corroborated our culture data with parallel analyses of in vivo samples, but we still have dots to connect to demonstrate that these changes relate to an increased risk of malignancy. All the signs are there, though."

TESTING TREATMENT OF EMPHYSEMA WITH LUNG STEM CELLS
Tuesday, June 5, 2012
http://www.fightaging.org/archives/2012/06/testing-treatment-of-emphysema-with-lung-stem-cells.php
Via EurekAlert!: "When autologous (self-donated) lung-derived mensenchymal stem cells (LMSCs) were transplanted endoscopically into 13 adult female sheep modeled with emphysema, post-transplant evaluation showed evidence of tissue regeneration with increased blood perfusion and extra cellular matrix content. Researchers concluded that their approach could represent a practical alternative to conventional stem cell-based therapy for treating emphysema. ... previous transplantation studies, many of which used an intravenous delivery method, have shown that [bone marrow derived mensenchymal stem cells (BM-MSCs)] have been only marginally successful in treating lung diseases. Further, therapeutic responses in those studies have been limited to animal models of inflammatory lung diseases, such as asthma and acute lung injury. To try and answer the questions surrounding the utility of BM-MSCs for treating advanced emphysema, a disease characterized by tissue destruction and loss of lung structural integrity, for this study the researchers isolated highly proliferative, mensenchymal cells from adult lung parenchyma (functional tissue) (LMSCs) and used an endoscopic delivery system coupled with a scaffold comprised of natural extracellular matrix components. ... despite the use of autologous cells, only a fraction of the LMSCs delivered to the lungs alveolar compartment appeared to engraft. Cell death likely occurred because of the failure of LMSCs to home to and bind within their niche, perhaps because the niche was modified by inflammation or fibrosis. These cells are attachment-dependent and failure to attach results in cell death. Their findings did suggest, however, that LMSCs were capable of contributing to lung remodeling leading to documented functional improvement rather than scarring 28 days post transplantation."

EXTENDING LIFE IN FLIES VIA PINK1 OVEREXPRESSION
Monday, June 4, 2012
http://www.fightaging.org/archives/2012/06/extending-life-in-flies-via-pink1-overexpression.php
Researchers became interested in the Pink1 gene and its protein product because mutations in it are associated with a form of Parkinson's disease. Pink1 appears to be important in mitochondrial quality control: it is a part of the machinery that ensures damaged mitochondria can be effectively destroyed. Regular readers will know that an accumulation of damaged mitochondria is an important contribution to aging, so it should is perhaps not surprising that boosting levels of Pink1 extends life, here demonstrated in flies: "Overexpression of the gene coding for α-synuclein has been shown to be an inherited cause of Parkinson disease. Our laboratory has previously co-expressed the parkin and Pink1 genes to rescue α-synuclein-induced phenotypes within a Drosophila model. To further investigate the effect of Pink1 in this model, we performed longevity and behavioral studies using several drivers to express the α-synuclein and Pink1 genes. Our findings showed that overexpression of Pink1 and overexpression of Pink1 with α-synuclein resulted in an increased lifespan when driven with the TH-Gal4 transgene. This increase in longevity was accompanied by an increased healthspan, as measured by mobility over time, suggesting that this is an example of improved functional aging. Our results indicate that, in the dopaminergic cells targeted by TH-Gal4, increased expression of α-synuclein and Pink1 together have a synergistic effect, allowing for enhanced protection and increased survival of the organism."

AN INTERVIEW WITH SONIA ARRISON
Monday, June 4, 2012
http://www.fightaging.org/archives/2012/06/an-interview-with-sonia-arrison.php
Over at the IEET blog, a video interview: "Sonia Arrison is the author of "100 Plus: How the Coming Age of Longevity Will Change Everything, from Careers and Relationships to Family and Faith." In this video, Sonia discusses: how and why she got interested in technology in general and transhumanism and regenerative medicine in particular; how science and technology will allow us to live longer and healthier lives; the most common objections against increased longevity; the implications thereof on major religions; cryonics; her take on the technological singularity and our chances of surviving it; the fact that we cannot simply sit down and wait for longevity to happen." As noted, the future isn't a conveyor belt automatically bringing us better medicine and extended healthy life: every advance has to be advocated, funded, and built by someone. If too few people are working on longevity science, then rejuvenation biotechnology will not be developed in time.

______________________________


<br> <br>View the full article

#13 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 17 June 2012 - 04:16 PM

FIGHT AGING! NEWSLETTER
June 18th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Discussions of Mind Uploading
- More on DNA Methylation and Aging
- A Good Article on Naked Mole-Rats
- On Sarcopenia and Therapies Under Investigation
- Discussion
- Latest Headlines from Fight Aging!
    - Xenobiotic Metabolizing Enzymes as Biomarker of Longevity
    - C1q and Reversing the Decline in Muscle Regeneration With Age
    - Testing a Cell Therapy to Regenerate the Cornea
    - A Successful Decellularized Vein Transplant
    - Considering the Business Economics of Alcor
    - Senescent Cells Create More Senescent Cells
    - Telomeres and Late Fatherhood
    - Working on Better Ways to Grow Bone
    - The State of Gene Therapy
    - Shaped Nanoparticles Target Narrowed Blood Vessels

DISCUSSIONS OF MIND UPLOADING

At some point it will be possible to completely and accurately replicate the structure and operations of a brain, either in software or using some form of dedicated machinery. Given the extremely rapid expansion of computing power, that point will arrive within a few decades - and then things start to get interesting on a number of fronts:

http://www.fightaging.org/archives/2012/06/mind-uploading-at-the-international-journal-of-machine-consciousness.php

"Whole brain emulation is the topic for today: being able to run all of the processes of a brain on some form of computing machinery other than the evolved biological structures we presently possess. Considered in the long term this is an important line of research, as radical life extension will ultimately require moving away from flesh and into some more robust form of machinery in order to better manage the risk of fatal accidents. 'Ultimately' here is a long way into the future, centuries or more, long after we have solved the basic problems of repairing our aging biology so as to attain continual youth. Some people will be satisfied with copying themselves from their biological substrate into a machine substrate and letting that machine copy continue on, but that seems to me little more than an expensive form of procreation - continuation of the self requires a slow transformation of the original, not a quick cut and paste of data to a new computing device. But this is an old and often rehashed argument between identity as pattern and identity as continuity.

"Regardless of how people decide to use the ability to host a conscious individual somewhere other than a human brain, the technologies of whole brain emulation will have to be built. They are a precursor to any program of replacing the brain's present biological machinery with something better. From where I stand, brain emulation is also the most plausible path to true artificial intelligence, which at this time looks far more likely to arise from attempts to duplicate and then improve on the operation of human brains than from efforts to improve expert systems of varying sorts.

"Reasonable people differ on this, of course, as even a brief survey of publications on artificial intelligence will tell you. If you find this topic interesting, you might look at the latest issue of the International Journal of Machine Consciousness, featuring many of the usual suspects from the transhumanist community - folk who have been putting in time on AI and molecular nanotechnology research for some years."

MORE ON DNA METHYLATION AND AGING

Our genes are decorated with appended chemical structures that determine the pace at which proteins are produced from their blueprints. DNA methylation is one such form of decoration, and it changes in response to circumstances and over the course of life:

http://www.fightaging.org/archives/2012/06/more-on-dna-methylation-and-aging.php

"DNA methylation changes with age, location within the body, and type of cell, a fuzzy and very complicated pattern of decorated genes. Some of the myriad changes are sufficiently similar from person to person to be a possible method to determine age quite accurately. Others are known to reflect the degree to which a person becomes frail with age. Many more are not understood at all, or may be largely random.

"A great many debates within aging science revolve around the difference between cause and consequence - and so too with DNA methylation. Is it a part of the expected attempts by the body to adapt to increasing levels of cellular damage caused by aging, or is at least some alteration in DNA methylation a form of damage in and of itself? Good arguments can be made either way, but for my money I'd be surprised to see significant levels of epigenetic changes that were anything other than the results of underlying damage and evolutionary adaptations that try (and ultimately fail) to cope with that damage.

"This debate is significant, of course, because of how it directs research and development funding. Will scientists try to patch over the root causes of aging by altering its secondary effects - inevitably doomed to be expensive and comparatively ineffective - or will they work to repair the true causes, and thereby remove the secondary effects for free? There's been a great deal too much work on patching over the cracks in the medicine of past decades, and in this age of biotechnology it seems a sin to continue that way when we don't have to."

A GOOD ARTICLE ON NAKED MOLE-RATS

Research into the longevity and cancer immunity of naked mole-rats has been underway for some years, but has reached the public eye only comparatively recently:

http://www.fightaging.org/archives/2012/06/a-good-article-on-naked-mole-rats.php

"Pitch dark, dank, and seething with saber-toothed, sausage-shaped creatures, the world of the African naked mole-rat is a hostile habitat. In the 1980s, scientists made the remarkable discovery that naked mole-rats live like termites with a single, dominant breeding queen and scores of nonbreeding adult helpers that never leave their natal colony. But the bizarreness doesn't stop there. Naked mole-rats, unlike other mammals, tolerate variable body temperatures, attributed to their lack of an insulatory layer of fur. Their pink skin is hairless except for sparse, whisker-like strands that crisscross the body to form a sensitive sensory array that helps them navigate in the dark. Both the naked mole-rat's skin and its upper respiratory tract are completely insensitive to chemical irritants such as acids and capsaicin, the spicy ingredient in chili peppers. Most surprisingly, they can survive periods of oxygen deprivation that would cause irreversible brain damage in other mammals, and they are also resistant to a broad spectrum of other stressors, such as the plant toxins and heavy metals found in the soils in which they live. Unlike other mammals, they never get cancer, and this maintenance of genomic integrity, even as elderly mole-rats, most likely contributes to their extraordinarily long life span. In contrast to similar-size mice that only live 2-4 years, naked mole-rats can survive and thrive, maintaining normal function and reproduction, into their 30s.

"Naked mole rats are in the press ever more often of late - their longevity and cancer resistance makes them an ideal subject of study for researchers who aim to tinker human metabolism into a better state. We're all mammals in this end of the biosphere, so perhaps some of the mechanisms used by exceptional species can be ported over to humans in the form of medicine - gene therapies or carefully designed protein treatments that replicate the effects of having a particular gene."

ON SARCOPENIA AND THERAPIES UNDER INVESTIGATION

Here I point out a good review paper that discusses present progress in finding ways to slow or reverse sarcopenia, the progressive loss of muscle mass and strength with aging:

http://www.fightaging.org/archives/2012/06/on-sarcopenia-and-various-therapies-under-investigation.php

"Sarcopenia, the age-related loss of skeletal muscle, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement, a decline in strength and power, and an increased risk of fall-related injuries. Since sarcopenia is largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostasis, and apoptosis, numerous targets exist for drug discovery. In this paper, we summarize the current understanding of the endocrine contribution to sarcopenia and provide an update on hormonal intervention to try to improve endocrine defects. Myostatin inhibition seems to be the most interesting strategy for attenuating sarcopenia other than resistance training with amino acid supplementation.

"Several researchers have investigated the effect of inhibiting myostatin to counteract sarcopenia using animals. Lebrasseur et al. found that treatment with a mouse chimera of antihuman myostatin antibody (24 mg/Kg, 4 weeks), a drug for inhibiting myostatin, elicited a significant increase in muscle mass and in running performance ... More recently, Murphy et al. showed, by way of once weekly injections, that a lower dose of this anti-human myostatin antibody (10 mg/Kg) significantly increased the fiber cross-sectional area (by 12%) and in situ muscle force (by 35%) of aged mice (21 mo old). These findings highlight the therapeutic potential of antibody-directed myostatin inhibition for sarcopenia by inhibiting protein degradation."

Work on myostatin therapies is one of the topics worthy of greater attention here, as this seems like it would be a generally beneficial gene therapy for everyone - something that, given a good safety profile, most people would want to undergo earlier in life.

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

XENOBIOTIC METABOLIZING ENZYMES AS BIOMARKER OF LONGEVITY
Friday, June 15, 2012
http://www.fightaging.org/archives/2012/06/xenobiotic-metabolizing-enzymes-as-biomarker-of-longevity.php
The continued search for ways to more quickly determine differences in expected longevity between members of the same species finds a potential marker: "Xenobiotic metabolism has been proposed to play a role in modulating the rate of aging. Xenobiotic-metabolizing enzymes (XME) are expressed at higher levels in calorically restricted mice (CR) and in GH/IGF-I-deficient long-lived mutant mice. In this study, we show that many phase I XME genes are similarly upregulated in additional long-lived mouse models, including "crowded litter" (CL) mice, whose lifespan has been increased by food restriction limited to the first 3 weeks of life, and in mice treated with rapamycin. Induction in the CL mice lasts at least through 22 months of age, but induction by rapamycin is transient for many of the mRNAs. Cytochrome P450s, flavin monooxygenases, hydroxyacid oxidase, and metallothioneins were found to be significantly elevated in similar proportions in each of the models of delayed aging tested, whether these are based on mutation, diet, drug treatment, or transient early intervention. The same pattern of mRNA elevation can be induced by 2 weeks of treatment with tert-butylhydroquinone, an oxidative toxin known to active Nrf2-dependent target genes. These results suggest that elevation of phase I XMEs is a hallmark of long-lived mice and may facilitate screens for agents worth testing in intervention-based lifespan studies."

C1Q AND REVERSING THE DECLINE IN MUSCLE REGENERATION WITH AGE
Friday, June 15, 2012
http://www.fightaging.org/archives/2012/06/c1q-and-reversing-the-decline-in-muscle-regeneration-with-age.php
Researchers here report on another way to tell old stem cells to get back to work on maintaining muscle tissue - though not one that has immediate application, as it requires removal of an important component of immune system function. Thus this is only promising if researchers can pick apart the different functions of this component and interfere only where it suppresses stem cell activity in muscle regeneration: "Wnt signaling plays critical roles in development of various organs and pathogenesis of many diseases, and augmented Wnt signaling has recently been implicated in mammalian aging and aging-related phenotypes. We here report that complement C1q activates canonical Wnt signaling and promotes aging-associated decline in tissue regeneration. Serum C1q concentration is increased with aging, and Wnt signaling activity is augmented during aging in the serum and in multiple tissues of wild-type mice, but not in those of C1qa-deficient mice. ... Skeletal muscle regeneration in young mice is inhibited by exogenous C1q treatment, whereas aging-associated impairment of muscle regeneration is restored by C1s inhibition or C1qa gene disruption. Our findings therefore suggest the unexpected role of complement C1q in Wnt signal transduction and modulation of mammalian aging."

TESTING A CELL THERAPY TO REGENERATE THE CORNEA
Thursday, June 14, 2012
http://www.fightaging.org/archives/2012/06/testing-a-cell-therapy-to-regenerate-the-cornea.php
Via EurekAlert!: "Regenerative medicine, or the use of specially grown tissues and cells to treat injuries and diseases, has been successful in treating disorders of a number of organs, including heart, pancreas, and cartilage. However, efforts to treat disorders of the corneal endothelium, a single cell layer on the inner surface of the cornea, with regenerative techniques have been less effective. Now, a group of scientists has developed a method that enhances the adhesion of injected corneal endothelial cells (CECs), allowing for successful corneal transplantation to repair pathological dysfunctions. ... Previous studies demonstrated that Rho-associated kinase (ROCK) signaling interferes with adhesion. We found that transplanting cultivated CECs in combination with a low-molecular weight compound that inhibits ROCK (ROCK inhibitor Y-27632), successfully achieved the recovery of corneal transparency. ... Using rabbit cells, researchers cultivated CECs in the lab and injected them into the anterior chamber of rabbit eyes with damaged corneal endothelia. Based on the recovery of the corneal endothelial function, they found that when the cultivated cells were injected along with Y-27632, the rabbit corneas regained complete transparency 48 hours after injection. ... Since rabbit CECs are highly prolific in vivo, the scientists performed another round of experiments with monkey CECs, which are more similar to those in humans. The transplantation of CECs in these primates also achieved the recovery of long-term corneal transparency with a monolayer of hexagonal cells, suggesting that cell adhesion modified by ROCK inhibitor may be an effective treatment for human corneal endothelial disorders."

A SUCCESSFUL DECELLULARIZED VEIN TRANSPLANT
Thursday, June 14, 2012
http://www.fightaging.org/archives/2012/06/a-successful-decellularized-vein-transplant.php
From the BBC: "A 10-year-old girl has had a major blood vessel in her body replaced with one grown with her own stem cells. ... A vein was taken from a dead man, stripped of its own cells and then bathed in stem cells from the girl, according to a study published in the Lancet. Surgeons said there was a "striking" improvement in her quality of life. This is the latest is a series of body parts grown, or engineered, to match the tissue of the patient. Last year, scientists created a synthetic windpipe and then coated it with a patient's stem cells. ... In this case, other options such as using artificial grafts to bypass the blockage, had failed. ... It used a process known as "decellularisation". It starts with a donor vein which is then effectively put through a washing machine in which repeated cycles of enzymes and detergents break down and wash away the person's cells. It leaves behind a scaffold. This is then bathed in stem cells from the 10-year-old's bone marrow. The end product is a vein made from the girl's own cells. ... The young girl was spared the trauma of having veins harvested from the deep neck or leg with the associated risk of lower limb disorders."

CONSIDERING THE BUSINESS ECONOMICS OF ALCOR
Wednesday, June 13, 2012
http://www.fightaging.org/archives/2012/06/considering-the-business-economics-of-alcor.php
An article from Cryonics Magazine: "Cryopreserved patients must be cared for for at least decades and some anticipate centuries. During this time, some caretaker organization must look after the patients. This involves paying the rent and utilities, replacing liquid nitrogen, maintaining and replacing dewars, hiring and paying staff, and a host of other activities that must be done reliably and economically. The usual arrangement is for the patient to make a lump sum payment into a common fund, the interest from which will then pay the expenses of maintaining a group of patients in cryopreservation for whatever period of time might be required. At Alcor, the lump sum payment is made into the PCT (Patient Care Trust), and the payment made by each patient is the 'PCT allocation,' taken from the total payment made by the patient at the time of cryopreservation. Determining the appropriate amount of the PCT allocation can raise questions whose answers are not always obvious and can sometimes be quite dilemmatic. ... Contractual and financial arrangements must usually be in place before a patient can be cryopreserved. The financial arrangements involve payment for both the up-front procedures and long term care. These payments are usually bundled, and at Alcor the total amount of money that is required is called the 'funding minimum'. The funding minimum is usually paid with life insurance. ... The focus of this article is on the lump sum payment made into the common fund from the funding minimum by the patient at the time of the patient's cryopreservation."

SENESCENT CELLS CREATE MORE SENESCENT CELLS
Wednesday, June 13, 2012
http://www.fightaging.org/archives/2012/06/senescent-cells-create-more-senescent-cells.php
The build up of senescent cells is one of the contributing causes of aging, and is partially due to the progressive failure of the immune system to destroy these cells as they crop up. Many of the changes that come with aging accelerate as they progress, and this piece provides one example as to why this is the case; for senescent cells, the more you have the faster they accumulate: "Cells may become senescent in an effort to protect the body such as when tumor suppressor genes shut down division to prevent cancer. However other sorts of damage may lead cells to stop dividing as well. A pivotal study last year showed elegantly using a trangenic approach that if senescent cells were regularly cleared from the body of mice, signs of aging in many tissues were dramatically reduced. The explanation for this result was that somehow senescent cells were damaging nearby cells, perhaps by excreting toxic materials. ... A newly published study [proves] or the first time that senescent cells do indeed damage nearby cells causing them to become senescent too. It also shows this occurs through direct cell to cell contact and resultant spread of reactive oxygen species. Furthermore it shows evidence this process occurs in the living organism as clusters of cells bearing senescent makers are found in mice livers. Clearly the next and important step for helping to reduce aging in humans is developing a safe and effective method presumably using a pharmacological agent in which senescent cells can be removed from the body."

TELOMERES AND LATE FATHERHOOD
Tuesday, June 12, 2012
http://www.fightaging.org/archives/2012/06/telomeres-and-late-fatherhood.php
A finding here ties into research suggesting that life can be lengthened through selective breeding at later ages - this, like the response to calorie restriction, is a form of metabolic variability that may have evolved to make a species better able to adapt to changing environmental circumstances: "Children and even grandchildren of older fathers may live longer than children of younger men. ... Scientists found that children born to fathers between the ages of late 30s to early 50s inherit longer 'telomeres' or tiny protective caps on the ends of chromosomes that protect against aging degeneration and disease. ... Researchers measured the telomere length of DNA by using blood samples collected from 1,779 young Filipino adults and their mothers and determined the ages of the children's fathers and grandfathers. Study results show that a person's telomeres became longer not only with their father's age at birth, but also with their paternal grandfather's age at their father's birth, meaning that the longevity effect is amplified over the generations. ... The findings suggest that delayed paternal reproduction can lead to cumulative, multi-generational increases in telomere length in offspring which may promote longer life. Researchers also believe that longer telomeres may delay sexual development, and instead invest energy into the extra resources necessary to maintain healthy functioning at more advanced ages. ... late fatherhood may serve as a sigh that mortality rates are low. ... If your father and grandfather were able to live and reproduce at a later age, this might predict that you yourself live in an environment that is somewhat similar - an environment with less accidental deaths or in which men are only able to find a partner at later ages. In such an environment, investing more in a body capable of reaching these late ages could be an adaptive strategy from an evolutionary perspective."

WORKING ON BETTER WAYS TO GROW BONE
Tuesday, June 12, 2012
http://www.fightaging.org/archives/2012/06/working-on-better-ways-to-grow-bone.php
An example of the sort of work presently taking place in the stem cell field: "scientists purified a subset of stem cells found in fat tissue and made from them bone that was formed faster and was of higher quality than bone grown using traditional methods, a finding that may one day eliminate the need for painful bone grafts that use material taken from the patient during invasive procedures. ... Traditionally, cells taken from fat had to be cultured for weeks to isolate the stem cells which could become bone, and their expansion increases risk of infection and genetic instability. ... [Researchers] used a cell sorting machine to isolate and purify human perivascular stem cells (hPSC) from adipose tissue and showed that those cells worked far better. They also showed that a growth factor called NELL-1 [enhanced] the bone formation in their animal model. ... People have shown that culture-derived cells could grow bone, but these are a fresh cell population and we didn't have to go through the culture process, which can take weeks. The best bone graft is still your own bone, but that is in limited supply and sometimes not of good quality. What we show here is a faster and better way to create bone that could have clinical applications. ... The purified human hPSCs formed significantly more bone [and] these cells are plentiful enough that patients with not much excess body fat can donate their own fat tissue. ... if everything goes well, patients may one day have rapid access to high quality bone graft material by which doctors get their fat tissue, purify that into hPSCs and replace their own stem cells with NELL-1 back into the area where bone is required. The hPSC with NELL-1 could grow into bone inside the patient, eliminating the need for painful bone graft harvestings. The goal is for the process to isolate the hPSCs and add the NELL-1 with a matrix or scaffold to aid cell adhesion to take less than an hour."

THE STATE OF GENE THERAPY
Monday, June 11, 2012
http://www.fightaging.org/archives/2012/06/the-state-of-gene-therapy.php
From The Scientist: "After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval. The concept is simple: if a mutated gene is causing a problem, replace or supplement it with a new, accurate copy. In theory, such a strategy could not just treat, but cure countless human genetic diseases. In practice, however, developing safe and effective gene therapies has not been easy. Even when identifying a disorder's genetic basis is fairly straightforward, finding the appropriate delivery vector to target the diseased tissues in the body, while avoiding unintended consequences, has challenged would-be gene therapists for more than 20 years. But more and more researchers are convinced that the technique is on the brink of becoming a common medical practice. ... In the last year alone, he says, major breakthroughs have been published for the use of gene therapy in patients with hemophilia, solid tumors, and leukemia, not to mention the dozens of trials yielding positive results for gene therapies to treat various types of blindness. ... It's just remarkable. These decades of work are suddenly really paying off. ... The history of medicine says every new technology starts with a great idea and then requires hard work and optimization. And I think that's exactly what's happened with gene therapy. Hurdles were identified - and there's always hurdles once you get into a complex human disease situation - and they've been addressed. ... The concepts aren't that much different than they were early on, but the tools are much better. Now [gene therapy] is actually fulfilling the promise that people said it would have."

SHAPED NANOPARTICLES TARGET NARROWED BLOOD VESSELS
Monday, June 11, 2012
http://www.fightaging.org/archives/2012/06/shaped-nanoparticles-target-narrowed-blood-vessels.php
A clever way to target an infused therapy to particular regions in the body by using their physical properties: "Treatment options [for atherosclerosis] are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects. Intravenous injection of a vasodilator (a substance that dilates blood vessels), such as nitroglycerin, dilates both the diseased vessels and the rest of our arteries. Blood pressure can thus drop, which would limit the desired increased blood flow generated by vasodilatation of diseased vessels and needed for example during a heart attack. In order to increase the effectiveness of treatments against atherosclerosis and to reduce side effects, a team of researchers [have] developed nanocontainers having the ability to release their vasodilator content exclusively to diseased areas. ... Though no biomarker specific to atherosclerosis has been identified, there is a physical phenomenon inherent to stenosis (the narrowing of blood vessels) known as shear stress. This force results from fluctuations in blood flow induced by the narrowing of the artery and runs parallel to the flow of blood. It is by making use of this phenomenon that the team of researchers has developed a veritable 'time bomb', a nanocontainer which, under pressure from the shear stress in stenosed arteries, will release its vasodilator contents. By rearranging the structure of certain molecules (phospholipids) in classic nanocontainers such as liposome, scientists were able to give them a lenticular shape as opposed to the normal spherical shape. In the form of a lens, the nanocontainer then moves through the healthy arteries without breaking. This new nanocontainer is perfectly stable, except when subjected to the shear stress of stenosed arteries."

______________________________


<br> <br>View the full article

#14 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 24 June 2012 - 02:36 PM

FIGHT AGING! NEWSLETTER
June 25th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- The Future Awaits its Makers
- Robin Hanson Donates $5,000 to the Brain Preservation Prize
- It Isn't That Easy to Just Kickstart Funding for Science
- Looking at Changes in Mortality in the Past Century
- Discussion
- Latest Headlines from Fight Aging!
    - Longevity Science and the Social Justice Viewpoint
    - Work on Preparing Xenotransplants With Decellularization
    - DLK and Nerve Regeneration
    - A Resveratrol Meta-Analysis
    - Mitochondrial Membrane Resistance to Explain Clam Longevity
    - Arguing Against the Role of Cytomegalovirus in Immune System Aging
    - Human Optic Cup Grown From Stem Cells
    - Arguing a Mechanism for DNA Damage to Drive Aging
    - CCR2 and the Immune System Versus Alzheimer's Disease
    - Apologism for Aging is Unproductive

THE FUTURE AWAITS ITS MAKERS

With a rapid enough pace of change, the near future looks ever more like today's science fiction:

http://www.fightaging.org/archives/2012/06/the-future-awaits-its-makers.php

"A fellow that you met today will, forty years from now, have an entirely artificial immune system. It is an early model, a prosthetic replacement that is a mix of synthetic cells and less organic medical nanomachines, and requires frequent work and an open data channel to keep in line. Obtaining it wasn't a choice - it is a new treatment for a small class of acquired autoimmune conditions that somehow manage to persist through complete removal and replacement of immune cell populations. It works; he doesn't get sick, at all. Ever.

"Nonetheless, you shook this man's hand today. That future lies in waiting.

"Earlier you passed by a kid who will outlive you, your plans, your memory, your immediate descendants, and the first phase of terraforming to take place on Mars. The young have it good these days: a solid eighty years of probable-worst-case life expectancy at birth that will take them well into the first age of radical life extension - and that even if the next twenty years take us through a miserable economic depression coupled with a spread of repressive regulatory regimes that effectively stifle life science research and its application. Many of the youngest children of today will live for centuries, and many of those will go on to live for thousands of years.

"You walked right by that kid. In fairness, he doesn't know either, of course.

"Then there's that new face at the office, fresh out of college: by the 2070s she'll be a shell of the person she was. A happy shell, however, the original exterior polished up by gene, cell, and enzyme therapies to minimize the changes of aging in skin and musculature, but all of the interior organs below the neck new from labs in Thailand and Vietnam over the years, grown from her own genetic material. That took money, even though it's second string organ biotechnology by that time - but the sharp average worker you can save enough to afford that sort of thing over a lifetime. It's not as though she'll be retiring any time soon, and better low on funds than living like a 80-year old from a century past.

"That probably didn't cross your mind today when the two of you happened to be in the same meeting."

ROBIN HANSON DONATES $5,000 TO THE BRAIN PRESERVATION PRIZE

The Brain Preservation Foundation continues to attract support for its initiatives, one of which is a technology prize for the team that can demonstrate preservation of fine structure in the brain for the long term:

http://www.fightaging.org/archives/2012/06/robin-hanson-donates-5000-to-the-brain-preservation-prize.php

"Cryonics is one existing way of preserving a human brain sufficiently well to enable a future resuscitation with more advanced technologies than are available today. Plastination is another possibility, but one that was never developed into a commercial service such as that offered by cryonics providers - arguably for no reason other than historical accident and the specialties of those who founded the cryonics movement. Interestingly there are currently a pair of teams competing in the Brain Preservation Prize, and they are employing quite different methods from cryonics and plastination. I see that economist Robin Hanson of Overcoming Bias is in favor of this initiative, as one might expect from his views on cryonics."

"An anonymous donor has actually funded a $100K Brain Preservation Prize, paid to the first team(s) to pass this test on a human brain, with a quarter of the prize going to those that first pass the test on a mouse brain. Cryonics and plastination teams have already submitted whole mouse brains to be tested. The only hitch is that the prize organization needs money (~25-50K$) to actually do the tests! This is the exceptionally worthy cause to which I am donating $5K, and to which I encourage others to donate. ... We seem close to having a feasible plastination technique, where for a few 10K$ or less one could fill a brain with plastic, saving its key brain info for future revival in an easily stored form. We may only lack donations of a similar amount to actually test that it does save this key brain info."

IT ISN'T THAT EASY TO JUST KICKSTART FUNDING FOR SCIENCE

There are fundamental differences between crowdfunding success for commercial products and crowdfunding success for research projects:

http://www.fightaging.org/archives/2012/06/you-cant-just-kickstart-a-science-project---it-isnt-that-easy.php

"Crowdfunding of commercial products is having a lengthy day in the sun at the moment. It has emerged from years of great success in small markets, such as the pen and paper gaming and indie publishing industries, and people are now applying the same models to fields where much more money is involved. ... If you have a dedicated community, then you want to turn that dedication into professional organizations and the funds to run them. This is always going to be a messy, organic process of development, but which perhaps may be open to improvement through the spread of a more formalized crowdfunding culture. But in any case, I wanted to expand on the point made in the quote above - that crowdfunding for scientific research is a radically different undertaking from crowdfunding for development of a commercial product. This seems worth emphasizing, given that a whole range of startups and new ventures seem to be trying to port over crowdfunding into the sciences pretty much as-is, or with just a few embellishments.

"The basic point of divergence between crowdfunding a product versus crowdfunding research is that in the former case the funders are definitively buying something concrete: that is their motivation and incentive. They are putting down money in expectation that what they are doing is submitting a preorder. Variations on the preorder theme are legion, but they all boil down to paying for a definitive item, a which will usually have fairly solid delivery date. Scientific research is notoriously bad when it comes to delivering on both those points, however. The work that is most amenable to crowdfunding consists of small projects that only incrementally add value to their fields - and which may not even do that, given the necessarily high failure rate for research.

"The challenge facing science crowdfunding is the same challenge faced by scientific advocates at all times: they do their part to grow communities of supporters and encourage those supporters to pay for research work. That work will give no immediate result, the eventual result may be hard for supporters to understand, it will likely not benefit them for some time, if ever, and in addition to all of that the undertaking will quite likely fail. Science is a high risk endeavor, with few short-term payoffs that people find rewarding - and thus it is a hard sell when held up against the allure of immediate gratification, candy, and shiny objects."

LOOKING AT CHANGES IN MORTALITY IN THE PAST CENTURY

Science and technology are, at root, a collection of endeavors and methods that aim to eliminate death and suffering, one cause at a time. Thus the principal focus tends to be on whatever is causing the most death and suffering - and with success in research and development, that focus shifts:

http://www.fightaging.org/archives/2012/06/a-look-at-the-changes-in-mortality-in-the-past-century.php

"The first thing to notice here is how much our mortality rate has dropped over the course of a century, largely due to big reductions in infectious diseases like tuberculosis and influenza. ... On the large scale, medicine chases the priorities of the now - and in wealthier regions of the world that has become cancer and heart disease. The size of the cancer and heart disease research communities reflects the present degree to which the two groups of conditions contribute to human mortality. What it does not yet reflect is the new and more meaningful unified way of looking at the conditions that kill the most people: that they are all caused by aging, and stem at root from a limited range of mechanisms and changes that happen over the years as a byproduct of our normal metabolism. We rust, and that rust blossoms into a thousand different failure modes. Yet medical science is still largely focused on end states, and patching over catastrophic damage rather than preventing its origins.

"To keep reducing the human mortality rate, the research community has to start in on prevention in the form of repair biotechnologies - ways to halt and reverse the earliest development of the age-related conditions that kill most people. It is as much a cultural change in the life sciences as it is a technical challenge, as the path ahead is fairly clear. This is why organizations like the SENS Foundation, mixing aggressive advocacy with targeted research work where few others are making progress, are so important. It is not so much that they will get the work done by themselves, but that they will spawn a sea change in the research community, such that many, many groups will tomorrow be performing similar work with similar end goals: to to be able to treat and reverse the course of aging.

"You might think of a focus on aging and its causes as the germ theory of today's medical community: a unifying set of ideas and resulting research strategies that will bring the bulk of the medical community onto a better path forward, one that will lead to a more rapid improvement in the human condition, and longer, healthier lives for all."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

LONGEVITY SCIENCE AND THE SOCIAL JUSTICE VIEWPOINT
Friday, June 22, 2012
http://www.fightaging.org/archives/2012/06/longevity-science-and-the-social-justice-viewpoint.php
It is always a good idea to learn more about how the other half of the world thinks. Most people are closer to the values of social justice than the values of libertarianism, for all that that sort of "justice" (i.e. forced redistribution and mob envy) is just as destructive of wealth and progress as communism or fascism when put into earnest practice. It becomes a tyranny of egalitarianism, a leveling down, a tearing down of the high points of society, the groups that produce advances in technology. One of the values of reading In Search of Enlightenment is seeing the thinking that leads someone enmeshed in the culture of social justice - whose members characteristically belittle or reject scientific progress and the markets that drive it - come to advocate for longevity science and the defeat of aging: "Over the past decade I have worked at the intersection of issues in political philosophy/theory and the medical sciences. I have tried to help bridge what I take to be a troublesome divide between the field most concerned with ideals of justice and equality, and scientific advances (especially in the field of biogerontology) which could profoundly improve human health and prosperity. These two things are linked in important ways, but there is very little actually written by theorists on these kinds of topics. Bridging this gap is an up-hill struggle for a variety of reasons. The theoretical concepts and normative theories developed in political philosophy over the past 4 decades either ignored the realities of morbidity (e.g. like the fact that aging is a major risk factor for disease) or just assumed people went through their complete lives as 'healthy and productive members of society'. This meant the (almost exclusive) focus of theories of distributive justice was on the distribution of wealth and income. A fair society could be measured, so went the reasoning, to a large extent by the pattern of the distribution of a society's wealth. And the extent to which theories of justice have expanded, in the last 2 decades, to tackle topics like global justice and health, they are still constrained by the original assumptions and limited perspectives/concepts with which the dominant normative theories were originally devised. In other words, taking a theory of domestic justice designed to apply to a healthy and affluent society and then trying to make a few modifications once you take disease and debt seriously is not, imho, a recipe for success."

WORK ON PREPARING XENOTRANSPLANTS WITH DECELLULARIZATION
Friday, June 22, 2012
http://www.fightaging.org/archives/2012/06/work-on-preparing-xenotransplants-with-decellularization.php
Decellularization involves stripping out the original cells from a donor organ and then repopulating it with cells grown from the recipient's tissue - thereby removing the possibility of immune rejection. One implication of this approach is that the donor doesn't necessarily have to be human: "In proof-of-concept research [a] team successfully used pig kidneys to make 'scaffolds' or support structures that could potentially one day be used to build new kidneys for human patients. The idea is to remove all animal cells - leaving only the organ structure or 'skeleton.' A patient's own cells would then be placed on the scaffold, making an organ that the patient theoretically would not reject. ... this is one of the first studies to assess the possibility of using whole pig kidneys to engineer replacement organs ... For the research, pig kidneys were soaked in a detergent to remove all cells, leaving behind the organ's 'skeleton,' including its system of blood vessels. In addition, the structure of the nephron - the kidney's functional unit - was maintained. The scaffolds were implanted in animals, where they were re-filled with blood and were able to maintain normal blood pressure, proving that the process of removing cells doesn't affect the mechanical strength of the vessels. ... It is important to identify new sources of transplantable organs because of the critical shortage of donor organs. These kidneys maintain their innate three-dimensional architecture, as well as their vascular system, and may represent the ideal platform for kidney engineering."

DLK AND NERVE REGENERATION
Thursday, June 21, 2012
http://www.fightaging.org/archives/2012/06/dlk-and-nerve-regeneration.php
To go along with a recent post on cell therapies for nerve regeneration, here researchers investigate a different set of mechanisms: "A protein required to regrow injured peripheral nerves has been identified by researchers. ... The finding, in mice, has implications for improving recovery after nerve injury in the extremities. It also opens new avenues of investigation toward triggering nerve regeneration in the central nervous system, notorious for its inability to heal. ... scientists show that a protein called dual leucine zipper kinase (DLK) regulates signals that tell the nerve cell it has been injured - often communicating over distances of several feet. The protein governs whether the neuron turns on its regeneration program. ... How does an injured nerve know that it is injured? How does it take that information and turn on a regenerative program and regrow connections? And why does only the peripheral nervous system respond this way, while the central nervous system does not? We think DLK is part of the answer. ... If an axon is severed somewhere between the cell body in the spinal cord and the muscle, the piece of axon that is no longer connected to the cell body begins to disintegrate. Earlier work showed that DLK helps regulate this axonal degeneration. And in worms and flies, DLK also is known to govern the formation of an axon's growth cone, the structure responsible for extending the tip of a growing axon whether after injury or during development. The formation of the growth cone is an important part of the early, local response of a nerve to injury. But a later response, traveling over greater distances, proves vital for relaying the signals that activate genes promoting regeneration. This late response can happen hours or even days after injury. But in mice, unlike worms and flies, [DLK] is not involved in an axon's early response to injury. Even without DLK, the growth cone forms. But a lack of DLK means the nerve cell body, nestled in the spinal cord far from the injury, doesn't get the message that it's injured. Without the signals relaying the injury message, the cell body doesn't turn on its regeneration program and the growth cone's progress in extending the axon stalls. ... A neuron that has seen a previous injury now has a different regenerative program than one that has never been damaged. We hope to be able to identify what is different between these two neurons - specifically what factors lead to the improved regeneration after a second injury. We have found that activated DLK is one such factor. We would like to activate DLK in a newly injured neuron to see if it has improved regeneration."

A RESVERATROL META-ANALYSIS
Thursday, June 21, 2012
http://www.fightaging.org/archives/2012/06/a-resveratrol-meta-analysis.php
Here is another paper suggesting that resveratrol isn't necessarily a great place to be spending hundreds of millions of dollars on research and development, given the poor results in studies that evaluate its effects. In an ideal world this money that would go towards improving biotechnology rather than the old-school approach of mining the natural world for compounds that maybe do more good than harm: "Resveratrol has shown evidence of decreasing cancer incidence, heart disease, metabolic syndrome and neural degeneration in animal studies. However, the effects on longevity are mixed. We aimed to quantify the current knowledge of life extension from resveratrol. We used meta-analytic techniques to assess the effect resveratrol has on survival, using data from 19 published papers, including six species: yeast, nematodes, mice, fruitflies, Mexican fruitflies and turquoise killifish. Overall, our results indicate that resveratrol acts as a life-extending agent. The effect is most potent in yeast and nematodes, with diminished reliability in most higher-order species. Turquoise killifish were especially sensitive to life-extending effects of resveratrol but showed much variation. Much of the considerable heterogeneity in our analysis was owing to unexplained variation between studies. In summary, we can report that few species conclusively show life extension in response to resveratrol. As such, we question the practice of the substance being marketed as a life-extending health supplement for humans."

MITOCHONDRIAL MEMBRANE RESISTANCE TO EXPLAIN CLAM LONGEVITY
Wednesday, June 20, 2012
http://www.fightaging.org/archives/2012/06/mitochondrial-membrane-resistance-to-explain-clam-longevity.php
You might recall the species of clam that can live for at least four centuries. Similarly, you might also recall the membrane pacemaker hypothesis that explains differences in longevity between species in terms of the resistance of cell membranes - and especially mitochondrial membranes - to damage. Here, the two topics are linked: "The deleterious reactive carbonyls released upon oxidation of polyunsaturated fatty acids in biological membranes are believed to foster cellular aging. Comparative studies in mammals and birds have shown that the susceptibility to peroxidation of membrane lipids (peroxidation index, PI) is negatively correlated to longevity. Long-living marine molluscs are increasingly studied as longevity models, and the presence of different types of lipids in the membranes of these organisms raises questions on the existence of a PI-longevity relationship. We address this question by comparing the longest-living metazoan species, the mud clam Arctica islandica (maximum reported longevity = 507 y) to four other sympatric bivalve molluscs greatly differing in longevity (28, 37, 92, and 106 y). We contrasted the acyl and alkenyl chain composition of phospholipids from the mitochondrial membranes of these species. The analysis was reproduced in parallel for a mix of other cell membranes to investigate if a different PI-longevity relationship would be found. The mitochondrial membrane PI was found to have an exponential decrease with increasing longevity among species and is significantly lower for A. islandica. The PI of other cell membranes showed a linear decrease with increasing longevity among species and was also significantly lower for A. islandica. These results clearly demonstrate that the PI also decreases with increasing longevity in marine bivalves and that it decreases faster in the mitochondrial membrane than in other membranes in general. Furthermore, the particularly low PI values for A. islandica can partly explain this species' extreme longevity." This emphasizes the importance of mitochondrial damage in aging and longevity, and thus the importance of research into mitochondrial repair biotechnologies for humans.

ARGUING AGAINST THE ROLE OF CYTOMEGALOVIRUS IN IMMUNE SYSTEM AGING
Wednesday, June 20, 2012
http://www.fightaging.org/archives/2012/06/arguing-against-the-role-of-cytomegalovirus-in-immune-system-aging.php
There's a fair amount of evidence implicating cytomegalovirus (CMV) in immune system decline, rhe theory here being that the immune system devotes ever more of its fixed resources to dealing with the largely harmless variants of this virus that it cannot clear. Here researchers argue against that view: "Aging is accompanied by the development of low grade systemic inflammation, termed 'inflammaging', characterised by raised serum C-reactive protein (CRP) and pro-inflammatory cytokines. Importantly, inflammaging is implicated in the pathogenesis of several of the major age-related diseases including cardiovascular disease, type 2 diabetes and dementia and is associated with increased mortality. The incidence of infection with the persistent herpes virus cytomegalovirus (CMV) also increases with age. Cross-sectional studies have proposed CMV infection as a significant driver of inflammaging, but a definitive case for CMV as a causative agent in inflammaging has not yet been made. We studied longitudinally 249 subjects (153 men, 96 women) who participated in the Hertfordshire Ageing Study at baseline (1993/5, mean age 67·5 years) and at 10 year follow up. At both times [subjects] provided blood samples for analysis of inflammatory status and CMV seropositivity. In the cohort as a whole, serum CRP and pro-inflammatory cytokines [were] increased between baseline and follow up ... These changes to cytokine status over time occurred equally in the 60% of subjects who were seropositive for CMV at baseline and follow up, the 8% who were CMV negative at baseline but who became CMV positive by the 10 year follow up, and also in the 32% who were CMV seronegative throughout. We conclude that CMV infection is not a primary causative factor in the age-related increase in systemic inflammation."

HUMAN OPTIC CUP GROWN FROM STEM CELLS
Tuesday, June 19, 2012
http://www.fightaging.org/archives/2012/06/human-optic-cup-grown-from-stem-cells.php
From Nature: researchers have "grown the precursor of a human eye in the lab. The structure, called an optic cup, is 550 micrometres in diameter and contains multiple layers of retinal cells including photoreceptors. The achievement has raised hopes that doctors may one day be able to repair damaged eyes in the clinic. ... the most exciting thing is that the optic cup developed its structure without guidance from [the] team. ... Until recently, stem-cell biologists had been able to grow embryonic stem-cells only into two-dimensional sheets. But over the past four years, [this group] has used mouse embryonic stem cells to grow well-organized, three-dimensional cerebral-cortex, pituitary-gland and optic-cup tissue. His latest result marks the first time that anyone has managed a similar feat using human cells. ... The various parts of the human optic cup grew in mostly the same order as those in the mouse optic cup. This reconfirms a biological lesson: the cues for this complex formation come from inside the cell, rather than relying on external triggers. ... retinal precursor cells spontaneously formed a ball of epithelial tissue cells and then bulged outwards to form a bubble called an eye vesicle. That pliable structure then folded back on itself to form a pouch, creating the optic cup with an outer wall (the retinal epithelium) and an inner wall comprising layers of retinal cells including photoreceptors, bipolar cells and ganglion cells. ... This resolves a long debate [over] whether the development of the optic cup is driven by internal or external cues."

ARGUING A MECHANISM FOR DNA DAMAGE TO DRIVE AGING
Tuesday, June 19, 2012
http://www.fightaging.org/archives/2012/06/arguing-a-mechanism-for-dna-damage-to-drive-aging.php
There is some debate over the degree to which accumulated nuclear DNA damage contributes to aging. Here researchers propose a class of mechanisms: "Aging is characterized by the inability of tissues to maintain homeostasis. This leads to an impaired response to stress and, as a consequence, an increased risk of morbidity and mortality. ... Aging is thought to be driven, at least in part, by the accumulation of stochastic damage in cells. ... However, the mechanism by which cellular damage drives aging is not known. The simplest model is that damage causes attrition of functional cells. But this is inadequate in light of emerging evidence that aging-related degenerative changes in old and damaged organisms can be delayed or reversed by circulating factors. These observations point instead toward the cellular response to damage being the key driver of aging. The transcription factor NF-κB is a central component of the cellular response to damage, stress, and inflammation ... Numerous studies report increased NF-κB activity with aging. ... Genetic depletion of NF-κB in the skin of transgenic mice reversed age-related gene expression and histologic changes, providing support for NF-κB activation playing a causal role in skin aging. ... it remains to be determined whether NF-κB activation drives systemic aging and whether NF-κB is a therapeutic target for attenuating and/or delaying aging-related degenerative changes. ... We found that NF-κB is stochastically activated in a variety of cell types with normal and accelerated aging and that genetic or pharmacologic inhibition of NF-κB activation delays the onset of numerous aging-related symptoms and pathologies. Inhibition of IKK/NF-κB activity reduced cellular senescence and oxidative damage, including DNA and protein damage, revealing that cellular stress responses promote further cellular damage. Our findings strongly suggest that inhibitors of the IKK/NF-κB pathway may delay damage and extend healthspan in patients with accelerated aging and chronic degenerative diseases of old age."

CCR2 AND THE IMMUNE SYSTEM VERSUS ALZHEIMER'S DISEASE
Monday, June 18, 2012
http://www.fightaging.org/archives/2012/06/ccr2-and-the-immune-system-versus-alzheimers-disease.php
One portion of the Alzheimer's research field is focused on immune therapies - training the immune system to attack and break down amyloid beta plagues characteristic of Alzheimer's disease. It is important to note that the buildup of signs of Alzheimer's, such as amyloid beta, occurs in most people to a lesser degree, whether or not they go on to develop the condition, and that the level of this sort of damage is associated with level of mental decline with aging. Here researchers show that this may all have something to do with how effective the immune system is in clearing out unwanted junk from the brain: "Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans. [Researchers] screened the expression levels of thousands of genes in blood samples from nearly 700 people. The telltale marker of immune system activity against beta-amyloid, a gene called CCR2, emerged as the top marker associated with memory in people. The team used a common clinical measure called the Mini Mental State Examination to measure memory and other cognitive functions. The previous work in mice showed that augmenting the CCR2-activated part of the immune system in the blood stream resulted in improved memory and functioning in mice susceptible to Alzheimer's disease. ... This is a very exciting result. It may be that CCR2-associated immunity could be strengthened in humans to slow Alzheimer's disease, but much more work will be needed to ensure that this approach is safe and effective."

APOLOGISM FOR AGING IS UNPRODUCTIVE
Monday, June 18, 2012
http://www.fightaging.org/archives/2012/06/apologism-for-aging-is-unproductive.php
Via the IEET: "Louis Begley vividly describes the last years of his mother's life, who had been a widow for the previous 40 years before her death. Begley lets us feel the pain in her joints and in her heart. He obviously sees aging as nothing but misery and loneliness. But I think he misses the point - he believes his mother's solitude is the reason of her woes, but it actually is aging, her declined health, pain and suffering - these are the real reasons of her tragedy. If she had been young she would have had no diseases, but only good looks and the opportunity to start over, but alas! she rots alive. Louis Begley caught the very overwhelming in its inevitability, horrifying feeling that it's all over, no need to buy new costumes. They will not be worn for a long time and they're not worth spending time and money. Mr. Begley was widely criticized - and by whom? Who do you think justified aging? The Executive Director and chief scientific officer of the Alzheimer's Drug Discovery Foundation wrote: 'Mr. Begley's bitter portrayal of aging is neither universal nor inevitable... Old age should never be measured by the metrics of youth. An adaptive rather than a maladaptive response to old age and even frailty is possible.' This is unbelievable. So wrong. In reality it's exactly the opposite - aging is universally debilitating and inevitable. While this type of words are coming out of the mouths of people who are the advocates for aging research, nothing good will happen. There will be no money for research to live longer in a younger body. And the reason is the faulty idea that aging can be healthy, productive, or enjoyable. It can't by definition."

______________________________


<br> <br>View the full article

#15 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 01 July 2012 - 04:08 PM

FIGHT AGING! NEWSLETTER
July 2nd 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- The Other Harm Caused by Mitochondrial DNA Damage
- Perverse Incentives and Underestimations of Longevity
- An Interview With Aubrey de Grey
- Early Medical Nanorobots Will Look Like Cells and Bacteria
- Discussion
- Latest Headlines from Fight Aging!
    - Age-Related Visual Impairment in Decline
    - Alcor 40 Conference, October 19th 2012
    - A Step Towards Better Blood
    - Demonstrating Genetically Corrected Stem Cells as a Therapy
    - Comments on Chemopreservation Versus Cryopreservation
    - Calorie Restriction Reduces Loss of Synaptic Plasticity
    - Mitochondrial Haplogroup Associations With Longevity in China
    - Another Way of Searching for Longevity-Related Mechanisms
    - Popular Press on Organ Tissue Engineering
    - In Situ Tissue Engineering of an Artery

THE OTHER HARM CAUSED BY MITOCHONDRIAL DNA DAMAGE

Mitochondria, the power plants of the cell, are very important in aging. Thus work towards biotechnologies to repair damage to mitochondria is also very important - and relatively close to realization, despite receiving far less funding than it deserves:

http://www.fightaging.org/archives/2012/06/the-other-harm-caused-by-mitochondrial-dna-damage-in-aging.php

"As I'm sure you all know by now, mitochondria are swarming powerplants within the cell, descendants of symbiotic bacteria that bear their own DNA separate from the DNA in the cell nucleus. Mitochondrial DNA provides the blueprints for proteins making up the machinery of a mitochondrion, but it isn't as well protected or as well repaired as nuclear DNA. Given that a lot of reactive compounds are funneled through mitochondria in the processes that keep a cell powered, it is only to be expected that mitochondrial DNA becomes progressively more damaged over time. The range of mechanisms that have evolved to deal with that damage cannot keep up over the long term, and as a result a small but significant portion of our cells fall into ruin on the way to old age, becoming populated by dysfunctional, damaged mitochondria, and causing a great deal of harm to surround tissues and bodily systems by exporting a flood of reactive biochemicals. You can read a longer and more detailed description of this process back in the Fight Aging! archives.

"So that is one side of the issue of mitochondrial DNA damage and its contribution to degenerative aging - and that in and of itself would be more than enough to make mitochondrial repair biotechnologies a research priority. There are many different potential ways of fixing or rendering irrelevant mitochondrial DNA damage, and allowing mitochondria to continue to function as well as they did at birth for an indefinite period of time. The sooner one of them is developed into a working therapy the better.

"In considering mitochondrial damage there is another, more straightforward process at work, however. Many types of cell normally operate fairly close to the limit of the power provided by their mitochondria, including important cell populations in the brain and nervous system. As mitochondrial DNA damage accumulates with age, power production - meaning the pace at which adenosine triphosphate (ATP) is produced - falls off and cells either die or malfunction far more often than they did in youth."

PERVERSE INCENTIVES AND UNDERESTIMATIONS OF LONGEVITY

Many of the institutions tasked with understanding trends in human longevity, a challenging task in this age of rapid development in biotechnology, operate under incentives that lead them to understate future estimates:

http://www.fightaging.org/archives/2012/06/perverse-incentives-and-underestimations-of-future-longevity.php

"A large industry is focused on getting these numbers right, or as close to right as is possible, as vast sums are promised to older folk, either as political entitlements or honestly obligated as a result of insurance contracts. Betting against increasing longevity seems like a fool's game, but nonetheless there is a lot of money to be made in that business - many large entities want to be protected from what is known as longevity risk, the risk that life spans will rise faster than expected and thus financial obligations will spiral out of control. Large entities are willing to pay for that insurance service, and taking on risk for a percentage is very much the core business of finance.

"In theory the people taking on that risk for a percentage know what they are doing, and they are the ones funding efforts to understand the risk - which in this case means models for future increases in human longevity due to advances in medicine and biotechnology. In practice? The risk gets sliced and diced and parceled out among the players in finance, that much is true. But I'm sure we all see the present results of that undertaking in other large industries, such as housing: when there is enough money involved the business becomes one of lies and politics, the fine art of pocketing profits, taking on unknown risks for short term gain, steering government policies, and raiding the public treasury to cover losses when it all goes south. When buying politicians and policy is a reasonable cost judged against the cost of contracts, buying politicians and policy becomes a part of doing business - and very lucrative, since it allows risk-bearers to try for the upside with the expectation that they will be bailed out if it fails.

"Thus a web of perverse incentives grows, benefiting the connected few at the expense of the many. In the course of all of this, there is an increasing pressure (and ability) to obscure or water down unfavorable data, especially when the interests of profiteers and government appointees coincide. Again, we've all seen this come to pass numerous times in recent years and prior decades. It is the way of the world, and just as much so when it comes to the future of human longevity:

"In 1981, the United Kingdom (UK) Office for National Statistics estimated that male life expectancy at birth would rise to 74 by 2031. It hit that age in 1994. In 2002, the 2031 estimate was 81, but we are now expected to pass that in 2019. This systematic underestimation of official life expectancy increases occurs around the world. It is not an accident. It is deliberate. Politicians put pressure on official agencies to do this, so that the full cost of longevity increases does not fall on them or the current generation of voters. The reason is clear: If more accurate and hence higher projection of life expectancy were produced today, then social security contributions would have to rise now rather than later - and this would be politically very unpopular."

AN INTERVIEW WITH AUBREY DE GREY

SENS Foundation cofounder Aubrey de Grey presented at the humanity+ conference in Melbourne, Australia, held earlier this year. Adam Ford, the conference coordinator, interviewed de Grey after the event, and later uploaded a slew of video segments from that interview to YouTube. You'll find a link to the playlist in the following Fight Aging! post:

http://www.fightaging.org/archives/2012/06/an-aubrey-de-grey-interview-from-the-melbourne-humanity-conference.php

EARLY MEDICAL NANOROBOTS WILL LOOK LIKE CELLS AND BACTERIA

Researchers are producing some impressive early technology demonstrations these days - assembled, artificial molecular machinery that starts to rival bacteria in complexity:

http://www.fightaging.org/archives/2012/06/early-medical-nanorobots-will-look-like-cells-and-bacteria.php

"If I mention medical nanorobotics, you might think of the designs put forward by Robert Freitas and others: molecular machines constructed largely from carbon that bear little relation to the cells and cellular system they are intended to interact with. Or you might think of the crude forerunners of those designs presently being tested in the laboratory, such as targeted nanoparticles and nanocontainers used to deliver drug compounds more precisely to where they are needed.

"But you and I are built out of nanorobots: each of our cells is effectively a structured collection of cooperating, programmable nanoscale robots. They are evolved rather than designed, but still represent a vast preexisting parts library for researchers interested in building the first generation of medical nanorobots. While it is true that there are good reasons for reinventing this wheel, such as gaining far greater performance than is possible from anything similar to our present biology, given that time is of critical importance in developing the next generation of medicine, why not use these existing designs?

"Researchers are already building the prototypes, far more advanced than simple targeted nanoparticles. Here, for example, is news of progress towards nanofactories. ... Scientists are reporting an advance toward treating disease with minute capsules containing not drugs - but the DNA and other biological machinery for making the drug. ... development of nanoscale production units for protein-based drugs in the human body may provide a new approach for treating disease. These production units could be turned on when needed, producing medicines that cannot be taken orally or are toxic and would harm other parts of the body. Until now, researchers have only done this with live bacteria that were designed to make proteins at disease sites. But unlike bacterial systems, artificial ones are modular, and it is easier to modify them. That's why [this research group] developed an artificial, remotely activated nanoparticle system containing DNA and the other 'parts' necessary to make proteins, which are the workhorses of the human cell and are often used as drugs. They describe the nanoscale production units, which are tiny spheres encapsulating protein-making machinery like that found in living cells. The resulting nanoparticles produced active proteins on demand when the researchers shined a laser light on them."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

AGE-RELATED VISUAL IMPAIRMENT IN DECLINE
Friday, June 29, 2012
http://www.fightaging.org/archives/2012/06/age-related-visual-impairment-in-decline.php
Steady progress in medicine has led to an ongoing reduction in many age-related conditions over the past few decades. Such as this, for example: "Today's senior citizens are reporting fewer visual impairment problems than their counterparts from a generation ago, according to a new [study]. Improved techniques for cataract surgery and a reduction in the prevalence of macular degeneration may be the driving forces behind this change, the researchers said. ... From 1984 until 2010, the decrease in visual impairment in those 65 and older was highly statistically significant. There was little change in visual impairments in adults under the age of 65. ... The [ study] shows that in 1984, 23 percent of elderly adults had difficulty reading or seeing newspaper print because of poor eyesight. By 2010, there was an age-adjusted 58 percent decrease in this kind of visual impairment, with only 9.7 percent of elderly reporting the problem. There was also a substantial decline in eyesight problems that limited elderly Americans from taking part in daily activities, such as bathing, dressing or getting around inside or outside of the home ... there are three likely reasons for the decline: (a) Improved techniques and outcomes for cataract surgery. (b) Less smoking, resulting in a drop in the prevalence of macular degeneration. © Treatments for diabetic eye diseases are more readily available and improved, despite the fact that the prevalence of diabetes has increased "

ALCOR 40 CONFERENCE, OCTOBER 19TH 2012
Friday, June 29, 2012
http://www.fightaging.org/archives/2012/06/alcor-40-conference-october-19th-2012.php
Cryonics provider Alcor is holding a 40th anniversary conference in October, and the presently announced program looks much like this: "Sebastian Seung on testing how well cryopreservation (and alternatives) preserves the connectome. Todd Huffman on brain scanning. Panel discussion on long-term financial planning, including investing strategies, inflation protection, and personal trusts. Aschwin and Chana de Wolf from Advanced Neural Biosciences on advances in cryonics-relevant research. Greg Fahy from 21st Century Medicine on advances in cryoprotection. Aubrey de Grey from the SENS Foundation. Joshua Mitteldorf on programmed aging. Anders Sandberg on 'Handling the unknowable and undecidable: rational decision making about future technology.' Catherine Baldwin on advances at Suspended Animation. Panel on medical monitoring devices for improving your chances of a quick response in case of a critical physiological failure. Max More on how to improve your prospects for an optimal cryopreservation."

A STEP TOWARDS BETTER BLOOD
Thursday, June 28, 2012
http://www.fightaging.org/archives/2012/06/a-step-towards-better-blood.php
Why not aim to improve on blood? Its primary function is to carry oxygen, and it has evolved to do the bare minimum necessary on this front - separate any part of the body from a supply of oxygen for a minute or so and you're in trouble. It would be nice, for example, to have blood with a reserve capacity of a few hours, achieved using nanomachines that store the surplus oxygen that the body doesn't otherwise extract from air breathed in. Even if the heart stopped or blood stopped flowing in some vital tissue, you'd have those few hours to seek medical help. Here is a gentle first step towards the technologies of better blood: researchers "designed tiny, gas-filled microparticles that can be injected directly into the bloodstream to quickly oxygenate the blood. The microparticles consist of a single layer of lipids (fatty molecules) that surround a tiny pocket of oxygen gas, and are delivered in a liquid solution. ... report that an infusion of these microparticles into animals with low blood oxygen levels restored blood oxygen saturation to near-normal levels, within seconds. When the trachea was completely blocked - a more dangerous 'real world' scenario - the infusion kept the animals alive for 15 minutes without a single breath, and reduced the incidence of cardiac arrest and organ injury. The microparticle solutions are portable and could stabilize patients in emergency situations, buying time for paramedics, emergency clinicians or intensive care clinicians to more safely place a breathing tube or perform other life-saving therapies. ... The microparticles would likely only be administered for a short time, between 15 and 30 minutes, because they are carried in fluid that would overload the blood if used for longer periods ... the particles are different from blood substitutes, which carry oxygen but are not useful when the lungs are unable to oxygenate them. Instead, the microparticles are designed for situations in which the lungs are completely incapacitated. ... Intravenous administration of oxygen gas was tried in the early 1900s, but these attempts failed to oxygenate the blood and often caused dangerous gas embolisms. ... We have engineered around this problem by packaging the gas into small, deformable particles. They dramatically increase the surface area for gas exchange and are able to squeeze through capillaries where free gas would get stuck."

DEMONSTRATING GENETICALLY CORRECTED STEM CELLS AS A THERAPY
Thursday, June 28, 2012
http://www.fightaging.org/archives/2012/06/demonstrating-genetically-corrected-stem-cells-as-a-therapy.php
This demonstrated technology platform has wide-ranging uses beyond muscular dystrophy. The ability to generate altered versions of a patient's own stem cell populations and then deliver them as needed could be a useful therapy for many conditions: "scientists have turned muscular dystrophy patients' fibroblast cells (common cells found in connective tissue) into stem cells and then differentiated them into muscle precursor cells. The muscle cells were then genetically modified and transplanted into mice. ... In this study, scientists focused on genetically modifying a type of cell called a mesoangioblast, which is derived from blood vessels and has been shown in previous studies to have potential in treating muscular dystrophy. However, the authors found that they could not get a sufficient number of mesoangioblasts from patients with limb-girdle muscular dystrophy because the muscles of the patients were depleted of these cells. Instead, scientists in this study 'reprogrammed' adult cells from patients with limb-girdle muscular dystrophy into stem cells and were able to induce them to differentiate into mesoangioblast-like cells. After these 'progenitor' cells were genetically corrected using a viral vector, they were injected into mice with muscular dystrophy, where they homed-in on damaged muscle fibres. The researchers also showed that when the same muscle progenitor cells were derived from mice the transplanted cells strengthened damaged muscle and enabled the dystrophic mice to run for longer on a treadmill than dystrophic mice that did not receive the cells."

COMMENTS ON CHEMOPRESERVATION VERSUS CRYOPRESERVATION
Wednesday, June 27, 2012
http://www.fightaging.org/archives/2012/06/comments-on-chemopreservation-versus-cryopreservation.php
There is some ongoing interest in plastination (or chemopreservation) as a possible alternative to cryonics (or cryopreservation) - though not yet enough for an initiative to arise that offers that service. Here is commentary on this topic: "Even if chemopreservation can be demonstrated to preserve the intricate wiring of the brain, it can be safely assumed that there will not be a massive change in demand for brain preservation technologies ... As a consequence, providers of chemopreservation will most likely operate in the same environment as providers of cryonics. That means that, as a general rule, there will be a delay between pronouncement of legal death and the start of procedures. ... There is an understandable tendency to compare brain preservation protocols under ideal conditions and favor the method that produces the best preservation. But support for either technology cannot be solely based on results produces under controlled lab conditions. Personal survival technologies should be evaluated under conditions that are most likely to be encountered by organizations that will offer them. ... One interesting aspect of the cryonics vs chemopreservation debate, though, is that it appears that some people simply feel more comfortable with one of the approaches. People who have shown the slightest interest in human cryopreservation can get really excited about the idea of chemical brain preservation. This indicates that if both approaches would be pursued actively, the growth of chemopreservation would not necessarily be at the expense of cryonics but there would be a growth in the total number of people making bio-preservation arrangements aimed at personal survival. [But] chemopreservation is not at the stage where it can be responsibly offered. The growth of this field requires a committed group of individuals who will research, develop, and implement this program. Chemopreservation does not need to be perfected before being offered (neither was cryonics) but so far most advocacy has been mostly at the conceptual level."

CALORIE RESTRICTION REDUCES LOSS OF SYNAPTIC PLASTICITY
Wednesday, June 27, 2012
http://www.fightaging.org/archives/2012/06/calorie-restriction-reduces-loss-of-synaptic-plasticity.php
Another of the many benefits of calorie restriction is outlined in this paper: "The author focused on the functional decline of synapses in the brain with aging to understand the underlying mechanisms and to ameliorate the deficits. The first attempt was to unravel the neuronal functions of gangliosides so that gangliosides could be used for enhancing synaptic activity. The second attempt was to elicit the neuronal plasticity in aged animals through enriched environmental stimulation and nutritional intervention. Environmental stimuli were revealed neurochemically and morphologically to develop synapses leading to enhanced cognitive function. Dietary restriction as a nutritional intervention restored the altered metabolism of neuronal membranes with aging, providing a possible explanation for the longevity effect of dietary restriction. These results obtained with aging and dementia models of animals would benefit aged people."

MITOCHONDRIAL HAPLOGROUP ASSOCIATIONS WITH LONGEVITY IN CHINA
Tuesday, June 26, 2012
http://www.fightaging.org/archives/2012/06/mitochondrial-haplogroup-associations-with-longevity-in-china.php
Mitochondria are the power plants of the cell and are important in aging: damage to their DNA contributes to degenerative aging through a complex process, and differences in mitochondrial resistance to damage is thought to go a long way towards determining variation in species life span. So it should not be surprising to see associations between different mitochondrial DNA haplogroups and human longevity, as is the case here: "Human longevity is an interesting and complicated subject, with many associated variations, geographic and genetic, including some known mitochondrial variations. The population of the Bama County of Guangxi Province of China is well known for its longevity and serves as a good model for studying a potential molecular mechanism. In this study, a full sequence analysis of mitochondrial DNA (mtDNA) has been done in ten Bama centenarians using direct sequencing. [Mitochondrial DNA was also] analyzed for a total of 313 Bama individuals with ages between 10 and 110 years. The results showed that there were seven mitochondrial variations [and] four haplogroups [in] 10 Bama centenarians. In the D-loop region of mtDNA, the mt146T occurred at a significantly lower frequency in those is the older age group (90-110 years) than in the middle (80-89 years) and in the younger (10-79 years) groups. The mt146T also had lower systolic blood pressure and serum markers such as total cholesterol, triglyceride and low density lipoprotein than did mt146C in the older age group. ... These results suggest that the mt146T/C polymorphisms in Guangxi Bama individuals may partly account for the Bama longevity."

ANOTHER WAY OF SEARCHING FOR LONGEVITY-RELATED MECHANISMS
Tuesday, June 26, 2012
http://www.fightaging.org/archives/2012/06/another-way-of-searching-for-longevity-related-mechanisms.php
Researchers are developing all sorts of methods for sifting through the mass of data on protein machinery used in our bodies, and some groups are finding novel ways to identify possible longevity-related proteins: "Despite a 10-100-fold difference in maximum lifespan (MLS), most known mammal species show similar phenotypes of aging. This observation suggests that the genetic determinants of mammalian aging and lifespan may be relatively plastic. The classical evolutionary theory of antagonistic pleiotropy posits that aging is an effect of the decrease in selection pressure that occurs after successful reproduction. Conversely, lifespan extension has been shown to occur when selection pressure increases in later age. Still relatively unexplored are the specific molecular mechanisms that determine differences in mammalian lifespan. Many mechanisms are possible and likely occur simultaneously, including changes in the sequence, structure, function, and expression of RNA and proteins. Here, we focus on changes in proteins caused by fixed substitutions. In this context, two recent studies predicted a simple consequence of the evolutionary theory: we might expect that proteins necessary for long mammalian lifespan would have fewer substitutions, i.e. show more conservation, in long-lived versus short-lived species. Thus, it may be possible to identify aging-related proteins [by] inferring and comparing some measure of such preferential substitutions, here called 'longevity-selected positions', among the several dozen mammal species whose proteomes are available. ... We analyzed 7,590 orthologous protein families in 33 mammalian species, accounting for body mass, phylogeny, and species-specific mutation rate. Overall, we found that the number of longevity-selected positions in the mammalian proteome is much higher than would be expected by chance. Further, these positions are enriched in domains of several proteins that interact with one another in inflammation and other aging-related processes, as well as in organismal development. We present as an example the kinase domain of anti-Müllerian hormone type-2 receptor (AMHR2). AMHR2 inhibits ovarian follicle recruitment and growth, and [its] longevity-selected positions cluster near a SNP associated with delayed human menopause. Distinct from its canonical role in development, this region of AMHR2 may function to regulate the protein's activity in a lifespan-specific manner."

POPULAR PRESS ON ORGAN TISSUE ENGINEERING
Monday, June 25, 2012
http://www.fightaging.org/archives/2012/06/popular-press-on-organ-tissue-engineering.php
Building new organs from a patient's own cells is a goal that is gaining more attention from the wider public and the mainstream press: "What if dying patients waiting for an organ transplant could receive a custom, lab-grown replacement rather than waiting for a donor organ? To some, this may sound like science fiction - and in many ways, it still is. But the advances in the field of regenerative medicine that made headlines last week suggest such lab-grown organs may become reality in the future. ... The idea of using a patient's own cells rather than relying on those of a donor is important because it eliminates the need to find a 'match.' For any transplant procedure there is a concern that tissues from a donor will be rejected by a recipient's body. Even though doctors carefully analyze specimens under a microscope to find the most compatible individuals, and even despite the powerful drugs used to prevent the recipient's immune system from attacking the new body part, the risk of rejection still causes doctors to hold their breath in the days following a transplant. Custom-made organs from a patient's own tissues would solve this problem, obviating the need for strong immune-suppressing medications that come with significant side effects. The other potential benefit lies in availability. Growing a replacement tissue or organ in the lab eliminates the dependence on waiting for a donor to die. These parts cannot be grown overnight, but with people currently waiting months to years for donor organs, there might be a point at which the amount of time taken to grow a replacement is shorter than the wait for a donated one. It's a bright future. But many hurdles remain before widespread use becomes a reality."

IN SITU TISSUE ENGINEERING OF AN ARTERY
Monday, June 25, 2012
http://www.fightaging.org/archives/2012/06/in-situ-tissue-engineering-of-an-artery.php
The logical progression for tissue engineering is to move to building inside the body rather than building outside and then transplanting the resulting new tissue. Here is an example of that trend: "The host site, the artery in this case, is an excellent source of cells and provides a very efficient growth environment. This is what inspired us to skip the cell culture altogether and create these cell-free synthetic grafts. ... [Researchers] designed the graft with three properties in mind. First, they chose a graft material - an elastic polymer called PGS - that is resorbed quickly by the body. Then, they examined graft porosity and selected parameters that allow immediate cell infiltration. [They wrapped] the vascular graft with a fibrous sheath to trap the cells. Finally, [researchers] wanted a coating for the grafts that would reduces blood clotting and bind many growth factors, so they used heparin, a molecule that does just that. ... [Researchers] made grafts as small as 1 mm in diameter and monitored the graft's transformation in vivo for three months. Because the graft was highly porous, cells were easily able to penetrate the graft wall, and mononuclear cells occupied many of the pores within three days. Within 14 days, smooth muscle cells - an important blood vessel builder - appeared. At 28 days, cells were distributed more evenly throughout the graft. At 90 days, most inflammatory cells were gone, which correlated with the disappearance of the graft materials. The artery was regenerated in situ and pulsed in sync with the host. Furthermore, the composition and properties of the new arteries are nearly the same as native arteries."

______________________________


<br> <br>View the full article

#16 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 08 July 2012 - 02:51 PM

FIGHT AGING! NEWSLETTER
July 9th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- A Lack of Biotechnology is the Only Limit on Human Longevity
- The All or Nothing Progress of Longevity Science
- Engineering Longevity in Nematodes
- Improving Cognition and Memory in Old Mice
- Discussion
- Latest Headlines from Fight Aging!
    - Considering Mitochondrial Dynamics in the Context of Aging
    - Stem Cell Transplant Explored as Alzheimer's Disease Therapy
    - Nitric Oxide and Aging Blood Vessels
    - Suggesting a Test of Rapamycin and Metformin Together
    - Calorie Restriction Boosts Stem Cell Function
    - Discussing IGF-1 and Heart Health in Mammals
    - On Osteoarthritis
    - AKH, Physical Activity, and Calorie Restriction Benefits
    - A Different Argument for the Age-Dependence of Cancer
    - Another Approach to Creating Blood Vessels in Engineered Tissue

A LACK OF BIOTECHNOLOGY IS THE ONLY LIMIT ON HUMAN LONGEVITY

As Aubrey de Grey notes, medicine is all about transcending the limits of biology. Where we have not yet transcended, such as in the matter of the maximum observed human life span, it is because the necessary biotechnology has not yet been developed:

http://www.fightaging.org/archives/2012/07/a-lack-of-biotechnology-is-the-only-limit-on-human-longevity.php

"Are there limits on human longevity? Sure. Few people will make it past a hundred years of age in the environment of today's medical technology - but today is today, and the technology of tomorrow will be a different story. If you want to talk about longevity and mortality rates, you have to qualify your position by stating what sort of applied biotechnologies are available. Longevity is a function of the quality and type of medicine that is available across a life span.

"It so happens that most of the advances in medicine achieved over the course of human history, the vast majority of which have occurred in the past fifty years, have solved problems that killed people early in life. Infectious disease, for example, is controlled to a degree that would have been thought utopian in the squalor of Victorian England. The things that kill older people are a harder set of challenges: great progress has been made in reducing mortality from heart disease in the past few decades, for example, but that is just one late stage consequence of the complex array of biochemical processes that we call aging.

"The point of this discussion? It is that tremendous progress in medicine, including the defeat or taming of many varied causes of death and disability, has not greatly lengthened the maximum human life span as experienced in practice. The research community hasn't really started in earnest on the work on rejuvenation biotechnology that will achieve that end - the story of medicine to date has been work on other line items, or largely futile attempts to patch over the failure modes that lie at the end of aging.

"There are things that need to be fixed that currently limit human life span. Since aging is only an accumulation of damage, there is in fact a gentle trend towards extended life as a result of general improvements across the board in medicine - perhaps one year of additional life with every five years of technological progress at the present time. On average, people with access to the modern environment of technology and support are suffering biological damage at the level of cells and molecular machinery more slowly across their lives. But this incidental life extension is slow going indeed.

"Given this history of medical progress you will find many life science researchers and advocates who view the human life span as bounded - they look to past progress and extrapolate to assume that future progress can only carry on improving things within the existing human maximum life span. In other words that more and more people will live in good health closer to that maximum, but that the maximum is set in stone. There's even a name for this goal, 'compression of morbidity'.

"This is a ridiculous view when considered in the light of reliability theory and aging, but it is widely held and therefore something that advocates for rejuvenation biotechnology must work to dismiss. The future of medicine in the next few decades is not about gaining a decade of life with no hope of pushing out human life span beyond 120 years - it is about building the alpha versions of medical technologies that can provide indefinite healthy life spans through periodic repair of the known forms of cellular and molecular damage that cause aging. But unless many more people come to understand this point, there will continue to be the same lack of support for research that will lead to radical change in the relationship of medicine and aging."

THE ALL OR NOTHING PROGRESS OF LONGEVITY SCIENCE

We all win together or we all lose together - there is little middle ground in the development of new medical technologies:

http://www.fightaging.org/archives/2012/07/the-all-or-nothing-progress-of-longevity-science.php

"Competition drives progress, but put enough humans into any field and the successful groups will start to form cartels in order to keep their leading position without having to compete as hard for it. It is inherent in the human condition that we self-sabotage very well and very aggressively just as soon as we achieve enough success to feel somewhat elevated over our less fortunate peers. Who can even begin to guess how many opportunities have been wasted, how much potential technological progress has been lost thanks to these urges?

"The world of technology is now remarkably flat. The majority of the amenities of modern technology are available to the majority of the world: the descendants of peasants can fly for the same cost as the bloodlines of kings, cars and mobile phones are ubiquitous, and holding vast wealth doesn't in fact give a person any great and massive advantage over the middle class - or even the poor in wealthier regions - when it comes to the variety of available medical technology. Every new advance moves rapidly from being comparatively expensive, faulty, and scarce to being comparatively cheap, reliable, and widespread - whether we are talking about air conditioning or heart surgery, though the pernicious effects of regulation slow down the applications of biotechnology to a crawl in comparison to other lines of technological progress.

"One of the defining features of our age is the degree to which the very wealthy and the very connected use the same technologies as the rest of us. When new technology is developed we all win - it doesn't matter which research or development group got there first, because we will all have access soon enough. What does matter is how soon that new technology arrives, and that is a function of the size and level of competition in the research and development communities. ... The larger the community, the more healthy competition, the better the outcome and the faster the progress towards the end goal. When it comes to the biotechnology of rejuvenation we will either all win together or we all lose together - there is little in the way of middle ground in technological progress. That result is entirely determined by how fast we can create this sort of future medicine, such as that outlined in the SENS proposals."

ENGINEERING LONGEVITY IN NEMATODES

A ground of researchers roll up their sleeves and methodically build a range of genetically superior nematode worm species:

http://www.fightaging.org/archives/2012/07/an-engineering-approach-to-extending-lifespan-in-nematodes.php

"If more life science researchers thought like engineers, we might see faster progress towards extended healthy longevity. One of the marks of pure engineering versus pure science is the willingness to pursue development of working solutions in the absence of full knowledge of the underlying principles. Both the Romans and the early British industrialists built superb bridges in the absence of a full understanding of structural and material science, not by chance but because they could deliberately and carefully use empirical knowledge to work around their ignorance of deeper scientific laws. So too there is much more room for empiricism in the development of medicine, and in longevity science in particular, than is presently practiced. In the scientific world, the favored next step following a demonstration of extended life in laboratory animals is to figure out every detail of how it works rather than explore the possibility of building a therapy - but both paths could be explored in parallel. In any case, here are results from a group of life science engineers, working with nematode worms:

"We have taken an engineering approach to extending the lifespan of Caenorhabditis elegans. Aging stands out as a complex trait, because events that occur in old animals are not under strong natural selection. As a result, lifespan can be lengthened rationally using bioengineering to modulate gene expression or to add [components from other species]. ... We overexpressed five genes that act in endogenous worm aging pathways, as well as two genes from zebrafish encoding molecular functions not normally present in worms. For example, we used zebrafish genes to alter mitochondrial function and innate immunity in ways not normally available to C. elegans and extended worm lifespan by ~40%. Next, we used a modular approach to extend lifespan by 130% by combining up to four components in the same strain. These results provide a platform to build worms having progressively longer lifespans.

"This project is conceptually similar to using engineering to increase the useful lifespan of a primitive machine (1931 Model T) using both parts from the model T as well as parts from a more advanced machine (2012 Toyota Corolla). Our results open the door to use engineering to go beyond the constraints of the C. elegans genome to extend its lifespan by adding non-native components."

IMPROVING COGNITION AND MEMORY IN OLD MICE

Separate research groups use different methods to improve brain functions in old mice:

http://www.fightaging.org/archives/2012/07/in-mice-rapamycin-improves-cognition-and-dna-methyltransferase-improves-memory.php

"The researchers, appointed in the School of Medicine at The University of Texas Health Science Center San Antonio, added rapamycin to the diet of healthy mice throughout the rodents' life span. Rapamycin, a bacterial product first isolated from soil on Easter Island, enhanced learning and memory in young mice and improved these faculties in old mice, the study showed. 'We made the young ones learn, and remember what they learned, better than what is normal,' said Veronica Galvan, Ph.D., assistant professor of physiology at the Barshop Institute for Longevity and Aging Studies, part of the UT Health Science Center. 'Among the older mice, the ones fed with a diet including rapamycin actually showed an improvement, negating the normal decline that you see in these functions with age.'

"Given that rapamcyin was shown in that study to boost levels of neurotransmitters associated with neural plasticity, the first inclination would be to link the improved capabilities of the mice to increased growth and adaptability in neurons across the course of life. Further research will no doubt show whether that is a reasonable hypothesis."

"Researchers from the University of Heidelberg had injected a virus that contains extra copies of the gene responsible for creating DNA methyltransferase into the hippocampus, area of the brain responsible for memory, of elderly mice that were showing signs of diminished memory. Afterwards, the team gave the mice a series of memory tests such as showing the mice a new object to investigate for a period of time, taking it away and presenting them with the same object the next day along with another new object.

"Past studies showed that younger more able-minded mice will immediately begin investigating the newer object, while older mice will spend equal amounts of time investigating both objects, having seemingly forgotten that they'd already seen the object the day before. The research team found that once the older mice were injected with the virus, the elderly mice had spent most of their time, 70 percent of the time, investigating the new object, suggesting that an increase of the enzyme restored their faulty memories to its original capacity. However, when researchers halved the amount of DNA methyltransferase produced by younger mice, the memory abilities deteriorated to that of non-treated older mice."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

CONSIDERING MITOCHONDRIAL DYNAMICS IN THE CONTEXT OF AGING
Friday, July 6, 2012
http://www.fightaging.org/archives/2012/07/considering-mitochondrial-dynamics-in-the-context-of-aging.php
A herd of mitochondria exists in every cell, producing the ATP necessary to power that cell. Damage to mitochondria is important in aging, but how damage progresses in a cell's mitochondrial population is complicated by the fact that these are not completely discrete and static entities. They multiply like bacteria (fission), can merge with one another (fusion), and can also exchange individual components of their molecular machinery - so damage can be both passed around or mitigated depending on circumstances. Here researchers build models to better understand this dynamic: "Mitochondria are organelles that play a central role as 'cellular power plants'. The cellular organization of these organelles involves a dynamic spatial network where mitochondria constantly undergo fusion and fission associated with the mixing of their molecular content. ... Mitochondrial dynamics and mitophagy play a key role in ensuring mitochondrial quality control. Impairment thereof was proposed to be causative to neurodegenerative diseases, diabetes, and cancer. Accumulation of mitochondrial dysfunction was further linked to aging. Here we applied a probabilistic modeling approach integrating our current knowledge on mitochondrial biology allowing us to simulate mitochondrial function and quality control during aging ... We demonstrate that cycles of fusion and fission and mitophagy indeed are essential for ensuring a high average quality of mitochondria, even under conditions in which random molecular damage is present. Prompted by earlier observations that mitochondrial fission itself can cause a partial drop in mitochondrial membrane potential, we tested the consequences of mitochondrial dynamics being harmful on its own. Next to directly impairing mitochondrial function, pre-existing molecular damage may be propagated and enhanced across the mitochondrial population by content mixing. In this situation, such an infection-like phenomenon impairs mitochondrial quality control progressively. However, when imposing an age-dependent deceleration of cycles of fusion and fission, we observe a delay in the loss of average quality of mitochondria. This provides a rational why fusion and fission rates are reduced during aging and why loss of a mitochondrial fission factor can extend life span in fungi. We propose the 'mitochondrial infectious damage adaptation' (MIDA) model according to which a deceleration of fusion-fission cycles reflects a systemic adaptation increasing life span."

STEM CELL TRANSPLANT EXPLORED AS ALZHEIMER'S DISEASE THERAPY
Friday, July 6, 2012
http://www.fightaging.org/archives/2012/07/stem-cell-transplant-explored-as-alzheimers-disease-therapy.php
Work on stem cell transplants in rats is outlined here: "Alzheimer's disease (AD) has been called the disease of the century with significant clinical and socioeconomic impacts. Epidemiological studies point out that AD affects 5% of the population over 65, and, parallel with increasing lifespan, the incidence of disease will rise dramatically. Clinically AD is characterized by a progressive learning capacity impairment and memory loss, especially memories of recent events ... Adult neural tissues have limited sources of stem cells, which makes neurogenesis in the brain less likely. Stem cells transplantation seems to be a promising strategy for treatment of several central nervous system (CNS) degenerative diseases such as AD, amyotrophic lateral sclerosis (ALS), and Parkinson's disease ... The present study aims to evaluate the effect of bone marrow mesenchymal stem cells (MSCs) grafts on cognition deficit in chemically and age-induced Alzheimer's models of rats. ... Two months after the treatments, cognitive recovery was assessed ... Results showed that MSCs treatment significantly increased learning ability and memory in both age- and [chemical]-induced memory impairment. Adult bone marrow mesenchymal stem cells show promise in treating cognitive decline associated with aging and [nucleus basalis magnocellularis] lesions."

NITRIC OXIDE AND AGING BLOOD VESSELS
Thursday, July 5, 2012
http://www.fightaging.org/archives/2012/07/nitric-oxide-and-aging-blood-vessels-1.php
Nitric oxide levels are a possible target for therapies aimed at some of the signs of aging in blood vessels: "Many disorders emerge with advancing aging, and cardiovascular diseases (CVD) are a major cause of morbidity and mortality in the elderly. The term vascular aging encompasses all the structural and functional alterations in the blood vessels with progressive aging. Both smooth muscle cells and intima layers are affected. These vascular changes lead to endothelial dysfunction, arterial stiffness in consequence of intense remodeling and calcification, impaired angiogenesis, greater susceptibility to vascular injury and atherosclerotic lesions. The mechanisms underlying vascular aging are complex and involve multiple pathways and factors ... In this complex scenario, vascular function depends on the balanced production/bioavailability of nitric oxide (NO), which is maintained by the normal activity of endothelial nitric oxide synthase (eNOS). On the other hand, excessive amount of NO produced by inducible nitric oxide synthase (iNOS) up-regulation contributes to vascular dysfunction. Evidence obtained from experimental models indicates that decreased NO bioavailability as well as increased reactive nitrogen species (RNS) production contributes to aging-associated vascular dysfunction. ... Pharmacological modulation of NO generation and expression/activity of NOS isoforms may represent a therapeutic alternative to prevent the progression of cardiovascular diseases."

SUGGESTING A TEST OF RAPAMYCIN AND METFORMIN TOGETHER
Thursday, July 5, 2012
http://www.fightaging.org/archives/2012/07/suggesting-a-test-of-rapamycin-and-metformin-together.php
Rapamycin extends life in mice through mechanisms similar to those of calorie restriction, but has serious side-effects - though researchers are working to separate the positive mechanisms from the undesirable negative mechanisms. Metformin is also thought to be a calorie restriction mimetic drug, but the evidence for it to extend life in mice is mixed. Here, researchers suggest trying both drugs at the same time in the hopes that metformin blunts some of the side-effects of rapamycin: "Treatment with rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) can increase mammalian life span. However, extended treatment with rapamycin results in increased hepatic gluconeogenesis concomitant with glucose and insulin insensitivity through inhibition of mTOR complex 2 (C2). Genetic studies show that increased life span associated with mTORC1 inhibition can be at least partially decoupled from increased gluconeogenesis associated with mTORC2 inhibition. Adenosine monophosphate kinase (AMPK) agonists such as metformin, which inhibits gluconeogenesis, [might] be expected to block the glucose dysmetabolism mediated by rapamycin."

CALORIE RESTRICTION BOOSTS STEM CELL FUNCTION
Wednesday, July 4, 2012
http://www.fightaging.org/archives/2012/07/calorie-restriction-boosts-stem-cell-function.php
It is known that calorie restriction increases stem cell capacity in aging, thereby helping to maintain tissues for longer. From Extreme Longevity, a recent commentary on the mechanisms involved: "Like it or not food lovers, the single most effective known means of extending animal lifespan is through reducing daily caloric intake. Though not definitively proven in humans, the success of this intervention has been demonstrated in myriad species in more than 50 years of research. ... A protein called mTOR is responsible for this effect. mTOR combines with two other proteins to mediate several important cellular processes. These include translation of mRNA into protein, mitochondrial activity, and autophagy. Caloric restriction inhibits mTOR activity which leads to longer lifespan. The new studies [convincingly] demonstrate that reduction of mTOR activity causes preservation of stem cell health. They increase in abundance and proliferative potential. One study shows this occurs in intestinal cells, and the other in muscle cells. In the instestinal cell study, the authors showed that it was actually supporter cells called Paneth cells that aided the health of stem cells when they were taken from calorie restricted animals. They further showed this effect was mediated by mTOR inhibition and that it was achieved by increasing the activity of another protein called Bst1, important in cell proliferation. In the muscle study, calorie restricted animals had greater muscle stem cell proliferative capacity too. And this effect was also seen when the stem cells were transplanted into non calorically restricted animals, suggesting the microenvironment or niche around the stem cells was key. ... taken together, the two studies indicate that preserving and enhancing stem-cell function in multiple tissues is one of the ways in which calorie restriction slows the ravages of aging."

DISCUSSING IGF-1 AND HEART HEALTH IN MAMMALS
Wednesday, July 4, 2012
http://www.fightaging.org/archives/2012/07/discussing-igf-1-and-heart-health-in-mammals.php
An open access commentary: "The mammalian heart must maintain its structural and functional integrity for decades, yet the response to damage in this vital organ is remarkably inadequate and often results in heart failure. Moreover, patients with chronic heart failure show profound metabolic changes, leading to peripheral abnormalities in addition to an initial cardiac impairment. Several evidences have suggested a relationship between the IGF-1 system and cardiovascular disease. Many cardiovascular risk factors, such as sedentary lifestyle, diabetes, smoking, oxidized low-density lipoprotein, obesity, psychological distress and reduced coronary flow reserve, have been associated with reduced IGF-1 levels. Conversely, human studies indicate that increased levels of IGF-1 are characterized by a decreased incidence of heart failure and mortality in elderly individuals. Nevertheless, the fact that IGF-1 can act either as a circulating hormone or as a local growth factor has confounded previous analyses of animal models in which transgenic IGF synthesized in extra-hepatic tissues was released into the circulation. Locally acting mIGF-1 isoform improves muscle regeneration and counters muscle wasting associated with diseases, including sarcopenia, muscular dystrophy and ALS. By contrast, circulating IGF-1 isoforms have been implicated in the restriction of lifespan and have contrasting effects on the heart when expressed as transgenes, variously promoting cell survival, or inducing prolonged hypertrophy with pathological consequences."

ON OSTEOARTHRITIS
Tuesday, July 3, 2012
http://www.fightaging.org/archives/2012/07/on-osteoarthritis.php
This open access review paper discusses what is known of osteoarthritis: "Half of all persons aged over 65 suffer from osteoarthritis (OA). As a matter of fact, age is the most prominent risk factor for the initiation and progression of OA. The common explanation for this is the cumulative effect of mechanical load over the years, resulting clinically in 'wear and tear' and pathologically in cartilagepathogenesis and progression of OA. Not only cartilage, but also subchondral bone, menisci, muscles as well as fat, and synovial tissues play an important role, notably in the early phase of OA. Therefore, OA has been referred to as a 'whole joint disease.' Despite a higher complexity, this concept has not only improved our understanding of the disease but also indicates potentially new treatment strategies. ... Inflammation in form of cellular infiltration of synovial tissue or subchondral bone and expression of inflammatory cytokines is more and more recognized as trigger of OA. It has been demonstrated that joint movement can exhibit anti-inflammatory mechanisms. Therefore physical activity or physiotherapy in the elderly should be encouraged, also in order to increase the muscle mass. A reduced stem cell capacity in the elderly is likely associated with a decrease of repair mechanisms of the musculoskeletal system. New treatment strategies, for example with mesenchymal stem cells (MSC) are investigated, despite clear evidence for their efficacy is lacking."

AKH, PHYSICAL ACTIVITY, AND CALORIE RESTRICTION BENEFITS
Tuesday, July 3, 2012
http://www.fightaging.org/archives/2012/07/akh-physical-activity-and-calorie-restriction-benefits.php
We know that autophagy seems to be required for calorie restriction to provide benefits to health and and longevity, and here researchers argue that exercise is also required: "Fruit flies on dietary restriction (DR) need to be physically active in order to get the lifespan extending benefits that come from their Spartan diet. ... flies on DR shift their metabolism toward increasing fatty acid synthesis and breakdown, specifically in muscle tissue. ... Dietary restriction is known to enhance spontaneous movement in a variety of species including primates, however this is the first examination of whether enhanced physical activity is necessary for its beneficial effects. This study establishes a link between DR-mediated metabolic activity in muscle, increased movement and the benefits derived from restricting nutrients. ... flies on DR who could not move or had inhibited fat metabolism in their muscle did not exhibit an extended lifespan. ... Our work argues that simply restricting nutrients without physical activity may not be beneficial in humans. ... The research also points to a potential target that could yield a drug that mimics the beneficial effects of DR. ... flies genetically engineered to overexpress the circulating peptide AKH (the fly equivalent of glucagon in mammals) showed increased fat metabolism, spontaneous activity and extended lifespan even though their diet was unrestricted. AKH plays a critical role in glucose and lipid metabolism. ... Our data suggests that DR may induce changes in muscle similar to those observed under endurance exercise and that molecules like AKH could serve as potential mimetics for DR that enhance activity and healthspan."

A DIFFERENT ARGUMENT FOR THE AGE-DEPENDENCE OF CANCER
Monday, July 2, 2012
http://www.fightaging.org/archives/2012/07/a-different-argument-for-the-age-dependence-of-cancer.php
The general view of cancer is that it occurs in the old because it depends on nuclear DNA mutations that accumulate over time - the more mutations, the greater the chance of one of them being suitable to trigger a cancer. Here a researcher argues that it has less to do with the number of mutations and more to do with the changing (and more damaged) state of tissue and systems in the body, which increases the ability of mutated cells to survive and prosper: "For evidence, DeGregori points first to the fact that by the time we stop growing in our late teens, we've already accumulated a large fraction of the mutations we will have in our lifetimes. 'There's a mismatch between the mutation curve and the cancer curve,' DeGregori says, meaning that if cancer were due to reaching a tipping point of, say, five or six mutations, we should see higher cancer rates in 20-year-olds, as this is when mutation rate is highest. Second, DeGregori points out that even healthy tissues are full of oncogenic mutations. 'These mutations are many times more common than the cancers associated with them,' DeGregori says. Simply, more mutations doesn't equal more cancer - not across the aging population and not even in specific tissues. DeGregori's final two points come from evolution. As we've evolved from one-celled, short-lived life forms into multicellular, long-lived humans, we've had to develop complicated machinery to maintain our tissues and avoid disease. 'But we're no better at preventing mutations than our yeast or bacteria cousins. You'd think if avoiding mutations was key to avoiding cancer, we'd be better at it than we are.' And finally, if these oncogenes were the evil super-villains they've been made out to be, capable of taking over surrounding tissue, then introducing oncogenes into mice stem cells should help rather than hurt these cells' survival. 'Rather, stem cells harboring the oncogenes tend to get weeded out,' says DeGregori. Instead of gathering mutations until they give us cancer, DeGregori says that as we age, the mechanisms that younger adults use to fight cancer, deteriorate. ... Our healthy cells are optimized for the conditions of our healthy, younger tissue. Change this balance, as does an oncogenic mutation, and they're no longer a perfect fit for the surroundings - healthy cells in young bodies quickly outcompete cells with cancerous mutations. But, 'when tissue is old, healthy cells are no longer a perfect fit, and mutations might help a cancer cell adapt in ways a healthy cell can't,' DeGregori says."

ANOTHER APPROACH TO CREATING BLOOD VESSELS IN ENGINEERED TISSUE
Monday, July 2, 2012
http://www.fightaging.org/archives/2012/07/another-approach-to-creating-blood-vessels-in-engineered-tissue.php
Many research groups are working on ways to overcome the challenge of generating suitable blood vessel networks for engineered tissue, as this is one of the major blocking issues in generating large tissue masses from scratch: "Researchers are hopeful that new advances in tissue engineering and regenerative medicine could one day make a replacement liver from a patient's own cells, or animal muscle tissue that could be cut into steaks without ever being inside a cow. Bioengineers can already make 2D structures out of many kinds of tissue, but one of the major roadblocks to making the jump to 3D is keeping the cells within large structures from suffocating; organs have complicated 3D blood vessel networks that are still impossible to recreate in the laboratory. Now [researchers] have developed an innovative solution to this perfusion problem: [rather] than trying to print a large volume of tissue and leave hollow channels for vasculature in a layer-by-layer approach, [they] focused on the vasculature first and designed free-standing 3D filament networks in the shape of a vascular system that sat inside a mold. As in lost-wax casting, a technique that has been used to make sculptures for thousands of years, the team's approach allowed for the mold and vascular template to be removed once the cells were added and formed a solid tissue enveloping the filaments. ... The researchers showed that human blood vessel cells injected throughout the vascular networks spontaneously generated new capillary sprouts to increase the network's reach, much in the way blood vessels in the body naturally grow. The team then created gels containing primary liver cells to test whether their technique could improve their function. ... Though these engineered tissues were not equivalent to a fully functioning liver, the researchers used cell densities that approached clinical relevance, suggesting that their printed vascular system could eventually be used to further research in lab-grown organs and organoids."

______________________________


<br> <br>View the full article

#17 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 15 July 2012 - 03:42 PM

FIGHT AGING! NEWSLETTER
July 16th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- New Organ 100 Launched
- The World of Aging Science Must Up-end and Change Itself
- An Australian Cryonics Provider
- Discussion
- Latest Headlines from Fight Aging!
    - Trehalose, Calorie Restriction, and Longevity in Yeast
    - Mitochondrial Haplotypes Correlate With Dementia Risk
    - Discussing Rapamycin
    - PGC-1alpha Versus Huntington's Disease
    - Alzheimer's Disease Considered as Synaptic Imbalance
    - Investigating the Mechanisms of Rheumatoid Arthritis
    - Investigating Precursor Ogliomers in Alzheimer's Disease
    - An Epigenetic Contribution to Osteoarthritis
    - Exercise Beneficial in Elderly
    - No Difference in Reprogrammed Cells From Old and Young Mice

NEW ORGAN 100 LAUNCHED

The Methuselah Foundation launched the New Organ 100 this past week, a social fundraising initiative for the New Organ Prize, which aims to greatly speed up tissue engineering of whole organs:

http://www.fightaging.org/archives/2012/07/new-organ-100-announced-by-the-methuselah-foundation.php

"Today, 3,000 people will die from organ failure, many due to the lack of replacement organs. In the U.S. alone, over 100,000 are stuck on a waiting list, and many more can't even get on a list. We need a revolution in medicine, and we need it as soon as possible. Regenerative medicine is coming of aging. Significant breakthroughs are beginning to happen, but the funding to move the science and technology forward remains woefully inadequate.

"The Methuselah Foundation is announcing today the New Organ 100 to kickstart a visible, popular movement with a singular purpose: make regenerative medicine famous to achieve whole organ manufacturing within 10 years. We invite you to be among the initial 100 New Organizers, the seeds of the movement who each make the same pledge: give $10 a month toward raising the New Organ Prize, and ask 10 friends and family to do the same.

"The goal of the New Organ Prize is simple: to stimulate progress while demonstrating the rising demand for greater R&D funding. 100% of gifts go toward growing the prize. Every gift is matched by donors to support the New Organ Fund, which funds our operations and investments in startups advancing critical technologies, such as Organovo's 3D bioprinter and Silverstone Solutions' kidney-matching software."

THE WORLD OF AGING SCIENCE MUST UP-END AND CHANGE ITSELF

If we want real results, meaning greatly extended healthy life spans, to arrive in our lifetimes, then things must change:

http://www.fightaging.org/archives/2012/07/the-world-of-aging-science-must-up-end-change-renew-itself.php

"It is unfortunate that popular culture, that ongoing conversation of countless threads that lies at the center of our diverse society, is so focused on drugs and pills as the sum of all medicine - anything that is consumed, and so especially when it comes to influencing the pace of aging. It is a terribly wrong, horribly damaging viewpoint, but one that is relentless propagated by the loudest voices, coincidentally also those who gain the most in the short term by creating a culture of customers for their products. When the world thinks of medicine for aging in terms of pills and potions, it shuts the door on support for real rejuvenation biotechnology, such as the detailed plans for development advocated by the SENS Foundation and others.

"Part of the process of building the true medicine of rejuvenation - which will look like gene therapies, tailored cell alterations, engineered enzymes to strip away harmful metabolic side-products, and so on - is obtaining the support and at least superficial understanding of the public at large. That is still very much lacking, and some fraction of the blame for that can be pinned on the short-sighted idiots of the "anti-aging" marketplace who propagate lies and myths about aging and what can be done about it in order to sell products that do next to nothing. They have spent so much time and effort on this over the past decades that they have shaped the visions of popular culture to follow their message - and that harms us all by stripping away possible support for meaningful research and development, and making it harder to create that support.

"The vast majority of commentary on aging, science, longevity, and what can be done about it is garbage at worst, and interesting but ultimately irrelevant to the future of our lives at best. Into the latter half falls work on calorie restriction mimetics such as metformin and rapamycin. They simply don't do enough to worth sinking billions of dollars into further research and development - though of course that research and development will happen anyway, regardless of my opinions on the matter. There are far better paths ahead than tinkering with compounds and genes that have modest effects, on a par with calorie restriction, and potentially serious side-effects to go along with that.

"If results are what matter - and I think they are the only measure worth considering given the pace of death caused by aging - then world of aging and longevity research should focus on the SENS vision of targeted, deliberate repair of specific forms of damage, and move on from the tired old model of patching the end results of damage by trying a lot of compounds to find some that sort of do something beneficial. Nor should research spend their time on the comparatively new approach of trying to slow down the pace at which damage accumulates - again by trying a bunch of compounds to find some that sort of do something beneficial.

"There are now far more effective paths forward for the treatment of aging than the approaches undertaken in past decades when biotechnology and the state of knowledge was too poor to do better. The world of aging science must up-end, change, become quite different. The SENS Foundation and the network of research groups working on related matters are doing the right thing. Big Pharma, the calorie restriction mimetic developers, the people searching for longevity genes or gene therapies to slow aging - they are heading down a side-path that will do little beyond generating new knowledge. Our lives will not be greatly lengthened by their efforts, as we will be old by the time that they produce therapies with modest effects on human life span by slowing down the pace at which damage accumulates. Ways to slow aging are of little value to those already aged. Our healthy lives will be significantly extended only by the successful development of methods of rejuvenation - of damage repair, ways to actually reverse the toll of aging on cells and systems."

Conveniently, the path to building these technologies is laid out in some detail:

http://www.fightaging.org/archives/2004/11/strategies-for-engineered-negligible-senescence.php

AN AUSTRALIAN CRYONICS PROVIDER

It looks like an Australian group are close to establishing a cryonics provider in that country:

http://www.fightaging.org/archives/2012/07/close-to-the-establishment-of-an-australian-cryonics-provider.php

"Provision of cryonics services, the low-temperature preservation of the mind's structure on death, is a 40-year-old concern. It is presently the only chance at a longer life available to the vast numbers of people who will age to death prior to the advent of rejuvenation biotechnology of the sort envisaged at the SENS Foundation. In a better world than the one we presently live in, cryonics would already be a world-wide and massive industry, preserving tens of millions of people every year - saving them from oblivion, and giving a chance at a long and interesting future in an age with the technology to restore a preserved person to active life. Sadly this is far from the case. The long term success of providers outside the US has yet to be achieved, for example, as has the sort of growth needed to turn this into a truly robust and competitive industry.

"But there are signs of progress, such as the establishment and continued existence of Russian cryonics provider Kriorus, and more spin-off technology development ventures like 21st Century Medicine. Another group worthy of notice is Stasis Systems Australia:

"Not-for-profit company Stasis Systems Australia is celebrating a key milestone of 10 investors, each paying $50,000 for the privilege of having their body stored when they die. Now the company is looking for a suitable location to build their super-cool facility, possibly in South Australia or New South Wales.

"Co-founder Mark Milton said he had been talking to both SA Health and the NSW Health Department and had received a sympathetic and supportive hearing. More than 250 people have been cryonically preserved around the world, and close to 2000 more have signed contracts with overseas providers, he said."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

TREHALOSE, CALORIE RESTRICTION, AND LONGEVITY IN YEAST
Friday, July 13, 2012
http://www.fightaging.org/archives/2012/07/trehalose-calorie-restriction-and-longevity-in-yeast.php
You might recall that a few years ago, researchers extended life in nematode worms by feeding them trehalose. Here, scientists link normal abundances of trehalose in yeast cells with the longevity induced by calorie restriction: "Our recent investigation of how a lifespan-extending caloric restriction (CR) diet alters the metabolic history of chronologically aging yeast suggested that their longevity is programmed by the level of metabolic capacity - including trehalose biosynthesis and degradation - that yeast cells developed prior to entry into quiescence. To investigate whether trehalose homeostasis in chronologically aging yeast may play a role in longevity extension by CR, in this study we examined how single-gene-deletion mutations affecting trehalose biosynthesis and degradation impact (1) the age-related dynamics of changes in trehalose concentration; (2) yeast chronological lifespan under CR conditions; (3) the chronology of oxidative protein damage, intracellular ROS level and protein aggregation; and (4) the timeline of thermal inactivation of a protein in heat-shocked yeast cells and its subsequent reactivation in yeast returned to low temperature. Our data imply that CR extends yeast chronological lifespan in part by altering a pattern of age-related changes in trehalose concentration. We outline a model for molecular mechanisms underlying the essential role of trehalose in defining yeast longevity by modulating protein folding, misfolding, unfolding, refolding, oxidative damage, solubility, and aggregation throughout lifespan." Trehelose stimulates autophagy in higher animals, the all-important set of mechanisms that recycle damaged cell components, so one would expect it to be beneficial there as well.

MITOCHONDRIAL HAPLOTYPES CORRELATE WITH DEMENTIA RISK
Friday, July 13, 2012
http://www.fightaging.org/archives/2012/07/mitochondrial-haplotypes-correlate-with-dementia-risk.php
Some mitochondrial DNA lineages are objectively better than others, as demonstrated by correlations with longevity in humans. Here is a correlation with dementia risk, which might be superficially explained by a greater ability to power fuel-hungry neurons, or greater resistance to mitochondrial damage over time: "Mitochondrial dysfunction is a prominent hallmark of Alzheimer's disease (AD). Mitochondrial DNA (mtDNA) damage may be a major cause of abnormal reactive oxidative species production in AD or increase neuronal susceptibility to oxidative injury during aging. The purpose of this study was to assess the influence of mtDNA sequence variation on clinically significant cognitive impairment and dementia risk in the population-based Health, Aging, and Body Composition (Health ABC) Study. We first investigated the role of common mtDNA haplogroups and individual variants on dementia risk and 8-year change on the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) among 1,631 participants of European genetic ancestry. Participants were free of dementia at baseline and incidence was determined in 273 cases from hospital and medication records over 10-12 follow-up years. Participants from haplogroup T had a statistically significant increased risk of developing dementia and haplogroup J participants experienced a statistically significant 8-year decline in 3MS, both compared with common haplogroup H. [Other variants were] associated with a significant decline in DSST score [or] 3MS score."

DISCUSSING RAPAMYCIN
Thursday, July 12, 2012
http://www.fightaging.org/archives/2012/07/discussing-rapamycin.php
A piece by author David Stipp gives an overview of the past few years of research into the effects of rapamycin: "The first strong evidence that a drug could slow aging in mammals came out in 2009 when scientists reported that chronically feeding doses of rapamycin to mice significantly extended their average and maximum lifespans. Yet rapamycin, a drug used to help prevent rejection of transplanted organs, causes multiple side effects in people, including elevated triglycerides and cholesterol, increasing the risk of heart disease; moderate immune suppression, perhaps increasing infection risks; and low blood platelet levels, which raises the specter of dangerous bleeding. In recent years another especially surprising and troubling side effect has come to the fore: Chronically taking large doses of rapamycin induces 'insulin insensitivity' in both rodents and humans, leading to rising blood sugar and potentially to type 2 diabetes. How do we reconcile such adverse effects with the drug's unprecedented ability to boost healthy aging and longevity, at least in mice? Some telling insights on this burning issue were recently published in two reports on rapamycin's effect on insulin and blood sugar: a mouse study that revealed a probable mechanism behind the effect and a theory paper suggesting that the purported diabetes risk has been overblown."

PGC-1ALPHA VERSUS HUNTINGTON'S DISEASE
Thursday, July 12, 2012
http://www.fightaging.org/archives/2012/07/pgc-1alpha-versus-huntingtons-disease.php
Via ScienceDaily: researchers "have identified two key regulatory proteins critical to clearing away misfolded proteins that accumulate and cause the progressive, deadly neurodegeneration of Huntington's disease (HD). ... It's a lead we can vigorously pursue, not just for Huntington's disease, but also for similar neurodegenerative conditions like Parkinson's disease and maybe even Alzheimer's disease. ... In HD, an inherited mutation in the huntingtin (htt) gene results in misfolded htt proteins accumulating in certain central nervous system cells. ... [Researchers] focused on a protein called PGC-1alpha, which helps regulate the creation and operation of mitochondria, the tiny organelles that generate the fuel required for every cell to function. ... It's all about energy. Neurons have a constant, high demand for it. They're always on the edge for maintaining adequate levels of energy production. PGC-1alpha regulates the function of transcription factors that promote the creation of mitochondria and allow them to run at full capacity. ... the mutant form of the htt gene interfered with normal levels and functioning of PGC-1alpha, [and] elevated levels of PGC-1alpha in a mouse model of HD virtually eliminated the problematic misfolded proteins. ... PGC-1alpha influenced expression of another protein vital to autophagy - the process in which healthy cells degrade and recycle old, unneeded or dangerous parts and products, including oxidative, damaging molecules generated by metabolism. For neurons, which must last a lifetime, the self-renewal is essential to survival. ... Mitochondria get beat up and need to be recycled. PGC-1alpha drives this pathway through another protein called transcription factor EB or TFEB. ... If you can induce the bioenergetics and protein quality control pathways of nervous system cells to function properly, by activating the PGC-1alpha pathway and promoting greater TFEB function, you stand a good chance of maintaining neural function for an extended period of time."

ALZHEIMER'S DISEASE CONSIDERED AS SYNAPTIC IMBALANCE
Wednesday, July 11, 2012
http://www.fightaging.org/archives/2012/07/alzheimers-disease-considered-as-synaptic-imbalance.php
From Maria Konovalenko: "I met Dr. Bredesen during the Buck Advisory Council meeting at the Buck Institute for Research on Aging in Novato, California on May 21. [The] Advisory Council consists of influential individuals who can contribute to Buck Institute's mission of advancing aging research. A very interesting crowd. ... Dale Bredesen opened the mini conference with his report on Alzheimer's research. The majority of scientists envision this horrible degenerative process as accumulation of toxic molecules, namely amyloid beta and tau proteins. Amyloid beta forms plaques between the cells and tau protein tangles inside the cells. These toxic proteins disrupt the functions of our neurons. ... So, Dr. Bredesen views Alzheimer's disease differently - as an imbalance between synaptic maintenance and synaptic reorganization. The thing is that for our brain to function properly we need to form connections between our neurons, and also we need to break down those connections that we no longer need. According to Dale Bredesen, this balance disrupts, it shifts towards synaptic reorganization, we loose our memory, face the horrors of loosing our consciousness and eventually we die. ... So how can we preserve this balance? Dr. Bredesen's lab studies the underlying mechanisms of neurodegeneration. There were able to find out that one of the things that contributes to the balance shift is the change in APP cleavage. APP is amyloid precursor protein. It is concentrated in synapses of our neurons. APP can break down into either two, or four parts. When it breaks down into 2 parts those proteins are sAPP alfa and CTF alfa. This is a 'good' combination. However, during aging amyloid precursor protein cleavage shifts towards the 'bad' combination, which is sAPP beta, Amyloid beta, Jcasp and C31. This is the shift in balance that leads to the onset of disease. The shift can be restored. The mouse strain that has one mutation that leads to not having APP to break down to Jcasp and C31 proteins leads to restoring memory in mice. But the most exciting thing is that Dr. Bredesen is testing a drug that shifts the APP cleavage balance back to normal."

INVESTIGATING THE MECHANISMS OF RHEUMATOID ARTHRITIS
Wednesday, July 11, 2012
http://www.fightaging.org/archives/2012/07/investigating-the-mechanisms-of-rheumatoid-arthritis.php
Researchers examine possible molecular mechanisms for rheumatoid arthritis in a paper published earlier in the year: "Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory and destructive joint disorder that affects tens of millions of people worldwide. Normal healthy joints maintain a balance between the synthesis of extracellular matrix (ECM) molecules and the proteolytic degradation of damaged ones. In the case of RA, this balance is shifted toward matrix destruction due to increased production of cleavage enzymes and the presence of (autoimmune) immunoglobulins resulting from an inflammation induced immune response. Herein we demonstrate that a polyclonal antibody against the proteoglycan biglycan (BG) causes tissue destruction that may be analogous to that of RA affected tissues. The effect of the antibody is more potent than harsh chemical and/or enzymatic treatments designed to mimic arthritis-like fibril de-polymerization. ... The specific antigen that causes the RA immune response has not yet been identified, although possible candidates have been proposed, including collagen types I and II, and proteoglycans (PG's) such as biglycan. We speculate that the initiation of RA associated tissue destruction in vivo may involve a similar non-enzymatic decomposition of collagen fibrils via the immunoglobulins themselves that we observe here ex vivo."

INVESTIGATING PRECURSOR OGLIOMERS IN ALZHEIMER'S DISEASE
Tuesday, July 10, 2012
http://www.fightaging.org/archives/2012/07/investigating-precursor-ogliomers-in-alzheimers-disease.php
The focus of research on Alzheimer's disease begins to shift away from amyloid plaques: "Cell death in the brain causes one to grow forgetful, confused and, eventually, catatonic. Recently approved drugs provide mild relief for symptoms but there is no consensus on the underlying mechanism of the disease. ... We don't know what the problem is in terms of toxicity. This makes the disease difficult to cure. ... Accumulations of amyloid plaques have long been associated with the disease and were presumed to be its cause. These long knotty fibrils, formed from misfolded protein fragments, are almost always found in the brains of diseased patients. Because of their ubiquity, amyloid fibrils were considered a potential source of the toxicity that causes cell death in the brain. However, the quantity of fibrils does not correspond with the degree of dementia and other symptoms. New findings support a hypothesis that fibrils are a by-product of the disease rather than the toxic agent itself. This paradigm shift changes the focus of inquiry to smaller, intermediate molecules that form and dissipate quickly. These molecules are difficult to perceive in brain tissue. ... For decades, it was believed that fibrils were a toxic species, but increasingly researchers are looking at small, soluble precursor forms of the fibrils, known as oligomers. ... These oligomers may be toxic by inserting themselves into membranes and causing a damage to the membrane. The membrane is critical for the cell viability."

AN EPIGENETIC CONTRIBUTION TO OSTEOARTHRITIS
Tuesday, July 10, 2012
http://www.fightaging.org/archives/2012/07/an-epigenetic-contribution-to-osteoarthritis.php
An example of the study of epigenetics starting to deliver targets for therapy: "scientists used human tissue samples to discover that those with osteoarthritis have a signature epigenetic change (DNA methylation) responsible for switching on and off a gene that produces a destructive enzyme called MMP13. This enzyme is known to play a role in the destruction of joint cartilage, making MMP13 and the epigenetic changes that lead to its increased levels, prime targets for osteoarthritis drug development. ... To make the discovery, [researchers] compared the extent to which DNA methylation was different in cartilage from patients suffering from osteoarthritis and healthy people of similar age. They found that at one small position, the gene for MMP13 had less DNA methylation in diseased patients. Then they confirmed that reduced methylation of this gene increases levels of the destructive enzyme MMP13. ... We've already seen how epigenetics has advanced our approach to cancer. Now we're seeing it with other diseases ... This study not only lays the groundwork for a new understanding of osteoarthritis, but also shows that the old 'either/or' nature v. nurture argument is outdated: epigenetics teaches us that nature (the daily wear and tear of joints) regulates nurture (the genes in our cartilage) to cause arthritis."

EXERCISE BENEFICIAL IN ELDERLY
Monday, July 9, 2012
http://www.fightaging.org/archives/2012/07/exercise-beneficial-in-elderly.php
Here is yet another study showing that exercise in the elderly produces benefits large enough to power a massive drug industry were they caused by a pill - yet most people fail to take advantage of the free advantages bestowed by regular exercise: "Aging and physical inactivity are 2 factors that favour the development of cardiovascular disease, metabolic syndrome, obesity, and diabetes. In contrast, adopting a habitual moderate exercise routine may be a nonpharmacological treatment alternative for neuroendocrine aging disorders. We aimed to assess the effects of moderate exercise training on the metabolic profiles of elderly people with sedentary lifestyles. Fourteen sedentary, healthy, elderly male volunteers participated in a moderate training regimen for 60 min/day, 3 days/week for 24 weeks at a work rate equivalent to their ventilatory aerobic threshold. ... Blood samples for analysis were collected at 3 intervals: at baseline (1 week before training began), and 3 and 6 months after training. The training promoted increased aerobic capacity (relative VO2, and time and velocity to VO2max) and reduced serum α-MSH after 3 months of training when compared with the baseline data. In addition, serum thyroid hormone (T3 and T4) was reduced after 6 months of training compared with baseline levels. Our results demonstrate that a moderate exercise training protocol improves the metabolic profile of older people, and metabolic adaptation is dependent on time." You will recall that lower thyroid hormone levels are associated with longevity in humans.

NO DIFFERENCE IN REPROGRAMMED CELLS FROM OLD AND YOUNG MICE
Monday, July 9, 2012
http://www.fightaging.org/archives/2012/07/no-difference-in-reprogrammed-cells-from-old-and-young-mice.php
In the last couple of years there have been promising indicators to suggest that age is no barrier to producing useful cells for therapy from a patient. Here is another: "Advanced age is associated with decreased stem cell activity. However, the effect of aging on the differentiation capacity of induced pluripotent stem (iPS) cells into cardiovascular cells has not been fully clarified. We investigated whether iPS cells derived from young and old mice are equally capable of differentiating into vascular progenitor cells, and whether these cells regulate vascular responses in vivo. iPS cells from mouse embryonic fibroblasts (young) or 21 month-old mouse bone marrow (old) were used. Fetal liver kinase-1 positive (Flk-1+) cells, as a vascular progenitor marker, were induced after 3 to 4 days of culture from iPS cells derived from young and old mice. ... purified Flk-1+ cells were directly injected into ischemic hindlimbs of nude mice. Revascularization of the ischemic hindlimb was significantly accelerated in mice transplanted with Flk-1+ cells derived from iPS cells from either young or old mice, as compared to control mice ... The degree of revascularization was similar in the two groups of ischemic mice injected with iPS cell-derived Flk-1+ cells from young or old mice. [The] properties of iPS cells derived from old mice are essentially the same as those of iPS cells from young mice, suggesting the functionality of generated iPS cells themselves to be unaffected by aging." It should be noted that while old cells seem to work just as well, the aged environment of the patient's body does present an obstacle to the benefits of cell therapies.

______________________________


<br> <br>View the full article

#18 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 22 July 2012 - 09:52 PM

FIGHT AGING! NEWSLETTER
July 23rd 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- More Press for the 2045 Initiative
- Video From the Genetics of Aging and Longevity Conference
- Does Anyone Really Care About Living Longer?
- Discussion
- Latest Headlines from Fight Aging!
    - Adding More Data to the Role of Nuclear DNA Damage in Aging
    - Possible Early Antibody Therapy for Alzheimer's Disease
    - Rapamycin Versus Macular Degeneration
    - Testing Blanket Blood Pressure Medication in Older People
    - Nanoscale Scaffolds and Stem Cells for Cartilage Repair
    - Linking Oxidative Stress With Age-Related Immune Decline
    - Alcor Donates to Brain Preservation Prize, is Declined
    - A Profile of Kenneth Hayworth, Brain Preservation Prize Founder
    - An Example of an Early Targeted Cancer Therapy
    - Progress in Building Muscle Tissue For Transplant

MORE PRESS FOR THE 2045 INITIATIVE

You'll no doubt recall the 2045 initiative backed by an enthusiastic high net worth Russian individual, which appears so far to be the opening stages of a serious long-term effort to convert a fraction of that net worth into the technologies needed for artificial, non-biological bodies capable of indefinitely supporting a human brain - and after that to move on to brain emulation and mind uploading:

http://www.fightaging.org/archives/2012/07/more-press-for-the-2045-initiative.php

"To my eyes, the most interesting aspect of this Russia 2045 initiative is that, unlike any other serious proposal I'm aware of, their focus is on getting out of biology and into machine bodies as rapidly as possible. ... In essence, this is a course to throw away as much of the body as possible as soon as possible - a path based on a different set of preconceptions about difficulty and efficiency on the road leading to an artificial brain hosting a once-biological human mind.

"First up is the development of robots that can be controlled by the human mind. After that, and ideally within 10 years, Itskov wants to develop robots that can actually host a flesh-and-blood human brain, via surgical transplant. In twenty years time, things get even more interesting: Itskov anticipates 'uploading' the contents of the human brain into a robot, yielding eternal life via artificial body. By 2045, he'd like to replace those 'bots entirely - with holograms. Since February, Itskov has stayed plenty busy working on his 'Avatar' plan ... With a lab of scientists reportedly already working on the program in Russia, Itskov has now branched out to the U.S, with plans to open a San Francisco office this summer and host a futurity conference - called Global Future Congress - in New York later this year.

"His next step: Itskov has published an open letter to the world's richest people, urging them to back the initiative - and consider volunteering themselves as potential avatars. 'I urge you to take note of the vital importance of funding scientific development in the field of cybernetic immortality and the artificial body. Such research has the potential to free you, as well as the majority of all people on our planet, from disease, old age and even death.'

"I'm of the opinion that this is not the most optimal path towards the defeat of aging, based on my understanding of the relative difficulty of building a full-featured neural interface and life support system for the brain versus realizing rejuvenation biotechnology that can repair the biological chassis we have now - even leaving aside the issue that an uploaded or emulated copy of your mind is just a copy of you, not you. In the long run we will all be wholly artificial, of course, but it seems premature to be aiming for that now versus after the advent of molecular nanotechnology and the capacity to build functional replacements for biological components (e.g. blood cells, brain cells, and so forth) that are better than the original. It is, however, very important for the general future of engineered longevity to have a diversity of approaches, disagreement, and enthusiastic people with resources and vision. At the very least, in a world in which artificial bodies are being developed with the stated goal of preventing people from aging to death, it becomes that much easier to gather support for work on the biotechnologies that can repair the damage of aging."

VIDEO FROM THE GENETICS OF AGING AND LONGEVITY CONFERENCE

The Science for Life Extension Foundation helped organize the 2nd International conference on the Genetics of Aging and Longevity, held back in April in Moscow. Thanks to the Foundation staff, video from the conference is starting to make its way to a YouTube channel:

http://www.fightaging.org/archives/2012/07/video-from-the-genetics-of-aging-and-longevity-conference.php

DOES ANYONE REALLY CARE ABOUT LIVING LONGER?

If you want to judge by actions rather than words, the answer might be quite close to "no":

http://www.fightaging.org/archives/2012/07/does-anyone-really-care-about-living-longer.php

"Regular exercise can extend life, but 90% of humanity would rather die than submit to a daily workout. ... Last week, an international conference in Brazil heard from scientist Professor Frank Booth, who gave a talk about how the lack of physical activity can be shown to significantly reduce lifespan. The current USA guidelines for physical activity are 30 minutes a day for somebody over 20 years old, but he reported that over 90% of people do not do this amount and are shortening their life as a result.

"Human psychology is hardwired to discount future rewards, a thing called time preference. The future reward that is an increased chance of being alive in sixty years tends to have a lower value for most people than, say, substituting a video game or nap for exercise right now. Sad but true. So there is more gaming, less exercise, and shorter lives on balance. Time preference is pretty good in the environment in which we evolved, but becomes increasingly less helpful the more civilized and technologically enabled that environment becomes.

"So equally, if low-cost life-extending therapies existed - along the lines of the rejuvenation biotechnologies proposed by the SENS Foundation - and not using them was viewed as something akin to failing to brush your teeth, then many of the same people who skip exercise would make the effort to head to the clinic every few years and thereby live longer. Social pressure also enters into value judgments, a cost to be measured alongside others. It is entirely possible that people of future years will be using longevity medicine for reasons that have little to do with their own longevity; after all, they will still be operating with the same time preference as we do. Being alive sixty years in the future has a small value for the average human being.

"This is one of the reasons why so very many people make themselves more sick than they have to be, and die younger than they might have. They didn't take care of themselves, despite knowing that they could do a better job. Separately, but a part of the same pattern of psychology, today there exists the realistic prospect of building actual, working means of rejuvenating the old. The path to achieving that end is just about as clear, straightforward, and well defined as medical research can ever be. We know what needs to be fixed, and there are numerous proposals for ways to fix it. But the public at large is not yet rallying to this cause.

"A cynic might say that they never will, and cite human nature as outlined above. Fortunately, it isn't necessary to persuade everyone. Even a sizable minority will be enough. We can point to successful minority support for research and development in many age-related diseases, for example - large research communities work on the common conditions of aging, despite that fact that everything said about aging and the value of life in the future applies there. There are ways around the basic problem of time preference as it applies to raising support for the medicine of human longevity. We just have to keep working away at it, just like the pioneers who built successful research communities for cancer, heart disease, dementia, and many other conditions that plague the old."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

ADDING MORE DATA TO THE ROLE OF NUCLEAR DNA DAMAGE IN AGING
Friday, July 20, 2012
http://www.fightaging.org/archives/2012/07/adding-more-data-to-the-role-of-nuclear-dna-damage-in-aging.php
We accumulate random nuclear DNA damage - mutations - as we age. This is understood to increase the risk of cancer, as the more mutations that occur the greater the chance that one will be of the rare type that can spawn a cancer, but there is some debate over the degree to which nuclear DNA damage contributes to aging itself. Here researchers add some more data to the picture: "Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows. [Researchers] have found that even in healthy people, stem cells in the blood routinely accumulate new mutations over the course of a person's lifetime. And their research shows that in many cases only two or three additional genetic changes are required to transform a normal blood cell already dotted with mutations into acute myeloid leukemia (AML). ... The study is the first to investigate how often mutations typically develop in healthy stem cells in the blood. ... In recent years, [researchers] have sequenced the genomes of 200 patients with AML to try to understand the mutations at the root of the disease. Without fail, each patient's leukemia cells held hundreds of mutations, posing a conundrum for scientists, who have long believed that all the mutations in a cancer cell are likely to be important for the disease to progress. ... But we knew all of these mutations couldn't be important. It didn't make any sense to us that so many mutations were present in all the cells in the tumor. ... Every person has about 10,000 blood stem cells in their bone marrow, and the researchers found that each stem cell acquires about 10 mutations over the course of a year. By age 50, a person has accumulated nearly 500 mutations in every blood stem cell. ... Mutations are known to develop in cells as we age, but no one had any idea how many mutations occur in blood stem cells and how frequently they develop. These random, background mutations occur during cell division and are unrelated to cancer. Our DNA can tolerate a huge number of these hits without any negative consequences. But if a cancer-initiating event occurs in one of these stem cells, it captures the genetic history of that cell, including the earlier mutations, and drives leukemia to develop. ... scientists were surprised to see that the total number of mutations varied by age, not by whether a patient had leukemia. Thus, a healthy person in his 40s had just about the same number of mutations in his blood stem cells as a leukemia patient of the same age had in his cancer cells."

POSSIBLE EARLY ANTIBODY THERAPY FOR ALZHEIMER'S DISEASE
Friday, July 20, 2012
http://www.fightaging.org/archives/2012/07/possible-early-antibody-therapy-for-alzheimers-disease.php
From the MIT Technology Review: "Alzheimer's patients given a drug that is already used to treat immune disorders saw their condition stabilize in a small study presented at a conference this week. Study participants were given the compound - known as intravenous Ig, or IVIg - for three years. During this period, they showed no signs of further cognitive decline or memory loss. ... All participants in the study had mild to moderate Alzheimer's disease. Only four received the optimal dose of IVIg over three years. These patients showed no decline from their baseline state in cognition, memory, daily functioning, or mood - all expected effects of the disease. Patients who initially received a placebo but were later switched to IVIg treatment declined more slowly while receiving the drug. IVIg [contains] a mixture of antibodies isolated from the pooled plasma of blood donated by healthy people. The assumption is that this blood by-product contains antibodies from the healthy donors that attack the damaged proteins in Alzheimer's patients. ... such results [should] inspire a large number of scientific studies aimed at identifying the functional ingredients in the immune mixture, so that others could potentially develop a synthetic form. ... I really do hope that it turns out to work, because then it gives a good platform to start finding out what components are in there, What is it in the IVIg - is it selective antibodies against beta-amyloid, against tau, or something else?"

RAPAMYCIN VERSUS MACULAR DEGENERATION
Thursday, July 19, 2012
http://www.fightaging.org/archives/2012/07/rapamycin-versus-macular-degeneration.php
A commentary on testing rapamycin as a therapy for age-related macular degeneration (AMD): "Although neovascular AMD only accounts for less than 15% of the overall age-related macular degeneration, it is responsible for over 80 percent of the severe vision loss cases. ... It was reported in 2004 that rapamycin (trade name sirolimus) treatment significantly reduced the extent of neovascularization [induced] in adult mice ... In an advance online publication this year [Kolosova et al] presented exciting results that rapamycin could actually prevent AMD-like retinopathy in an aging rat model that more closely resembles human AMD pathology. They investigated the effect of rapamycin on spontaneous retinopathy in senescence- accelerated OXYS rats. OXYS rats were treated orally with either 0.1 or 0.5 mg/kg rapamycin, which was given together with food. Rapamycin was found in a dose-dependent manner to reduce the incidence and severity of retinopathy, and attenuated AMD disease progression. Some histological abnormalities associated with retinopathy were notably reduced ... significantly, rapamycin prevented destruction of ganglionar neurons in the retina. Rapamycin did not exert any adverse effects on the retina in control disease-free Wistar rats, suggesting that it is safe."

TESTING BLANKET BLOOD PRESSURE MEDICATION IN OLDER PEOPLE
Thursday, July 19, 2012
http://www.fightaging.org/archives/2012/07/testing-blanket-blood-pressure-medication-in-older-people.php
What happens if everyone in later years regularly takes common blood pressure and cholesterol medications, even if healthy? Researchers have been running trials: "Results of a randomised trial [show] that a four-component Polypill given to people aged 50 and over to reduce their risk of heart attack and stroke, the most common causes of death worldwide, achieved large reductions in blood cholesterol and blood pressure, the main causes of these two diseases. ... The results observed in the trials had been accurately predicted in an earlier paper [before] any Polypill had been made. The Polypill, a tri-layered tablet, contains three blood pressure lowering medicines and a statin for lowering cholesterol. This was given to people without a history of cardiovascular disease aged 50 or more. They experienced a 12 percent reduction in blood pressure and a 39 percent reduction in LDL cholesterol (the 'harmful' cholesterol), achieving levels typical of people aged 20 years. ... The health implications of our results are large. If people took the Polypill from age 50, an estimated 28 percent would benefit by avoiding or delaying a heart attack or stroke during their lifetime; on average, those who benefit would gain 11 years of life without a heart attack or stroke. ... This is the first trial in people selected on the basis of age alone without the need for a medical examination or tests - setting the scene for the prevention of first heart attacks and strokes in the general population without requiring a medical examination or special tests. ... Our trial shows that the predicted effects of the Polypill can be achieved in practice. The expected impact on preventing what is now the world's leading cause of death is large - about a two-thirds reduction in heart attacks and strokes."

NANOSCALE SCAFFOLDS AND STEM CELLS FOR CARTILAGE REPAIR
Wednesday, July 18, 2012
http://www.fightaging.org/archives/2012/07/nanoscale-scaffolds-and-stem-cells-for-cartilage-repair.php
Via EurekAlert!: "tissue engineers have used tiny, artificial fiber scaffolds thousands of times smaller than a human hair to help coax stem cells into developing into cartilage, the shock-absorbing lining of elbows and knees that often wears thin from injury or age. ... Rather than just patching the problem with short-term fixes, like surgical procedures such as microfracture, we're building a temporary template that mimics the cartilage cell's natural environment, and taking advantage of nature's signals to biologically repair cartilage damage. ... Unlike skin, cartilage can't repair itself when damaged. For the last decade, [researchers have] been trying to better understand the development and growth of cartilage cells called chondrocytes, while also trying to build scaffolding that mimics the cartilage cell environment and generates new cartilage tissue. This environment is a 3-dimensional mix of protein fibers and gel that provides support to connective tissue throughout the body, as well as physical and biological cues for cells to grow and differentiate. In the laboratory, the researchers created a nanofiber-based network using a process called electrospinning, which entails shooting a polymer stream onto a charged platform, and added chondroitin sulfate [to] serve as a growth trigger. After characterizing the fibers, they made a number of different scaffolds from either spun polymer or spun polymer plus chondroitin. They then used goat bone marrow-derived stem cells (a widely used model) and seeded them in various scaffolds to see how stem cells responded to the material. ... compared to cells growing without scaffold, these cells developed into more voluminous, cartilage-like tissue. ... The investigators then tested their system in an animal model. They implanted the nanofiber scaffolds into damaged cartilage in the knees of rats, and compared the results to damaged cartilage in knees left alone. They found that the use of the nanofiber scaffolds improved tissue development and repair as measured by the production of collagen, a component of cartilage. The nanofiber scaffolds resulted in greater production of a more durable type of collagen, which is usually lacking in surgically repaired cartilage tissue."

LINKING OXIDATIVE STRESS WITH AGE-RELATED IMMUNE DECLINE
Wednesday, July 18, 2012
http://www.fightaging.org/archives/2012/07/linking-oxidative-stress-with-age-related-immune-decline.php
Mitochondrial damage is one of the reasons that levels of damaging oxidative compounds rise in the body with age - known as oxidative stress. At the level of molecular machinery, having reactive molecules flying around in large numbers will cause important mechanisms to break down more often. It is generally thought that increased oxidative stress contributes to a range of dysfunctions, and here researchers link it with immune system decline: "Aging is known to affect immune function, a phenomenon known as immunosenescence ... Our study has uncovered several ways in which aging can worsen the body's overall ability to mount an effective immune response. ... All cells generate chemicals called free radicals as a normal part of metabolism. These highly reactive, unstable molecules can readily damage proteins, lipids and other cellular components ... Cells keep 'oxidative stress' in check by producing several enzymes that are scavengers of free radicals. But in aging, increased production of free radicals coupled with cells' decreased production of antioxidant enzymes cause a buildup of damaged proteins and other molecules that can be toxic to cells. The current study is the first to examine whether age-related oxidative stress compromises the function of a type of immune cell called dendritic cells. ... When you are exposed to viruses or bacteria, these cells engulf the pathogens and present them to the immune system ... [Researchers] isolated dendritic cells from aging mice and found that oxidation-damaged proteins had accumulated in those cells and had caused harmful effects. For example, oxidatively modified proteins hampered the function of endosomes, the cell's organelle where pathogens are inactivated. When the mice were injected with a potent antioxidant in the abdominal cavity daily for two weeks, some of the effects of oxidative stress were reversed. This finding has implications for designing vaccines or therapies for humans, especially the elderly, whose weakened immune systems increase their susceptibility to infections and cancer, and reduces vaccine effectiveness. ... Many elderly people respond very poorly to vaccination, so perhaps a cycle of therapy with antioxidants before vaccination might improve their immune response to vaccines."

ALCOR DONATES TO BRAIN PRESERVATION PRIZE, IS DECLINED
Tuesday, July 17, 2012
http://www.fightaging.org/archives/2012/07/alcor-donates-to-brain-preservation-prize-is-declined.php
These things happen: "How well does cryopreservation (with current methods) work? Is the process sufficiently preserving personal identity-critical information stored in the brain? Are there any alternatives that might be as good or better? Although the Alcor Library already contains evidence that, under good conditions, we are preserving neural connections (the totality of which is now sometimes being referred to as the 'connectome'), more evidence is desirable. The Brain Preservation Foundation is offering a $100,000+ Brain Preservation Technology Prize in order to stimulate the scientific evaluation of such technologies as cryopreservation and chemopreservation (aldehyde or other chemical fixation followed by embedding in solid resin). The goal of the prize is to lead to 'the development of an inexpensive and reliable hospital surgical procedure which verifiably preserves the structural connectivity of 99.9% of the synapses in a human brain if administered rapidly after biological death.' ... A few days ago, Alcor announced that it would contribute $10,000 to the Brain Preservation Foundation toward the costs of testing both cryopreservation and chemopreservation. The Foundation has declined our donation because of concerns that it might be perceived as influencing the judges' decisions. Even though Alcor was not a competitor for the prize, we can understand the Foundation's concern. We will instead look for other ways to validate existing cryopreservation methods, as well as continue to improve them."

A PROFILE OF KENNETH HAYWORTH, BRAIN PRESERVATION PRIZE FOUNDER
Tuesday, July 17, 2012
http://www.fightaging.org/archives/2012/07/a-profile-of-kenneth-hayworth-brain-preservation-prize-founder.php
From the Chronicle of Higher Education: "By 2110, Hayworth predicts, mind uploading - the transfer of a biological brain to a silicon-based operating system - will be as common as laser eye surgery is today. ... While a graduate student at the University of Southern California, he built a machine in his garage that changed the way brain tissue is cut and imaged in electron microscopes. The combination of technical smarts and entrepreneurial gumption earned him a grant from the McKnight Endowment Fund for Neuroscience, a subsidiary of the McKnight Foundation, and an invitation to Harvard, where he stayed, on a postdoctoral fellowship, until April. To understand why Hayworth wants to plastinate his own brain you have to understand his field - connectomics, a new branch of neuroscience. A connectome is a complete map of a brain's neural circuitry. ... He looks at the growth of connectomics - especially advances in brain preservation, tissue imaging, and computer simulations of neural networks - and sees something else: a cure for death. In a new paper in the International Journal of Machine Consciousness, he argues that mind uploading is an 'enormous engineering challenge' but one that can be accomplished without 'radically new science and technologies.' ... to Hayworth, science is about overturning expectations: 'If 100 years ago someone said that we'd have satellites in orbit and little boxes on our desks that can communicate across the world, they would have sounded very outlandish.' One hundred years from now, he believes, our descendants will not understand how so many of us failed for so long to embrace immortality. In an unpublished essay, 'Killed by Bad Philosophy,' he writes, 'Our grandchildren will say that we died not because of heart disease, cancer, or stroke, but instead that we died pathetically out of ignorance and superstition' - by which he means the belief that there is something fundamentally unknowable about consciousness, and that therefore it can never be replicated on a computer."

AN EXAMPLE OF AN EARLY TARGETED CANCER THERAPY
Monday, July 16, 2012
http://www.fightaging.org/archives/2012/07/an-example-of-an-early-targeted-cancer-therapy.php
One of the ways in which new means of targeting therapies to specific cells in the body - such as cancer cells - will arrive in the clinic more rapidly is for their developers to use existing approved drugs. That isn't necessarily the way to build objectively better therapies, but it will cost far less to run the regulatory gauntlet: "researchers have developed a novel system to simultaneously deliver a sustained dose of both an immune-system booster and a chemical to counter the cancer's secretions, resulting in a powerful therapy that, in mice, delayed tumor growth, sent tumors into remission and dramatically increased survival rates. The new immunotherapy incorporates well-studied drugs, but delivers them using nanolipogels (NLGs), a new drug transport technology the researchers designed. The NLGs are nanoscale, hollow, biodegradable spheres, each one capable of accommodating large quantities of chemically diverse molecules. The spheres appear to accumulate in the leaky vasculature, or blood vessels, of tumors, releasing their cargo in a controlled, sustained fashion as the spherule walls and scaffolding break down in the bloodstream. For the recent experiments, the NLGs contained two components: an inhibitor drug that counters a particularly potent cancer defense called transforming growth factor-β (TGF-β), and interleukin-2 (IL-2), a protein that rallies immune systems to respond to localized threats. ... The current study targeted both primary melanomas and melanomas that have spread to the lung, demonstrating promising results with a cancer that is well-suited to immunotherapy and for which radiation, chemotherapy and surgery tend to prove unsuccessful, particularly when metastatic." It's worth remembering that the medicine presently available in the clinic is not really available because it is better for patients, but rather because it is better at getting past regulatory hurdles - these two properties sometimes overlap, but are not the same at all.

PROGRESS IN BUILDING MUSCLE TISSUE FOR TRANSPLANT
Monday, July 16, 2012
http://www.fightaging.org/archives/2012/07/progress-in-building-muscle-tissue-for-transplant.php
Researchers are making progress towards building useful muscle tissue from scratch, suitable for transplant: "exercise is a key step in building a muscle-like implant in the lab with the potential to repair muscle damage from injury or disease. In mice, these implants successfully prompt the regeneration and repair of damaged or lost muscle tissue, resulting in significant functional improvement. ... For the study, small samples of muscle tissue from rats and mice were processed to extract cells, which were then multiplied in the lab. The cells, at a rate of 1 million per square centimeter, were placed onto strips of a natural biological material. The material, derived from pig bladder with all cells removed, is known to be compatible with the body. Next, the strips were placed in a computer-controlled device that slowly expands and contracts - essentially 'educating' the implants on how to perform in the body. ... The next step was implanting the strips in mice with about half of a large muscle in the back (latissimus dorsi) removed to create functional impairment. While the strips are 'muscle-like' at the time of implantation, they are not yet functional. Implantation in the body [prompts] further development. ... The scientists compared four groups of mice. One group received no surgical repair. The other groups received implants prepared in one of three ways: one was not exercised before implantation, one was exercised for five to seven days, and one had extra cells added midway through the exercise process. The results showed that exercising the implants made a significant difference in both muscle development and function. ... The implant that wasn't exercised, or pre-conditioned, was able to accelerate the repair process, but recovery then stopped. On the other hand, when you exercise the implant, there is a more prolonged and extensive functional recovery. Through exercising the implant, you can increase both the rate and the magnitude of the recovery."

______________________________


<br> <br>View the full article

#19 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 29 July 2012 - 08:38 PM

FIGHT AGING! NEWSLETTER
July 30th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- An Interview With David Gobel, Methuselah Foundation CEO
- Pharmaceutical Innovation and Longevity Gains
- Biochemistry (Moscow)'s Programmed Aging Issue
- Discussion
- Latest Headlines from Fight Aging!
    - A Single-Issue Political Party for Longevity Science
    - FDA Reaches to Regulate (i.e. Block) Simple Stem Cell Therapies
    - A Review of Skeletal Muscle Mitochondria in Aging
    - Towards Functional Blood Vessels Grown From Fat Cells
    - A Review: Physical Activity Increases Life Expectancy
    - Regenerating Bone With Scaffolds and Gene     - Assessing mTOR Signaling in Human Aging
    - Modifying Old Heart Stem Cells to Boost Regenerative Capacity
    - Enhanced Energy Metabolism Contributes to Extended Lifespan Through Calorie Restriction
    - Identifying Genetic Changes that Reduce Stem Cell Aging

AN INTERVIEW WITH DAVID GOBEL, METHUSELAH FOUNDATION CEO

David Gobel here discusses some of the aims of the Methuselah Foundation's New Organ initiative:

http://www.fightaging.org/archives/2012/07/an-interview-with-david-gobel-methuselah-foundation-ceo-1.php

"By promoting extension of the statistical healthy lifespan, Methuselah has been a major influence on the public and scientific community's perception of the acceptability and value of increasing the maximum human lifespan and health-span. Starting in 2003 via the Methuselah Mouse Prize (four winners to date) and the tireless work of Methuselah volunteers - notably, Dr. Aubrey de Grey - the concept of engineering the delay of the human 'expiration date' went from a ridiculous sci-fi fantasy to a non-controversial goal that serious scientists can now pursue without destroying their careers. The only controversy today is not if it will happen, but how soon it will happen.

"On the second point of personal longevity, Methuselah has initiated a New Organ Prize that will incent the creation of something blindingly obviously needed. New parts for people. If a car can run perfectly well as if it had just come off the assembly line 110 years after being built because of replacement parts, why should humans be second class citizens to cars? Why should the 30,000 people who need new hearts at any given time be stuck with death as the likely outcome when your old corvair can easily get a rebuilt fuel pump? It is completely ridiculous, and we intend to do all we can to end the horror of the 'Dialysis Matrix,' for those needing kidneys currently suffer year after year in silence. So, New Parts For People is our current focus, because no one dies statistically - we die one unique and irreplaceable person at a time. Often because we just need a new part."

PHARMACEUTICAL INNOVATION AND LONGEVITY GAINS

One researcher has been crunching numbers for the past decade or so to illustrate the correlation between measures of the pace of progress in medicine and the pace of increasing human longevity:

http://www.fightaging.org/archives/2012/07/papers-on-pharmaceutical-innovation-and-longevity-gains.php

"We examine the impact of pharmaceutical innovation, as measured by the vintage of prescription drugs used, on longevity, using longitudinal, country-level data on 30 developing and high-income countries during the period 2000-2009. We control for fixed country and year effects, real per capita income, the unemployment rate, mean years of schooling, the urbanization rate, real per capita health expenditure (public and private), the DPT immunization rate, HIV prevalence and tuberculosis incidence.

"Life expectancy at all ages and survival rates above age 25 increased faster in countries with larger increases in drug vintage. The increase in drug vintage was the only variable that was significantly related to all of these measures of longevity growth. ... Pharmaceutical innovation is estimated to have accounted for almost three-fourths of the 1.74-year increase in life expectancy at birth in the 30 countries in our sample between 2000 and 2009, and for about one third of the 9.1-year difference in life expectancy at birth in 2009 between the top 5 countries (ranked by drug vintage in 2009) and the bottom 5 countries (ranked by the same criterion)."

BIOCHEMISTRY (MOSCOW)'S PROGRAMMED AGING ISSUE

The Biochemistry (Moscow) journal has provided open access to the English-language version of its latest issue on programmed aging:

http://www.fightaging.org/archives/2012/07/biochemistry-moscows-issue-on-programmed-aging.php

"Some debate continues within the scientific community over the degree to which aging is programmed, which aspects of aging are programmed, and whether it is fair to call the body's characteristic responses to accumulated stochastic damage a form of programmed aging. Patterns of gene expression clearly change in fairly defined ways with aging, for example, and it is well known that stem cell populations decline and become less active - but is that just a reaction to levels of damage, or something else? This feeds into discussion over strategy when it comes to how to approach development of therapies for aging. Is it sufficient to repair all cellular and molecular damage caused by the operation of metabolism, because all forms of programmed aging are just reaction to that damage? Or even after researchers realize the SENS vision of rejuvenation biotechnology, would they then have to build further genetic therapies to block forms of decline that proceed independently of damage? From my view of what is known, I think the evidence leans more towards the former than the latter situation - and either way, we should still be working to realize rejuvenation biotechnology."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

A SINGLE-ISSUE POLITICAL PARTY FOR LONGEVITY SCIENCE
Friday, July 27, 2012
http://www.fightaging.org/archives/2012/07/a-single-issue-political-party-for-longevity-science.php
In a number of countries one plausible path to advocacy for a cause is the establishment of a single issue political party - see, for example, the original Green Party or Pirate Party as successful examples of the type in Europe. The Russian longevity science community is beginning to take this approach: "On July 19, we made the first step towards the creation of the Longevity Party. The initiative group of 10 people gathered together in Moscow to establish the first political party aimed at extending human lifespan using technological advances. ... Among these 10 people were Mikhail Batin, Alexey Turchin, Leonid Kaganov and Elena Milova. This is the very first step in the long and hard process of legally registering a political party. I believe this is one of the most important things that happened in the past few years in fighting aging. Nowhere in the world ever before have people expressed their desire to live longer in the form of a political movement. ... The main goal of the Longevity Party is to increase human lifespan so that people could live for as long as they would like to and remain young and healthy. We would like to achieve this goal by promoting scientific research and technological advances in regenerative medicine, genetics of aging and longevity, neuroscience, computer modeling of biological processes and other areas of life extension. ... The next big thing we need to do is to finalize the Program of the Party. Then we have to have at least 2 people in 42 regions of Russia as representatives of the Party and have the founding meeting after which the Party can be registered and eventually appear in the voting ballots. Our goal is to influence the authorities to support life extension technologies and increase funding for research aimed at improving people's health and extending longevity."

FDA REACHES TO REGULATE (I.E. BLOCK) SIMPLE STEM CELL THERAPIES
Friday, July 27, 2012
http://www.fightaging.org/archives/2012/07/fda-reaches-to-regulate-ie-block-simple-stem-cell-therapies.php
The FDA seems to be succeeding in the courts with regard to shutting down the few groups in the US trying to offer first generation stem cell therapies, and placing a heavy burden of regulation upon them. This most likely means that for another decade or so the only realistic way to access most of the present variety of stem cell therapies will continue to be medical tourism: "It's official: stem cells are drugs. At least, that's the opinion of the US district court in Washington DC, which has ruled that the Food and Drug Administration (FDA) has the authority to regulate clinics offering controversial stem cell therapies. Treatments in which stem cells are harvested from bone marrow and injected straight back into the same patient are deemed part of routine medical practice - not regulated by the US government. But if the cells are subjected to more than 'minimal manipulation', the FDA maintains that the therapy becomes a 'drug', which must be specifically approved for use. It was on this basis that in 2008 the FDA began moves to shut down Regenerative Sciences, a clinic in Broomfield, Colorado, that treats orthopaedic problems using a stem cell therapy called Regenexx. ... Regenexx consists of mesenchymal stem cells, which give rise to tissues including bone and cartilage, taken from a patient's bone marrow and grown in culture for about two weeks. Centeno has published a series of case reports describing its use to treat joint problems - but no controlled clinical trials. ... Regenerative Sciences challenged the FDA's authority to regulate its activities, setting the stage for a legal fight. In 2010, the FDA sought an injunction to take Regenexx off the market. This has now been granted in the court's ruling. Christopher Centeno, medical director of Regenerative Sciences, vows to appeal. 'This is really round one. Our position remains that a patient's cells are not drugs.'"

A REVIEW OF SKELETAL MUSCLE MITOCHONDRIA IN AGING
Thursday, July 26, 2012
http://www.fightaging.org/archives/2012/07/a-review-of-skeletal-muscle-mitochondria-in-aging.php
An open access paper: "Aging is characterized by a progressive loss of muscle mass and muscle strength. Declines in skeletal muscle mitochondria are thought to play a primary role in this process. Mitochondria are the major producers of reactive oxygen species, which damage DNA, proteins, and lipids if not rapidly quenched. Animal and human studies typically show that skeletal muscle mitochondria are altered with aging, including increased mutations in mitochondrial DNA, decreased activity of some mitochondrial enzymes, altered respiration with reduced maximal capacity at least in sedentary individuals, and reduced total mitochondrial content with increased morphological changes. However, there has been much controversy over measurements of mitochondrial energy production, which may largely be explained by differences in approach and by whether physical activity is controlled for. These changes may in turn alter mitochondrial dynamics, such as fusion and fission rates, and mitochondrially induced apoptosis, which may also lead to net muscle fiber loss and age-related sarcopenia. Fortunately, strategies such as exercise and caloric restriction that reduce oxidative damage also improve mitochondrial function. While these strategies may not completely prevent the primary effects of aging, they may help to attenuate the rate of decline."

TOWARDS FUNCTIONAL BLOOD VESSELS GROWN FROM FAT CELLS
Thursday, July 26, 2012
http://www.fightaging.org/archives/2012/07/towards-functional-blood-vessels-grown-from-fat-cells.php
Another of the numerous different efforts to build blood vessels from a patient's own cells: "Researchers have grown small blood vessels in a lab using stem cells from fat gathered through liposuction. Such cultured blood vessels might someday play a role in transplant operations, including heart bypass surgery. ... Many more steps are involved before heart surgery patients can benefit from this technique. ... First, we will need to make a fully functional vessel. Ours works, but does not yet achieve physiological mechanical properties. [Then] we will need to show that stem cells obtained from old, sick people can also be used to make a functional vessel and that this works in an animal model. ... All in all, [we] are still five to 10 years away from seeing this being tested in people. ... For the study, researchers using liposuction extracted adult stem cells from fat and turned them into smooth muscle cells. Adult stem cells are considered to be undifferentiated, which means they hold the potential to morph into specialized cell types. ... The extracted cells were 'seeded' onto a very thin collagen membrane. As they multiplied, researchers rolled them into tubes with the diameter of small blood vessels (3 millimeters). In three to four weeks, they were able to grow usable blood vessels."

A REVIEW: PHYSICAL ACTIVITY INCREASES LIFE EXPECTANCY
Wednesday, July 25, 2012
http://www.fightaging.org/archives/2012/07/a-review-physical-activity-increases-life-expectancy.php
An open access review: "Physical activity reduces many major mortality risk factors including arterial hypertension, diabetes mellitus type 2, dyslipidemia, coronary heart disease, stroke, and cancer. All-cause mortality is decreased by about 30% to 35% in physically active as compared to inactive subjects. The purpose of this paper was to synthesize the literature on life expectancy in relation to physical activity. A systematic PubMed search on life expectancy in physically active and inactive individuals was performed. In addition, articles comparing life expectancy of athletes compared to that of nonathletes were reviewed. Results of 13 studies describing eight different cohorts suggest that regular physical activity is associated with an increase of life expectancy by 0.4 to 6.9 years. Eleven studies included confounding risk factors for mortality and revealed an increase in life expectancy by 0.4 to 4.2 years with regular physical activity. Eleven case control studies on life expectancy in former athletes revealed consistently greater life expectancy in aerobic endurance athletes but inconsistent results for other athletes. None of these studies considered confounding risk factors for mortality. In conclusion, while regular physical activity increases life expectancy, it remains unclear if high-intensity sports activities further increase life expectancy."

REGENERATING BONE WITH SCAFFOLDS AND GENE THERAPY
Wednesday, July 25, 2012
http://www.fightaging.org/archives/2012/07/regenerating-bone-with-scaffolds-and-gene-therapy.php
Another group working on bone regeneration: "researchers have developed an innovative scaffold material (made from collagen and nano-sized particles of hydroxyapatite) which acts as a platform to attract the body's own cells and repair bone in the damaged area using gene therapy. The cells are tricked into overproducing bone producing proteins known as BMPs, encouraging regrowth of healthy bone tissue. This is the first time these in-house synthesised nanoparticles have been used in this way and the method has potential to be applied to regenerate tissues in other parts of the body. ... Previously, synthetic bone grafts had proven successful in promoting new bone growth by infusing the scaffold material with bone producing proteins. These proteins are already clinically approved for bone repair in humans but concerns exist that the high doses of protein required in clinical treatments may potentially have negative side effects for the patient such as increasing the risk of cancer. Other existing gene therapies use viral methods which also carry risks. By stimulating the body to produce the bone-producing protein itself, using non-viral methods these negative side effects can be avoided and bone tissue growth is promoted efficiently and safely."

ASSESSING MTOR SIGNALING IN HUMAN AGING
Tuesday, July 24, 2012
http://www.fightaging.org/archives/2012/07/assessing-mtor-signaling-in-human-aging.php
The target of rapamycin (TOR) gene is widely studied by researchers working on the mechanisms of aging and enhanced longevity provided by calorie restriction. Here a team pull in more data from human populations: "Interventions which inhibit TOR activity (including rapamycin and caloric restriction) lead to downstream gene expression changes and increased lifespan in laboratory models. However, the role of mTOR signaling in human aging is unclear. We tested the expression of mTOR-related transcripts in two independent study cohorts; the InCHIANTI population study of aging and the San Antonio Family Heart Study (SAFHS). ... 8 genes were robustly associated with age in both cohorts. Genes involved in insulin signaling (PTEN, PI3K, PDK1), ribosomal biogenesis (S6K), lipid metabolism (SREBF1), cellular apoptosis (SGK1), angiogenesis (VEGFB), insulin production and sensitivity (FOXO), cellular stress response (HIF1A) and cytoskeletal remodeling (PKC) were inversely correlated with age, whereas genes relating to inhibition of ribosomal components (4EBP1) and inflammatory mediators (STAT3) were positively associated with age in one or both datasets. We conclude that the expression of mTOR-related transcripts is associated with advancing age in humans. Changes seen are broadly similar to mTOR inhibition interventions associated with increased lifespan in animals. Work is needed to establish whether these changes are predictive of human longevity and whether further mTOR inhibition would be beneficial in older people." It is worth recalling that we humans are unusually long-lived for mammals of our size; it is certainly possible that we evolved to consistently use some of the same mechanisms that are only turned on with calorie restriction in smaller mammals.

MODIFYING OLD HEART STEM CELLS TO BOOST REGENERATIVE CAPACITY
Tuesday, July 24, 2012
http://www.fightaging.org/archives/2012/07/modifying-old-heart-stem-cells-to-boost-regenerative-capacity.php
The stem cell research community is increasingly headed in the direction of finding ways to reverse or work around the age-related decline in regenerative capacity, driven by changes in stem cells and their niches: "Since patients with heart failure are normally elderly, their cardiac stem cells aren't very healthy. We modified these biopsied stem cells and made them healthier. It is like turning back the clock so these cells can thrive again. ... Modified human stem cells helped the signaling and structure of the heart cells, which were biopsied from elderly patients. Researchers modified the stem cells in the laboratory with PIM-1, a protein that promotes cell survival and growth. Cells were rejuvenated when the modified stem cells enhanced activity of an enzyme called telomerase, which elongates telomere length. Telomeres are 'caps' on the ends of chromosomes that facilitate cell replication. Aging and disease results when telomeres break off. ... There is no doubt that stem cells can be used to counter the aging process of cardiac cells caused by telomere degradation. ... The technique increased telomere length and activity, as well as increasing cardiac stem cell proliferation, all vital steps in combating heart failure. While human cells were used, the research was limited to the laboratory. Researchers have tested the technique in mice and pigs and found that telomere lengthening leads to new heart tissue growth in just four weeks. ... Modifying aged human cardiac cells from elderly patients adds to the cell's ability to regenerate damaged heart muscle, making stem cell engineering a viable option."

ENHANCED ENERGY METABOLISM CONTRIBUTES TO EXTENDED LIFESPAN THROUGH CALORIE RESTRICTION
Monday, July 23, 2012
http://www.fightaging.org/archives/2012/07/enhanced-energy-metabolism-contributes-to-extended-lifespan-through-calorie-restriction.php
Here is an open access paper that looks at some of the mechanisms of calorie restriction in nematode worms - and you'll note that PEPCK-C manipulation, shown to extend life and improve health in mice, also works in the same way in this lower species: "Caloric restriction (CR) markedly extends lifespan and improves the health of a broad number of species. Energy metabolism fundamentally contributes to the beneficial effects of CR, but the underlying mechanisms that are responsible for this effect remain enigmatic. A multidisciplinary approach that involves quantitative proteomics, immunochemistry, metabolic quantification and lifespan analysis was used to determine how CR, which occurs in the C. elegans eat-2 mutants, modifies energy metabolism of the worm, and whether the observed modifications contribute to the CR-mediated physiological responses. A switch to fatty acid metabolism as an energy source and an enhanced rate of energy metabolism by eat-2 mutant nematodes was detected. Lifespan analyses validated the important role of these previously unknown alterations of energy metabolism in the CR-mediated longevity of nematodes. As observed in mice, the over-expression of the gene for the nematode analogue of the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C) caused a marked extension of lifespan in C. elegans, presumably by enhancing energy metabolism ... We conclude that an increase, not a decrease in fuel consumption, via an accelerated oxidation of fuels in the TCA cycle is involved in lifespan regulation; this mechanism may be conserved across phylogeny."

IDENTIFYING GENETIC CHANGES THAT REDUCE STEM CELL AGING
Monday, July 23, 2012
http://www.fightaging.org/archives/2012/07/identifying-genetic-changes-that-reduce-stem-cell-aging.php
Here researchers note a genetic alteration that reduces age-related changes in one stem cell population: "Upon aging, the number of hematopoietic stem cells (HSCs) in the bone marrow increases while their repopulation potential declines. Moreover, aged HSCs exhibit lineage bias in reconstitution experiments with an inclination towards myeloid at the expense of lymphoid potential. The adaptor protein Lnk is an important negative regulator of HSC homeostasis, as Lnk deficiency is associated with a 10-fold increase in HSC numbers in young mice. However, the age-related increase in functional HSC numbers found in wild type (WT) HSCs was not observed in Lnk-deficient animals. Importantly, HSCs from aged Lnk null mice possess greatly enhanced self-renewal capacity and diminished exhaustion, as evidenced by serial transplant experiments. In addition, Lnk deficiency ameliorates the aging-associated lineage bias. Transcriptome analysis revealed that WT and Lnk-deficient HSCs share many aging-related changes in gene expression patterns. Nonetheless, Lnk null HSCs displayed altered expression of components in select signaling pathways with potential involvement in HSC self-renewal and aging. Taken together, these results suggest that loss of Lnk partially mitigates age-related HSC alterations."

______________________________


&lt;br&gt; &lt;br&gt;View the full article

#20 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 05 August 2012 - 03:23 PM

FIGHT AGING! NEWSLETTER
August 6th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- New Organ: Up to $15,000 For Social Network Engagement
- What is Aging?
- Premature Considerations of Immortality
- From a Recent Symposium on Cryonics and Dementia
- Discussion
- Latest Headlines from Fight Aging!
    - The Brain is Plastic For Life
    - Yet Another Theory to Explain Gender Differences in Longevity
    - Engineering Viruses to Make a Better Targeted Cancer Therapy
    - Tracking and Identifying Cancer Stem Cells
    - Increased Resistance to Cellular Stress Common to Many Forms of Induced Longevity
    - SENS Foundation Seeking Lysosomal Biology Team Lead
    - Measuring Impaired Autophagy With Aging in the Pancreas
    - The Point of Slowing Aging
    - A Comparative Cellular and Molecular Biology of Longevity Database
    - Modest Success in a Cancer Vaccine Trial

NEW ORGAN: UP TO $15,000 FOR SOCIAL NETWORK ENGAGEMENT

The New Organ 100 initiative continues to attract matching funds:

http://www.fightaging.org/archives/2012/07/new-organ-up-to-15000-for-social-network-engagement.php

"The New Organ Prize is a technology prize aimed at speeding development of tissue engineered complex organs, founded by the Methuselah Foundation. To win, a competitor must build a complex organ from a patient's own stem cells, transplant it, and have it function for two years - without making use of present stepping stone technologies such as decellularization that still require a donor organ. Start with cells and end up with patient-matched organs: that is the vision.

"One of the projects currently undertaken by the New Organ volunteers is the New Organ 100 initiative, focused on crowdsourcing the first stage of prize fundraising, raising awareness, and building support in the large community of organ donors, organ recipients, and their supporters.

"As matters proceed, the New Organ Prize continues to attract matching donations and incentives. The latest is an offer by investor Michael Matula: for every like or share on Facebook, or follower on Twitter, he will donate $1 to the prize fund - up to $15,000. In an ideal world, every reader here would think enough of the initiative to head on over and donate a modest amount, or start a fundraiser and talk a few friends into supporting the initative. If you're not up for that, however, then consider stretching your mouse fingers so far as to like the New Organ 100 page."

http://www.neworgan.org/100/

WHAT IS AGING?

What is aging? Like art, we know it if we see it. But once down to the detail level of evolutionary fitness, population mortality rates, and biological mechanisms, a consistent definition becomes a little challenging:

http://www.fightaging.org/archives/2012/08/what-is-aging-1.php

"In 1991, the book Evolutionary Biology of Aging offered the following definition of aging: a persistent decline in the age-specific fitness components of an organism due to internal physiological deterioration (Rose, 1991). This definition has since been used by others a number of times. However, it was only a modest generalization of a definition proffered by Alex Comfort over three editions (1956-1979) of his key book The Biology of Senescence (Comfort, 1979): "a progressive increase throughout life, or after a given stadium, in the likelihood that a given individual will die, during the next succeeding unit of time, from randomly distributed causes." ... Yet a mere definition does not necessarily tell a scientist what causally underlies the phenomenon that is so defined. The latter issue is much broader, implicitly raising fundamental scientific questions regarding mechanisms."

PREMATURE CONSIDERATIONS OF IMMORTALITY

It seems there has been a fair degree of discussion on the topic of immortality of late, more than is usual:

http://www.fightaging.org/archives/2012/08/premature-considerations-of-immortality.php

"For whatever reason, a number of public voices seem to be talking about immortality all of a sudden, largely meaning physical immortality in the sense of immunity to aging but vulnerability to fatal accidents. Topics ebb and flow like tides, I suppose, the signs of many hidden connections that underlie our culture - that grand conversation of innumerable threads held in the myriad communication channels available to us. ... Immortality can be a useful term - such as on the occasions on which you want to plant a flag a long way out in the discussion and make waves. It is, I think, becoming less useful with time, however. So many people use it without meaning or with so many varied and half-thought meanings that it is, like 'anti-aging', becoming more harmful than helpful. Too much baggage, too many charlatans of various types hitching their carts to the bandwagon.

"Putting in serious time and thought on physical immortality - $5 million here and $5 million there adds up pretty quickly - seems to me to be premature. There is a great deal of work that lies between here and first generation rejuvenation biotechnology, something that will allow us to live additional decades in good health, never mind what comes after that. The rise and rapid obsolescence of many massive industries in medicine will happen over the next fifty years in order to extend the outer limits of human health and life span far beyond the present century-and-a-bit. Each of those churning engines of progress will see millions of individuals working in hundreds of competing companies, a world of intricate detail.

"The result of all of that? Possibly humans that can live for two centuries or more before hitting as-yet unknown limits to presently envisaged biological repair technologies. This is a drop in the ocean of time. But that will give a hundred years of grace in which to work feverishly on the next generations of technology: replacements for biological systems, improving on the ways to repair and rebuild our cells, merging with our machines as those machines become ever smaller and more capable. The world of a century and a half from now will be as distant and strange and capable to us as our tools and society would seem to a 18th century peasant.

"My point is that many transformative, world-sweeping changes brought by advancing technology will occur in the decades between now and even a mere hard-fought doubling of the human life span. We'll be starting in earnest to settle the Moon and Mars by then. Our machines will be able to think for themselves. Desktop and motile nanofactories will be capable of fabricating everything from houses to gene therapies from raw materials. A sea of historical and cultural manuscripts will be written on those changes, and still fail to easily capture the scope of the way in which the world changes.

"And then it starts over again, ever building new and greater edifices as we push on to overcome the next set of limits to the human condition. All of this grand and complex near future of increasing longevity and massive change seems far more worthy of thought than immortality, given the length of the road between here and there, and how much has to be done to even start talking seriously about lives of tens of thousands of years."

FROM A RECENT SYMPOSIUM ON CRYONICS AND DEMENTIA

The folk of the Institute for Evidence Based Cryonics hosted a symposium on cryonics and dementia last month, and some of the presentation materials are available online:

http://www.fightaging.org/archives/2012/07/from-a-recent-symposium-on-cryonics-and-dementia.php

"Cryonics is the low-temperature preservation of the deceased, as rapidly as possible after death so as to preserve the fine structure of the brain before it can be damaged or decay. The body, or at least the head, are also preserved - but that is largely incidental to the real purpose, which is to store the mind encoded in the structure of neural tissue. For so long as that mind exists in low-temperature storage it has time to wait out progress in technology, the dawn of an age of medical molecular nanotechnology, and advanced tissue engineering capable of restoring that brain to live in a new body. If you have the technology to de-vitrify a brain whilst maintaining its mind, so the thinking goes, then building a body from stem cells is pretty straightforward by comparison.

"In any case, my point here is the the focus of cryonics is the brain, its structure, and the mind. Threats to the fabric of the mind are of greater importance than threats to the rest of the body in this way of looking at the world, as there exist a range medical conditions that can destroy your mind well prior to death, placing you just as far beyond help as if you burned to death, were lost at sea, or simply buried."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

THE BRAIN IS PLASTIC FOR LIFE
Friday, August 3, 2012
http://www.fightaging.org/archives/2012/08/the-brain-is-plastic-for-life.php
We have a great deal more control over the age-related decline of the brain than was once thought - "use it or lose it", and the ability to affect change through challenging the mind. Yet it remains the case that new biotechnology and medicine will be required to get to where we want to be, a world without the risk of dementia, fuzzy memory, and slow cognition. Still, the plasticity of the aging brain is encouraging: "There is growing evidence that, beyond what was previously believed, the adult human brain is remarkably malleable and capable of new feats - even in the last decades of life. In fact, new experiences can trigger major physical changes in the brain within just a few days, and certain conditions can accelerate this physical, chemical and functional remodeling of the brain. ... We used to think that the brain was completely formed by development and its basic structure didn't change much in adults, but as research went on we discovered that wasn't true, at least in the cerebral cortex. We now know that an underlying portion of the brain called the thalamus, which feeds the cortex information from our senses, is also remarkably plastic. ... There is no evidence that there is any part of the adult brain that is not plastic. But studies indicate that some aspects of musical training, such as the ability to perceive temporal patterns, require the brain to be trained during early developmental periods when its primed for certain types of stimuli. For other aspects of musical development, such as the ability to perceive and repeat a sequence of tones, it's irrelevant whether you've had that experience and training early in life. ... The brain is plastic for life. The fundamental thing that determines how much [persons with brain disorders] will improve is the level of their initial impairment, but not their age."

YET ANOTHER THEORY TO EXPLAIN GENDER DIFFERENCES IN LONGEVITY
Friday, August 3, 2012
http://www.fightaging.org/archives/2012/08/yet-another-theory-to-explain-gender-differences-in-longevity.php
There is no shortage of theories as to why women live longer than men - an apparently simple question, but one balanced on such a mountain of complex data and partial knowledge that it cannot be definitively answered at the present time. Here is another theory for the stack: "Mitochondria are inherited only from mothers, never from fathers, so there is no way to weed out mutations that damage a male's prospects. ... [Researchers] analysed the mitochondria of 13 different groups of male and female fruit flies. Mitochondria, which exist in almost all animal cells, convert food into the energy that powers the body. ... the results point to numerous mutations within mitochondrial DNA that affect how long males live, and the speed at which they age. ... Intriguingly, these same mutations have no effects on patterns of ageing in females. All animals possess mitochondria, and the tendency for females to outlive males is common to many different species. Our results therefore suggest that the mitochondrial mutations we have uncovered will generally cause faster male ageing across the animal kingdom. ... They suggest this is because there is no evolutionary reason for the faults that affect males to be picked up - because mitochondria are passed down by females. ... If a mitochondrial mutation occurs that harms fathers, but has no effect on mothers, this mutation will slip through the gaze of natural selection, unnoticed. Over thousands of generations, many such mutations have accumulated that harm only males, while leaving females unscathed."

ENGINEERING VIRUSES TO MAKE A BETTER TARGETED CANCER THERAPY
Thursday, August 2, 2012
http://www.fightaging.org/archives/2012/08/engineering-viruses-to-make-a-better-targeted-cancer-therapy.php
Some viruses show promise in terms of preferentially attacking cancer cells - but they can be engineered to be far more effective in the role of therapeutic agent: "Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, they can also infect normal cells - without doing any harm to them - so a large portion of viruses is lost during therapy. [Researchers] have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In a second step, they equipped the viruses with a molecular key for infecting cancer cells. ... the researchers chose H1 parvoviruses, which normally infect rodents but are also infectious for human cells. H1 viruses kill tumor cells on the basis of their natural properties, i.e., their genetic material does not need to be modified for them to do so. ... The viruses exclusively destroy cancer cells. But with the same efficiency that they infect cancer cells, they also infect healthy cells. There they do not cause any damage and cannot replicate, but we lose a large portion of therapeutic viruses every time ... To solve this problem, the researchers [first] modified the genetic material of the virus in such a way that it loses its ability to infect cells. In a second step, this non-infectious virus was equipped with a molecular key for cancer cells. ... This is first evidence that it is basically possible to modify properties of H1 according to a plan. We will surely need several more attempts in order to target the viruses more specifically to cancer cells in the second step. We also already have ideas how to further enhance the infectious capacity and the potential to destroy cancer cells."

TRACKING AND IDENTIFYING CANCER STEM CELLS
Thursday, August 2, 2012
http://www.fightaging.org/archives/2012/08/tracking-and-identifying-cancer-stem-cells.php
Any commonality in present in varied types of cancer is important, as it provides a potential path to a comparatively low-cost, robust suite of therapies that work for many cancers - and a robust cancer cure is an important component of any future rejuvenation biotechnology toolkit. Here researchers add some weight to the cancer stem cell hypothesis: "Cancer researchers can sequence tumour cells' genomes, scan them for strange gene activity, profile their contents for telltale proteins and study their growth in laboratory dishes. What they have not been able to do is track errant cells doing what is more relevant to patients: forming tumours. Now three groups studying tumours in mice have done exactly that. Their results support the ideas that a small subset of cells drives tumour growth and that curing cancer may require those cells to be eliminated. It is too soon to know whether these results - obtained for tumours of the brain, the gut and the skin - will apply to other cancers, [but if they do], there is going to be a paradigm shift in the way that chemotherapy efficacy is evaluated and how therapeutics are developed. ... Underlying this scenario is the compelling but controversial hypothesis that many tumours are fuelled by 'cancer stem cells' that produce the other types of cancer cell, just as ordinary stem cells produce normal tissues. ... The papers provide clear experimental evidence that cancer stem cells exist ... They have made a major contribution to validating the concept of cancer stem cells. ... Researchers are already busy hunting for ways to kill these cells; now they have more tools to tell whether such a strategy will work."

INCREASED RESISTANCE TO CELLULAR STRESS COMMON TO MANY FORMS OF INDUCED LONGEVITY
Wednesday, August 1, 2012
http://www.fightaging.org/archives/2012/08/increased-resistance-to-cellular-stress-common-to-many-forms-of-induced-longevity.php
An open access paper, and an example of the way in which researchers are closing in on common mechanisms that explain the operation of many diverse ways found to extend healthy life in laboratory animals: "Many mutations that increase animal lifespan also confer stress tolerance, suggesting that cytoprotective mechanisms underpin the regulation of longevity. It has not been established, however, whether the induction of individual cytoprotective pathways is essential for lifespan extension, or merely correlated. To establish whether the regulatory pathways for the induction of cytoprotective responses are key in the extension of lifespan, we performed an RNAi screen for gene inactivations that decouple the activation of cytoprotective pathways from xenobiotic stimuli that normally induce them. The screen identified 29 genes that constitute the regulatory cascades of the unfolded protein response, oxidative stress response, and detoxification. ... If cytoprotective responses contribute directly to lifespan extension, inactivation of these genes would be expected to compromise the extension of lifespan conferred by decreased insulin/IGF-1 signaling, disruption of mitochondrial function, or caloric restriction ... We find that inactivation of 25 of 29 cytoprotection-regulatory genes shortens the extension of longevity normally induced by decreased insulin/IGF-1 signaling, disruption of mitochondrial function, or caloric restriction, without disrupting normal longevity nearly as dramatically. These data demonstrate that induction of cytoprotective pathways is central to longevity extension."

SENS FOUNDATION SEEKING LYSOSOMAL BIOLOGY TEAM LEAD
Wednesday, August 1, 2012
http://www.fightaging.org/archives/2012/08/sens-foundation-seeking-lysosomal-biology-team-lead.php
A research position is open at the SENS Foundation: "SENS Foundation is hiring for our research center located in Mountain View, CA. We are seeking a team lead for our LysoSENS group to work both on established projects and new independent lysosomal-based research geared towards the SENS mission ... Qualified candidates will have a Ph.D. in the chemical/biological sciences and at least 5 years of work experience that must include prior project management experience. Duties will include bench work, management of a small team of lab researchers, the preparation of grant proposals, internal and external progress reports, individual and collaborative publication. The project lead will develop, interpret and implement standards, procedures, and protocols for the LysoSENS research program and may collaborate on determining strategic directions in the research program. Bench experience should include standard laboratory techniques, including but not limited to standard cell biology/biochemistry/molecular biology techniques. Good fundamental laboratory skills to include safety, microbial and mammalian cell culture. Experiments may include cell culture, transfection, organelle (lysosomal) purification and imaging, microscopy, protein production and analysis in addition to supervisory duties. As a project lead, candidates must have the ability to design, develop and direct experiments that establish the viability of the SENS mission and chosen therapeutic goals."

MEASURING IMPAIRED AUTOPHAGY WITH AGING IN THE PANCREAS
Tuesday, July 31, 2012
http://www.fightaging.org/archives/2012/07/measuring-impaired-autophagy-with-aging-in-the-pancreas.php
Autophagy is the important collection of processes that break down damaged cellular components and unwanted metabolic byproducts. More autophagy improves the health of the organism and extends longevity, while less autophagy leads to the reverse. Boosted autophagy appears to contribute strongly to a number of life-extending interventions, including calorie restriction, and researchers have achieved such goals as reverting aged liver function to youthful levels by increasing the effectiveness of autophagic processes. Unfortunately, autophagy declines with age as the cellular components that carry out the process become damaged and overwhelmed by metabolic waste products. Here researchers measure the impact of reduced autophagy with age in the pancreas: "Type 2 diabetes is characterized by a deficit in β-cell function and mass, and its incidence increases with age. ... Impaired or deficient autophagy is believed to cause or contribute to aging and age-related disease. Autophagy may be necessary to maintain structure, mass, and function of pancreatic β-cells. In this study, we investigated the effects of age on β-cell function and autophagy in pancreatic islets of 4-month-old (young), 14-month-old (adult), and 24-month-old (old) male Wistar rats. We found that islet β-cell function decreased gradually with age. Protein expression of [autophagy markers] exhibited a marked decline in aged islets. The expression of Lamp-2, a good indicator of autophagic degradation rate, was significantly reduced in the islets of old rats, suggesting that autophagic degradation is decreased in the islets of aged rats. [Markers] of mitochondrial and nuclear DNA oxidative damage exhibited strong immunostaining in old islets. Analysis by electron microscopy demonstrated swelling and disintegration of cristae in the mitochondria of aged islets. These results suggest that β-cell and autophagic function in islets decline simultaneously with increasing age in Wistar rats, and that impaired autophagy in the islets of older rats may cause accumulation of misfolded and aggregated proteins and reduce the removal of abnormal mitochondria in β-cells, leading to reduced β-cell function. Dysfunctional autophagy in islets during the aging process may be an important mechanism leading to the development of type 2 diabetes." Reversing the decline in autophagy by restoring lysosomal function is a part of the SENS vision for rejuvenation biotechnology.

THE POINT OF SLOWING AGING
Tuesday, July 31, 2012
http://www.fightaging.org/archives/2012/07/the-point-of-slowing-aging.php
This abstract encapsulates the point made by advocates of slowing aging through metabolic manipulation by drugs or other means - that it is a far better approach than the present dominant methodologies of treating various end-stages of aging separately, and by patching over the symptoms rather than treating root causes: "Atherosclerosis, hypertension, obesity, diabetic complications, cancer, benign prostate hyperplasia, Alzheimer and Parkinson diseases, age-related macular degeneration, osteoarthritis, osteoporosis, and seborrheic keratosis are strongly associated with aging, implying a common underlying process. Each disease is treated separately and, in most cases, symptomatically. Suppression of aging itself should delay or treat all age-related diseases, thus increasing healthy life span and maximal longevity. But, is it possible to slow down aging? Recent evidence indicates that the target of rapamycin signaling pathway is involved in cellular senescence and organismal aging. Preclinical and clinical studies demonstrated the therapeutic effects of rapamycin in diverse age-related diseases. One simple reason why a single drug is indicated for so many age-related diseases is that it inhibits the aging process."

A COMPARATIVE CELLULAR AND MOLECULAR BIOLOGY OF LONGEVITY DATABASE
Monday, July 30, 2012
http://www.fightaging.org/archives/2012/07/comparative-cellular-and-molecular-biology-of-longevity-database.php
Researchers recently announced a database of interesting material on the biology of longevity - one of a growing number of publicly available online databases in this field: "Discovering key cellular and molecular traits that promote longevity is a major goal of aging and longevity research. One experimental strategy is to determine which traits have been selected during the evolution of longevity in naturally long-lived animal species. This comparative approach has been applied to lifespan research for nearly four decades, yielding hundreds of datasets describing aspects of cell and molecular biology hypothesized to relate to animal longevity. Here, we introduce a Comparative Cellular and Molecular Biology of Longevity Database [as] a compendium of comparative cell and molecular data presented in the context of longevity. This open access database will facilitate the meta-analysis of amalgamated datasets using standardized maximum lifespan (MLSP) data (from AnAge). The first edition contains over 800 data records describing experimental measurements of cellular stress resistance, reactive oxygen species metabolism, membrane composition, protein homeostasis, and genome homeostasis as they relate to vertebrate species MLSP."

MODEST SUCCESS IN A CANCER VACCINE TRIAL
Monday, July 30, 2012
http://www.fightaging.org/archives/2012/07/modest-success-in-cancer-vaccine-trial.php
German researchers trialing a generally applicable cancer vaccine technology find that it improves on chemotherapy, but remains a long way from a cure. Still, this is generally how matters proceed: first results are only first results, and much improvement lies ahead. "Researchers [have] published the results of two clinical studies using the kidney-cancer vaccine IMA901 ... It is composed of ten synthetic tumor-associated peptides (TUMAPs), which activate the body's own killer T-cells against the tumor. Unlike chemotherapy, this process targets the body's immune responses and mobilizes them to attack the cancer. The studies show that this active immunization against cancer can be successful and extend the life of a patient for longer than even the latest chemotherapy techniques - with far fewer side-effects. ... All of the medications previously used have brought about a clear improvement in reducing tumor growth in cancer of the kidneys, but they did not lead to the desired extension of the patient's life and certainly did not cure the patient. ... The study shows that in kidney-cancer patients with documented T-cell reactions against two or more tumor-associated peptides, the immune reaction and clinical progress were clearly linked. That confirms the hypothesis that cancer treatments can be further developed by broadly activating the immune system against various target structures on the surface of the tumor. ... The principle applied here - of active immunization against cancer antigens previously identified in cancer cells - can be used against practically all types of cancer. ... researchers have published similarly successful clinical studies in the case of bowel cancer [and] prostate cancer. Immatics is currently carrying out studies on treatments for glioblastoma [a common and malignant brain tumor] and further studies for treating liver cancer and ovarian carcinoma are in the pipeline."

______________________________


&lt;br&gt; &lt;br&gt;View the full article

#21 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 12 August 2012 - 08:34 PM

FIGHT AGING! NEWSLETTER
August 13th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Ultimately, Self-Interest Will Emerge as a Driving Force
- Replacement Parts: Xenotransplantion Versus Organ Engineering
- Regrowing the Esophageal Lining
- Contemplating the Causes of Immunosenescence
- Discussion
- Latest Headlines from Fight Aging!
    - Proposing a Hyperfunction Theory of Aging
    - Towards a Blood Test for Alzheimer's Disease
    - Looking for Longevity-Related MicroRNAs in Centenarians
    - On Oxidative Stress and NAD+ Metabolism in Aging
    - Cosmism and Views of Radical Life Extension
    - A Terrible Reason to Oppose Healthy Life Extension
    - A Therapeutic Target for Dry Macular Degeneration
    - Eurosymposium on Healthy Aging Announced
    - Plan to Live for Longer than You Think You Will
    - On Intermittent Fasting

ULTIMATELY, SELF-INTEREST WILL EMERGE AS A DRIVING FORCE

Self-interest is a potent thing, especially when it comes to retaining one's health and life in the face of threats to both:

http://www.fightaging.org/archives/2012/08/ultimately-self-interest-will-emerge-as-a-driving-force.php

"At the present time two groups of people well placed to influence progress in rejuvenation biotechnology are, for the most part, acting against their own self-interest. It is generally the case that such situations do not last: self-interest wins out in the long term.

"On the one hand we have the world's high net worth individuals, most of whom do very little in the way of funding research into aging or the conditions of aging. It is their inaction that is opposed to their own self-interest: they are all aging to death at the same pace as the rest of us, after all. When it comes to access to medical technology the world is remarkably flat: the poor struggle in this as in everything else, but the wealthy have no more ability to buy a way out of aging (or heart disease, or cancer, or any of the other conditions that attend aging) right this instant than does anyone else. What they do have is a far greater ability to create a near future in which rejuvenation biotechnologies exist and are just as widely available as any present day clinical procedure.

"It is in the self-interest of everyone who can significantly speed up the development of ways to reverse aging to set forth and do exactly that - but very few are making the effort. At some point it will become evident to the public and the world at large that aging to death whilst surrounding by wealth is insanity in an age in which those resources could be used for the development of age-reversing medicine: ways to repair mitochondrial DNA, break down accumulated metabolic byproducts that clog up cells, clear out senescent cells, restore declining stem cell activity, and so forth. But as yet this is not obvious enough to those people who matter.

"The second group acting against their own self-interest in the matter of rejuvenation biotechnology are those researchers who could be working on relevant scientific projects but are not. Much of the aging research community doesn't in fact do any more than study aging, and the minority who do work on development of therapies are largely investigating the slow and unproductive path of slowing aging via metabolic manipulation. A far better road exists: the pursuit of ways to repair the damage that causes aging, as outlined by the SENS Foundation but by no means limited to their chosen methods of implementation. Work on the repair of aging is far more likely to produce radical advances in medicine worthy of this age of accelerating progress: ways to restore the old to vigor and greatly extend health human life. Researchers who are not working on something that looks a lot like SENS are locking themselves out of the most interesting and most valuable room in the house.

"But as I said above, self-interest tends to win out in the long run. As more attention is given to SENS, longevity science, and the repair of aging, it becomes ever more likely it is that self-interest will emerge as a driving force in funding and research."

REPLACEMENT PARTS: XENOTRANSPLANTATION VERSUS ORGAN ENGINEERING

A recent article looks at competition between two lines of research, both aimed at building replacement organs that are matched to a patient's own tissues:

http://www.fightaging.org/archives/2012/08/replacement-parts-xenotransplantation-versus-organ-engineering.php

"Faced with this common problem, Vacanti and Cooper have championed very different solutions. Cooper thinks that the best hope of providing more organs lies in xenotransplantation - the act of replacing a human organ with an animal one. From his time in Cape Town to his current position at the University of Pittsburgh, he has been trying to solve the many problems that occur when pig organs enter human bodies, from immune rejection to blood clots. Vacanti, now at Massachusetts General Hospital, has instead been developing technology to create genetically tailored organs out of a patient's own cells, abolishing compatibility issues. 'I said to myself: why can't we just make an organ?' he recalls.

"In the race to solve the organ shortage, xenotransplantation is like the slow and steady tortoise, still taking small steps after a long run-up, while organ engineering is more like a sprinting hare, racing towards a still-distant finish line. Most of those betting on the race are backing the hare. Industry support has dried up for xenotransplantation after years of slow progress, leaving public funders to pick up the expensive tab. Stem cells, meanwhile, continue to draw attention and investment. But both fields have made important advances in recent years, and the likely winner of their race - or whether it will result in a draw - is far from clear."

REGROWING THE ESOPHAGEAL LINING

Here is an example of the present current cutting edge of tissue engineering in practice - using decellarized animal tissues and producing better results than more traditional methods of reconstructive surgery:

http://www.fightaging.org/archives/2012/08/tissue-engineering-to-regrow-the-esophageal-lining.php

"The scaffolding is 'extracellular matrix,' or ECM - a matrix or tissue framework developed from pig tissue from which all the pig's cells have been removed. The ECM naturally contains growth factors and proteins among other molecules that appear to signal the recipient's adult stem cells, and possibly other cells, to transform themselves into site-specific cells needed at that particular location of the body. ... For the right candidate for the surgery, Dr. Jobe cuts the cylindrical tube of lining at either end of the damaged area [of the esophagus], as if he were removing a damaged piece of pipe, before pulling it out of the throat in a way similar to taking off a tube sock. If nothing else were done, resultant scarring would prevent swallowing and clog the throat. The ECM process regenerates healthy tissue without scarring.

"Next Dr. Jobe uses pig ECM that Dr. Badylak developed and now produced commercially to form a new esophageal lining. The ECM tube is soaked until it is flaccid and then slipped over a collapsed spring-like stent. Once in place, the stent is expanded until it presses the ECM against the esophageal wall where the lining had been removed. In a process known as wallpapering, the stent holds the ECM in place until it adheres to the wall. In a matter of days the ECM fully attaches to the esophagus wall to serve as a framework for stem cells or other cells to migrate there and heed signals from the ECM or from neighboring esophagus cells to transform into esophageal lining. Soon after the surgery with the stent in place, the patient can consume liquids. Full replacement of the lining occurs within several weeks. In time, the pig ECM is replaced naturally with human tissue."

CONTEMPLATING THE CAUSES OF IMMUNOSENESCENCE

The immune system fails in characteristic ways with aging, entering a state known as immunosenescence in which it causes chronic inflammation and fails to protect against pathogens or destroy unwanted cells. The immune system fails faster for some people than others, however. Here researchers propose that infection with cytomegalovirus (CMV) in youth leads to a faster decline in the immune system in older years, and thus have a lot to do with differences in aging between populations:

http://www.fightaging.org/archives/2012/08/contemplating-the-causes-of-immunosenescence.php

"Is immunosenescence an intrinsic ageing process leading to dysregulation of immunity or an adaptive response of the individual to pathogen exposure? Age-associated differences in bone marrow immune cell output and thymic involution suggest the former. Accepted hallmarks of immunosenescence (decreased numbers and percentages of peripheral naïve T cells, especially CD8+ cells, and accumulations of memory T cells, especially late-stage differentiated CD8+ cells) suggest the latter, viewed as the result of depletion of the reservoir of naïve cells over time by contact with pathogens and their conversion to memory cells, the basis of adaptive immunity."

"One very striking difference [between industrialized Western populations and those of poorer regions is that in] the 'wild-type' situation, all humans are infected with CMV from the age of ca. 2 months on, when they no longer receive only anti-CMV antibody in the mother's milk, but also the infectious virus that has reactivated in the meantime. CMV-negativity is an artifact of civilization, hygiene and decreased breast feeding. Hence, in our pilot study of young and old men in rural Pakistan, all the young were already CMV-positive. As 'old' is viewed as [greater than] 50 years in this society, we sought to establish whether age-associated differences in immune phenotypes that we and others had established in older European and US populations were similar in Pakistanis, and whether they manifested earlier in the latter.

"We concluded that there were two major differences between the Pakistani population and the historical controls of [subjects from Western, industrialized regions]. One was that we did indeed see age-associated differences in CD8+ T cells earlier in the Pakistanis, and the other was that we saw for the first time in a healthy population that not only the CD8+ subset but also the CD4 + T cells were affected. This we had otherwise only seen in pathological European populations, eg. those with Alzheimer's. We interpret this to mean that the level of 'antigenic stress' in the Pakistani population, old at 50, could indeed be leading to 'premature immunosenescence'."

You'll find more on cytomegalovirus as a cause of immune system decline back in the Fight Aging! archives. One possible treatment would involve targeting and destroying the memory T cells devoted to CMV, thus freeing up space for other immune cells that focus on destroying threats:

http://www.fightaging.org/archives/2010/04/quantifying-the-harm-done-by-cytomegalovirus.php
http://www.fightaging.org/archives/2006/12/when-and-how-does-the-decay-of-your-immune-system.php

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

PROPOSING A HYPERFUNCTION THEORY OF AGING
Friday, August 10, 2012
http://www.fightaging.org/archives/2012/08/proposing-a-hyperfunction-theory-of-aging.php
There are a great many theories of aging, and here is another for the pile from a researcher who leans towards aging as genetic programming rather than aging as accumulated damage: "The biological mechanisms at the heart of the aging process are a long-standing mystery. An influential theory has it that aging is the result of an accumulation of molecular damage, caused in particular by reactive oxygen species (ROS) produced by mitochondria. This theory also predicts that processes that protect against oxidative damage (involving detoxification, repair and turnover) protect against aging and increase lifespan. ... However, recent tests of the oxidative damage theory, many using the short-lived nematode worm Caenorhabditis elegans, have often failed to support the theory. This motivates consideration of alternative models. One new theory [proposes] that aging is caused by hyperfunction, i.e. over-activity during adulthood of processes (particularly biosynthetic) that contribute to development and reproduction. Such hyperfunction can lead to hypertrophy-associated pathologies, which cause the age increase in mortality. ... Here we assess whether the hyperfunction theory is at all consistent with what is know about C. elegans aging, and conclude that it is. In particular, during adulthood C. elegans show a number of changes that may reflect pathology and/or hyperfunction. Such changes seem to contribute to mortality, at least in some cases (e.g. yolk accumulation). ... Our assessment suggests that the hyperfunction theory is a plausible alternative to the molecular damage theory to explain aging in C. elegans."

TOWARDS A BLOOD TEST FOR ALZHEIMER'S DISEASE
Friday, August 10, 2012
http://www.fightaging.org/archives/2012/08/towards-a-blood-test-for-alzheimers-disease.php
Progress towards a non-invasive test for Alzheimer's disease: "Reliability and failure to replicate initial results have been the biggest challenge in this field. We demonstrate here that it is possible to show consistent findings. ... [Researchers] measured the levels of 190 proteins in the blood of 600 study participants [including] healthy volunteers and those who had been diagnosed with Alzheimer's disease or mild cognitive impairment (MCI). MCI, often considered a harbinger for Alzheimer's disease, causes a slight but measurable decline in cognitive abilities. A subset of the 190 protein levels (17) were significantly different in people with MCI or Alzheimer's. When those markers were checked against data from 566 people participating in the multicenter Alzheimer's Disease Neuroimaging Initiative, only four markers remained: apolipoprotein E, B-type natriuretic peptide, C-reactive protein and pancreatic polypeptide. Changes in levels of these four proteins in blood also correlated with measurements from the same patients of the levels of proteins [beta-amyloid] in cerebrospinal fluid that previously have been connected with Alzheimer's. The analysis grouped together people with MCI, who are at high risk of developing Alzheimer's, and full Alzheimer's. ... Though a blood test to identify underlying Alzheimer's disease is not quite ready for prime time given today's technology, we now have identified ways to make sure that a test will be reliable."

LOOKING FOR LONGEVITY-RELATED MICRORNAS IN CENTENARIANS
Thursday, August 9, 2012
http://www.fightaging.org/archives/2012/08/looking-for-longevity-related-micrornas-in-centenarians.php
Efforts continue to correlate longevity with the activity levels of specific genes: "MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression and play a critical role in development, homeostasis, and disease. Despite their demonstrated roles in age-associated pathologies, little is known about the role of miRNAs in human aging and longevity. ... We employed massively parallel sequencing technology to identify miRNAs expressed in B-cells from Ashkenazi Jewish centenarians, i.e., those living to a hundred and a human model of exceptional longevity, and younger controls without a family history of longevity. ... we discovered a total of 276 known miRNAs and 8 unknown miRNAs ranging several orders of magnitude in expression levels, a typical characteristics of saturated miRNA-sequencing. A total of 22 miRNAs were found to be significantly upregulated, with only 2 miRNAs downregulated, in centenarians as compared to controls. Gene Ontology analysis of the predicted and validated targets of the 24 differentially expressed miRNAs indicated enrichment of functional pathways involved in cell metabolism, cell cycle, cell signaling, and cell differentiation. A cross sectional expression analysis of the differentially expressed miRNAs in B-cells from Ashkenazi Jewish individuals between the 50th and 100th years of age indicated that expression levels of miR-363* declined significantly with age. Centenarians, however, maintained the youthful expression level. This result suggests that miR-363* may be a candidate longevity-associated miRNA.

ON OXIDATIVE STRESS AND NAD+ METABOLISM IN AGING
Thursday, August 9, 2012
http://www.fightaging.org/archives/2012/08/on-oxidative-stress-and-nad-metabolism-in-aging.php
NAD+ is featured in the energy generation cycle that takes place in mitochondria within cells, as well as many other roles. Its levels appear to influence and be influenced by all sorts of mechanisms related to longevity and aging. "Nicotinamide adenine dinucleotide (NAD+) is an essential electron transporter in mitochondrial respiration and oxidative phosphorylation. In genomic DNA, NAD+ also represents the sole substrate for the nuclear repair enzyme, poly(ADP-ribose) polymerase (PARP) and the sirtuin family of NAD-dependent histone deacetylases. Age associated increases in oxidative nuclear damage have been associated with PARP-mediated NAD+ depletion and loss of SIRT1 activity in rodents. In this study, we further investigated whether these same associations were present in aging human tissue. Human pelvic skin samples were obtained from consenting patients aged between 15-77 and newborn babies (0-1 year old) ... DNA damage correlated strongly with age in both males and females whereas lipid oxidation (MDA) levels increased with age in males but not females. PARP activity significantly increased with age in males and inversely correlated with tissue NAD+ levels. These associations were less evident in females. A strong negative correlation was observed between NAD+ levels and age in both males and females. SIRT1 activity also negatively correlated with age in males but not in females. Strong positive correlations were also observed between lipid peroxidation and DNA damage, and PARP activity and NAD+ levels in post pubescent males. This study provides quantitative evidence in support of the hypothesis that hyperactivation of PARP due to an accumulation of oxidative damage to DNA during aging may be responsible for increased NAD+ catabolism in human tissue. The resulting NAD+ depletion may play a major role in the aging process, by limiting energy production, DNA repair and genomic signalling."

COSMISM AND VIEWS OF RADICAL LIFE EXTENSION
Wednesday, August 8, 2012
http://www.fightaging.org/archives/2012/08/cosmism-and-views-of-radical-life-extension.php
A piece on the continuing tradition of Russian cosmism, influential on the transhumanist movement and the modern community that advocates for radical life extension through biotechnology: "According to Dr. Igor Vishev (b. 1933), a distinguished Russian scientist and philosopher, it is likely that there are people alive today who will never die. Just stop for a moment and think about that. Alive today. Never die. ... Vishev's line of thought is a 21st-century variation of Russian cosmism, a philosophical tendency that started with the eccentric 19th-century librarian and thinker Nikolai Fedorov (1829-1903) and continued through the 20th century ... Vishev is convinced that medical technology is advancing so rapidly that sometime later in this century, Homo sapiens will become Homo immortalis. He believes that our current lifespan of up to 90 or, in extreme instances, slightly over 100 years, is not cast in stone or fixed in nature but an evolutionary stage out of which we are now emerging. Genetic engineering, replacement of natural organs with artificial instruments, nanotechnology, and other developing technologies could now extend our lives well beyond today's assumed limits. He proposes that a 200-year-old person is a present possibility, and a person who could live at least as long as a 2,000-year-old redwood tree is certainly imaginable. Such longevity will be self-propelling. New discoveries during the 200-year (or 2,000-year) lifespan would make what Vishev calls 'practical immortality' a fairly safe bet. By 'practical' he means 'realizable' but not absolute. People could still die, accidentally or otherwise, but eventually techniques of 'practical resurrection,' toward which today's cloning is a primitive first step, would be able to restore life to those who somehow lose it. Vishev's philosophy, which he calls 'practical immortology,' is an attempt to shift our entire culture and worldview from one based on the certainty of human mortality to one based on the prospect of human immortality. This shift requires radical new directions not only in science and technology but in economics, politics, morality, ecology, art - everything. Not easy, of course, but he thinks it's possible."

A TERRIBLE REASON TO OPPOSE HEALTHY LIFE EXTENSION
Wednesday, August 8, 2012
http://www.fightaging.org/archives/2012/08/a-terrible-reason-to-oppose-healthy-life-extension.php
Here is a short piece on the immortal dictator argument that shows up from time to time as one of the reasons given to continue to let billions die of aging: "But what if, the critics continue, you had a dictator who could live more or less for thousands of years? Wouldn't it be a good thing if he was guaranteed to die at some point and the people he oppressed had a chance to start anew? Wouldn't the sacrifice be worth it? No, it wouldn't, and here's why. Basically, we're being asked to give a potential means of extending our life spans so we can be sure that just a small handful of people and their cronies would be dead at some point in time. We can't always kill them or depose them, so we'll be outsourcing the assassination to nature. Anyone see the problem here? Of the over seven billion people who aren't dictators, who do we think is expendable enough to die alongside our targets for the sake of the anti-dictator cause? If I may reach for a little hyperbole, how different is the logic that all the billions who will die in the process are fair game because their death helps the cause from that of all terrorist groups who believe that civilians of the countries they hate can be on the hit list because killing them hurts an enemy and may force him to retreat? This is a rather crass way of saying that the ends justify the means and I doubt that they really do in this case. We could take this logic further and cast all modern medicine as being a dictator enabling technology. Maybe last week Assad would've tripped, fallen, hurt himself, then got his wound infected and was soon dead from septic shock, helping to end the civil war in Syria. Does this mean we must now give up our disinfectants and advanced medical treatments to make sure bad people die easier?"

A THERAPEUTIC TARGET FOR DRY MACULAR DEGENERATION
Tuesday, August 7, 2012
http://www.fightaging.org/archives/2012/08/a-therapeutic-target-for-dry-macular-degeneration.php
Via ScienceDaily, news of a possible basis for a therapy to block the progression of dry macular degeneration: "Previous research [showed] that in human eyes with geographic atrophy [GA] there is a deficiency of the enzyme DICER1, leading to accumulation of toxic Alu RNA molecules in the retinal pigmented epithelium. Another paper [showed] that when these RNAs build up in the eye they trigger activation of an immune complex known as the NLRP3 inflammasome. In turn, this leads to the production of a molecule known as IL-18, which causes death of retinal pigmented epithelial cells and vision loss by activating a critical protein known as MyD88. Importantly, [researchers] found evidence that activity of the inflammasome, IL-18, and MyD88 were all increased in human eyes with GA. They then showed that blocking any of these components could prevent retinal degeneration in multiple disease models. The researchers are excited that blocking these pathways could herald a new potential therapy for GA, for which there is no approved treatment."

EUROSYMPOSIUM ON HEALTHY AGING ANNOUNCED
Tuesday, August 7, 2012
http://www.fightaging.org/archives/2012/08/eurosymposium-on-healthy-aging-announced.php
A conference to be held this coming December in Brussels: "Your presence can be key to convince the European Commission to count more on biology of ageing, preventive and regenerative medicine to extend healthy lives in the not so distant future. Heales (Healthy Life Extension Society) is a European non-governmental association promoting and advocating scientific research into longevity and biogerontology. We are a group of biologists, biochemists, medical doctors and diverse other professions throughout Europe. Having followed the evolution of the European Innovation Partnership on Active and Healthy Ageing we have reached the conclusion that biology of ageing needs to be highlighted more clearly as an important solution. Innovations based on biology of ageing can contribute to improve healthy life in a very significant way and we want to address this message to the European Union through this conference. In this conference, we will let scientists explain how their research contributes or can contribute to extend the healthy lifespan of European citizens; we will put scientists, entrepreneurs, medical doctors and other key actors together to build the business of long term health, towards a living Europe rather than a dying Europe. We hope that people who work for the European Union, politically active persons and others will be interested and will further help biology of aging reach concrete implementations."

PLAN TO LIVE FOR LONGER THAN YOU THINK YOU WILL
Monday, August 6, 2012
http://www.fightaging.org/archives/2012/08/plan-to-live-for-longer-than-you-think-you-will.php
Advice on financial planning for those who are not paying attention to progress in medicine: "My take on the mortality tables [used in financial planning]: they are excessively pessimistic. The mortality tables assume a fairly static biomedical treatment environment in which only small incremental improvements to medical care are possible. No discontinuities are part of the forecast. This seems a very big mistake. On the horizon we can see the approach of effective gene therapies, cell therapies, and other treatments that attack the underlying mechanisms of aging. The scientists doing research on these treatments will succeed. Once they do we will have biotechnology that enables us to repair aged tissue. For a long time mortality has declined fairly slowly. That's because we've had no tools for attacking the underlying mechanisms of aging. Our bodies gradually wear out just like bodies 50 or 100 years ago. We've got medical treatments that reduce the consequences of failing tissue (e.g. blood pressure medicine) and treatments that slow the rate of development of some types of problems (e.g. cholesterol lowering drugs). But we can't do much about the rate at which we accumulate mutations or the rate at which we accumulate toxic intracellular junk. We aren't going to stay helpless against aging tissues. The legions of scientists experimenting with pluripotent stem cells, tissue engineering, gene therapies, and other promising therapies will succeed and they will succeed in the first half of the 21st century. Once we can fix and replace failing parts the mortality tables go out the window as we gain the ability to do what we can now do to old cars: replace parts and keep on going. At some point in the 21st century we will reach actuarial escape velocity where the rate at which we can repair the body exceeds the rate at which pieces of the body wear out and fail. Our rejuvenated bodies will then go on for many more decades and eventually centuries. In a nutshell: If you are in your 30s or below I think your odds of dying of old age are remote. Whether folks in their 40s, 50s, and beyond will live to benefit from rejuvenation therapies probably depends on how long they will live naturally. Someone who is 50 years old and has 40 years to go even without biomedical advances will certainly live long enough to enjoy the benefits of biotechnologies that will enable them to live well beyond 90 years."

ON INTERMITTENT FASTING
Monday, August 6, 2012
http://www.fightaging.org/archives/2012/08/on-intermittent-fasting-1.php
The BBC on intermittent fasting, from the Horizon series: "Scientists are uncovering evidence that short periods of fasting, if properly controlled, could achieve a number of health benefits. ... Calorie restriction, eating well but not much, is one of the few things that has been shown to extend life expectancy, at least in animals. We've known since the 1930s that mice put on a low-calorie, nutrient-rich diet live far longer. There is mounting evidence that the same is true in monkeys. ... One area of current research into diet is Alternate Day fasting (ADF), involving eating what you want one day, then a very restricted diet (fewer than 600 calories) the next, and most surprisingly, it does not seem to matter that much what you eat on non-fast days. [Researchers] carried out an eight-week trial comparing two groups of overweight patients on ADF. ... If you were sticking to your fast days, then in terms of cardiovascular disease risk, it didn't seem to matter if you were eating a high-fat or low-fat diet on your feed (non-fast) days."

______________________________


<br> <br>View the full article

#22 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 19 August 2012 - 10:01 PM

FIGHT AGING! NEWSLETTER
August 20th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Don't Argue Incrementalism in a Time of Revolutionary Change
- Removing the Pressure of Impending Death
- A Thought on Priorities
- Discussion
- Latest Headlines from Fight Aging!
    - Everyone Suffers the Downward Spiral of Exercise Capacity
    - More Blood Vessel Engineering
    - Nanofactories to Produce and Target Drugs in the Body
    - Nanoparticles and RNA Interference Versus Cancer
    - An Improvement in Engineered Pancreatic Tissue
    - The Possibility of a Vaccine for Heart Disease
    - The Next Step in Building a Better Eye Prosthesis
    - Gadd45a Orchestrates Much of Muscle Atrophy
    - On Boredom and Radical Life Extension
    - "Not a harmless part of the aging process"

DON'T ARGUE INCREMENTALISM IN A TIME OF REVOLUTIONARY CHANGE

History provides us with some interesting examples of rapid technological innovation that have parallels to the present situation in biotechnology, medicine, and human longevity: steady progress is suddenly replaced with a great leap forward in capacity and quality.

http://www.fightaging.org/archives/2012/08/dont-argue-incrementalism-in-a-time-of-revolutionary-change.php

"The cautious majority believes that human life span will continue to increase, but only incrementally, much as it has done for the past few decades - both life expectancy at birth and life expectancy after 60, due to the continued introduction of new medical technologies. (Which proceeds far more slowly than it could, thanks to the heavy hand of the state). One faction of epidemiologists even argues for the possibility of a dip in overall life expectancy as present trends in obesity take their toll - to their eyes the consequences of being overweight look set to outweigh modest gains due to advances in medicine.

"To my mind, arguing for incrementalism in any trend relating to medicine at the present time is choosing to go against the tide. The biotechnologies that underpin advances in medicine are going through a period of massive, revolutionary change. While it is true that organizations such as the FDA do pretty much everything short of shooting scientists to slow down and increase the cost of turning research into therapies, the rapid pace of progress in the life sciences will win through.

"Allow me to put forward a historical analogy: standing in 2012 and arguing a case for gentle future changes in life expectancy over the next few decades, based on the past few decades, is something like standing in 1885 or so and arguing that speed and convenience of passenger travel will steadily and gently increase in the decades ahead. The gentleman prognosticator of the mid-1880s could look back at steady progress in the operating speed of railways and similar improvement in steamships throughout the 19th century. He would be aware of the prototyping of various forms of engine that promised to allow carriages to reliably proceed at the pace of trains, and the first frail airships that could manage a fair pace in flight - though by no means the equal of speed by rail.

"Like our present era, however, the end of the 19th century was a time of very rapid progress and invention in comparison to the past. In such ages trends are broken and exceeded. Thus within twenty years of the first crudely powered and fragile airships, heavier than air flight launched in earnest: a revolutionary change in travel brought on by the blossoming of a completely new branch of applied technology. By the late 1920s, the aircraft of the first airlines consistently flew four to five times as fast as the operating speed of trains in 1880, and new lines of travel could be set up for a fraction of the cost of a railway. Little in the way of incrementalism there: instead a great and sweeping improvement accomplished across a few decades and through the introduction of a completely new approach to the problem.

"This is one of many historical examples of discontinuities in gentle trends brought about by fundamentally new technologies. Returning to the medicine of the present day, there are any number of lines of work we could point to as analogous to the embryonic component technologies of an aircraft in 1885. They are still in the lab, or only being trialed, or still under development - but they exist in great numbers. There are the SENS technologies; a range of advanced applications of immunotherapy; targeting methodologies to safely destroy specific cell types; organ engineering; and others. Just because we can't see the exact shape of the emerging technologies that will be constructed atop these foundations doesn't make them any less likely to be created: great changes are coming down the line in medicine. The future is not one of steady and incremental progress."

REMOVING THE PRESSURE OF IMPENDING DEATH

What of a world in which people are not faced by the certainty of aging to death?

http://www.fightaging.org/archives/2012/08/removing-the-pressure-of-impending-death.php

"At root, medicine is driven by the urge remain alive. ... Consider a world with the means to prevent aging - say, though a package of therapies that a person undergoes every twenty years or so. Infusions of fresh stem cell populations, engineered enzymes to degrade metabolic waste products that build up in and around cells to impair their function, some form of mitochondrial DNA repair, culling excess memory T cells, and so on. These therapies prevent and reverse the build up of damage, allowing a body to continue in good health indefinitely. There is no good reason for them to be any more expensive than your average run of clinical treatments today: they would require little time from a physician, and would operate in much the same way for everyone, allowing economies of scale in production and distribution.

"In such a society, all of the pressures associated with the short span of life we presently enjoy evaporate. We are so steeped in that omnipresent pressure of time that it's somewhat hard to envisage what a society without it would look like. Every strategic decision that we make in the course of our lives is based on time - that we have ever less of it remaining, the clock is ticking, and have only a few shots at getting anything significant accomplished. It requires a decade to become truly talented in any particular profession or skill, for example, and at least a few years to figure out whether not we can follow through to that level. That is a vast investment of time when we only have a few decades in which we are at our prime. The same goes for careers and relationships of any significance. We are pressured and choices have great weight precisely because we must forever give up an ocean of possibilities in order to swim in any particular pool.

"There is a related school of thought among those opposed to engineering longevity: they say that the pressures of time created by the fact that we age to death due to our inadequate medical technology are a good thing. To me this has the look of rushing to justify what is, regardless of what might be, but they argue that the industry of individuals and humanity as a whole requires the deadline of dying; that without it, no-one would accomplish anything. They look upon the unending holocaust of death and destruction caused by aging - 100,000 lives every day, all they knew, all they could accomplish in the future, all they might have done, erased - and say it is necessary.

"This is a hideous nonsense, serving to illustrate that little but a veneer separates us from the barbarians who actively slaughtered millions in past decades. It is true that rapid progress is very necessary in today's world - but we need it because we are dying, and the only way to save ourselves is through technological progress. The faster the better, every increment of speed representing countless lives that might be saved on some future date. If more people were more aware and more interested in doing something about this, we might move faster yet towards the biotechnologies of rejuvenation. Unfortunately, for all that each and every human life is shaped completely by the foreknowledge of future disability and death, all too few are willing to help change this state of affairs.

"But so what if the medical technologies that can prevent death by aging make our societies slower-paced, more considered, less energetic? I'm not of the mind that this is a terrible thing - free-wheeling use of a resource is characteristic of wealth, and when we are wealthy in time, we will have the luxury to use it in ways that presently make little sense, or are called wasteful. Caring about waste is a sign of poverty, a sign that we don't have enough of whatever we worry about wasting, which in turn suggests we should do all we can to accumulate more of it. Besides, I don't for one moment believe that the slowing of economic engines and technological progress will in fact happen as feared by those who advocate for the continuation of mass death and suffering. There are all sorts of economic pressures upon human action that have next to nothing to do with aging and our current all-too-short span of life: consider the shifting desires for security, food, property, knowledge, and novelty, for example. The timescales on which those urges operate will not much change in an ageless society, as people will still have the same human nature as exists today. There will continue to be dynamic and ever-changing industries devoted to keeping people fed, clothed, and entertained."

A THOUGHT ON PRIORITIES

It is sometimes hard to avoid idle comparisons between flows of money and time in our society:

http://www.fightaging.org/archives/2012/08/a-thought-on-priorities.php

"Let us contemplate for a moment the level of effort that people put in to just one method of papering over just one of the changes caused by aging - just to keep up appearances, and making no difference at all to the underlying processes that cause degeneration. The method I had in mind is the use of dye to camouflage the progressive graying of hair. The fading of color of hair is an early sign that stem cell populations are responding to rising levels of damage, becoming less active in maintaining tissue. For whatever reason the pigment cells that give hair its color are more sensitive than others to the accumulating cellular and molecular damage of aging. Painting your hair in brightly colored chemicals does absolutely nothing other than cover up the evidence of this process, of course. You're still degenerating underneath that dye.

"Individually, touching up graying hair isn't a great undertaking, and nor does it cost much. But when many, many people do it, that adds up. Ten years ago, hair dye was an industry with $7 billion in yearly sales worldwide - give or take. While that certainly includes the Manic Panic youth brigade, a large fraction of that commerce involves coloring gray hair. So it's not a stretch to suggest that the world's elder folk have a great enough interest in hair dye to fund the NIA several times over, or for something more constructive, provide the budget to implement the SENS vision of rejuvenation biotechnology a couple of times every year.

"This sort of comparison serves to illustrate just how small research and development expenditures in medicine are in comparison to almost any form of day to day commerce. They tell us nothing about how to change that state of affairs, however. It's already something of a mystery as to why people are so relentlessly irrational when it comes to directing resources towards actual improvements in health and longevity versus papering over the cracks with hair dye or funding culturally accepted fraud in the form of 'anti-aging' products.

"Is it the case that people decide between funding research and hiding the gray, and choose to hide the gray? Or is it that funding meaningful research doesn't really even enter that choice matrix? To reframe these questions, is the solution to adequately funding the best and most promising longevity science more a matter of persuasion or more a matter of education?"

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

EVERYONE SUFFERS THE DOWNWARD SPIRAL OF EXERCISE CAPACITY
Friday, August 17, 2012
http://www.fightaging.org/archives/2012/08/everyone-suffers-the-downward-spiral-of-exercise-capacity.php
Other than calorie restriction, regular exercise is the most potent presently available method available to maintain health and extend life expectancy - which is actually more of a criticism of our lack of advanced biotechnology than praise for the merits of exercise. Exercise is beneficial even for the elderly, however, and one part of the downward spiral that comes with age is that loss of strength and increasing frailty constrain the ability to exercise sufficiently vigorously to obtain its benefits. This is true even for the longest-lived humans: "Ageing is a continuum of biological processes characterized by progressive adaptations which can be influenced by both genetic and physiological factors. In terms of human maturation, physically and cognitively functional centenarians certainly represent an impressive example of successful healthy ageing. However, even in these unique individuals, with the passage of time, declining lung function and sarcopenia lead to a progressive fall in maximal strength, maximal oxygen uptake, and therefore reduced exercise capacity. The subsequent mobility limitation can initiate a viscous downward spiral of reduced physical function and health. Emerging literature has shed some light on this multi-factorial decline in function associated with aging and the positive role that exercise and physical capacity can play in the elderly. Recognizing the multiple factors that influence ageing, the aim of this review is to highlight the recently elucidated limitations to physical function of the extremely old and therefore evaluate the role of exercise capacity in the health and longevity of centenarians."

MORE BLOOD VESSEL ENGINEERING
Friday, August 17, 2012
http://www.fightaging.org/archives/2012/08/more-blood-vessel-engineering-1.php
Many research groups are working on building blood vessels. Here is one: scientists "have developed [an] artificial functioning blood vessel outside of the body, made from reprogrammed stem cells from human skin. The team also saw the cells develop into a blood vessel inside the body for the first time. The new technique could have real potential to treat patients with heart disease [by] either injecting the reprogrammed cells into the leg or heart to restore blood flow or grafting an artificially developed vessel into the body to replace blocked or damaged vessels. ... this new study demonstrates that a new type of partial stem cell developed from fibroblasts (skin cells) can be reprogrammed into vascular cells before going into the body, which have no risk turning into tumours. The [team] introduced four genes to human fibroblasts in the laboratory to reprogramme them into partial stem cells so they could become vascular cells. When these newly created cells were injected into an ischemic leg (a leg with restricted blood flow) in an animal model, the function of the leg was improved. The process of developing vascular cells from skin cells took two weeks, which makes a personalised approach of turning a patient's own skin cells into vascular cells feasible for treatment of vessel-blocking related diseases. The researchers say the next step is to test this approach in cells from patients with vascular disease."

NANOFACTORIES TO PRODUCE AND TARGET DRUGS IN THE BODY
Thursday, August 16, 2012
http://www.fightaging.org/archives/2012/08/nanofactories-to-produce-and-target-drugs-in-the-body.php
Another branch of targeted therapies is the design of nanofactories that can be steered to specific locations in the body and there produce proteins and other drugs in response to local conditions or external commands. Early work in this field is underway: "Science is one step closer to producing drugs in the right place at the right time in the body, avoiding the collateral damage of untargeted treatments. Researchers [have] designed nanoparticles that can be stimulated via UV light to produce proteins on demand in vivo. The new method, which involves packaging the molecular machinery for making proteins into a membraned capsule, allows the researchers to spatially and temporally regulate protein production ... The scientists created the nano-sized 'protein factories' by using lipids to encapsulate polymerase and other machinery necessary for protein production from E. coli, along with a DNA plasmid containing a gene of interest. To block transcription until the right moment, they added a DNA 'photo-labile cage' to the plasmid - a small chemical that inhibits transcription but is cleaved by exposure to UV light. To test the principle in vivo, the researchers used luciferase as the reporter protein and injected mice with the nanovesicles. After zapping them with UV light at the site of injection, they were able to measure a local burst of luminescence. ... We have a long way to go still before we have a drug factory that will land in a target tissue to produce a drug of interest ... The study has proved the principle of the first step - getting the protein expressed on signal - but future research will need to ensure that the nanoparticles and the proteins they produce aren't toxic in the wrong place, and that they get to the right location. Targeting the nanoparticles to the appropriate tissues might be achieved by 'decorating' the surface of the vesicles with specific proteins."

NANOPARTICLES AND RNA INTERFERENCE VERSUS CANCER
Thursday, August 16, 2012
http://www.fightaging.org/archives/2012/08/nanoparticles-and-rna-interference-versus-cancer.php
A novel form of targeted therapy under development in the cancer research community: "By sequencing cancer-cell genomes, scientists have discovered vast numbers of genes that are mutated, deleted or copied in cancer cells. This treasure trove is a boon for researchers seeking new drug targets, but it is nearly impossible to test them all in a timely fashion. To help speed up the process, [researchers] have developed RNA-delivering nanoparticles that allow for rapid screening of new drug targets in mice. In their first mouse study [they] showed that nanoparticles that target a protein known as ID4 can shrink ovarian tumors.What we did was try to set forth a pipeline where you start with all of the targets that are pouring out of genomics, and you sequentially filter them through a mouse model to figure out which ones are important. By doing that, you can prioritize the ones you want to target clinically using RNA interference ... researchers decided to focus on the ID4 protein because it is overexpressed in about a third of high-grade ovarian tumors (the most aggressive kind), but not in other cancer types. The gene, which codes for a transcription factor, appears to be involved in embryonic development: It gets shut down early in life, then somehow reactivates in ovarian tumors. To target ID4, [researchers] designed a new type of RNA-delivering nanoparticle. Their particles can both target and penetrate tumors, something that had never before been achieved with RNA interference. ... Within the nanoparticles, strands of RNA are mixed with a protein that further helps them along their journey: When the particles enter a cell, they are encapsulated in membranes known as endosomes. The protein-RNA mixture can cross the endosomal membrane, allowing the particles to get into the cell's main compartment and start breaking down mRNA. In a study of mice with ovarian tumors, the researchers found that treatment with the RNAi nanoparticles eliminated most of the tumors."

AN IMPROVEMENT IN ENGINEERED PANCREATIC TISSUE
Wednesday, August 15, 2012
http://www.fightaging.org/archives/2012/08/an-improvement-in-engineered-pancreatic-tissue.php
From ScienceDaily: "researchers have built pancreatic tissue with insulin-secreting cells, surrounded by a three-dimensional network of blood vessels. The engineered tissue could pave the way for improved tissue transplants to treat diabetes. The tissue [has] some significant advantages over traditional transplant material that has been harvested from healthy pancreatic tissue. The insulin-producing cells survive longer in the engineered tissue, and produce more insulin and other essential hormones ... When they transplanted the tissue into diabetic mice, the cells began functioning well enough to lower blood sugar levels in the mice. ... The well-developed blood vessel network built into the engineered tissue is key to its success, the researchers concluded. The blood vessels encourage cell-to-cell communication, by secreting growth hormones and other molecules, that significantly improve the odds that transplanted tissue will survive and function normally. ... One reason transplants fail [is] that the islets are usually transplanted without any accompanying blood vessels. ... Until the islets begin to connect with a person's own vascular system, they are vulnerable to starvation. The 3-D system developed by [the] researchers tackled this challenge by bringing together several different cell types to form a new transplantable tissue. Using a porous plastic material as the scaffold for the new tissue, the scientists seeded the scaffold with mouse islets, tiny blood vessel cells taken from human umbilical veins, and human foreskin cells that encouraged the blood vessels to develop a tube-like structure. ... The advantages provided by this type of environment are really profound ... the number of islets used to lower blood sugar levels in the mice was nearly half the number used in a typical islet transplant. Islets grown in these rich, multicellular environments lived three times as long on average as islets grown by themselves."

THE POSSIBILITY OF A VACCINE FOR HEART DISEASE
Wednesday, August 15, 2012
http://www.fightaging.org/archives/2012/08/the-possibility-of-a-vaccine-for-heart-disease.php
Via EurekAlert!: "Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system. A number of research studies have demonstrated inflammation's role in fueling plaque buildup, also known as atherosclerosis, which is the underlying cause of most heart attacks and strokes, but knowledge of which immune cells are key to this process has been limited - until now. Researchers [have] identified the specific type of immune cells (CD4 T cells) that orchestrate the inflammatory attack on the artery wall. Further, the researchers discovered that these immune cells behave as if they have previously seen the antigen that causes them to launch the attack. ... The thing that excites me most about this finding is that these immune cells appear to have 'memory' of the molecule brought forth by the antigen-presenting cells. Immune memory is the underlying basis of successful vaccines. This means that conceptually it becomes possible to consider the development of a vaccine for heart disease. [Researchers believe] the antigen involved is actually a normal protein that the body mistakes as being foreign and therefore launches an immune attack resulting in inflammation in the arteries. ... Essentially, we're saying that there appears to be a strong autoimmune component in heart disease. Consequently, we could explore creating a 'tolerogenic' vaccine, such as those now being explored in diabetes, which could induce tolerance by the body of this self-protein to stop the inflammatory attack."

THE NEXT STEP IN BUILDING A BETTER EYE PROSTHESIS
Tuesday, August 14, 2012
http://www.fightaging.org/archives/2012/08/the-next-step-in-building-a-better-eye-prosthesis.php
Present prosthetic retina technology consists of an implanted electrode grid; progress is increasing the resolution by adding more electrodes to the grid. Here researchers take a different route, investigating ways to encode information such that neural cells will better process the resulting image: "More than 20 million people worldwide become blind owing to the degeneration of their retina, the thin tissue at the back of the eye that turns light into a neural signal. Only one prosthesis has been approved for treatment of the condition - it consists of an array of surgically implanted electrodes that directly stimulate the optic nerve and allow patients to discern edges and letters. Patients cannot, however, recognize faces or perform many everyday tasks. Sheila Nirenberg, a physiologist at the Weill Medical College at Cornell University in New York thinks that the problem is at least partially down to coding. Even though the retina is as thin as tissue paper, it contains several layers of nerves that seem to encode light into neural signals. 'The thing is, nobody knew the code,' she says. Without it, Nirenberg believes that visual prostheses will never be able to create images that the brain can easily recognize. Now, she and her student, Chethan Pandarinath, have come up with a code and developed a device that uses it to restore some sight in blind mice. The duo began by injecting nerve cells in the retinas of their mice with a genetically engineered virus. The virus had been designed to insert a gene that causes the cells to produce a light-sensitive protein normally found in algae. When a beam of light was then shown into the eye, the protein triggered the nerve cells to send a signal to the brain, performing a similar function to healthy rod and cone cells. Rather than feeding visual signals directly into the eye, they processed them using a code that the pair had developed by watching how a healthy retina responds to stimuli. After receiving the encoded input, the mice were able to track moving stripes, something that they hadn't been able to do before. The pair then looked at the neural signals that the mice were producing and used a different, 'untranslate', code to figure out what the brain would have been seeing. The encoded image was clearer and more recognizable than the non-encoded one. ... Nirenberg hopes to test the system in human trials soon. The encoding is simple enough to be done by a microchip, which, together with a small video camera could fit onto a pair of glasses. The camera would record a signal and the encoder would then flash it directly onto the genetically treated nerve cells in the eye."

GADD45A ORCHESTRATES MUCH OF MUSCLE ATROPHY
Tuesday, August 14, 2012
http://www.fightaging.org/archives/2012/08/gadd45a-orchestrates-much-of-muscle-atrophy.php
An important regulatory gene for muscle atrophy is identified: "We now understand a key molecular mechanism of skeletal muscle atrophy. This finding could help us find a therapy for treating muscle atrophy in patients. ... The team has identified a single protein, called Gadd45a, and determined that it orchestrates 40 percent of the gene activity that ultimately causes skeletal muscle to atrophy. ... The researchers learned that Gadd45a affected muscles in two main ways: it instructed muscle cells to produce fewer proteins (needed to maintain muscle), and it caused proteins already existing in muscle fibers to break down. The result on both counts: muscle atrophy. The team then turned to find out how Gadd45a did its work. The nucleus of a muscle cell that is stressed changes from a cigar shape to a swollen bulb, with enlarged nucleoli (protein containers inside the nucleus). When Adams and his team injected Gadd45a into a muscle cell, the nucleus changed shape the same way as if it were stressed. ... To put this all together, it means Gadd45a is going into the muscle nucleus, and it totally changes it, so much so that the changes are visible. It's turning genes on, and it's turning genes off. It's changed the cell. ... Gadd45a changes roughly 600 genes associated with muscle atrophy, by increasing mRNAs charged either with breaking down muscle proteins or reducing muscle protein growth. ... Gadd45a is like a central switch for muscle atrophy. If you can block it, you can conceivably stunt muscle atrophy to a large extent."

ON BOREDOM AND RADICAL LIFE EXTENSION
Monday, August 13, 2012
http://www.fightaging.org/archives/2012/08/on-boredom-and-radical-life-extension.php
Some people knee-jerk against the prospect of a greatly extended healthy life by thinking of boredom - they can't imagine what they'd do with additional time. To my mind this fits well with the demographic who are ambivalent about being alive at all. To live a longer or shorter life will always be a choice, however. You won't have to undergo the rejuvenation therapies when they are available, just as you don't have to exercise, eat less, or otherwise maintain your health today: a shorter life is right there for the taking, if you feel so inclined. Here is a piece from io9 on the subject: "Some futurists predict that we'll be able to halt the aging process by the end of this century - if not sooner. The prospect of creating an ageless society is certainly not without its critics, with concerns ranging from the environmental right through to the spiritual. One of the most common objections to radical life extension, however, is the idea that it would be profoundly boring to live forever, and that by consequence, we should not even attempt it. So are the critics right? Let's take a closer look at the issue and consider both sides. To help us make sense of the problem, we spoke to two experts who have given this subject considerable thought: Bioethicist Nigel Cameron, the President of the Center for Policy on Emerging Technologies, and philosopher Mark A. Walker, Assistant Professor and Richard L. Hedden Chair of Advanced Philosophical Studies at New Mexico State University. It was through our conversations with them that we realized how difficult this question is to answer - mostly because no one has ever lived long enough to know. But given what's at stake, it's an issue that's certainly worth considering. Now, before we get into the discussion, there are a couple of things to note. First, this is not idle speculation. An increasing number of gerontologists, biologists, and futurists are predicting significant medical breakthroughs in the coming decades that could result in so-called 'negligible senescence' - the indefinite prolongation of healthy human life. And second, this discussion is limited to the question of boredom. Clearly, there are many other serious implications to radical life extension, but those are outside the scope of this article. Okay, let's do this thing."

"NOT A HARMLESS PART OF THE AGING PROCESS"
Monday, August 13, 2012
http://www.fightaging.org/archives/2012/08/not-a-harmless-part-of-the-aging-process.php
There is a pervasive mythology surrounding aging: that it includes many harmless changes, things that are "normal" and therefore not worthy of the attention of medicine. This is all nonsense. All changes that happen with aging are damage-driven declines, but because the overall effect is so disastrous it can be hard to pin down and separate out the lesser components. As biotechnology improves, we will see ever more pieces of aging segmented off and named as specific diseases - but in reality it's all harmful, and the full breadth of aging should be fought against: researchers "say a common condition called leukoaraiosis, made up of tiny areas in the brain that have been deprived of oxygen and appear as bright white dots on MRI scans, is not a harmless part of the aging process, but rather a disease that alters brain function in the elderly. ... In the past, leukoaraiosis has been considered a benign part of the aging process, like gray hair and wrinkles. ... [Researchers] performed functional MRI (fMRI) scans on cognitively normal elderly participants recruited from the Mayo Clinic Study of Aging between 2006 and 2010. In 18 participants, the amount of leukoaraiosis was a moderate 25 milliliters, and in 18 age-matched control participants, the amount of disease was less than five milliliters. The patients were imaged in an MRI scanner as they performed a semantic decision task by identifying word pairs and a visual perception task that involved differentiating straight from diagonal lines. ... Although both groups performed the tasks with similar success, the fMRI scans revealed different brain activation patterns between the two groups. Compared to members of the control group, patients with moderate levels of leukoaraiosis had atypical activation patterns, including decreased activation in areas of the brain involved in language processing during the semantic decision task and increased activation in the visual-spatial areas of the brain during the visual perception task. ... Different systems of the brain respond differently to disease. White matter damage affects connections within the brain's language network, which leads to an overall reduction in network activity."

______________________________


<br> <br>View the full article

#23 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 26 August 2012 - 01:39 PM

FIGHT AGING! NEWSLETTER
August 27th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- The Concept of "Aging Successfully" Seems Wrongheaded
- Nascent Brainmaking
- A Political Party for the 2045 Initiative
- Alcor and Cryonics in the Popular Press
- Discussion
- Latest Headlines from Fight Aging!
    - Identifying Cancer Stem Cells for Melanoma
    - Testing Stem Cells From Amniotic Fluid as a Stroke Therapy
    - Investigating the Gene Network of Calorie Restriction
    - Obesity Correlates With Faster Mental Decline
    - SIRT6 Overexpression Extends Mean Lifespan in Male Mice
    - A Cautionary Note on Arranging Your Cryopreservation in Advance
    - Slowing Stem Cell Aging
    - An In-Depth Look at Organovo
    - Reviewing the Regulation of Autophagy in Aging
    - Failing Neural Plasticity and Age-Related Memory Decline

THE CONCEPT OF "AGING SUCCESSFULLY" SEEMS WRONGHEADED

There is no "successful terminal cancer" movement. So why so much focus on the idea of "successful aging?" This is one of many examples of the way in which the medical community is far more accepting of the suffering caused by aging to death than that caused by other form of progressive disability or medical condition:

http://www.fightaging.org/archives/2012/08/the-concept-of-aging-successfully-seems-wrongheaded.php

"The concept of 'successful aging' is one put forward by a fairly wide-ranging group of people in medicine and research. When you break it down, 'aging successfully' means that a bunch of really horrible things happen to you and your body, and then you die, but at least you weren't suffering as much as those guys over there. This seems wrongheaded on a number of levels. It is the sort of thing that a researcher talks about when they are trying to avoid any mention of lengthening human life through medicine - which was at one time very much required ... This is no longer completely the case, but old habits die hard and there remains a sizable contingent in the research community who refuse to acknowledge that extending life is an ongoing goal. Hence talk of 'successful aging' and 'compression of morbidity' in connection with efforts to eliminate age-related disease or slow the pace at which people decline in old age. Anything other than raising the prospect of extending maximum life span in addition to healthy life span.

This is all somewhat complicated by the fact that no good definition for successful aging exists - and, really, how could it? In trying, you'll end up with something as ridiculous and self-defeating as the first paragraph in this post. You are in effect, and within the bounds of the philosophy of medicine, setting out to define an acceptable level of suffering, pain, and degeneration, rather than proposing to do treat it - which I think becomes ever more evident the more that you think about the whole thing. ... Implicit in this is the acceptance of aging and disability - the underlying assumption that aging must happen, and along with it great suffering. Aging cannot be successful. It is not a success to suffer, degenerate, and die. It isn't success to point out other people who are suffering more than you are. This whole way of thinking about about aging is a wrong, bad path that leads away from what needs to be done, which is to consider aging as a medical issue that should be addressed, just like every other medical issue that causes pain and hardship."

NASCENT BRAINMAKING

Here is an example of the degree to which tissue engineers have progressed in their understanding of how to grow a brain:

http://www.fightaging.org/archives/2012/08/nascent-brainmaking.php

"Yoshiki Sasai, a stem-cell biologist at the RIKEN Center for Developmental Biology in Kobe, Japan, [has] impressed many researchers with his green-fingered talent for coaxing neural stem cells to grow into elaborate structures. As well as the optic cup, he has cultivated the delicate tissue layers of the cerebral cortex and a rudimentary, hormone-making pituitary gland. He is now well on the way to growing a cerebellum - the brain structure that coordinates movement and balance.

"What does one do with the ability to tissue engineer a brain? This will be possible not too many years from now. It's not as obviously useful as the ability to engineer a heart, as the brain can't be replaced outright in the same way - although that said it seems possible, based on present knowledge, for a least a few small portions of the brain to be successfully transplanted without affecting the mind. Not every part of the brain is greatly involved in the data and processing mechanisms that make up the self. But this seems as though it will be far harder than transplanting any other organ elsewhere in the body, and hard enough that parallel lines of research into repairing tissue in situ through stem cells and signaling manipulation may win out from the outset. So the likely primary benefit resulting from the sort of work carried out by Sasai's group will be knowledge: information that can be applied to the development of ways to rebuild damaged brain tissue in place rather than building outside the body and then undergoing a transplant operation."

A POLITICAL PARTY FOR THE 2045 INITIATIVE

The formation of single issue political parties focused on engineered longevity and scientific development to that end seems to be a strategy very much in the air at the moment.

http://www.fightaging.org/archives/2012/08/a-political-party-for-the-2045-initiative.php

"I note that the Russian community behind the well-backed 2045 initiative are trying their hands at launching a political party to further the cause. There is a website for the Evolution 2045 party concept; at this point it would seem to be chiefly worthwhile as a way to gain some additional insight into the thinking of those steering the 2045 initiative. ... The Initiative 2045 announces the creation of its own political party - 'Evolution 2045' - in order to advocate for a new strategy for human development. This is a Russia-based party, but its goals are international and global. Our ultimate goal is to inspire other countries to follow suit, and compete not in the arms race, but in the race for building a bright future for mankind.

"Single issue political parties are a long-standing and widely used methodology for advancing particular causes in Europe and further East, far more so than across the pond in the US, though they do exist there as well. In most European countries you'll find a range of these organizations, some more successful than others. The Green parties are perhaps the exemplar of the type, formed around a movement and grown to staid success in terms of delivering their message, with the Pirate parties as another, younger and still dynamic example.

"Either way, radical optimism about what can be achieved in the near future - if we just worked at it - is in comparatively short supply in our culture. Visionaries who talk about the path to humanity ascendant are a small minority in comparison to the masses and the talking heads who are blinkered by the present and look little further than the bounds of what is. So more vision and more optimism are very welcome, even if harnessed to a program that isn't my first choice for how to proceed towards engineering greatly extended lives."

ALCOR AND CRYONICS IN THE POPULAR PRESS

Some positive coverage of the cryonics industry to look over:

http://www.fightaging.org/archives/2012/08/a-positive-popular-press-article-on-alcor-and-cryonics.php

"The public attitude towards cryonics has shifted greatly over the past ten years, at least as measured by the changing tenor of articles in the popular press. They are more favorable, more respectful, and more accurate on technical details. So greater exposure and publicity over the past decade has brought benefits, and increasing familiarity with the topic has allowed more people to overcome whatever knee-jerk reactions they normally have to all novel ideas. This is a positive trend, perhaps driven as much by the general proliferation of media enabled by the internet as by efforts made by the cryonics community, and will hopefully continue apace.

"The Alcor Life Extension Foundation is the world's leading provider of cryonics, the practice of using ultra-cold temperatures to preserve humans until such a time when medicine is advanced enough to restore good health. The widely-held belief that it involves freezing is actually something of a red herring. As soon as possible after legal death is pronounced, cryoprotectant solution - a sort of antifreeze - is administered to a patient through their circulatory system, entering almost every cell in the body. Known as vitrification, this process avoids ice crystal formation and allows the body to be cooled with virtually no freezing damage, before being placed in liquid nitrogen in a Dewar container and moved to storage indefinitely.

"For a long time cryonics was dismissed by many as science-fiction, an unnatural or even immoral procedure, but while the company make no bones about cryonics being an entirely speculative process, futurist and Alcor chief executive Max More says that the field is gaining legitimacy in the eyes of others. 'People have certainly grown less hostile,' he told Metro. 'In terms of how science looks at cryonics we've definitely seen an improvement over time.' Mr More added that Alcor's teams which intervene at members' deathbeds are also being treated more favourably by doctors. 'Our relationship with hospitals and hospices has also improved; they used to be very adversarial and reluctant to even let us in, now hospital staff are usually fascinated and want to help in any way they can. They even let us position our equipment in the room next to the patient before clinical death, their whole attitude has really turned around.'"

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

IDENTIFYING CANCER STEM CELLS FOR MELANOMA
Friday, August 24, 2012
http://www.fightaging.org/archives/2012/08/identifying-cancer-stem-cells-for-melanoma.php
The cancer stem cell hypothesis continues to show promise as a way to strike at the root of many different forms of cancer: "Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A [new study] shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators. ... We've seen ALDH as a stem cell marker in other cancer types, but not in melanoma, and until now its function has been largely unknown. ... [Researchers] transplanted ALDH+ and ALDH- melanoma cells into animal models, showing the ALDH+ cells were much more powerfully tumorigenic. In the same ALDH+ cells, the group then silenced the gene that creates this protein, finding that with ALDH knocked down, melanoma cells died in cultures and lost their ability to form tumors in animal models. In cell cultures, silencing this ALDH gene also sensitized melanoma cells to existing chemotherapies. When the group explored human tumor samples, they found distinct subpopulations of these ALDH+ cells, which made up about 0.1-0.2 percent of patients' primary tumors. In samples of metastatic melanoma - the most aggressive form of the disease - the percentage of ALDH+ cells was greater, even over 10 percent in some tumors, further implying the powerful danger of these cells."

TESTING STEM CELLS FROM AMNIOTIC FLUID AS A STROKE THERAPY
Friday, August 24, 2012
http://www.fightaging.org/archives/2012/08/testing-stem-cells-from-amniotic-fluid-as-a-stroke-therapy.php
Many different sources of stem cells remain under investigation, such as those derived from amniotic fluid: "We recently reported isolation of viable rat amniotic fluid-derived stem (AFS) cells. Here, we tested the therapeutic benefits of AFS cells in a rodent model of ischemic stroke. Adult male Sprague-Dawley rats received a 60-minute middle cerebral artery occlusion (MCAo). Thirty-five days later, animals exhibiting significant motor deficits received intravenous transplants of rat AFS cells or vehicle. At days 60-63 post-MCAo, significant recovery of motor and cognitive function was seen in stroke animals transplanted with AFS cells compared to vehicle-infused stroke animals. Infarct volume [was] significantly reduced, coupled with significant increments in the cell proliferation marker, Ki67, and the neuronal marker, MAP2, in the dentate gyrus (DG) and the subventricular zone (SVZ) of AFS cell-transplanted stroke animals compared to vehicle-infused stroke animals. ... This study reports the therapeutic potential of AFS cell transplantation in stroke animals, possibly via enhancement of endogenous repair mechanisms."

INVESTIGATING THE GENE NETWORK OF CALORIE RESTRICTION
Thursday, August 23, 2012
http://www.fightaging.org/archives/2012/08/investigating-the-gene-network-of-calorie-restriction.php
Research into the detailed mechanisms of calorie restriction continues apace: "Dietary restriction (DR), limiting nutrient intake from diet without causing malnutrition, delays the aging process and extends lifespan in multiple organisms. The conserved life-extending effect of DR suggests the involvement of fundamental mechanisms, although these remain a subject of debate. To help decipher the life-extending mechanisms of DR, we first compiled a list of genes that if genetically altered disrupt or prevent the life-extending effects of DR. We called these DR-essential genes and identified more than 100 in model organisms such as yeast, worms, flies, and mice. In order for other researchers to benefit from this first curated list of genes essential for DR, we established an online database called GenDR. To dissect the interactions of DR-essential genes and discover the underlying lifespan-extending mechanisms, we then used a variety of network and systems biology approaches to analyze the gene network of DR. We show that DR-essential genes are more conserved at the molecular level and have more molecular interactions than expected by chance. Furthermore, we employed a guilt-by-association method to predict novel DR-essential genes. In budding yeast, we predicted nine genes related to vacuolar functions; we show experimentally that mutations deleting eight of those genes prevent the life-extending effects of DR. Three of these mutants [had] extended lifespan under ad libitum, indicating that the lack of further longevity under DR is not caused by a general compromise of fitness. These results demonstrate how network analyses of DR using GenDR can be used to make phenotypically relevant predictions. ... comparing the influence of gene expression changes during DR on the interactomes of multiple organisms led us to suggest that DR commonly suppresses translation, while stimulating an ancient reproduction-related process."

OBESITY CORRELATES WITH FASTER MENTAL DECLINE
Thursday, August 23, 2012
http://www.fightaging.org/archives/2012/08/obesity-correlates-with-faster-mental-decline.php
Here is another of many studies to link being overweight with cognitive decline: "People who are obese and suffer from high blood pressure and other problems linked to heart disease and diabetes may also see a faster decline in their mental abilities, according to a new study ... Yet even obese people without these physical conditions experienced a faster decline in functions such as memory, the researchers noted. This finding belies the concept of being obese and healthy ... Participants came from the long-running Whitehall II study, which began in 1985 and follows British civil servants from middle age onward. For the new findings, researchers followed more than 6,400 people aged 39 to 63 for 10 years. At the start of the study, they recorded patients' risk factors, including weight. During the follow-up decade, participants also took tests on memory, reasoning and overall mental function at three intervals. People with metabolic syndrome who were also obese saw a more rapid decline - 22.5 percent faster - in their mental function than those who weren't obese and didn't suffer from the syndrome. Moreover, those who did not have metabolic syndrome but were obese also saw mental function decline more quickly than participants who were not obese."

SIRT6 OVEREXPRESSION EXTENDS MEAN LIFESPAN IN MALE MICE
Wednesday, August 22, 2012
http://www.fightaging.org/archives/2012/08/sirt6-overexpression-extends-mean-lifespan-in-male-mice.php
Some more data to add to the muddy waters of sirtuin research: "Since the discovery that overexpression of yeast Sir2 deacetylase extends lifespan by as much as 30% over a decade ago, much effort has been invested in researching whether this effect is conserved in higher organisms as well. Indeed, in worms and flies, two separate groups found that SIR2 extended lifespan as well, by 50% and 18%, respectively. ... In parallel to the work in worms and flies, researchers were trying to make headway in the role of sirtuins in higher organisms. There are seven mammalian homologs to the yeast Sir2, SIRT1-SIRT7. SIRT1 is the most well-researched and has been shown to regulate metabolism and age-related diseases. However, SIRT1 overexpression did not increase lifespan, although this was said to be due to the relatively weak expression of the transgene. Therefore, a role for sirtuins in regulating lifespan of mammals looked bleak. Despite the controversy surrounding sirtuins and longevity, there has never been any doubt that mammalian sirtuins are important regulators of health and disease. Previous results from our lab have shown SIRT6 to be involved in the calorie restriction response, and demonstrate that SIRT6 overexpression in mice protects against diet-induced obesity and its metabolic consequences. These results, along with data that SIRT6 knockout mice display a premature aging-like phenotype, prompted us to turn towards SIRT6 as a potential regulator of mammalian aging. Over the course of three years, we measured the lifespan of mice overexpressing exogenous SIRT6 (MOSES). This study was performed in two separate lines from distinct founders, to ensure that the random integration of the transgene into the genome did not influence the results. We found that the gene insertion in both lines did not disrupt any neighboring genes, and results were similar in both lines. In this way we overcame the issue of site-specific integration, which was previously shown to be a problem in sirtuin studies. Additionally, we chose to work with a mixed background, to ensure no strain-specific effects. Strikingly, both male MOSES lines had significant mean and median lifespan extension, of 14.5% and 9.9%. Even more interesting, there was no lifespan extension in either female lines examined, attesting to a gender-specific role for SIRT6."

A CAUTIONARY NOTE ON ARRANGING YOUR CRYOPRESERVATION IN ADVANCE
Wednesday, August 22, 2012
http://www.fightaging.org/archives/2012/08/a-cautionary-note-on-arranging-your-cryopreservation-in-advance.php
In the latest case report from Alcor, there is a cautionary note on the need to solidify the arrangements and financing of cryopreservation before the last minute: "Alcor member A-2628 (he wishes his identity to be kept private) was pronounced legally deceased on July 23, 2012. A whole body member, A-2628 became Alcor's 112th patient. On Friday, July 20th, Alcor was notified through the TeleMed alert system that a 90 year old individual wishing to be cryopreserved was in serious condition in a Las Vegas hospital. This individual had filled out an application for membership in 2009 (and was provisionally assigned the number A-2628) but never followed through with the necessary paperwork and funding. Since he became unable to make cryonics arrangements, this case had to be treated as a third-party arrangement. Because of the greater risk involved, Alcor requires additional conditions to be met before accepting such a case. These conditions are rarely met. These include some past interest in cryonics on the part of the person for whom cryopreservation is sought; lack of opposition by close relatives; finances in place without undue hardship; no long ischemic time; and informed consent of persons making the arrangement. This case was one of the rare ones to proceed, in large part due to the determined efforts of A-2628's granddaughter supported by the family accountant."

SLOWING STEM CELL AGING
Tuesday, August 21, 2012
http://www.fightaging.org/archives/2012/08/slowing-stem-cell-aging.php
Via the New Scientist: "Could we stem the tide of ageing by delaying the deterioration of stem cells? A new compound that appears to do just that could help us find ways to protect our organs from age-related wear and tear, experiments in mice suggest. As we age, so do our mesenchymal stem cells (MSCs): their numbers in our bone marrow decline, and those that are left lose the ability to differentiate into the distinct cell types - such as bone, cartilage, fat and possibly muscle cells - that help in the healing process. ... We think this ageing of stem cells may be linked to the onset of some age-related disorders, such as osteoporosis ... Earlier research in mice had suggested that the prion protein expressed by MSCs might play a role in holding back stem cell ageing. Mice lacking the prion protein were less able to regenerate blood cells. [Researchers] have now found that the prion protein performs a similar function in humans - older MSCs from human bone marrow expressed less of the protein than younger ones. In a bid to find a compound that might slow MSC ageing, the team tested numerous molecules known to target prion proteins on dishes of human stem cells. One molecule emerged as a potential candidate - stem cells treated with it produced 300 times the number of cells over 250 days than untreated stem cells. The treated cells kept on dividing for longer. The team then injected treated cells into the thigh bones of mice, and three days later found that they had produced three times as many new cells as they would normally produce. After five weeks, there were 10 times as many cells. The new cells appeared to be of higher quality, too, and readily differentiated into bone and fat cells, as well as those that support the tissue and blood vessels. [Researchers] think the molecule works by helping the prions protect the stem cells from the DNA damage associated with normal ageing."

AN IN-DEPTH LOOK AT ORGANOVO
Tuesday, August 21, 2012
http://www.fightaging.org/archives/2012/08/an-in-depth-look-at-organovo.php
For those following the progress of Organovo, a business-focused review: "In the classical approach to tissue engineering, cells are seeded and grown in a biocompatible matrix designed to direct cell differentiation and function. Scaffoldings play an important role in providing the cell architecture for structure and migration, as well as enabling the diffusion of vital nutrients and expressed product. Unfortunately, there are challenges that exist with the classical approach. Scaffolds, made from both natural and synthetic polymers, must be engineered to degrade at a rate in which the cells within them deposit and build their own extracellular matrix. Scaffold choice, immunogenicity, degradation rate, toxicity of degradation products, host inflammatory responses, fibrous tissue formation due to scaffold degradation, and mechanical mismatch with the surrounding tissue are key issues that may affect the long term behavior of the engineered construct, and directly interfere with its primary biological function. Additionally, scaffolds may elicit adverse host responses and interfere with direct cell-cell interaction. To get around the challenges of classical tissue engineering, Organovo has developed the first 3D bioprinter, called NovoGen MMX. The NovoGen MMX Bioprinter is a novel, fully automated, hardware and software platform developed to fabricate three-dimensional (3D) primary human or other living mammalian cells into tissue, with tremendous cellular viability and biology that is superior to even an animal model. Organovo's NovoGen MMX mechanical extruder enables the fabrication of three-dimensional tissue constructs in a wide variety of geometries (tubular structures, networked sheets, etc...). The speed and precision of this instrument enables the production of small-scale tissue models for drug discovery as well as various drug absorption and toxicology assays. NovoGen MMX works similar to an inkjet printer, in where cells are printed in tiny spheres; essentially 'bio-ink'. The concept of bioprinting relies on the demonstrated principle that groups of individual cells will self-assemble to generate aggregates, through the actions of cell surface proteins that bind to each other and form junctions. Furthermore, if two or more compatible self-assembled aggregates are placed in close proximity, under the proper conditions they will fuse to generate larger, more complex structures."

REVIEWING THE REGULATION OF AUTOPHAGY IN AGING
Monday, August 20, 2012
http://www.fightaging.org/archives/2012/08/reviewing-the-regulation-of-autophagy-in-aging.php
Autophagy, a collection of processes by which a cell breaks down damaged components to recycle their materials, is important in many mechanisms known to extend life in various laboratory animals. Better maintained cells are better for a longer life: more autophagy is a good thing, but it declines with age, because of a gradual buildup of materials that cannot be recycled and thus clog up the cellular components that perform autophagy - and for other, less well understood reasons. Here is an open access review on some of the controlling mechanisms: "One part of the aging process involves a decline in cellular housekeeping functions disturbing the maintenance of organism homeostasis. The accumulation of damaged and defective components increases cellular stress, for example, oxidative stress, which activates cellular defence mechanisms including NF-κB signaling pathway and innate immunity system, such as inflammasomes. Aging is associated with a low-grade proinflammatory phenotype which further interferes with housekeeping and cellular homeostasis. Recent studies have indicated that autophagy is a crucial cleansing system preventing inflammation but its capacity clearly declines with aging. The NF-κB signaling system and the autophagic degradation pathway have been closely conserved during evolution and emerging studies indicate that these systems have many context-dependent interactions with each other. We will review the recent literature on the control mechanisms of autophagy by NF-κB signaling and particularly we will focus on its context-dependent regulation during the aging process."

FAILING NEURAL PLASTICITY AND AGE-RELATED MEMORY DECLINE
Monday, August 20, 2012
http://www.fightaging.org/archives/2012/08/failing-neural-plasticity-and-age-related-memory-decline.php
An open access paper: "Cognitive impairment associated with subtle changes in neuron and neuronal network function rather than widespread neuron death is a feature of the normal aging process in humans and animals. Despite its broad evolutionary conservation, the etiology of this aging process is not well understood. However, recent evidence suggests the existence of a link between oxidative stress in the form of progressive membrane lipid peroxidation, declining neuronal electrical excitability and functional decline of the normal aging brain. The current study applies a combination of behavioural and electrophysiological techniques and pharmacological interventions to explore this hypothesis in a gastropod model (Lymnaea stagnalis feeding system) that allows pinpointing the molecular and neurobiological foundations of age-associated long-term memory (LTM) failure at the level of individual identified neurons and synapses. ... Classical appetitive reward-conditioning induced robust LTM in mature animals in the first quartile of their lifespan but failed to do so in animals in the last quartile of their lifespan. LTM failure correlated with reduced electrical excitability of two identified serotonergic modulatory interneurons (CGCs) critical in chemosensory integration by the neural network controlling feeding behaviour. Moreover, while behavioural conditioning induced delayed-onset persistent depolarization of the CGCs known to underlie appetitive LTM formation in this model in the younger animals, it failed to do so in LTM-deficient senescent animals. ... The results identify the CGCs as cellular loci of age-associated appetitive learning and memory impairment in Lymnaea and buttress the hypothesis that lipid peroxidation-dependent depression of intrinsic excitability is a hallmark of normal neuronal aging."

______________________________


<br> <br>View the full article

#24 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 02 September 2012 - 02:15 PM

FIGHT AGING! NEWSLETTER
September 3rd 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- A Perspective on Progress in Longevity Science
- What's Really Delaying the Defeat of Aging?
- Absent Optimism
- Everyone Has a Plan to Save Medicare
- Discussion
- Latest Headlines from Fight Aging!
    - SIRT6 Overexpression Reverses DNA Repair Decline in Aging Mice
    - A Good Lifestyle Makes a Difference Even Late in Life
    - Impact of Mid-Life Fitness on Later Risk of Age-Related Disease
    - No Extension of Average Lifespan in Primate Study of Calorie Restriction
    - A View of Diet and Aging
    - Work on Blocking Damage in Brain Injury
    - More on DNA Methylation and Human Longevity
    - Cytomegalovirus and Type 2 Diabetes Risk
    - How Long Do You Want to Live?
    - Wiring Up Engineered Tissue

A PERSPECTIVE ON PROGRESS IN LONGEVITY SCIENCE

Here is an overview of some of what I see when looking out on the world of research and development relating to engineered longevity, spurred by someone who asked whether it was plausible for aging to be defeated by 2029:

http://www.fightaging.org/archives/2012/08/an-outline-of-progress-in-longevity-science.php

"The bottom line is that the research community and state of the field today is very different from that of even a mere ten years ago. This is a time of rapid change and progress: far more is known and far more impressive feats of medicine can be performed in the lab and the clinic. There is every reason to believe that ten years from now we'll be able to say the same thing. Costs in biotechnology and life science research are falling rapidly, and with that trend more research can be accomplished in each new year.

"That said, however, the only way that we'll see significant inroads into the defeat of aging by 2029 is for the SENS Foundation and its attendant research community to undergo the same sort of growth over the next decade as has been exhibited in recent years by regenerative medicine, calorie restriction research, or study of the genetics of longevity. A growth to billions in funding and thousands of researchers, in other words. It will require at least that and a decade of time in order to have a 50/50 shot at reversing aging in old mice in the lab - which is to say something that can make them live at least twice as long as they otherwise would have done.

"Of all the items covered in this post, only SENS provides a path towards achieving this end. Even regenerative medicine and complete control over stem cells can't offer the possibility of reversing aging in and of itself - it is only the way to reverse one component of aging, the decline of tissue maintenance and frailty that results from stem cells shutting down. You will still get nailed by your own mitochondria and the build up of metabolic byproducts even if your stem cells are perfectly restored.

"[So], no, there is no plausible road to the defeat of aging by 2029. But there is a plausible road to the first laboratory demonstrations of real, meaningful, but partial age reversal by then, ways to actually repair the root biological causes of aging rather than just slow it down. Whether that happens or not depends absolutely on funding - there are more than enough scientists and research groups out there who would work on the SENS vision for rejuvenation biotechnology if given a budget, but as of yet not enough funding sources to make it a reality."

WHAT'S REALLY DELAYING THE DEFEAT OF AGING?

Aubrey de Grey of the SENS Foundation answers this question in an open access editorial from the Rejuvenation Research journal:

http://www.fightaging.org/archives/2012/08/whats-really-delaying-the-defeat-of-aging.php

"In the mid-1990s, when I decided to switch from computer science to gerontology, I recognized that the creation of a credible assault on aging would require solving three basic problems: (1) Creating a credible plan; (2) getting the people best placed to implement it to be interested in doing so; and (3) giving them the financial resources to get on with the job.

"I broke the back of the first problem in mid-2000, when I realized that regenerative medicine - repairing the accumulating damage of aging - will probably be far simpler and easier to implement than the alternative followed by most biogerontologists, namely slowing the creation of that damage. By that time, I had also done most of the heavy lifting of item 2 (as I continued to do thereafter), by connecting with leading researchers worldwide, mostly face to face at conferences, and improving their understanding of how their expertise could be productively applied to aging. By way of illustration, quite a few of the most prestigious such people are named on the front cover of this journal as associate editors, and they accepted such a position for that reason. But what about item 3?

"Unfortunately, I cannot tell so positive a story with respect to financial resources. Nearly a decade ago, I began to make public predictions of how soon we would achieve success in our crusade. I did so, as I still do, in the manner that (for better or worse) preoccupies the general public, namely in terms of longevity, but I have always been careful to incorporate two key caveats: (1) The level of uncertainty of the time frames, even if only scientific uncertainty is considered, and (2) the reliance of such estimates on adequate funding.

"The first of these caveats is often elided, but it is simple: I estimate that we have a 50% chance of achieving the milestone of "robust human rejuvenation" (essentially, the rejuvenation of 60 year olds comprehensively enough that they won't be biologically 60 again until they're chronologically 90) within 25 years, but I also estimate that we have at least a 10% chance of not getting there in 100 years. But...that is all subject to the second caveat, namely funding.

"Tragically, the level of funding that has been forthcoming during the past decade is only a few percent (at most) of what is necessary. The rate of progress in research to defeat aging has been quite amazing in view of that, but nonetheless, I estimate that it has been only about one-third of what could have been achieved with 10-20 times more money."

ABSENT OPTIMISM

Our culture is far too short-sighted, focused on what is, and pessimistic, and that harms the prospects for progress:

http://www.fightaging.org/archives/2012/08/absent-optimism.php

"For a society in the midst of accelerating, rapid, and evident technological progress, public discussion and attitudes show a surprising lack of optimism for the future. Optimism of course exists, but nowhere near as widely as it should. It seems self-evident at this point that a golden era lies ahead in which we defeat disease and aging, colonize the solar system, and expand the limits of what it means to be human. We and our descendants will discard pain and suffering along the way, just as we have already discarded so much of the pain and suffering that our ancestors bore. ... The upward ramp of the necessary underlying technology is within our grasp. But you wouldn't think this from listening to the public. Much of the world seems convinced that nothing but collapse and catastrophe lies ahead: their view of the future is the ever-mistaken Malthusian collection of beliefs revolving around static resources that are exhausted. They fail to see the dynamism of resource generation and progress that proved past Mathusians just as wrong as the present crop."

EVERYONE HAS A PLAN TO SAVE MEDICARE

There are any number of people out there putting forward their proposals:

http://www.fightaging.org/archives/2012/08/everyone-has-a-plan-to-save-medicare.php

"Having a plan to save Medicare is somewhat like wearing a tie or cufflinks, in that it is somewhat de reigueur in some parts of society - but ultimately a cultural signal of belonging, of little value otherwise. The economic future of the US is somewhat grim; the decline of an empire is inevitable as its increasingly unaccountable elite class debauch the currency, centralize power, and regulate all aspects of a citizen's life. They tax and waste ever more of the flow of resources whilst destroying the freedom and competition needed for the creation of those resources - in much the same way as a cancer is parasitic to its host but ultimately destroys both host and itself. This is an inexorable progression of society, built upon the foundation of human nature and the individual actions and interactions of millions of people. It has happened over and again and is just about as likely as the tide to be turned aside.

"So having a plan to save Medicare is rather like having a plan to save a part of your cancer. That portion in the lower left, perhaps. Medicare is but one part of the network of regulation, perverse incentives, and regulatory capture that causes medicine in the US to be ever more expensive, wasteful, and poor in quality. It's large enough to be considered in the context of the more general economic decline across the board, which occurs for roughly the same set of reasons, and is just as hard to turn back. Medicine is in a more advanced state of socialist decrepitude than most other US industries, but the same process operates throughout society.

"From there let me segue into a discussion of responses to shortage. Regulation inevitably creates shortage and rationing: we see this in the provision of medicine in countries like Canada and the UK, where regulators set up waiting systems or simply forbid treatment, especially to the old. Much of the public discussion that results from this state of affairs looks at what to do about the shortages - though of course without a great deal of reflection on how they came to exist in the first place, sad to say. There are two broad lines of thinking here: firstly, use less of whatever is rationed; secondly try to create more of whatever is in short supply.

"One of the defining and frankly rather sorry aspects of our age is that public debates veer towards cutting back on use far more often than towards creating abundance. See the bulk of the environmentalist or other Malthusian movements for example - they have little to say about building more of whatever it is they think is in short supply.

"When it comes to Medicare, and given that very few people are calling to get rid of the whole system and let freedom and free markets rule the day, the two sides of the coin look much like (a) a call for increased rationing of services to ensure that people use less in the way of medicine, and (b) a call for ways to create greater health such that people use less in the way of medicine. There are of course many different approaches to either of these paths, but both ultimately sidestep the real issue, the real cause of the problem - and this again is absolutely characteristic of debate over societal organization and politics in our age."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

SIRT6 OVEREXPRESSION REVERSES DNA REPAIR DECLINE IN AGING MICE
Friday, August 31, 2012
http://www.fightaging.org/archives/2012/08/sirt6-overexpression-reverses-dna-repair-decline-in-aging-mice.php
This interesting research result adds a little more to the debate over whether nuclear DNA damage is relevant to aging beyond its effects on cancer risk - though I think it's still a bit early to point to differences in DNA repair as the definitive cause of SIRT6-related longevity in mice: researchers "found that the decline in a cell's ability to repair DNA during aging coincided with a global reduction in the levels of proteins involved in the repair process. [They] tried to reverse the age-related decline in DNA repair efficiency by restoring the proteins to their original levels and found only one protein, SIRT6, did the trick. ... [Other research results have shown] that overexpressing the SIRT6 protein extended the lifespans of mice. Our research looked at DNA repair and found a reason for the increased longevity, and that is SIRT6's role in promoting more efficient DNA repair. ... The next step [is] to study the factors that regulate SIRT6, in an effort to learn more about the early stages of the DNA repair process. ... multiple groups are trying to develop drugs that activate SIRT6, and [researchers hope] that this research will one day lead to therapies that help extend a person's lifespan and treat cancer. ... SIRT6 plays a critical role in repairing the most dangerous type of DNA damage: double-strand breaks. DNA is a two-stranded molecule, and breaks can occur to one strand of the molecule or to both. In the case of single-strand breaks, the unbroken strand guides the repair process and the DNA molecule is typically restored to its original state. However, double-strand breaks, in which both strands are severed, are particularly hazardous because they are more difficult to repair and can lead to a rearrangement of the cell's genetic material."

A GOOD LIFESTYLE MAKES A DIFFERENCE EVEN LATE IN LIFE
Friday, August 31, 2012
http://www.fightaging.org/archives/2012/08/a-good-lifestyle-makes-a-difference-even-late-in-life.php
Keeping up on the health basics makes a difference even in the last years of life: "It is well known that lifestyle factors, like being overweight, smoking and heavy drinking, predict death among elderly people. But is it uncertain whether these associations are applicable to people aged 75 years or more. So a team of researchers based in Sweden measured the differences in survival among adults aged 75 and older based on modifiable factors such as lifestyle behaviours, leisure activities, and social networks. The study involved just over 1,800 individuals who were followed for 18 years (1987-2005). Data on age, sex, occupation, education, lifestyle behaviours, social network and leisure activities were recorded. During the follow-up period 92% of participants died. Half of the participants lived longer than 90 years. Survivors were more likely to be women, be highly educated, have healthy lifestyle behaviours, have a better social network, and participate in more leisure activities than non-survivors. The results show that smokers died one year earlier than non-smokers. Former smokers had a similar pattern of survival to never smokers, suggesting that quitting smoking in middle age reduces the effect on mortality. Of the leisure activities, physical activity was most strongly associated with survival. The average age at death of participants who regularly swam, walked or did gymnastics was two years greater than those who did not. Overall, the average survival of people with a low risk profile (healthy lifestyle behaviours, participation in at least one leisure activity, and a rich or moderate social network) was 5.4 years longer than those with a high risk profile (unhealthy lifestyle behaviours, no participation in leisure activities, and a limited or poor social network). Even among those aged 85 years or older and people with chronic conditions, the average age at death was four years higher for those with a low risk profile compared with those with a high risk profile. In summary, the associations between leisure activity, not smoking, and increased survival still existed in those aged 75 years or more, with women's lives prolonged by five years and men's by six years, say the authors. These associations, although attenuated, were still present among people aged 85 or more and in those with chronic conditions."

IMPACT OF MID-LIFE FITNESS ON LATER RISK OF AGE-RELATED DISEASE
Thursday, August 30, 2012
http://www.fightaging.org/archives/2012/08/impact-of-mid-life-fitness-on-later-risk-of-age-related-disease.php
How you manage your health in earlier parts of your life will have an effect further down the line: "To examine the association between midlife fitness and chronic disease outcomes in later life, participant data from the Cooper Center Longitudinal Study were linked with Medicare claims. We studied 18,670 healthy participants (21.1% women; median age, 49 years) who survived to receive Medicare coverage from January 1, 1999, to December 31, 2009. Fitness estimated by Balke treadmill time was analyzed [according] to age- and sex-specific quintiles. Eight common chronic conditions were defined [and] associations between midlife fitness and the number of conditions were assessed. ... After 120,780 person-years of Medicare exposure with a median follow-up of 26 years, the highest quintile of fitness [was] associated with a lower incidence of chronic conditions [in men and women]. After multivariate adjustment, higher fitness [was] associated with a lower risk of developing chronic conditions in [men and women]. ... In this cohort of healthy middle-aged adults, fitness was significantly associated with a lower risk of developing chronic disease outcomes during 26 years of follow-up. These findings suggest that higher midlife fitness may be associated with the compression of morbidity in older age."

NO EXTENSION OF AVERAGE LIFESPAN IN PRIMATE STUDY OF CALORIE RESTRICTION
Thursday, August 30, 2012
http://www.fightaging.org/archives/2012/08/no-extension-of-average-lifespan-in-primate-study-of-calorie-restriction.php
A discussion on published results from this primate study suggest that both it and a comparison study are different in ways that make it harder to pull rigorous conclusions from the data - beyond the fact that diet clearly has influence, and the effects of calorie restriction on life span (average and maximum) are expected to be smaller in longer-lived species versus shorter-lived speces: "Scientists have found that calorie restriction - a diet composed of approximately 30 percent fewer calories but with the same nutrients of a standard diet - does not extend years of life or reduce age-related deaths in a 23-year study of rhesus monkeys. However, calorie restriction did extend certain aspects of health. ... The survival results in the study reported [by] NIA researchers differ from those published in 2009 by NIA-supported investigators at the University of Wisconsin-Madison. The Wisconsin study followed two groups of rhesus monkeys for 20 years and found that monkeys on a calorie-restricted diet lived longer than those on a standard diet. Beyond longevity, the parallel NIA and Wisconsin studies have reported similar beneficial health effects of calorie-restriction. Both studies found that certain age-related diseases - including diabetes, arthritis, diverticulosis and cardiovascular problems - occurred at an earlier age in monkeys on the standard diet compared to those on calorie restriction. However, this observation was not statistically significant in the NIA study. NIA researchers did find that monkeys started on calorie restriction at an early age had a statistically significant reduction in cancer incidence. NIA researchers also found that while calorie restriction had a beneficial effect on several measures of metabolic health and function in monkeys who were started on the special diet regimen during old age (at 16 to 23 years), it did not have the same positive outcome for monkeys started on calorie restriction at a young age (less than 14 years). In the Wisconsin study, all the monkeys were 7 to 14 years when started on calorie restriction. ... Differences in the monkeys' meal and other nutritional factors were cited as possible explanations for NIA's and Wisconsin's different outcomes. Both studies used a similar percentage of calorie restriction with their intervention groups; however, the Wisconsin monkeys in both the calorie restricted and control groups were eating more and weighed more than the matched NIA monkeys. ... NIA researchers cited genetics as another possible reason for their differing results. NIA monkeys had a greater genetic diversity, originating from China and India. Wisconsin's monkeys came only from an Indian colony."

A VIEW OF DIET AND AGING
Wednesday, August 29, 2012
http://www.fightaging.org/archives/2012/08/a-view-of-diet-and-aging.php
A review paper: "Nutrition has important long-term consequences for health that are not only limited to the individual but can be passed on to the next generation. It can contribute to the development and progression of chronic diseases thus effecting life span. Caloric restriction (CR) can extend the average and maximum life span and delay the onset of age-associated changes in many organisms. CR elicits coordinated and adaptive stress responses at the cellular and whole-organism level by modulating epigenetic mechanisms (e.g., DNA methylation, posttranslational histone modifications), signaling pathways that regulate cell growth and aging (e.g., TOR, AMPK, p53, and FOXO), and cell-to-cell signaling molecules (e.g., adiponectin). The overall effect of these adaptive stress responses is an increased resistance to subsequent stress, thus delaying age-related changes and promoting longevity. In human, CR could delay many diseases associated with aging including cancer, diabetes, atherosclerosis, cardiovascular disease, and neurodegenerative diseases."

WORK ON BLOCKING DAMAGE IN BRAIN INJURY
Wednesday, August 29, 2012
http://www.fightaging.org/archives/2012/08/work-on-blocking-damage-in-brain-injury.php
Some of the damage that occurs in brain injury is secondary to the initial trauma and takes place at the level of cellular components. Researchers here demonstrate a possible way to stop that from happening: "Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury (TBI) and preserved function that would otherwise have been impaired. ... For the study, the research team conducted a global assessment of all the phospholipids in rat brain cells. This revealed that damage from TBI was nonrandom and mostly involved cardiolipin, a phospholipid that is found in the membranes that form mitochondria, the cell's powerhouse. They noted that in the healthy animal, only 10 of the 190 cardiolipin species were modified by oxygen, but after a brain injury, the number of oxidized species rose many-fold. The researchers then developed an agent, called XJB-5-131, which can cross the blood-brain barrier and prevent the oxidation of cardiolipin. Using an established research model of severe TBI, the agent or a placebo was injected into the bloodstream of rats five minutes and again 24 hours after head injury. In the weeks that followed, treated animals performed akin to normal on tests of balance, agility and motor coordination, learning, and object recognition, while placebo-treated animals showed significant impairment. The results indicate that blocking cardiolipin oxidation by XJB-5-131 protected the brain from cell death. ... a targeted oxidation-blocker might also be beneficial in the treatment of other neurological disorders, such as Parkinson's disease, amyotrophic lateral sclerosis, or ALS, and stroke."

MORE ON DNA METHYLATION AND HUMAN LONGEVITY
Tuesday, August 28, 2012
http://www.fightaging.org/archives/2012/08/more-on-dna-methylation-and-human-longevity.php
A great deal of data is being generated on patterns of DNA methylation, aging, and variations in human longevity: "(1) we evaluated the DNA methylation from peripheral leukocytes of 21 female centenarians, their 21 female offspring, 21 offspring of both non-long-lived parents, and 21 young women ... (2) we compared the DNA methylation profiles of these populations ... We observed an age-related decrease in global DNA methylation and a delay of this process in centenarians' offspring. Interestingly, literature data suggest a link between the loss of DNA methylation observed during aging and the development of age-associated diseases. Genome-wide methylation analysis evidenced DNA methylation profiles specific for aging and longevity: (1) aging-associated DNA hypermethylation occurs predominantly in genes involved in the development of anatomical structures, organs, and multicellular organisms and in the regulation of transcription; (2) genes involved in nucleotide biosynthesis, metabolism, and control of signal transmission are differently methylated between centenarians' offspring and offspring of both non-long-lived parents, hypothesizing a role for these genes in human longevity. Our results suggest that a better preservation of DNA methylation status, a slower cell growing/metabolism, and a better control in signal transmission through epigenetic mechanisms may be involved in the process of human longevity. These data fit well with the observations related to the beneficial effects of mild hypothyroidism and insulin-like growth factor I system impairment on the modulation of human lifespan."

CYTOMEGALOVIRUS AND TYPE 2 DIABETES RISK
Tuesday, August 28, 2012
http://www.fightaging.org/archives/2012/08/cytomegalovirus-and-type-2-diabetes-risk.php
Cytomegalovirus (CMV) is a persistent and very common herpesvirus that is thought to be a major contributor to the age-related decline of the immune system, due to an ever increasing portion of its limited number of cells becoming specialized to CMV and thus unavailable for other duties. Various past studies have linked CMV with forms of age-related frailty, but here the researchers find an association with type 2 diabetes - which is interesting and perhaps somewhat unexpected, given that type 2 diabetes is essentially a lifestyle disease: "Cytomegalovirus (CMV) infection has been reported to contribute to the pathogenesis of type 1 diabetes and post-transplantation diabetes. However, CMV infection has not been evaluated as a possible risk factor for type 2 diabetes. Our aim was to investigate potential associations between CMV seropositivity, CMV IgG antibody level and glucose regulation in the oldest old. ... CMV seropositive subjects were more likely to have type 2 diabetes (17.2% vs 7.9%), had a higher level of HbA1c and higher non-fasting glucose in the oldest olds. These associations remained significant after adjustment for possible confounders. CMV IgG antibody level was not significantly associated with glucose regulation ... In the oldest old, CMV seropositivity is significantly associated with various indicators of glucose regulation. This finding suggests that CMV infection might be a risk factor for the development of type 2 diabetes in the elderly."

HOW LONG DO YOU WANT TO LIVE?
Monday, August 27, 2012
http://www.fightaging.org/archives/2012/08/how-long-do-you-want-to-live.php
Here is an example to show that the urge to conform is somewhat stronger than the urge to live, and never mind the urge to think critically. People will tend to say that they want to be in the majority position now, no matter what that might be, and depending on how you phrase the question, the vast majority will tell you that they want to age to death and have a life that is no longer than that of their parents. Yet if longer lives were already common, those very same people would answer that they wanted to live those longer lives. It is frustrating, to say the least, the degree to which people live in the moment and blind themselves to what might be created: "How many years might be added to a life? A few longevity enthusiasts suggest a possible increase of decades. Most others believe in more modest gains. And when will they come? Are we a decade away? Twenty years? Fifty years? Even without a new high-tech 'fix' for aging, the United Nations estimates that life expectancy over the next century will approach 100 years for women in the developed world and over 90 years for women in the developing world. (Men lag behind by three or four years.) Whatever actually happens, this seems like a good time to ask a very basic question: How long do you want to live? Over the past three years I have posed this query to nearly 30,000 people at the start of talks and lectures on future trends in bioscience, taking an informal poll as a show of hands. To make it easier to tabulate responses I provided four possible answers: 80 years, currently the average life span in the West; 120 years, close to the maximum anyone has lived; 150 years, which would require a biotech breakthrough; and forever, which rejects the idea that life span has to have any limit at all. I made it clear that participants should not assume that science will come up with dramatic new anti-aging technologies, though people were free to imagine that breakthroughs might occur - or not. The results: some 60 percent opted for a life span of 80 years. Another 30 percent chose 120 years, and almost 10 percent chose 150 years. Less than 1 percent embraced the idea that people might avoid death altogether. These percentages have held up as I've spoken to people from many walks of life in libraries and bookstores; teenagers in high schools; physicians in medical centers; and investors and entrepreneurs at business conferences. I've popped the question at meetings of futurists and techno-optimists and gotten perhaps a doubling of people who want to live to 150 - less than I would have thought for these groups. Rarely, however, does anyone want to live forever, although abolishing disease and death from biological causes is a fervent hope for a small scattering of would-be immortals."

WIRING UP ENGINEERED TISSUE
Monday, August 27, 2012
http://www.fightaging.org/archives/2012/08/wiring-up-engineered-tissue.php
This is interesting, the early stirrings of something that may change the tenor of future tissue engineering if carried through to its logical conclusions. Why build a plain heart if you can build a sensor-laden heart with its own embedded network for monitoring and medical intervention? From the release: "A multi-institutional research team has developed a method for embedding networks of biocompatible nanoscale wires within engineered tissues. These networks - which mark the first time that electronics and tissue have been truly merged in 3D - allow direct tissue sensing and potentially stimulation, a potential boon for development of engineered tissues that incorporate capabilities for monitoring and stimulation, and of devices for screening new drugs. ... One of the major challenges in developing bioengineered tissues is creating systems to sense what is going on (e.g., chemically, electrically) within a tissue after it has been grown and/or implanted. Similarly, researchers have struggled to develop methods to directly stimulate engineered tissues and measure cellular reactions. ... In the body, the autonomic nervous system keeps track of pH, chemistry, oxygen and other factors, and triggers responses as needed. We need to be able to mimic the kind of intrinsic feedback loops the body has evolved in order to maintain fine control at the cellular and tissue level. ... With the autonomic nervous system as inspiration, [scientists] built mesh-like networks of nanoscale silicon wires - about 80 nm in diameter - shaped like flat planes or in a 'cotton-candy'-like reticular conformation. The networks were porous enough to allow the team to seed them with cells and encourage those cells to grow in 3D cultures. ... Previous efforts to create bioengineered sensing networks have focused on 2D layouts, where culture cells grow on top of electronic components, or on conformal layouts where probes are placed on tissue surfaces. It is desirable to have an accurate picture of cellular behavior within the 3D structure of a tissue, and it is also important to have nanoscale probes to avoid disruption of either cellular or tissue architecture."

______________________________


<br> <br>View the full article

#25 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 09 September 2012 - 02:12 PM

FIGHT AGING! NEWSLETTER
September 10th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Discussion
- Considering a Negative Result for Primate Calorie Restriction
- Personal Survival and Swimming Against the Cultural Currents
- Fat Tissue: Where Did it All Go Wrong?
- Latest Headlines from Fight Aging!
    - Nanog Reverses Some Aspects of Stem Cell Aging
    - Longevity in Mammals as an Ancient Phenomenon
    - A Chart of Changing Mortality Rates and Life Expectancy
    - Jnk3 as a Potential Target for Alzheimer's Therapy
    - On α-synuclein and Neurodegeneration
    - Reproductive Tissues Influence Life Span
    - Manipulation of Osteopontin Can Reverse Declining Muscle Regeneration
    - Stem Cell Transplant Restores Feeling After Spinal Injury
    - On Extending Life in Mice Via Telomerase Expression
    - Bioscience and Pushing the Limits of Lifespan

CONSIDERING A NEGATIVE RESULT FOR PRIMATE CALORIE RESTRICTION

The latest data from one of the primate studies of calorie restriction, health, and longevity, should be considered in context:

http://www.fightaging.org/archives/2012/09/considering-a-negative-result-for-primate-calorie-restriction.php

"As I'm sure you noticed, the latest data from one of the two long-running primate studies of calorie restriction is being presented in the press as a negative result: no extension of mean life span in the rhesus monkeys in that study. This contrasts with another study that may or may not presently show a modest extension of primate life span with calorie restriction, depending on how you feel about the way in which the researchers are interpreting their data.

"The press are largely running with 'calorie restriction doesn't work,' but that's because the mainstream media is shallow, either reprinting a superficial summary or at best treating each new research result in isolation rather than considering it in the context of the field as a whole. Doing the job properly, employing actual knowledge and analysis, takes more time and doesn't sell any more papers - so why bother? This is why the media should chiefly be used as a flagging mechanism; if you see discussion of a topic, note that it happened and then do your own research and analysis.

"In science, each new set of data and consequent analysis should be added to the existing array for a given topic. Progressing towards a greater understanding is an incremental affair, especially given than a large proportion of studies and data are flawed in some way ... So what should we take away from the results of the two ongoing primate studies of life span and health under calorie restriction? After two decades one shows a modest boost to life span, the other no increase, and both show health benefits resulting from calorie restriction - though to different degrees. The control groups are fed differently, one allowed to eat as much as they like, the other on a set diet that has more calories than the restricted group. The composition of the diets in the two studies are also different. Even the genetic heritage of the rhesus monkeys involved is different enough for scientists to consider it significant, given the many but tenuous relationships to longevity found in the human genome over the past decade.

"When looking beyond these studies to the broader context of data derived from a range of human studies and countless studies in mice, we see that calorie restriction absolutely, definitely has a large positive impact on health and longevity in shorter-lived mammals, and a large positive impact on measures of health in humans.

"The first important point to consider is that these studies add to the weight of data and theory suggesting the effect of calorie restriction on the life span of longer-lived primates is small. Consider that any study is going produce results somewhere statistical map of what is possible and plausible: if two studies both show no extension or only a modest extension of life, then there would have to be a good reason to continue to believe that a large extension of life is possible. This concurs with the present scientific consensus and reasonable expectations: if calorie restriction could produce a 40% extension of maximum human life span, as it does in mice, then we'd have known about it since the age of antiquity. Our history is rife with cloistered groups that practiced austere lifestyles, after all, and many of them existed in periods of comparative wealth wherein suitable levels of nutrition were readily available.

"A second important point is that this latest primate data in no way detracts from the health benefits produced by calorie restriction and demonstrated in numerous human studies. These research results are impressive: if calorie restriction were a drug, people would be falling over themselves to get a hold of it, as it leads to benefits that go far beyond anything that medical science can presently offer a basically healthy individual.

"The future of calorie restriction research at the level of investigation and understanding - as opposed to attempts to build calorie restriction mimetic drugs - will, I suspect, involve a great deal of thought on how to reconcile significant beneficial effects on measures of health and disease risk with an apparently small beneficial effect on life span. That isn't an intuitive outcome given the view of aging as an accumulation of damage, and the straightforward relationship between better health measures and greater life span extension in shorter-lived mammals like mice or rats. What is does indicate is that some of the differences in metabolism between mammals species are very significant when it comes to life span: one hypothesis is that some of the beneficial metabolic changes brought about in mice by calorie restriction are essentially already running by default in your average human, and account for our present longevity in comparison to similarly sized mammals.

"So from the perspective of a dispassionate observer of metabolic science, calorie restriction continues to offer a tremendous and ever-deepening opportunity to really dig into the operation and evolution of mammalian biochemistry. From the perspective of those of us who want to live very much longer than our predecessors, calorie restriction has to be nothing more than a common sense health practice, akin to flossing and exercise, but not something that we hang unrealistic hopes on. Real progress in living longer must come from medical science, from efforts to build rejuvenation biotechnologies that can repair the damage that causes aging. Absent advances in longevity medicine we will age and die just like our ancestors, no matter what we eat; taking care of our health is, like supporting research initiatives in longevity science, one more optimization to help us live long enough to see the deployment of therapies to treat and reverse aging."

PERSONAL SURVIVAL AND SWIMMING AGAINST THE CULTURAL CURRENTS

Its fair to say that at this time most people don't put in much thought or effort when it comes to living a longer, healthier life. The mainstream of our culture is somewhere between indifferent and hostile to this goal. But research of biotechnologies that can achieve reversal of aging in the old requires widespread support in order to grow to become a powerful, rapidly moving field like stem cell medicine or cancer research. So we are currently swimming against the current, in an uphill struggle to persuade and raise funding for building therapies for aging - and that won't be the first time this happens in a matter crucial to personal survival:

http://www.fightaging.org/archives/2012/09/personal-survival-and-swimming-against-the-cultural-currents.php

"[The] additional cost in time and resources imposed [on longevity science] by the nature of our present culture is an existential threat. It threatens to kill us by ensuring that the development of effective ways to reverse aging in the old arrive too late. Given that progress in this field of science and technology is a matter of persuading funding sources and raising money to accomplish known goals, it could be argued that this is a fight to change the prevailing culture rather than a matter of research. If we want to live, it's a fight we have to win - or at least convince a few tens of millions to become supporters of longevity science in the same way that most people are supporters of cancer research.

"But let us look to the future, at what I see as a loosely analogous cultural battle that will start to arrive at around the same time as the means to reverse aging - one that will also present an existential threat to personal survival.

"Consider that at some point in the next few decades it will become possible to simulate and then emulate a human brain. That will enable related technological achievements as reverse engineering of memory, a wide range of brain-machine interfaces, and strong artificial intelligence. It will be possible to copy and alter an individual's mind: we are at root just data and operations on that data. It will be possible for a mind to run on computing hardware rather than in our present biology, for minds to be copied from a biological brain, and for arbitrary alterations of memory to be made near-immediately. This opens up all of the possibilities that have occupied science fiction writers for the past couple of decades: forking individuals, merging in memories from other forks, making backups, extending a human mind through commodity processing modules that provide skills or personality shards, and so on and so forth.

"There is already a population of folk who would cheerfully take on any or all of these options. I believe that this population will only grow: the economic advantages for someone who can edit, backup, and fork their own mind are enormous - let alone the ability to consistently take advantage of a marketplace of commodity products such as skills, personalities, or other fragments of the mind.

"But you'll notice I used what I regard as a malformed phrase there: 'someone who can edit, backup, and fork their own mind.' There are several sorts of people in the world; the first sort adhere to some form of pattern theory of identity, defining the self as a pattern, wherever that pattern may exists. Thus for these folk it makes sense to say that 'my backup is me', or 'my fork is me.' The second sort, and I am in this camp, associate identity with the continuity of a slowly changing arrangement of mass and energy: I am this lump of flesh here, the one slowly shedding and rebuilding its cells and cellular components as it progresses. If you copy my mind and run it in software, that copy is not me. So in my view you cannot assign a single identity to forks and backups: every copy is an individual, large changes to the mind are equivalent to death, and it makes no sense to say something like 'someone who can edit, backup, and fork their own mind.'

A copy of you is not you, but there is worse to consider: if the hardware that supports a running brain simulation is anything like present day computers, that copy isn't even particularly continuous. It is more like an ongoing set of individuals, each instantiated for a few milliseconds or less and then destroyed, to be replaced by yet another copy. If self is data associated with particular processing structures, such as an arrangement of neurons and their connections, then by comparison a simulation is absolute different: inside a modern computer or virtual machine that same data would be destroyed, changed, and copied at arbitrary times between physical structures - it is the illusion of a continuous entity, not the reality.

That should inspire a certain sense of horror among folk in the continuity of identity camp, not just because it is an ugly thing to think about, but because it will almost certainly happen to many, many, many people before this century ends - and it will largely be by their own choice, or worse, inflicted upon them by the choice of the original from whom the copy was made.

This is not even to think about the smaller third group of people who are fine with large, arbitrary changes to their state of mind: rewriting memories, changing the processing algorithms of the self, and so on. At the logical end of that road lie hives of software derived from human minds in which identity has given way to ever-changing assemblies of modules for specific tasks, things that transiently appear to be people but which are a different sort of entity altogether - one that has nothing we'd recognize as continuity of identity. Yet it would probably be very efficient and economically competitive.

The existential threat here is that the economically better path to artificial minds, the one that involves lots of copying and next to no concern for continuity of identity, will be the one that dominates research and development. If successful and embedded in the cultural mainstream, it may squeeze out other roads that would lead to more robust agelessness for we biological humans - or more expensive and less efficient ways to build artificial brains that do have a continuity of structure and identity, such as a collection of artificial neurons that perform the same functions as natural ones.

This would be a terrible, terrible tragedy: a culture whose tides are in favor of virtual, copied, altered, backed up and restored minds is to my eyes little different from the present culture that accepts and encourages death by aging. In both cases, personal survival requires research and development that goes against the mainstream, and thus proceeds more slowly.

Sadly, given the inclinations of today's futurists - and, more importantly, the economic incentives involved - I see this future as far more likely than the alternatives. Given a way to copy, backup, and alter their own minds, people will use it and justify its use to themselves by adopting philosophies that state they are not in fact killing themselves over and again. I'd argue that they should be free to do so if they choose, just the same as I'd argue that anyone today should be free to determine the end of his or her life. Nonetheless, I suspect that this form of future culture may pose a sizable set of hurdles for those folk who emerge fresh from the decades in which the first early victories over degenerative aging take place."

FAT TISSUE: WHERE DID IT ALL GO WRONG?

In this post, an interesting open access paper on the evolutionary origins of our present challenges with fat tissue.

http://www.fightaging.org/archives/2012/09/fat-tissue-where-did-it-all-go-wrong.php

"Accumulation of excess body fat is easy to accomplish in a wealthy society, and it has very unpleasant consequences over the long term. The more time you spend carrying additional visceral fat tissue, the higher your risk of suffering all of the common age-related diseases in later life, the greater your expected medical bills, and the shorter your life expectancy. This is all well understood and widely ignored: the urges to eat and laze are strong in the average human.

"The way in which our bodies grasp at nutrients and aggressively store any excess as fat tissue didn't evolve because it is harmful, however. It evolved because it provides an advantage to survival and propagation of the species - at least it did while we occupied an evolutionary niche characterized by unreliable access to food. When we leave that niche for one with reliably abundant nutrition, these metabolic mechanisms become a maladjustment. We have succeeded ourselves out of the obvious and ugly scenarios of famine and into the more subtle scenarios of self-sabotage. Change in our environment is now self-directed and far faster than evolution can keep up with: we are the masters of our own destiny, and what goes on in our heads becomes more important than many other factors when it comes to health, longevity, and our environment."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

NANOG REVERSES SOME ASPECTS OF STEM CELL AGING
Friday, September 7, 2012
http://www.fightaging.org/archives/2012/09/nanog-reverses-some-aspects-of-stem-cell-aging.php
It's been a while since nanog was discussed here; it's one of the genes associated with early efforts to reprogram somatic cells into stem cells and seems to be important in the activity of embryonic stem cells. Here researchers are investigating the reversal of stem cell aging: "Although the therapeutic potential of mesenchymal stem cells (MSC) is widely accepted, loss of cell function due to donor aging or culture senescence are major limiting factors hampering their clinical application. Our laboratory recently showed that MSC originating from older donors suffer from limited proliferative capacity and significantly reduced myogenic differentiation potential. This is a major concern, as the patients most likely to suffer from cardiovascular disease are elderly. Here we tested the hypothesis that a single pluripotency associated transcription factor, namely Nanog, may reverse the proliferation and differentiation potential of BM-MSC from adult donors. Microarray analysis showed that [expressing Nanog] markedly upregulated genes involved in cell cycle, DNA replication and DNA damage repair and enhanced the proliferation rate and clonogenic capacity of [adult] BM-MSC. Notably, Nanog reversed the myogenic differentiation potential and restored the contractile function of [adult] BM-MSC to a similar level as that of neonatal BM-MSC. ... Overall, our results suggest that Nanog may be used to overcome the effects of organismal aging on BM-MSC, thereby increasing the potential of MSC from aged donors for cellular therapy and tissue regeneration."

LONGEVITY IN MAMMALS AS AN ANCIENT PHENOMENON
Friday, September 7, 2012
http://www.fightaging.org/archives/2012/09/longevity-in-mammals-as-an-ancient-phenomenon.php
An interesting view on the evolutionary depths of longevity in mammals, achieved through analysis of presently available genomes: "It is widely assumed that our mammalian ancestors, which lived in the Cretaceous era, were tiny animals that survived massive asteroid impacts in shelters, and evolved into modern forms after dinosaurs went extinct, 65 Mya. The small size of most Mesozoic mammalian fossils essentially supports this view. Paleontology, however, is not conclusive regarding the ancestry of extant mammals, because Cretaceous and Paleocene fossils are not easily linked to modern lineages. Here we use full-genome data to estimate the longevity and body mass of early placental mammals. Analysing 36 fully-sequenced mammalian genomes, we reconstruct two aspects of the ancestral genome dynamics ... Linking these molecular evolutionary processes to life history traits in modern species, we estimate that early placental mammals had a life-span above 25 years, and a body mass above one kilogram. This is similar to current primates, cetartiodactyls or carnivores, but markedly different from mice or shrews, challenging the dominant view about mammalian origin and evolution. Our results imply that long-lived mammals existed in the Cretaceous era, and were the most successful in evolution, opening new perspectives about the conditions for survival to the Cretaceous-Tertiary crisis."

A CHART OF CHANGING MORTALITY RATES AND LIFE EXPECTANCY
Thursday, September 6, 2012
http://www.fightaging.org/archives/2012/09/a-chart-of-changing-mortality-rates-and-life-expectancy.php
This chart from the Scientific American clearly illustrates the progress in tackling heart disease over the past few decades, a factor that is driving a steady rise in life expectancy at older ages. Mortality rates for this range of conditions are falling quite dramatically: "A baby born in the U.S. this year is likely to live to blow out 78 birthday candles - a far longer average life span than someone born even in the 1960s. Heart disease is still the biggest killer but it, along with fatal infectious diseases and infant mortality have all fallen to much lower levels in the past half century. Researchers are now hard at work tackling the growing afflictions, such as nervous system diseases and Alzheimer's, which are far more likely to attack the ever more senescent population. ... Researchers are exploring two main approaches to extending healthy human life span. One camp believes we should focus on curing disease and replacing damaged body parts via stem cell therapies. Another camp believes we must slow the aging process on the cellular and molecular levels." If you include the SENS approach to repair of the causes of aging under "curing disease and replacing damaged body parts", then this describes the most important issue of our time in the life sciences: will the research community take an effective path or not in the treatment of aging? This will determine how long we all live.

JNK3 AS A POTENTIAL TARGET FOR ALZHEIMER'S THERAPY
Thursday, September 6, 2012
http://www.fightaging.org/archives/2012/09/jnk3-as-a-potential-target-for-alzheimers-therapy.php
Via ScienceDaily: "Scientists have found that eliminating an enzyme from mice with symptoms of Alzheimer's disease leads to a 90 percent reduction in the compounds responsible for formation of the plaques linked to Alzheimer's disease. ... The key to reducing A-beta peptides was the elimination of an enzyme called jnk3. This enzyme stimulates a protein that produces A-beta peptides, suggesting that when jnk3 activities are high, A-beta peptide production increases - increasing chances for their accumulation and formation into plaques. The researchers also observed that jnk3 activities in brain tissue from Alzheimer's disease patients were increased by 30 to 40 percent when compared to normal human brain tissue. Jnk3 activity typically remains low in the brain, but increases when physiological abnormalities arise. ... [Researchers] deleted jnk3 genetically from Alzheimer's disease model mice carrying the mutations that are found among early-onset Alzheimer's disease patients. In six months, the deletion of the enzyme had lowered A-beta peptide production by 90 percent, which persisted over time, with a 70 percent reduction seen at 12 months in these mice. When the researchers saw that elimination of jnk3 dramatically lowered A-beta peptides in the mice, they also looked for effects on cognitive function at 12 months. The deletion of jnk3 improved cognitive function significantly, reaching 80 percent of normal, while cognitive function in disease model mice was 40 percent of normal. The number of brain cells, or neurons, in the Alzheimer's disease mice was also increased with jnk3 deletion, reaching 86 percent of the value in normal mice, while the neuron numbers were only 74 percent in Alzheimer's model mice."

ON α-SYNUCLEIN AND NEURODEGENERATION
Wednesday, September 5, 2012
http://www.fightaging.org/archives/2012/09/on--synuclein-and-neurodegeneration.php
In recent years a build up of α-synuclein has been shown to be important in some neurodegenerative conditions: "The discovery of α-synuclein has had profound implications concerning our understanding of Parkinson's disease (PD) and other neurodegenerative disorders characterized by α-synuclein accumulation. In fact, as compared with pre-α-synuclein times, a "new" PD can now be described as a whole-body disease in which a progressive spreading of α-synuclein pathology underlies a wide spectrum of motor as well as nonmotor clinical manifestations. Not only is α-synuclein accumulation a pathological hallmark of human α-synucleinopathies but increased protein levels are sufficient to trigger neurodegenerative processes. α-Synuclein elevations could also be a mechanism by which disease risk factors (e.g., aging) increase neuronal vulnerability to degeneration. An important corollary to the role of enhanced α-synuclein in PD pathogenesis is the possibility of developing α-synuclein-based biomarkers and new therapeutics aimed at suppressing α-synuclein expression. The use of in vitro and in vivo experimental models, including transgenic mice overexpressing α-synuclein and animals with viral vector-mediated α-synuclein transduction, has helped clarify pathogenetic mechanisms and therapeutic strategies involving α-synuclein. These models are not devoid of significant limitations, however. Therefore, further pursuit of new clues on the cause and treatment of PD in this post-α-synuclein era would benefit substantially from the development of improved research paradigms of α-synuclein elevation."

REPRODUCTIVE TISSUES INFLUENCE LIFE SPAN
Wednesday, September 5, 2012
http://www.fightaging.org/archives/2012/09/reproductive-tissues-influence-life-span.php
A review paper: "Aging and reproduction are two defining features of our life. Historically, research has focused on the well-documented decline in reproductive capacity that accompanies old age, especially with increasing maternal age in humans. However, recent experiments in model organisms such as worms, flies and mice have shown that a dialogue in the opposite direction may be widely prevalent, and that signals from reproductive tissues have a significant effect on the rate of aging of organisms. This pathway has been described in considerable detail in the nematode Caenorhabditis elegans. Molecular genetic studies suggest that signals from the germline control a network of transcriptional regulators that function in the intestine to influence longevity. This network includes conserved, longevity-promoting Forkhead Box (FOX)-family transcription factors such as DAF-16/FOXO and PHA-4/FOXA, nuclear hormone receptors (NHRs) as well as a transcription elongation factor, TCER-1/TCERG1. Genomic and targeted molecular analyses have revealed that these transcription factors modulate autophagy, lipid metabolism and possibly other cellular processes to increase the length of the animal's life."

MANIPULATION OF OSTEOPONTIN CAN REVERSE DECLINING MUSCLE REGENERATION
Tuesday, September 4, 2012
http://www.fightaging.org/archives/2012/09/manipulation-of-osteopontin-can-reverse-declining-muscle-regeneration.php
Muscle mass and strength decline with age, and researchers continue to explore the mechanisms by which this happens: "Skeletal muscle regeneration following injury is accompanied by rapid infiltration of macrophages, which play a positive role in muscle repair. Increased chronic inflammation inhibits the regeneration of dystrophic muscle, but the properties of inflammatory cells are not well understood in the context of normal muscle aging. This work uncovers pronounced age-specific changes in the expression of osteopontin (OPN) in CD11b+ macrophages present in the injured old muscle as well as in the blood serum of old injured mice and in the basement membrane surrounding old injured muscle fibers. Furthermore, young CD11b+ macrophages enhance regenerative capacity of old muscle stem cells even when old myofibers and old sera are present; and neutralization of OPN similarly rejuvenates the myogenic responses of old satellite cells in vitro and notably, in vivo. This study highlights potential mechanisms by which age related inflammatory responses become counter-productive for muscle regeneration and suggests new strategies for enhancing muscle repair in the old."

STEM CELL TRANSPLANT RESTORES FEELING AFTER SPINAL INJURY
Tuesday, September 4, 2012
http://www.fightaging.org/archives/2012/09/stem-cell-transplant-restores-feeling-after-spinal-injury.php
Via the New Scientist: "For the first time, people with broken spines have recovered feeling in previously paralysed areas after receiving injections of neural stem cells. Three people with paralysis received injections of 20 million neural stem cells directly into the injured region of their spinal cord. The cells, acquired from donated fetal brain tissue, were injected between four and eight months after the injuries happened. The patients also received a temporary course of immunosuppressive drugs to limit rejection of the cells. None of the three felt any sensation below their nipples before the treatment. Six months after therapy, two of them had sensations of touch and heat between their chest and belly button. The third patient has not seen any change. ... The fact we've seen responses to light touch, heat and electrical impulses so far down in two of the patients is very unexpected. They're really close to normal in those areas now in their sensitivity. ... The sensory gains, first detected at three months post-transplant, have now persisted and evolved at six months after transplantation. We clearly need to collect much more data to demonstrate efficacy, but our results so far provide a strong rationale to persevere with the clinical development of our stem cells for spinal injury. ... We need to keep monitoring these patients to see if feeling continues to affect lower segments of their bodies. These are results after only six months, and we will follow these patients for many years. ... There could be several reasons why the stem cells improve sensitivity ... They might help to restore myelin insulation to damaged nerves, improving the communication of signals to and from the brain. Or they could be enhancing the function of existing nerves, replacing them entirely or reducing the inflammation that hampers repair."

ON EXTENDING LIFE IN MICE VIA TELOMERASE EXPRESSION
Monday, September 3, 2012
http://www.fightaging.org/archives/2012/09/on-extending-life-in-mice-via-telomerase-expression.php
Suitable genetic engineering of telomerase can extend life in mice, but it isn't a straightforward process, and it is unclear as to how this would translate to humans given the complex relationship between telomere biology and aging on the one hand and the differences between humans and mice on the other: "The absence of telomerase [and consequent] telomere shortening in somatic cells plays a controversial role in mammalian aging. On the one hand, genetic knockout of telomerase function in mice has little noticeable effect on the aging of first-generation mutants. Serious phenotypic consequences are seen only in the fourth through sixth generations of such mutants when premature aging-associated phenotypes appear. This is because the normal length of mouse telomeres is sufficient for several mouse life spans, including all of the cell divisions associated with development. On the other hand, ectopic expression of the catalytic subunit of telomerase (telomerase reverse transcriptase, TERT) in epithelial cells has been reported to extend life span by up to 40% in mice engineered to be cancer-resistant. Unfortunately, ectopic expression of TERT in wild-type mice or mutations in human TERT increase cancer risk. There is evidence that active telomerase [and consequently] long telomeres protect cells from the metabolic and mitochondrial compromise that occurs when shortened telomeres induce p53 ... Ironically, shortened telomeres also result in increased cancer rates, probably due to increased genomic instability. Consistent with a homeostatic mechanism is the observation that telomerase reactivation has been shown to partially reverse tissue degeneration in aged telomerase-deficient mice (fourth generation). There is a paradox here: Mouse chromosomes possess enough reserve telomere length to fuel cell divisions for up to six organismal generations, yet mice apparently have at least a subset of cells in which dysfunction is linked to shorter telomeres and/or the absence of telomerase within a single life span. This paradox relates to the critical question of whether sufficient clinical benefit could result from ectopic telomerase expression in human aging and in diseases associated with shortened telomeres ... Of course, one potentially important difference is that humans have significantly shorter telomeres than mice."

BIOSCIENCE AND PUSHING THE LIMITS OF LIFESPAN
Monday, September 3, 2012
http://www.fightaging.org/archives/2012/09/bioscience-and-pushing-the-limits-of-lifespan.php
A short article on longevity science than manages to miss most of the interesting work presently taking place by focusing on the mainstream of metabolic manipulation to slow aging and researchers who talk about compression of morbidity without extending life: "As scientists make new breakthroughs in understanding the mechanics of aging, the upper limits of aging might be changing for Homo sapiens. Already, life expectancy has increased dramatically since the late nineteenth century, when it was 40 for males and 42 for females at birth, and age 58 and 59 respectively if they survived to age 10 (infant mortality was much higher in 1890). Life expectancy is expected to keep rising to perhaps age 100 sometime in the 22nd century, according to the United Nations. This comes from better hygiene and nutrition, and also from bio-med breakthroughs that range from antibiotics to targeted therapies for cancer and robotic surgery. Is it possible that new waves of discoveries might take us on a path of even more dramatic increases in life extension? Until recently, mainstream scientists would have answered with an emphatic no, suggesting that this was a fantasy offered up by alchemists, charlatans, and pseudo-scientists. Two trends have shifted this point of view. The first is a realization that aging is one of the greatest risk factors for many diseases, and therefore needs to be seriously addressed by biomedical researchers. Not with a primary endpoint of radically prolonging life, which remains controversial, but as a major element of conventional research into understanding and combating cancer, diabetes, heart disease, and other chronic diseases of the elderly. The second trend is that scientists have succeeded in upping the lifespan of many animals, sometimes dramatically, discoveries that have launched wide-ranging research into the mechanics of aging. The big question is: Can these processes be replicated in humans?"

______________________________


<br> <br>View the full article

#26 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 16 September 2012 - 05:17 PM

FIGHT AGING! NEWSLETTER
September 17th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- An Update on Progress in LysoSENS Research
- If Today's Young People Die of Aging, It Will Be By Choice
- Destruction of Senescent Cells May Not Be Sufficient
- Discussion
- Latest Headlines from Fight Aging!
    - Vote for SENS Foundation at Chase Community Giving
    - Spurring Regeneration of Axons in Spinal Injury
    - Struggling With the Separation of Aging and Disease
    - Reversing Deafness Caused by Nerve Cell Damage
    - How to Interpret Life Expectancy Numbers
    - Prostate Cancer Stem Cells Identified
    - Growing Ears to Order
    - Investigating the Mechanisms of Atherosclerosis
    - The Impact of Advancing Age on Muscle

AN UPDATE ON PROGRESS IN LYSOSENS RESEARCH

While receiving far less funding than it deserves, the LysoSENS research program is making progress - largely thanks to the support of the community, as funds for this research are almost entirely derived from charitable and philanthropic donations:

http://www.fightaging.org/archives/2012/09/progress-in-lysosens-bacterial-enzymes-deployed-in-cell-culture-to-break-down-7-ketocholesterol.php

"LysoSENS is the oldest extant research program of the SENS Foundation, started back when the SENS program ran under the auspices of the Methuselah Foundation. In brief, LysoSENS is the development of a means of biomedical remediation. A whole range of harmful metabolic byproducts build up in human tissue with age, and we lack the means to break them down, or break them down fast enough. Some of these compounds simply cause harm, while others actually progressively impair the ability of cells to remove any unwanted chemicals, leading to what is known as the garbage catastrophe in aging - cells overwhelmed with broken protein machinery and waste products.

"To do something about this issue we need ways to break down these waste products, such as those that make up lipofuscin, a mix of compounds that bloat and degrade the cellular recycling machinery known as lysosomes. Lipofuscin is implicated in a range of age-related diseases (as well as a class of genetic conditions known as lysosomal storage diseases). The LysoSENS project aims to discover bacterial enzymes capable of breaking down lipofuscin constituents and other important damaging compounds, and which can safely be introduced to human tissue. Researchers will then build a therapy to deliver these enzymes to where they are needed in our cells.

"We have long known that such enzymes must exist, because places such as graveyards and battlefields do not exhibit a buildup of lipofuscin - something is eating it all. So the LysoSENS project started out by sifting through bacteria in soil samples, testing to see which of the bacterial species in the samples could consume harmful compounds such as 7-ketocholesterol, and then isolating the responsible enzymes.

"This has been going on for a few years now, of course, and progress has been made - even at the all-too-low levels of funding available for this work. At this stage in the project a number of candidate enzymes that break down 7-ketocholesterol have been identified, and researchers are now putting them through their paces in cell cultures. One enzyme at least is worthy of a published paper:

"7-Ketocholesterol (7KC) is a cytotoxic oxysterol that plays a role in many age-related degenerative diseases. 7KC formation and accumulation often occurs in the lysosome, which hinders enzymatic transformations that reduce its toxicity and increase the sensitivity to lysosomal membrane permeabilization.

"We assayed the potential to mitigate 7KC cytotoxicity and enhance cell viability by overexpressing 7KC-active enzymes in human fibroblasts. One of the enzymes tested, a cholesterol oxidase engineered for lysosomal targeting, significantly increased cell viability in the short term upon treatment with up to 50 µM 7KC relative to controls. These results suggest targeting the lysosome for optimal treatment of oxysterol-mediated cytotoxicity, and support the use of introducing novel catalytic function into the lysosome for therapeutic and research applications.

"The success of the approach employed by the team at Rice makes this enzyme, Chromobacterium sp. DS1 cholesterol oxidase, an important step toward a true rejuvenation biotechnology - a therapy that can target and repair damage that underlies the diseases and disabilities of the aging process. SENS Foundation is pleased to continue backing Dr. Mathieu's research, so that further work can move us closer to making such treatments a reality."

IF TODAY'S YOUNG PEOPLE DIE OF AGING, IT WILL BE BY CHOICE

The future is what we choose to make of it:

http://www.fightaging.org/archives/2012/09/if-todays-young-people-die-of-aging-it-will-be-by-choice.php

"It is possible that folk in middle age today, myself included, won't be able to take advantage of rejuvenation biotechnologies - if, for example, development continues to be funded poorly, broader public support for the reversal of aging fails to emerge, or the first thirty year cycle of research, development, and commercialization fails to produce meaningful results. As Aubrey de Grey notes, minimal levels of funding seem to be the most obvious and plausible blocking issue for the foreseeable future. The young have few such worries: they have time to wait out failed business cycles, slow-moving research, public opposition, and an economic collapse between now and when they would absolutely need rejuvenation therapies. A good fraction of the children born in the past few years will live a thousand years in youthful health and vigor, thanks to an upward, accelerating curve in biotechnology.

"So from my perspective it is indeed the case that the only way today's young folk will die of aging is if they choose to do so - such as by failing to support the goal of engineered longevity because they believe that people should age and die, or because they haven't given much thought to living a life any different from that of their parents and grandparents, or because they choose to remain ignorant of medicine and its future. Those are all choices in the broadest sense, and possibly stupid, though it's worth considering that actual stupidity and mere lack of attention given to a particular topic look much the same from a distance.

"Few of us pay more than a tiny amount of attention to anything beyond our specialties, but this is one of those rare eras in which a great deal hinges on paying attention to a specific field. The future of biotechnology has to potential to reshape and greatly extend all of our lives, and remaining ignorant or on the sidelines only adds to the chance that the necessary advances will arrive too late for us."

DESTRUCTION OF SENESCENT CELLS MAY NOT BE SUFFICIENT

Senescent cells accumulate in our tissues with age, and cause harm. The obvious way to deal with this is to destroy them and allow them to be replaced by the normal processes of regeneration and tissue maintenance - but this may not be sufficient:

http://www.fightaging.org/archives/2012/09/destruction-of-senescent-cells-may-not-be-sufficient.php

"Senescent cells build up in our tissues with age. These cells have become damaged or passed the Hayflick limit and thus fallen out of the normal cell cycle of division. They should either self-destruct or be destroyed by the immune system, and until that happens they secrete all sorts of undesirable signaling compounds that tend to harm surrounding tissues. The more senescent cells you have, the more harm they cause - and the growth in their numbers with passing years is one of the root contributing causes of aging.

"Given this outline, plans for dealing with the problem tend to involve identifying and destroying senescent cells - removing the cells from the picture is fairly clearly the way to go. The destroying part is pretty easy (there is no shortage of methods to kill cells) but the identification part is still a challenge, despite considerable progress from the cancer research community in building ways to target specific cell populations via aspects of their surface chemistry or other characteristics. At this point the state of the art demonstration of improved health in mice through destruction of senescent cells requires a combination approach of gene engineering and a targeted therapy, which isn't terribly practical as the basis for a human therapy.

"Progress will be made nonetheless, and a near-future brace of therapies that remove the contribution of senescent cells to aging seems to be very plausible at this point. Yet this all assumes that senescent cells can be wiped out on an ongoing basis without consequence: a fair enough assumption for most tissues, made up of cells that are replaced and replenished on an ongoing basis. Recent research suggests, however, that cells that are far less readily replaced or are normally not replaced at all in the life span of an individual also turn senescent with age - such as those in the brain.

"So if this research holds up we can't just rampage through the body and destroy everything that looks like a senescent cell. More discrimination is needed, which in turn means more complex therapies and a greater understanding of differences in biochemistry between the cell populations of interest. More to the point, we will also need some method of reversing this senescence-like state in the brain and nervous system cells that we want to keep around. Will a general repair of all of the known forms of cellular damage be sufficient for that? Is neural dysfunction absolutely a consequence of the damage modes described by the Strategies for Engineered Negligible Senescence? It seems unlikely that we'll get a solid answer to that question until SENS version 1.0 is implemented in mice, but the initial expectation would be that yes, it is."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

VOTE FOR SENS FOUNDATION AT CHASE COMMUNITY GIVING
Friday, September 14, 2012
http://www.fightaging.org/archives/2012/09/vote-for-sens-foundation-at-chase-community-giving.php
SENS Foundation manages a program of research, development, and advocacy for rejuvenation biotechnology - building the foundation for therapies that will reverse aging in the old by repairing the cellular and biochemical damage that causes it. At present the Chase Community Giving event at Facebook is winding to a close on the 19th of this month, with $10,000 grants provided to those charities given the most votes by the community. So if you have a Facebook account, take a few moments to head on over to the SENS Foundation page and add your vote. Similar past events have demonstrated that there are more than enough SENS supporters out there to win any charitable popularity measure like this; so vote before the 19th and pass it on to your friends.

SPURRING REGENERATION OF AXONS IN SPINAL INJURY
Friday, September 14, 2012
http://www.fightaging.org/archives/2012/09/spurring-regeneration-of-axons-in-spinal-injury.php
Researchers continue to make progress in induced nerve regeneration: "researchers were able to regenerate 'an astonishing degree' of axonal growth at the site of severe spinal cord injury in rats. Their research revealed that early stage neurons have the ability to survive and extend axons to form new, functional neuronal relays across an injury site in the adult central nervous system (CNS). The study also proved that at least some types of adult CNS axons can overcome a normally inhibitory growth environment to grow over long distances. Importantly, stem cells across species exhibit these properties. ... The scientists embedded neural stem cells in a matrix of fibrin [mixed] with growth factors to form a gel. The gel was then applied to the injury site in rats with completely severed spinal cords. ... Using this method, after six weeks, the number of axons emerging from the injury site exceeded by 200-fold what had ever been seen before. The axons also grew 10 times the length of axons in any previous study and, importantly, the regeneration of these axons resulted in significant functional improvement. ... The grafting procedure resulted in significant functional improvement: On a 21-point walking scale, without treatment, the rats score was only 1.5; following the stem cell therapy, it rose to 7 - a score reflecting the animals' ability to move all joints of affected legs. Results were then replicated using two human stem cell lines, one already in human trials for ALS. ... We obtained the exact results using human cells as we had in the rat cells."

STRUGGLING WITH THE SEPARATION OF AGING AND DISEASE
Thursday, September 13, 2012
http://www.fightaging.org/archives/2012/09/struggling-with-the-separation-of-aging-and-disease.php
There is a school of thought that declares the average pace of degenerative aging as "normal" and states that any faster degenerations should be broken out and called "disease." This is somewhat manageable at the level of taxonomy, where you are only cataloging and describing the various ways in which bodily parts and systems break down, but as a system of thought it falls down badly once you have the ability to look under the hood to see what is going in our biochemistry. All of aging and age-related disease descend from the same collection of damage-causing processes, which like rust in a metal construction can lead to any number of different forms of ultimate structural failure - but all stemming from the same root causes. So trying to draw a dividing line between aging and disease produces issues and unnecessary additional work, especially if the researcher is trying to treat only "disease" but let "aging" progress, as you can see from the opening paragraphs in this paper: "Aging of the musculoskeletal system starts early and is detrimental to multiple functions of the whole organism, since it leads to disability and degenerative diseases. The age-related musculoskeletal changes are important in medical risk assessment and care because they influence the responses to treatment and outcomes of therapy. ... There are two major problems that one faces while trying to disentangle the biological complexity of the musculoskeletal aging: (a) it is a systemic, rather than 'compartmental,' problem, which should be dealt with accordingly, (b) the aging per se is neither well defined nor reliably measurable. A unique challenge of studying any age-related process is a need of distinguishing between the 'norm' and 'pathology,' which are interwoven in the aging. When another dimension is added, namely genetics underlying the system's functioning, even less is known about this aspect, and attempts to decipher genetic relationships between the system's components are few. ... To disentangle the aging-related pathology from the homeostasis particular for aging steady-state, is a challenging task. Despite the multiple definitions of the aging process were proposed, there is no single agreed upon and reliable measurement, therefore underlying molecular mechanism of aging is still not fully understood. The definition of aging is complicated by the occurrence of various diseases that modify body functions and tissue structures; these disease-related changes that are common in older persons are often hard to delineate from the aging process per se."

REVERSING DEAFNESS CAUSED BY NERVE CELL DAMAGE
Thursday, September 13, 2012
http://www.fightaging.org/archives/2012/09/reversing-deafness-caused-by-nerve-cell-damage.php
Researchers here use stem cells to partially reverse of a form of deafness in laboratory animals: "Deafness is a condition with a high prevalence worldwide, produced primarily by the loss of the sensory hair cells and their associated spiral ganglion neurons (SGNs). Of all the forms of deafness, auditory neuropathy is of particular concern. This condition, defined primarily by damage to the SGNs with relative preservation of the hair cells, is responsible for a substantial proportion of patients with hearing impairment. Although the loss of hair cells can be circumvented partially by a cochlear implant, no routine treatment is available for sensory neuron loss, as poor innervation limits the prospective performance of an implant. Using stem cells to recover the damaged sensory circuitry is a potential therapeutic strategy. Here we present a protocol to induce differentiation from human embryonic stem cells (hESCs) using signals involved in the initial specification of the otic placode. We obtained two types of otic progenitors able to differentiate in vitro into hair-cell-like cells and auditory neurons that display expected electrophysiological properties. Moreover, when transplanted into an auditory neuropathy model, otic neuroprogenitors engraft, differentiate and significantly improve auditory-evoked response thresholds. These results should stimulate further research into the development of a cell-based therapy for deafness."

HOW TO INTERPRET LIFE EXPECTANCY NUMBERS
Wednesday, September 12, 2012
http://www.fightaging.org/archives/2012/09/how-to-interpret-life-expectancy-numbers.php
Here is a good discussion on some common errors in the use of life expectancy data - such as mistaking period life expectancy (a statistical measure of health and medical technology) for cohort life expectancy (how long people actually live). It doesn't touch on the great uncertainty in predictions of future longevity due to the rapid pace of development in biotechnology, but is still an interesting read: "The US Government estimated its population had a life expectancy of 78.5 years in 2009. If you type 'life expectancy' into Google, it will spit back the World Bank estimate of 78.2 years in 2010. You've likely read numbers close to these in textbooks and articles. But what do these numbers actually mean? You might guess from the first that someone born in the United States in 2009 could be expected to live about 78.5 years. This is not the case! It actually measures how long someone would be expected to live if every year of their life was spent in 2009. In other words, there is no accounting for progress that decreases mortality rates. And that's on purpose. It is what is known as a 'period life expectancy'. Period life expectancies are used to track the general health of a population. With them you can easily compare one country to another. You can also monitor general population health over time. But the number you want if you'd like to know how long people will actually live is known as a 'cohort life expectancy'. It measures how long someone born in a particular year (a cohort) can be expected to live. It is also not in the US Government yearly mortality report for 2009. The reason is that we won't know it until everyone born in 2009 is dead! That will hopefully take a long long time."

PROSTATE CANCER STEM CELLS IDENTIFIED
Wednesday, September 12, 2012
http://www.fightaging.org/archives/2012/09/prostate-cancer-stem-cells-identified-1.php
Another form of cancer turns out to have a core of stem cells that can be targeted: "the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue samples of prostate cancer and found that patients with more aggressive or metastatic tumors had more of these cancer 'stem' cells. ... The study also defines a new therapeutic strategy for patients with prostate cancer, consisting of a combination of standard chemotherapy and two pharmacological agents that inhibit key signaling pathways associated with embryonic development and cell differentiation. Results showed that chemotherapy eliminated differentiated tumor cells, whereas the signaling pathway inhibitors selectively depleted the cancer stem cell population. Some of these inhibitors are already in clinical trials, and some are FDA-approved. ... By targeting these newly identified cancer 'stem' cells, we are attacking the foundation of tumor growth, rather than treating the symptoms of it."

GROWING EARS TO ORDER
Tuesday, September 11, 2012
http://www.fightaging.org/archives/2012/09/growing-ears-to-order.php
Researchers are making progress in growing replacement ears, using a mix of old and new methods in tissue engineering and reconstructive surgery: "Using a computer model of a patient's remaining ear, scientists craft a titanium framework covered in collagen, the stuff that gives skin elasticity and strength. They take a snip of cartilage from inside the nose or between the ribs and seed the scaffold with these cells. This is incubated for about two weeks in a lab dish to grow more cartilage. When it's ready to implant, a skin graft is taken from the patient to cover the cartilage and the ear is stitched into place. Scientists in her lab have maintained lab-grown sheep ears [for] 20 weeks, proving it can be done successfully and last long-term. They also have grown anatomically correct human ears from cells. These have been implanted on the backs of lab rats to keep them nourished and allow further research. ... Now they are ready to seek approval from the Food and Drug Administration to implant these into patients - probably in about a year."

INVESTIGATING THE MECHANISMS OF ATHEROSCLEROSIS
Tuesday, September 11, 2012
http://www.fightaging.org/archives/2012/09/investigating-the-mechanisms-of-atherosclerosis.php
News of an advance in the understanding of atherosclerosis: "Researchers [are] one step closer to understanding why plaque bursts in coronary arteries and causes heart attacks. The clue might be something called microRNA-145. MicroRNAs are short chains of bossy molecules that scientists are increasingly coming to realize control a wide variety of biological processes. ... most heart attacks occur when plaques rupture like a broken eggshell and release their contents into the artery. Researchers are therefore looking for ways to reduce the size of plaques and make them more stable. One of the key questions is what causes the outer layer of the plaque to finally burst - a layer of smooth muscle cells known as the fibrous cap. These cells undergo 'phenotypic transformation' in response to various stressful environments and cardiovascular risk factors, making them more likely to rupture and cause heart attacks. MicroRNA-145 is one of the factors that appear to play a critical role in preventing the transformation of vascular smooth muscle cells into rupture-prone cells. In atherosclerosis-prone animals, microRNA-145-based gene therapy reduced the plaque size by approximately 50 per cent and increased the collagen content of the plaque and fibrous cap area by 40 to 50 per cent, indicating that this therapy can reduce plaque buildup and also make it less prone to rupture, the inciting event of heart attacks. The researchers also found that in human atherosclerotic plaques, the amount of microRNA-145 was reduced compared to normal arteries that were free of plaque, providing supporting human insights to the animal study."

THE IMPACT OF ADVANCING AGE ON MUSCLE
Monday, September 10, 2012
http://www.fightaging.org/archives/2012/09/the-impact-of-advancing-age-on-muscle.php
Our muscles decline with age for reasons that seem likely to soon be treatable. Finding ways to retain muscle mass and strength would hopefully allow older people to continue to be active and exercising, thus removing this contribution to the frailty that leads into a downward spiral of health in late life: "Changing demographics make it ever more important to understand the modifiable risk factors for disability and loss of independence with advancing age. For more than two decades there has been increasing interest in the role of sarcopenia, the age-related loss of muscle or lean mass, in curtailing active and healthy aging. There is now evidence to suggest that lack of strength, or dynapenia, is a more constant factor in compromised wellbeing in old age and it is apparent that the decline in muscle mass and the decline in strength can take quite different trajectories. ... An understanding of the impact of aging on skeletal muscle will require attention to both the changes in muscle size and the changes in muscle quality. ... Cross-sectional studies comparing young (18-45years) and old (older than 65years) samples show dramatic variation based on the technique used and population studied. The median of values of rate of loss reported across studies is 0.47% per year in men and 0.37% per year in women. Longitudinal studies show that in people aged 75years, muscle mass is lost at a rate of 0.64-0.70% per year in women and 0.80-00.98% per year in men. Strength is lost more rapidly. Longitudinal studies show that at age 75years, strength is lost at a rate of 3-4% per year in men and 2.5-3% per year in women. Studies that assessed changes in mass and strength in the same sample report a loss of strength 2-5 times faster than loss of mass. Loss of strength is a more consistent risk for disability and death than is loss of muscle mass."

______________________________


<br> <br>View the full article

#27 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 23 September 2012 - 04:36 PM

FIGHT AGING! NEWSLETTER
September 24th 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- Thoughts on Aging Research in Canada
- Between Zeus and the Salmon
- A Hole-Based Taxonomy for Theories of Aging
- Articles on Plastination
- Discussion
- Latest Headlines from Fight Aging!
    - Genetic Hotspots for Diseases of Aging
    - A Look at the Allen Institute for Brain Science
    - Correlating Progressive Frailty in Aging With Parental Longevity
    - Using Fruit Flies to Study Immune System Aging
    - Calorie Restriction Greatly Slows Protein Turnover
    - A Different View of Aging
    - Longevity in Mammals as a Way to Extend Life of Male Offspring
    - A Review of Vascular Aging
    - 3rd World Congress on Targeting Mitochondria, November 2012
    - Progress in Tailor-Made Organs

THOUGHTS ON AGING RESEARCH IN CANADA

From the In Search of Enlightenment blog:

http://www.fightaging.org/archives/2012/09/thoughts-on-aging-research-in-canada.php

"I attended [an] interesting talk on the 5 year priorities and vision of Canada's Institute of Aging. Many interesting issues arose in the talk and the discussion that followed that illustrate the ongoing challenges which the field of biogerontology faces. ... For a population to approach a life expectancy near 100 years we would have to eliminate most cancers, heart disease and stroke. Considering we have not yet eliminated any one of these diseases, the suggestion that we will continue to increase life expectancy at the same rate as we have in the past is simply unfounded. Take mice in the laboratory. On average, they could life about 2 years if they are fed, protected from predators, etc. Can we get them to live significantly longer by trying to treat all the diseases that afflict them in late life? No. ... We should invest more research dollars into the biology of aging than we do into any one specific disease of aging (e.g. cancer, heart disease, etc.). Unfortunately my sense is that we don't come even close to this. Biogerontology continues to be disadvantaged as a field of scientific inquiry.

"My sense of things, from hearing about the vision of the Institute and the new priorities it has identified, is that the Institute of Aging in Canada still struggles to get the respect, funding and support it deserves. This is no doubt due to many factors, such as the dominance of disease research, misconceptions about the true causes of health disparities, misguided sensibilities of fairness, ageist attitudes, and a general ignorance of the biology of aging and evolutionary biology in general. This makes selling the science to politicians and the general public a really tough sell. But I believe it is something that must be done if we hope to add healthy years to late life. So we must soldier on...."

BETWEEN ZEUS AND THE SALMON

Here are pointers to an overview of recent advances, present strategy, and dominant viewpoints in the mainstream of aging research - those researchers who are interested only in investigation of the mechanisms of aging or gently slowing aging through genetic and metabolic alterations:

http://www.fightaging.org/archives/2012/09/between-zeus-and-the-salmon.php

"This is a goodly amount of reading material, and will probably keep you busy for a weekend or two. It's written from the conservative mainstream point of view, which is to say that it expresses the assumptions that (a) any future change in human longevity will be incremental and small, because (b) no radical advances in biotechnology applicable to aging are waiting in the wings, and © manipulation of longevity-related genes to slow aging is the best way forward, even though it will be slow, hard, challenging work. This is wrong, wrong, wrong - but that's always the way of the mainstream. They are there to be surprised and disrupted by suddenly rushing technological advancement, discontinuities in the pace of progress that occur increasingly frequently in this age of ours. If you want to understand this mainstream of longevity research and its viewpoints on present day and near future challenges in the field, however, then this is a great resource."

A HOLE-BASED TAXONOMY FOR THEORIES OF AGING

There are, it has to be said, a great many theories of aging. It occurs to me that we can classify most theories of aging according to where they stand with respect to the hole we find ourselves in - that hole being the inconvenient fact that we're all aging to death, and progressively increasing suffering and pain lies in each of our personal futures:

http://www.fightaging.org/archives/2012/09/a-hole-based-taxonomy-for-theories-of-aging.php

ARTICLES ON PLASTINATION

Plastination is the basis for a technology platform that might, in the years ahead, compete with low-temperature vitrification as a way to preserve a brain sufficiently well to also preserve the mind it contains. Preservation, such as that presently offered by the cryonics industry, gives an individual a shot at waiting out the future development of molecular nanotechnologies that could restore him to active life. This is the best chance on offer for those born too soon to benefit from the rejuvenation biotechnology that will emerge over the next few decades:

http://www.fightaging.org/archives/2012/09/a-couple-of-articles-on-plastination.php

"Assuming that brain plastination eventually comes into practice, the first step, regrettably, is that you have to die. This could be in or near a hospital, hospice, or your home. Moments after your death, a response team will start the process of emergency glutaraldehyde perfusion (EGP) for protein fixation (a kind of advanced embalming process). This has to happen within 15 minutes of your death, otherwise the first phase of neural degradation will start to set in; brain cells start to die on account of oxygen deprivation. The infusion of this molecule by the response team basically freezes your brain into place, creating a snapshot of your identity and your long term memories - though you might lose some short-term memories when you resume life after reanimation, just as sometimes happens after brain trauma today. ... After this, your body will be moved to a centralized facility where, over the course of several months, your brain will be carefully removed and placed into a bath. ... It's at this point that a chemical called osmium tetroxide fixes all the fats and fluid membranes in the brain cells. Then, a series of acetone-like solvents are used to convert the brain into plastic where it can be stored at room temperature. ... All the water gets leached, out, but all the protein (and presumably, the other critical features) is still there, and so are all the neural connections, as are all the neural weightings - including the three dimensional structure."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

GENETIC HOTSPOTS FOR DISEASES OF AGING
Friday, September 21, 2012
http://www.fightaging.org/archives/2012/09/genetic-hotspots-for-diseases-of-aging.php
Some interesting results from genetic research: scientists "have shown definitively that a small number of places in the human genome are associated with a large number and variety of diseases. In particular, several diseases of aging are associated with a locus which is more famous for its role in preventing cancer. For this analysis, [researchers] cataloged results from several hundred human Genome-Wide Association Studies (GWAS) from the National Human Genome Research Institute. These results provided an unbiased means to determine if varied different diseases mapped to common 'hotspot' regions of the human genome. This analysis showed that two different genomic locations are associated with two major subcategories of human disease. ... More than 90 percent of the genome lacked any disease loci. Surprisingly, however, lots of diseases mapped to two specific loci, which soared above all of the others in terms of multi-disease risk. The first locus at chromosome 6p21, is where the major histocompatibility (MHC) locus resides. The MHC is critical for tissue typing for organ and bone marrow transplantation, and was known to be an important disease risk locus before genome-wide studies were available. Genes at this locus determine susceptibility to a wide variety of autoimmune diseases ... The second place where disease associations clustered is the INK4/ARF (or CDKN2a) tumor suppressor locus [also known as p16]. This area, in particular, was the location for diseases associated with aging: atherosclerosis, heart attacks, stroke, Type II diabetes, glaucoma and various cancers. ... The finding that INK4/ARF is associated with lots of cancer, and MHC is associated with lots of diseases of immunity is not surprising - these associations were known. What is surprising is the diversity of diseases mapping to just two small places: 30 percent of all tested human diseases mapped to one of these two places. This means that genotypes at these loci determine a substantial fraction of a person's resistance or susceptibility to multiple independent diseases. ... In addition to the MHC and INK4/ARF loci, five less significant hotspot loci were also identified. Of the seven total hotspot loci, however, all contained genes associated with either immunity or cellular senescence. Cellular senescence is a permanent form of cellular growth arrest, and it is an important means whereby normal cells are prevented from becoming cancerous. It has been long known that senescent cells accumulate with aging, and may cause aspects of aging. This new analysis provides evidence that genetic differences in an individual's ability to regulate the immune response and activate cellular senescence determine their susceptibility to many seemingly disparate diseases."

A LOOK AT THE ALLEN INSTITUTE FOR BRAIN SCIENCE
Friday, September 21, 2012
http://www.fightaging.org/archives/2012/09/a-look-at-the-allen-institute-for-brain-science.php
A comprehensive understanding of the brain is an important line item for future medical development, as the research community will have to develop ways to repair the brain and reverse aspects of its aging while preserving the structures that encode the mind. Here is a look at one of the higher profile projects of recent years: "Paul Allen, the 59-year-old Microsoft cofounder [has] plowed $500 million into the Allen Institute for Brain Science, a medical Manhattan Project that he hopes will dwarf his contribution as one of the founding fathers of software. The institute, scattered through three buildings in Seattle's hip Fremont neighborhood, is primarily focused on creating tools, such as the mouse laser, which is technically a new type of microscope, that will allow scientists to understand how the soft, fleshy matter inside the human skull can give rise to the wondrous, mysterious creative power of the human mind. ... His first $100 million investment in the Allen Institute resulted in a gigantic computer map of how genes work in the brains of mice, a tool that other scientists have used to pinpoint genes that may play a role in multiple sclerosis, memory and eating disorders in people. Another $100 million went to creating a similar map of the human brain, already resulting in new theories about how the brain works, as well as maps of the developing mouse brain and mouse spinal cord. These have become essential tools for neuroscientists everywhere. Now Allen, the 20th-richest man in America, with an estimated net worth of $15 billion, has committed another $300 million for projects that will make his institute more than just a maker of tools for other scientists, hiring several of the top minds in neuroscience to spearhead them. One effort will try to understand the mouse visual cortex as a way to understand how nerve cells work in brains in general. Other projects aim to isolate all the kinds of cells in the brain and use stem cells to learn how they develop. Scientists think there may be 1,000 of these basic building blocks, but they don't even know that. 'In software,' Allen says, 'we call it reverse engineering.'"

CORRELATING PROGRESSIVE FRAILTY IN AGING WITH PARENTAL LONGEVITY
Thursday, September 20, 2012
http://www.fightaging.org/archives/2012/09/correlating-progressive-frailty-in-aging-with-parental-longevity.php
A nice demonstration of the degree to which the pace of aging is inherited - but remember that for the vast majority of us, lifestyle choices have more influence than genes, while progress in medical technology trumps all such concerns: "Various measures incorporated in geriatric assessment have found their way into frailty indices (FIs), which have been used as indicators of survival/mortality and longevity. Our goal is to understand the genetic basis of healthy aging to enhance its evidence base and utility. We constructed a FI as a quantitative measure of healthy aging and examined its characteristics and potential for genetic analyses. Two groups were selected from two separate studies. One group (OLLP for offspring of long-lived parents) consisted of unrelated participants at least one of whose parents was age 90 or older, and the other group of unrelated participants (OSLP for offspring of short-lived parents), both of whose parents died before age 76. FI(34) scores were computed from 34 common health variables and compared between the two groups. The FI(34) was better correlated than chronological age with mortality. The mean FI(34) value of the OSLP was 31% higher than that of the OLLP. The FI(34) increased exponentially, at an instantaneous rate that accelerated 2.0% annually in the OLLP and 2.7 % in the OSLP consequently yielding a 63% larger accumulation in the latter group. The results suggest that accumulation of health deficiencies over the life course is not the same in the two groups, likely due to inheritance related to parental longevity. Consistent with this, [sibling pairs] were significantly correlated regarding FI(34) scores, and heritability of the FI(34) was estimated to be 0.39. ... Variation in the FI(34) is, in part, due to genetic variation; thus, the FI(34) can be a phenotypic measure suitable for genetic analyses of healthy aging."

USING FRUIT FLIES TO STUDY IMMUNE SYSTEM AGING
Thursday, September 20, 2012
http://www.fightaging.org/archives/2012/09/using-fruit-flies-to-study-immune-system-aging.php
An open access review paper that looks at the use of fruit flies in studying the details of immune system aging: "Aging is a complex process that involves the accumulation of deleterious changes resulting in overall decline in several vital functions, leading to the progressive deterioration in physiological condition of the organism and eventually causing disease and death. The immune system is the most important host-defense mechanism in humans and is also highly conserved in insects. Extensive research in vertebrates has concluded that aging of the immune function results in increased susceptibility to infectious disease and chronic inflammation. Over the years, interest has grown in studying the molecular interaction between aging and the immune response to pathogenic infections. The fruit fly Drosophila melanogaster is an excellent model system for dissecting the genetic and genomic basis of important biological processes, such as aging and the innate immune system, and deciphering parallel mechanisms in vertebrate animals. Here, we review the recent advances in the identification of key players modulating the relationship between molecular aging networks and immune signal transduction pathways in the fly. Understanding the details of the molecular events involved in aging and immune system regulation will potentially lead to the development of strategies for decreasing the impact of age-related diseases, thus improving human health and life span."

CALORIE RESTRICTION GREATLY SLOWS PROTEIN TURNOVER
Wednesday, September 19, 2012
http://www.fightaging.org/archives/2012/09/calorie-restriction-greatly-slows-protein-turnover.php
Examination of the sweeping low-level changes in biochemistry brought on by calorie restriction continues apace: "Calorie restriction (CR) promotes longevity. A prevalent mechanistic hypothesis explaining this CR effect suggests that protein degradation, including mitochondrial autophagy, is increased, thereby removing damaged proteins. At steady state, increased catabolism must be balanced by increasing mitochondrial biogenesis and protein synthesis, resulting in faster protein replacement rates. To test this hypothesis, we measured replacement kinetics and concentrations of hundreds of proteins in vivo in long-term CR and ad libitum -fed mice ... CR reduced absolute synthesis and breakdown rates of almost all measured hepatic proteins and prolonged half-lives of most (~80%), particularly mitochondrial proteins ... Proteins with related functions exhibited coordinated changes in concentration as well as replacement rates. ... In summary, our combination of dynamic and quantitative proteomics suggest that long-term CR reduces mitochondrial biogenesis and mitophagy are reduced. Our findings contradict the theory that CR increases mitochondrial protein turnover, and provide compelling evidence that cellular fitness is accompanied by reduced global protein synthetic burden."

A DIFFERENT VIEW OF AGING
Wednesday, September 19, 2012
http://www.fightaging.org/archives/2012/09/a-different-view-of-aging.php
This author defines aging as "an age-dependent trajectory of interacting system states - the sum of all molecular and physiological states and their interaction networks, many but not all of which shift in a consistent direction over time. This definition broadens our focus to include components that do not themselves depend on age, but which cohabit networks containing components that do. Gene-environment interactions are a case in point, wherein environmental variation can help to shape the age-structure of a population despite being quite obviously independent of age. Perhaps the best-established genetic pathway to influence lifespan is insulin-like signaling, believed to have evolved at least in part for its ability to maximize reproduction under favorable environments while postponing both reproduction and individual mortality under conditions of crowding or insufficient food ... Since natural populations are polymorphic for ostensibly rate-limiting components of this pathway, it is likely that individuals genetically predisposed to low insulin-like signaling should survive famine better than those geared for higher signaling and shorter lifespan. This is a conclusion of some import for population biologists, since the age-composition of any population must then be modified by the availability of food. A particularly instructive example is the near-ubiquitous evolutionary requirement for species or their constituent populations to survive extended periods of famine. Groups experiencing more prolonged famines (or just over-wintering, if their lifespans are measured in weeks) will have more diverse age structures, including an increased number of individuals for whom reproduction has been delayed. ... The same potential also exists for gene-gene interactions (including genes that dictate dietary preferences) to affect long-term survival. For example, only one component of a gene network may actually be age-dependent, while other genes create the background context of homeostatic states and their oscillations within which age-dependent genes must function. An increased probability of death with age could then arise from components undergoing essentially monotonic age-dependent declines, confronting extreme-value system states (in variable but age-independent parameters) to which they cannot respond adequately in any essential tissue or organ. Alternatively, an age-dependent increase in the variance of system oscillations may exceed the response range of one or more age-independent gene functions. In either case, the precise cause of death or debility will vary in a stochastic way, appearing as the 'weakest link' in any one tissue or organism, although the underlying age-associated changes may be common to many or all cell types and individuals."

LONGEVITY IN MAMMALS AS A WAY TO EXTEND LIFE OF MALE OFFSPRING
Tuesday, September 18, 2012
http://www.fightaging.org/archives/2012/09/longevity-in-mammals-as-a-way-to-extend-life-of-male-offspring.php
The members of a number of mammal species, ourselves included, live long past their reproductive years. The question would be why this postreproductive longevity has evolved: what advantage does it confer? For humans, the grandmother hypothesis suggests that it has something to do with enhancing the survival of grandchildren, but this is debated. Here, researchers look at killer whales to argue that the advantage lies in enhanced survival of the male children of long-lived mothers: "Prolonged life after reproduction is difficult to explain evolutionarily unless it arises as a physiological side effect of increased longevity or it benefits related individuals (i.e., increases inclusive fitness). There is little evidence that postreproductive life spans are adaptive in nonhuman animals. By using multigenerational records for two killer whale (Orcinus orca) populations in which females can live for decades after their final parturition, we show that postreproductive mothers increase the survival of offspring, particularly their older male offspring. This finding may explain why female killer whales have evolved the longest postreproductive life span of all nonhuman animals." Male mammals are capable of siring offspring far later in life than females, so if a longer-lived mother can increase the number of years in which a male child continues to mate, that would constitute an advantage even if the mother can no longer reproduce.

A REVIEW OF VASCULAR AGING
Tuesday, September 18, 2012
http://www.fightaging.org/archives/2012/09/a-review-of-vascular-aging.php
An open access paper: "'Man is as old as his arteries.' This old aphorism has been widely confirmed by epidemiological and observational studies establishing that cardiovascular diseases can be age-related in terms of their onset and progression. Besides, with aging come a number of physiological and morphological changes that alters cardiovascular function and lead to subsequently increased risk of cardiovascular disease, even in health asymptomatic individuals. Even though different adaptive mechanisms to protect blood vessels against mild stress have been described, the aging process induces a progressive failure of protective mechanisms, leading to vascular changes. The outcomes of the aging-related modifications are the impairment of homeostasis of the irrigated organs and resultant target organ damage. The increasing mean age of the population in industrialized countries has turned out to be an economic and public health problem, as the increase in life expectancy goes in parallel with high incidence of several pathological conditions, despite unprecedented advances in prevention, diagnostics, and treatment. Of all aging-related illness, cardiovascular diseases remain the leading cause of morbidity and mortality in the elderly, and thus it is imperative to understand the mechanism underlying cardiovascular senescence."

3RD WORLD CONGRESS ON TARGETING MITOCHONDRIA, NOVEMBER 2012
Monday, September 17, 2012
http://www.fightaging.org/archives/2012/09/3rd-world-congress-on-targeting-mitochondria-november-2012.php
Progress towards ways to repair mitochondria is very important: a way to fix our age-damaged mitochondria is a necessary part of any toolbox of therapies capable of reversing aging. An upcoming conference provides some insight into the present state of research: "After the success of the two first editions held in 2010 & 2011, the Scientific Committee of the International Society of Antioxidants in Nutrition and Health (ISANH) decided to organize the 3rd World Congress on Targeting Mitochondria which will be held in Berlin in November 8-9, 2012. Mitochondrial dysfunctions are associated with hundred of pathologies such as cancer, diabetes, neurodegenerative diseases, migraine, infertility, kidney diseases, liver diseases, toxicity of HIV drugs, aging... It is becoming a necessity and an urge to know why and how to target mitochondria with bioactive molecules, drugs or nutrients in order to treat and prevent pathologies and chronic diseases. This 3rd World Congress on Targeting Mitochondria will cover a variety of new strategies and innovations as well as clinical applications in Mitochondrial Medicine. ... The Scientific Committee has selected two hot topics for this year's meeting. The first topic involves Mito-Devices, which are novel tools for probing mitochondrial function under physiological and pathological conditions. The second topic focuses on Mito-Engineering, i.e. novel strategies and means towards manipulations of mitochondrial function. Mito-devices and Mito-engineering are essential for making mitochondria-targeted therapeutics clinical feasible, therefore clinical applications are the underlying theme of the 3rd edition of Targeting Mitochondria."

PROGRESS IN TAILOR-MADE ORGANS
Monday, September 17, 2012
http://www.fightaging.org/archives/2012/09/progress-in-tailor-made-organs.php
A popular science article on recent progress in organ engineering: "Implanting such a 'bioartificial' organ would be a first-of-its-kind procedure for the field of regenerative medicine, which for decades has been promising a future of ready-made replacement organs - livers, kidneys, even hearts - built in the laboratory. For the most part that future has remained a science-fiction fantasy. Now, however, researchers like Dr. Macchiarini are building organs with a different approach, using the body's cells and letting the body itself do most of the work. ... So far, only a few organs have been made and transplanted, and they are relatively simple, hollow ones - like bladders and [windpipes] ... But scientists around the world are using similar techniques with the goal of building more complex organs. At Wake Forest University in North Carolina, for example, where the bladders were developed, researchers are working on kidneys, livers and more. Labs in China and the Netherlands are among many working on blood vessels. The work of these new body builders is far different from the efforts that produced artificial hearts decades ago. Those devices, which are still used temporarily by some patients awaiting transplants, are sophisticated machines, but in the end they are only that: machines. Tissue engineers aim to produce something that is more human. They want to make organs with the cells, blood vessels and nerves to become a living, functioning part of the body. Some, like Dr. Macchiarini, want to go even further - to harness the body's repair mechanisms so that it can remake a damaged organ on its own."

______________________________


<br> <br>View the full article

#28 Marios Kyriazis

  • Guest
  • 466 posts
  • 255
  • Location:London UK

Posted 24 September 2012 - 09:46 AM

Interesting collection of articles and research. Rather conservative though

#29 reason

  • Guardian Reason
  • 1,101 posts
  • 248
  • Location:US

Posted 30 September 2012 - 01:11 PM

FIGHT AGING! NEWSLETTER
October 1st 2012

The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and proven medical advances to live healthy, longer lives. This newsletter is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite it in any way you see fit, the only requirements being that you provide attribution and a link to Fight Aging!

______________________________

CONTENT

- A Way to Insert New Mitochondria into Cells
- Future Directions for Fight Aging!
- Progress in Tackling Muscle Aging
- Commentary on the Relevance of Progeria Research
- Discussion
- Latest Headlines from Fight Aging!
    - Shorter People Tend to Live Longer
    - Rate of Increase of Short Telomeres Predicts Longevity in Mammals
    - Overexpressing Fatty-Acid-β-Oxidation-Related Genes Extends Fly Lifespan
    - A Mammal With Superior Regeneration
    - A Few More Longevity-Associated Gene Variants
    - Eunuchs as a Poor Way to Study the Influence of Male Hormones on Aging
    - Nanoparticles to Reliably Target Mitochondria
    - Early Results from a Progeria Therapy Trial
    - An Interesting Comment From a Google Ventures Partner
    - When I'm 164: An Interview With David Ewing Duncan

A WAY TO INSERT NEW MITOCHONDRIA INTO CELLS

The mitochondria swarming in our cells become damaged as a result of performing their biological function, and this damage is a potent contribution to the aging process. Various methodologies are proposed to eliminate this issue, and here is news of progress on one front:

http://www.fightaging.org/archives/2012/09/a-way-to-insert-new-mitochondria-into-cells.php

"Scientists demonstrate that cells will ingest and adopt appropriately engineered mitochondria, adding them to the existing herd without the need for any intervention beyond placing the engineered mitochondria into the same cell culture. The researchers are calling their process peptide-mediated mitochondrial delivery ... As you can imagine, this immediately leads one to think in terms of an infusion-type therapy, where a fluid solution containing hordes of mitochondria can be introduced into tissues and be taken up into cells. The mitochondria themselves can be cultivated like bacteria from a sample from the patient, which is gene engineered to fix issues such as genetic diseases caused by mutations in mitochondrial DNA - or they can be from a donor.

"In a more liberated, free-wheeling future, this sort of approach might be widely used to swap out the mitochondria you are born with for a better set. It is already the case that some mitochondrial lineages have been shown to be better than others in terms of functionality and durability. Looking further ahead, we might see optimal mitochondria: artificially created biological machines that do the same job, but designed to remove the issues that cause harm and aging in the natural version.

"The ability to insert new mitochondria is a viable approach for genetic diseases, where the patient's lineage is damaged. The new fully functional mitochondria will dilute the effects of the established mitochondria, and may largely replace them with time. Thinking on this points out the major issue with wholesale mitochondrial replacement, however: it's not the case that functional mitochondria will necessarily out-compete non-functional mitochondria within a cell over the long haul. Consider that the situation becomes something like competition between bacterial strains in an enclosed environment: whichever strain has the advantage will eventually win out. This picture is complicated by the fact that mitochondria swap components among themselves, but still seems to be a useful model when thinking about results.

"For the genetic disease sufferers, it should be comforting to see that the researchers demonstrated repair of cells with broken mitochondria by inserting working mitochondria. For aging, however, the picture is less certain. After all, the problems caused by damaged mitochondria in aging occur because these damaged cellular components have an advantage to survival - they are damaged in a way that evades the surveillance mechanisms designed to weed out broken, harmful mitochondria. So it isn't clear that throwing in a bunch of working mitochondria will help all that much; one might imagine a short-lived benefit, but then you're right back to where you were before.

"Which is not to say that people shouldn't try this. I say run up some old flies or nematode worms and infuse them with fresh new mitochondria, see what happens. A study in nematodes in particular should proceed fairly straightforwardly from being able to do this in cell cultures."

FUTURE DIRECTIONS FOR FIGHT AGING!

Fight Aging! has been somewhat static in focus and traffic for the past five years at least. Is there anything that can or should be done about changing this state of affairs? Some thoughts on possible strategies and changes of focus can be found in the following post:

http://www.fightaging.org/archives/2012/09/possible-future-directions-for-fight-aging.php

PROGRESS IN TACKLING MUSCLE AGING

Muscles decline with age, and the frailty and weakness that result are a part of the downward spiral of aging. A range of different strategies and mechanisms are emerging as researchers dig into how this process happens. News of progress on two fronts appeared recently:

http://www.fightaging.org/archives/2012/09/inhibiting-fgf2-in-mice-slows-muscle-stem-cell-decline-with-age.php

"Rare muscle stem cells are located inside each skeletal muscle of the body. Also called satellite cells, due to their position on the surface of the muscle fibers they serve and protect, these cells are essential to maintaining the capacity of muscles to regenerate. Satellite cells are able to generate new, differentiated muscle cells while keeping their identity as stem cells, retaining the ability to maintain and repair muscle tissue. Normally in a resting or dormant state, satellite cells respond rapidly to repair injured tissues. The current study finds that aging muscle stem cells lose their ability to maintain a dormant state, so that when called upon to repair injured muscle, they are unable to mount an adequate response. ... Just as it is important for athletes to build recovery time into their training schedules, stem cells also need time to recuperate, but we found that aged stem cells recuperate less often. We were surprised to find that the events prior to muscle regeneration had a major influence on regenerative potential.

"In a series of experiments in mice, the authors found that a developmental protein called fibroblast growth factor-2 (FGF2) is elevated in the aging muscle stem cell microenvironment and drives stem cells out of the dormant state. Satellite cells that are forced to replicate lose the ability to maintain their identity as stem cells, reducing the stem cell population. The authors also found that blocking the age-related increase in FGF signaling both in aged satellite cells or in the cellular microenvironment protected against stem cell loss, maintained stem cell renewal during aging and dramatically improved the ability of aged muscle tissue to repair itself."

http://www.fightaging.org/archives/2012/09/an-update-on-myostatin-research.php

"Blocking myostatin function in normal mice causes them to bulk up by 25 to 50 percent. What is not known is which cells receive and react to the myostatin signal. Current suspects include satellite cells and muscle cells themselves. In this latest study, researchers used three approaches to figure out whether satellite cells are required for myostatin activity. They first looked at specially bred mice with severe defects in either satellite cell function or number. When they used drugs or genetic engineering to block myostatin function in both types of mice, muscle mass still increased significantly compared to that seen in mice with normal satellite cell function, suggesting that myostatin is able to act, at least partially, without full satellite cell function.

"To further confirm their theory that myostatin acts primarily through muscle cells and not satellite cells, the team engineered mice with muscle cells lacking a protein receptor that binds to myostatin. If satellite cells harbor most of the myostatin receptors, removal of receptors in muscle cells should not alter myostatin activity, and should result in muscles of normal girth. Instead, what the researchers saw was a moderate, but statistically significant, increase in muscle mass. The evidence once again, they said, suggested that muscle cells are themselves important receivers of myostatin signals. ... since the results give no evidence that satellite cells are of primary importance to the myostatin pathway, even patients with low muscle mass due to compromised satellite cell function may be able to rebuild some of their muscle tone through drug therapy that blocks myostatin activity.

"Everybody loses muscle mass as they age, and the most popular explanation is that this occurs as a result of satellite cell loss. If you block the myostatin pathway, can you increase muscle mass, mobility and independence for our aging population? [Our] results in mice suggest that, indeed, this strategy may be a way to get around the satellite cell problem."

COMMENTARY ON THE RELEVANCE OF PROGERIA RESEARCH

A therapy for the rare accelerated aging condition progeria is showing some benefits in a trial. Is this relevant to work on normal aging?

http://www.fightaging.org/archives/2012/09/commentary-on-progeria-therapy-trials-at-the-sens-foundation.php

"All of us at SENS Research Foundation are inspired by the rapid progress that was made against this tragic disease ... However, it is also important not to read too much into this apparent advance in regards to its implications for the development of new medicines against the diseases and disabilities of aging. In particular, the common characterization of HGPS 'progeria' as a disease of 'premature aging' leads some to expect that this research has direct implications for the development of rejuvenation biotechnologies, targeting the damage and disabilities of aging.

"It is true that the splicing defect responsible for formation of progerin is sporadically active in wild-type cells, and that number of cells in which progerin is present and the level at which it appears do appear to rise with aging. However, such cells are rare enough, and their progerin levels low enough, as to seem highly unlikely to meaningfully contribute to tissue dysfunction with aging, at least within the bounds of a currently-normal lifespan. Additionally, there is evidence that progerin can be turned over in the nuclear lamina, and the causal relationship between the higher prevalence of progerin in aging cells and cellular senescence or disease are not clear, leaving open the possiblity that repair of well-established forms of aging damage may in turn lead to the reversal or obviation of this phenomenon.

"Notably, the need to remove 'senescent' cells as part of a comprehensive panel of rejuvenation biotechnologies is already clear from first principles, and its potential to ameliorate aspects the frailty and disability of aging has been demonstrated in proof-of-concept rejuvenation research, rendering the specific role of progerin in the process moot. That is, removing 'senescent' cells is essential whether progerin accumulation is a cause or a consequence of cellular senescence, and will be equally effective as a regenerative medical therapy against age-related disability in either case."

DISCUSSION

The highlights and headlines from the past week follow below. Remember - if you like this newsletter, the chances are that your friends will find it useful too. Forward it on, or post a copy to your favorite online communities. Encourage the people you know to pitch in and make a difference to the future of health and longevity!

______________________________

LATEST HEADLINES FROM FIGHT AGING!

SHORTER PEOPLE TEND TO LIVE LONGER
Friday, September 28, 2012
http://www.fightaging.org/archives/2012/09/shorter-people-tend-to-live-longer.php
It is thought that size in humans relates to life expectancy via aspects of metabolism such as growth hormone - less growth hormone means a smaller size but longer life in mammal species. Ames dwarf mice are an example of this taken to an extreme through genetic engineering, lacking growth hormone but living more than 60% longer than their peers. From an evolutionary perspective, an abundance of food and good health in early life or gestation is thought to trigger a more aggressive front-loading of growth and fertility - which comes at the cost of faster decline once an individual is beyond their reproductive lifespan: "Sardinians have been studied extensively looking for clue to long lifespan. In the current study researchers analyzed the role of a person's height in their eventual lifespan. The researchers analyzed the height of men when they entered the military at age 20 between the years of 1866 and 1915. A total of 685 subjects were analysed. These heights were then related to the persons eventual age at death. It was found that shorter people (shorter than 161.1 cm) lived significantly longer on average than taller people (taller 161.1cm). Furthermore at age 70, taller people lived on average 2 years less than shorter people. At age 70 each quarter inch of height reduced lifespan by one year. The authors write: In conclusion, shorter people and taller people exhibit differences in longevity. Although a tall body generally reflects abundant nutrition and good living conditions during the growth period, this height has negative ramifications as well. Biological mechanisms indicate that a larger body places greater stress on cells, tissues, and organs, which can reduce longevity."

RATE OF INCREASE OF SHORT TELOMERES PREDICTS LONGEVITY IN MAMMALS
Friday, September 28, 2012
http://www.fightaging.org/archives/2012/09/rate-of-increase-of-short-telomeres-predicts-longevity-in-mammals.php
Telomeres are the protective caps at the end of chromosomes. They shorten with cell division, and so are part of the clock which decides when a cell reaches the Hayflick limit and ceases dividing. There is much more to it than this, however: telomere length across all the cells in a piece of living tissue is dynamic, as there are processes that lengthen telomeres as well - such as the activity of telomerase. In general average telomere length erodes with age, reflecting the progressive breakdown of the body's ability to maintain itself - but this proceeds quite differently in different tissues and different species. It can even be reversed in the short term if the health of an individual improves, though in the long term the overall progression is still downhill. Shorter average telomere length has been correlated with measures of health in statistical studies, but data allowing prediction of longevity for an individual has proven elusive to date. Here, however, a more sophisticated measure of telomere dynamics is show to be predictive of life span in individual mice: "Aberrantly short telomeres result in decreased longevity in both humans and mice with defective telomere maintenance. Normal populations of humans and mice present high interindividual variation in telomere length, but it is unknown whether this is associated with their lifespan potential. To address this issue, we performed a longitudinal telomere length study along the lifespan of wild-type and transgenic telomerase reverse transcriptase mice. We found that mouse telomeres shorten ∼100 times faster than human telomeres. Importantly, the rate of increase in the percentage of short telomeres, rather than the rate of telomere shortening per month, was a significant predictor of lifespan in both mouse cohorts, and those individuals who showed a higher rate of increase in the percentage of short telomeres were also the ones with a shorter lifespan. These findings demonstrate that short telomeres have a direct impact on longevity in mammals, and they highlight the importance of performing longitudinal telomere studies to predict longevity."

OVEREXPRESSING FATTY-ACID-β-OXIDATION-RELATED GENES EXTENDS FLY LIFESPAN
Thursday, September 27, 2012
http://www.fightaging.org/archives/2012/09/overexpressing-fatty-acid--oxidation-related-genes-extends-fly-lifespan.php
Researchers here investigate another portion of the mechanisms of metabolism that are influenced by calorie restriction and many of the known longevity genes. This sort of discovery helps to fill in a very complicated landscape of intertwining effects and controllers of effects - at some point in the not too distant future the research community will be able to set out a complete map of how all of the longevity genes and known ways to extend life in laboratory animals relate to one another and work through an overlapping set of mechanisms: "In this study, we demonstrated that the overexpression of fatty-acid-β-oxidation-related genes extended median and maximum lifespan [in flies] and increased stress resistance, suggesting that the level of fatty-acid β-oxidation regulates lifespan. Consistent with our results, many investigations have suggested fatty-acid β-oxidation as a lifespan determinant. One of the well-known longevity-candidate genes, AMPK reportedly regulates fatty-acid synthesis and oxidation. Moreover, calorie restriction and [insulin/insulin-like growth factor (IGF) signaling (IIS)] have been reported to promote fatty-acid β-oxidation. In addition, enigma mutant, which exhibits oxidative stress resistance and a longevity phenotype, was found to encode a fatty-acid-β-oxidation related enzyme. ... However, the present study is the first to provide direct evidence that the modulation of fatty-acid-β-oxidation components extends lifespan. Our data showed that lifespan extension by dietary restriction decreased with the overexpression of fatty-acid β-oxidation-related genes, indicating that lifespan extension by fatty-acid-β-oxidation components is associated with dietary restriction. It was previously reported that calorie restriction increased whole-body-fat oxidation. Energy deprivation subsequent to calorie restriction activates AMPK, which subsequently enables the increase of fatty-acid oxidation necessary to utilize the energy resource. These findings suggested that fatty acid oxidation and dietary restriction are related by same underlying mechanisms."

A MAMMAL WITH SUPERIOR REGENERATION
Thursday, September 27, 2012
http://www.fightaging.org/archives/2012/09/a-mammal-with-superior-regeneration.php
We mammals just can't regenerate as well as lower animals - but we all evolved from the same ancestors, so the suspicion is that we might retain at least some of the necessary mechanisms to regrow organs and limbs, just buried and inactive. Some studies have uncovered possible hints of this: you might recall the gene engineered MRL mice that have superior regenerative abilities due to inactivation of p21, for example. Here, researchers note the discovery of superior natural regenerative abilities in a rodent species - which should hopefully lead to some further insight into how we might make humans regenerate more capably: "Two species of African spiny mouse have been caught at something no other mammal is known to do - completely regenerating damaged tissue. ... Acomys kempi and Acomys percivali [have] skin that is brittle and easily torn, which helps them to escape predators by jettisoning patches of their skin when caught or bitten. ... whereas normal laboratory mice (Mus musculus) grow scar tissue when their skin is removed, African spiny mice can regrow complete suites of hair follicles, skin, sweat glands, fur and even cartilage. Tissue regeneration has not been seen in mammals before, but it is common in crustaceans, insects, reptiles and amphibians. Some lizards can regrow only their tails, whereas some salamanders can regenerate entire limbs, complete with bones and muscle. The researchers say that their next step will be to work out the molecular mechanisms and genetic circuits that direct the regeneration process. It's unlikely that these mice have evolved an entirely new method of regrowing tissue ... Rather, the genes that direct regeneration in salamanders are probably switched off in mammals, but have been switched back on in African spiny mice. ... By looking at the common genetic blueprints that exist across vertebrates, we hope to find the ones that we could activate in humans. We just need to figure out how to dial the process in mammals back to do something the entire system already knows how to do."

A FEW MORE LONGEVITY-ASSOCIATED GENE VARIANTS
Wednesday, September 26, 2012
http://www.fightaging.org/archives/2012/09/a-few-more-longevity-associated-gene-variants.php
There are many genes associated with longevity, but one of the present challenges in this research is that few such correlations seem to exist in multiple populations - implying that there is a very large set of individually small contributions from our genes, and that different lineages and lifestyles have significantly different maps of genes to longevity: "Men and women have a different life expectancy. Not unexpectedly, several genes involved in lifespan determination have been found to influence the probability of achieving longevity differently in men and women. This investigation examines the association between longevity and polymorphisms of follicle-stimulating hormone receptor (FSHR, Asn680Ser polymorphism) and peroxisome proliferator-activated receptor gamma (PPARG, Pro12Ala polymorphism), two genes that previous investigations suggested may exert a gender-specific influence on human longevity. A sample of 277 individuals (mean age: 82.9±5.7years) was recruited in 2000. Based on mortality data collected in 2009, the sample was divided into two groups of subjects surviving over 90 years (long-lived) or not (controls). The frequency of FSHR 680 Ser/Ser genotype was significantly higher in the sample of long-lived women compared to controls, indicating that FSHR 680 Ser/Ser genotype may favor survival to more than 90 years of age only in women. In contrast, the frequency of PPARG Pro/Ala genotype was significantly higher in the sample of male subjects who died before 90 years than in the long-lived, suggesting that carrying PPARG Pro/Ala genotype may prevent the attainment of advanced age only in men. We then searched the literature for studies reporting a differential role for the genetic component in male and female longevity; to do this, we selected longevity genes with a gender-specific effect. A review of the studies showed that genetic factors tend to have a greater relevance in determining longevity in men than in women."

EUNUCHS AS A POOR WAY TO STUDY THE INFLUENCE OF MALE HORMONES ON AGING
Wednesday, September 26, 2012
http://www.fightaging.org/archives/2012/09/eunuchs-as-a-poor-way-to-study-the-influence-of-male-hormones-on-aging.php
A paper that compares genealogical records of Korean eunuchs with their intact peers from past centuries has been doing the rounds, with the data showing a higher life span for the eunuchs. However, there is considerable skepticism from the rest of the research community - there are any number of ways to sneak in a bias towards longer-lived, more robust individuals: how the data came into being; how it is analyzed; how the eunuchs originally came into their position; their life style differences; and so forth. So it is hard to see any good way to discuss the role of male hormones in relation to this data, given all of the potential confounding factors not addressed by the authors. For example, only 81 of 385 recorded eunuchs had enough information present in the genealogy to pin down a life span. This alone could contain a bias towards longer-lived, more active, or more privileged individuals: there is no reason to think that these 81 are representative. But this is the nature of scientific research - individual research results have to be read skeptically and in the broader context of their field: "Historically, eunuchs have been employed as guards and servants in harems across the Middle East and Asia. The Imperial court of the Korean Chosun Dynasty (1392-1910) also had eunuchs. Eunuchs of the Chosun Dynasty lived with privileges: Korean eunuchs were conferred with official ranks and were legally allowed to marry, a practice that was officially banned in the Chinese Empire. In addition, married couples were also entitled to have children by adopting castrated boys or normal girls. The boys lost their reproductive organs in accidents, or they underwent deliberate castration to gain access to the palace before becoming a teenager. ... Several studies have described the long-term consequences of castration in eunuchs, but there have been no data on the lifespan of eunuchs. We examined the lifespan of Korean eunuchs by analyzing the Yang-Se-Gye-Bo - a genealogy record of Korean eunuchs. To our knowledge, this is the only record of eunuch-family histories in the world. ... The Yang-Se-Gye-Bo contains the records of 385 eunuchs. From these records, the lifespans of 81 eunuchs could be identified. The average lifespan of this group was 70.0 ± 1.76 years. As lifespan is affected by genetic and socio-economic factors, we compared the lifespan of eunuchs with the lifespan of men from three non-eunuch families of similar social status, who lived during the same time periods. ... The average lifespan of eunuchs [was] 14.4-19.1 years longer than the lifespan of non-castrated men of similar socio-economic status. Our study supports the idea that male sex hormones decrease the lifespan of men."

NANOPARTICLES TO RELIABLY TARGET MITOCHONDRIA
Tuesday, September 25, 2012
http://www.fightaging.org/archives/2012/09/nanoparticles-to-reliably-target-mitochondria.php
Technology platforms for the delivery of therapies to the mitochondria in our cells are both important and showing signs of progress. There are any number of ways in which we would like to manipulate our mitochondria, most importantly to repair or work around damage to their DNA because that is one of the contributing causes of aging. Given a general method for placing any therapy inside mitochondria we should see more development and experimentation in ways to repair them. Here, researchers "have refined the nanoparticle drug delivery process further by using nanoparticles to deliver drugs to a specific organelle within cells. By targeting mitochondria, 'the powerhouse of cells,' the researchers increased the effectiveness of mitochondria-acting therapeutics used to treat cancer, Alzheimer's disease and obesity in studies conducted with cultured cells. ... The mitochondrion is a complex organelle that is very difficult to reach, but these nanoparticles are engineered so that they do the right job in the right place. [Researchers] used a biodegradable, FDA-approved polymer to fabricate their nanoparticles and then used the particles to encapsulate and test drugs that treat a variety of conditions. ... getting drugs to the mitochondria is no simple feat. Upon entering cells, nanoparticles enter a sorting center known as the endosome. The first thing [researchers] had to demonstrate was that the nanoparticles escape from the endosome and don't end up in the cells' disposal center, the lysosome. The mitochondria itself is protected by two membranes separated by an interstitial space. The outer membrane only permits molecules of a certain size to pass through, while the inner membrane only permits molecules of a given range of charges to pass. The researchers constructed a library of nanoparticles and tested them until they identified the optimum size range - 64 to 80 nanometers, or approximately 1,000 times finer than the width of a human hair - and an optimum surface charge, plus 34 millivolts. ... the components they used to create the nanoparticles are FDA approved and that their methods are highly reproducible and therefore have the potential to be translated into clinical settings. The researchers are currently testing their targeted delivery system in rodents and say that preliminary results are promising."

EARLY RESULTS FROM A PROGERIA THERAPY TRIAL
Tuesday, September 25, 2012
http://www.fightaging.org/archives/2012/09/early-results-from-a-progeria-therapy-trial.php
Researchers here show data resulting from a therapy targeting the underlying cause of progeria. Accelerated aging conditions are extremely rare, but this is interesting to the rest of us because the same mechanisms that run wild in progeria sufferers apparently occur in a minor way during normal aging - so a cure for progeria might have some utility for the rest of us as well: "Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal 'rapid-aging' disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system ... Twenty-eight children from sixteen countries participated in the two-and-a-half year drug trial, representing 75 percent of known Progeria cases worldwide at the time the trial began. Of those, 26 are children with the classic form of Progeria. ... One in three children demonstrated a greater than 50 percent increase in annual rate of weight gain or switched from weight loss to weight gain, due to increased muscle and bone mass. ... On average, skeletal rigidity (which was highly abnormal at trial initiation) improved to normal levels after FTI treatment. ... Arterial stiffness, strongly associated with atherosclerosis in the general aging population, decreased by 35 percent. Vessel wall density also improved with treatment."

AN INTERESTING COMMENT FROM A GOOGLE VENTURES PARTNER
Monday, September 24, 2012
http://www.fightaging.org/archives/2012/09/an-interesting-comment-from-a-google-ventures-partner.php
Via CNBC: "Google's Venture fund is planning to invest $1 billion in a wide-range of start-ups over the next five years, but the firm isn't necessarily looking for the next Facebook, Twitter or other media related business. ... 'There's a whole world of innovation out there outside of social media. It's a huge growth area, but we're investing a lot of money in life sciences,' said William Maris, Google Ventures managing partner. ... Maris said the fund seeks entrepreneurs that 'have a healthy disregard for the impossible' with forward-thinking ideas, especially in biotech. Maris said some of the areas he is interested in include businesses that are focused on radical life extension, cryogenics and nanotechnology. ... 'Part of my job is to discern the fine line between crazy and genius,' Maris said. 'We're looking for entrepreneurs that want to change the world for the better and that's important. So I do think our values are a little bit different than the typical sort of venture capitalist you might meet.'" This is just a comment, of course, and at present the fund isn't invested in anything that works directly towards the defeat of aging: one partner's views don't necessarily have anything to do with how the fund moves in aggregate. One of the real challenges in longevity science today is that there's little to effectively commercialize, even if you want to be really aggressive and pull results right out of research into an unregulated region of the world for development as a therapy. Things don't get interesting until SENS programs or similar start to deliver results that can be turned into an early product, or the tissue engineers and stem cell researchers make more of an inroad into reversing the changes in stem cell populations that occur with age. The leading edge of all this is still a few years away at the very earliest, and more like at least a decade for much of it, so far as I can see.

WHEN I'M 164: AN INTERVIEW WITH DAVID EWING DUNCAN
Monday, September 24, 2012
http://www.fightaging.org/archives/2012/09/when-im-164-an-interview-with-david-ewing-duncan.php
Author David Ewing Duncan is presently touting a new book on aging and aging research entitled "When I'm 164". Here is an audio interview: "With a new understanding of the biology of aging, we may be on the cusp of pushing life expectancy to ages once considered unimaginable. Journalist and author David Ewing Duncan in his book When I'm 164, examines the potential technologies that could lead us to radical life extension and some of the consequences should science bring about a dramatic demographic shift. We spoke to Duncan about his book, how close we are to scientific advancements in the area, and why not everyone wants to live forever. ... While riffing on the Beatle's song 'When I'm 64,' the book surveys the increasingly legitimate science of radical life extension - from Healthy Living and Genetics to Regeneration and Machine Solutions - and considers the pluses and minuses of living to age 164, or beyond; everything from the impact on population and the cost of living to what happens to love, curiosity, and health. He shares classic stories and myths of people determined to defeat aging and death, and offers real-life tales of the techno-heroes and optimists who believe that technology can solve the 'problem' of aging. Concluding that anti-aging technologies will probably succeed in the next 30-50 years despite his earlier skepticism, he brings us back to the age-old question: 'will you still need me, will you still feed me, when I'm...'"

______________________________


<br> <br>View the full article

Click HERE to rent this BIOSCIENCE adspot to support LongeCity (this will replace the google ad above).

#30 Marios Kyriazis

  • Guest
  • 466 posts
  • 255
  • Location:London UK

Posted 01 October 2012 - 05:39 AM

The Fight Aging Newsletter is great and useful in a variety of ways. However its focus is quite restricted. It is now slowly becoming clear that in order to conquer aging we need to widen our outlook. We will not achieve our aims if we just concentrate on cells, DNA or molecules. We need to also consider evolutionary, social and ethics concepts, as well as wider matters such as transhumanism, cosmology, energy, entropy, information and other complex systems.

An interest in simple DNA/Cell biology is simplistic and is becoming outdated.
  • Agree x 1




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users